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Fibromatoses belong to the soft tissue tumors and arise in the connective tissue. 
They represent semimalignant lesions, characterized by invasive growth and a 
tendency to local recurrence, but lacking the formation of metastases. Depending on 
the sites of involvement, they are categorized as deep and superficial fibromatoses. 
Deep or aggressive fibromatoses occur extra- and intraabdominally, whereas the 
predilection sites for superficial fibromatoses are the palmar and plantar 
aponeuroses. The tumor cells exhibit features of myofibroblasts, a cell type that 
possesses attributes of both fibroblasts and smooth muscle cells. They are 
embedded in an abundant, collagen rich extracellular matrix. Aggressive and 
superficial fibromatoses are characterized by a nuclear accumulation of N-terminally 
dephosphorylated, active β-catenin. β-catenin exerts a crucial function in the 
adhesive complex at the cell membrane, as well as in the nucleus as a transcription 
cofactor of the canonical Wnt pathway. The nuclear accumulation of β-catenin is in 
most of the cases of aggressive fibromatoses derived from a biallelic mutation of the 
tumor suppressor gene adenomatous polyposis coli (APC; familial adenomatous 
polyposis) or a monoallelic mutation of the oncogene β-catenin itself (sporadic form). 
The reason for the nuclear accumulation of β-catenin in superficial fibromatosis 
remains to be elucidated.  
 
The present study is divided into three chapters. The aim of the first chapter was the 
identification of genes differentially expressed in aggressive and superficial 
fibromatoses as compared to reference normal fibrous tissue. This was accomplished 
by means of Agilent gene expression microarrays. In addition, the differentially 
expressed genes between the tumors were analyzed. Newly identified regulated 
genes may serve as markers for differentiating those soft tissue tumors, as well as 
contribute to the understanding of the common and discriminative mechanisms being 
responsible for the pathogenesis of aggressive and superficial fibromatoses. Chapter 
II covers the description of experiments aimed at the establishment and characte-
rization of primary tumor cell and normal fibroblast cultures. They should represent 
the basis for studying the functional relevance of proteins encoded by the determined 
differentially expressed genes. Chapter III deals with the impact of the Wnt ligand 
WNT5A on the canonical and non-canonical Wnt signalling pathways in the primary 
tumor cell culture of an aggressive fibromatosis (Aggr6). WNT5A was found to be 
regularly highly overexpressed in tumor tissues of aggressive fibromatosis as 
compared to superficial fibromatosis or normal fibrous tissue.  
 
 
Chapter I 
 
For the Agilent 60mer-oligonucleotide microarray experiments, total RNA from 10 
individual aggressive fibromatoses and 15 individual superficial fibromatoses were 
pooled to generate an aggressive fibromatosis RNA pool and a superficial 
fibromatosis RNA pool. As a reference, RNA samples from five fibrous tissues were 
pooled. In addition, RNA samples derived from 5 single aggressive fibromatoses and 
1 single superficial fibromatosis were hybridized on individual arrays. To find genes 
that most significantly differentiate in their expressions the tissues analyzed, the 
following stringent selection criteria were applied: an absolute expression level of at 
least 500, a fold-change of at least two and a p-value of 0.01 or less. By this means, 
2’429 known genes could be identified that differentiate the three tissue pools from 
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each other (aggressive fibromatosis / reference fibrous tissue: 1’113 overexpressed 
(↑), 860 downregulated (↓); superficial fibromatosis / reference fibrous tissue: 724 ↑, 
707 ↓; superficial fibromatosis / aggressive fibromatosis: 226 ↑, 275 ↓). A hierarchical 
clustering analysis, based on the ratios of the absolute expression levels of those 
genes between the tumor tissues and the reference fibrous tissue, built two clusters, 
separating the samples of aggressive fibromatosis from the ones of superficial 
fibromatosis. The differential expressions of 30 selected genes could be confirmed 
without exception using real-time RT-PCR. One of those genes represents WNT5A, 
which is regularly highly overexpressed in aggressive fibromatosis as compared to 
superficial fibromatosis and reference fibrous tissue.  
 
Using the software ‘DAVID’, about half of the selected 2’429 genes could be 
associated with a biological process.  
 
In the list of genes commonly differentiating the two tumors from the reference fibrous 
tissue, the following biological processes were statistically significantly 
overrepresented: Wnt signalling pathway, TGFβ signalling pathway, PI3K-AKT 
signalling pathway, extracellular matrix (ECM) components, ECM-receptor 
interaction, adherens junction and cell adhesion molecules (CAMs), proliferation, 
cytoskeleton, as well as complement and coagulation cascades. Whereas the Wnt 
signalling pathway is known to play a crucial role in the pathogenesis of both 
aggressive and superficial fibromatoses, the formation of superficial fibromatosis has 
been associated with a deregulated TGFβ signalling pathway. The involvement of the 
PI3K-AKT pathway in the pathogenesis of fibromatoses has been described so far in 
only one report in superficial fibromatosis. Both tumors are characterized by a 
pronounced accumulation of ECM proteins. Since tumor cells of fibromatoses 
represent myofibroblasts, differences in the composition of the cytoskeleton, 
especially of the alpha smooth muscle actin (α-SMA) containing 5nm actin filaments, 
are obvious. Alterations in cell-cell and cell-ECM interactions, as well as dysfunctions 
in the regulation of proliferation, are commonly involved in tumorigenesis.  
 
Interestingly, in the list of genes differentiating the two tumors from each other, most 
of the above mentioned biological processes are statistically overrepresented as well. 
The exceptions represent the PI3K-AKT pathway and the process of proliferation that 
commonly differentiate the two tumors from the reference fibrous tissue, but do not 
discriminate aggressive from superficial fibromatosis. Those differentially expressed 
genes represent attractive candidates for distinguishing the two tumors on the protein 
level using immunohistochemistry. Examples are thrombospondin 4 (THBS4), an 
ECM component that positively influences the activity of the TGFβ signalling pathway 
and was found to be highly overexpressed in superficial fibromatosis, Amphiregulin 
(AREG), a member of the epidermal growth factor (EGF) family, and WNT5A (a 
ligand of the Wnt signalling cascades). The latter two are highly overexpressed in 
aggressive fibromatosis. 
 
The identities of the differentially expressed components of the three signalling 
pathways were analyzed in more detail. They were grouped according to their 
functions into pathway activity inducers, inhibitors and pathway target genes. This 
approach aimed to deduce informations about differential activities within these 
pathways between the tissues analyzed. Although some restrictions of the validity of 
the resulting informations must be considered, the following findings could be 
deduced from the analysis of the data: 
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An overexpression of pathway activators and target genes indicates that the Wnt and 
the TGFβ signalling pathway are more active in both tumors as compared to the 
reference fibrous tissue. In addition, an upregulation of Wnt pathway activity inhibitors 
in fibromatoses suggests that a negative feedback loop mechanism may try to 
counterbalance an excessive Wnt signalling pathway activity in both tumors. In the 
Wnt and the TGFβ pathway, there is an extensive overlap of differentially expressed 
components in aggressive and superficial fibromatoses, reflecting prominent 
similarities in the deregulation of those pathways in both fibromatoses. 
 
For the analysis of the PI3K-AKT pathway, a different approach was applied. The 
PI3K-AKT pathway exerts diverse effects on cells, including an inhibition of apoptosis 
and an activation of proliferation. Thereby, the serine threonine kinase AKT plays a 
central role, by modulating the function of diverse downstream proteins, both on the 
protein (phosphorylation, ubiquitination) and the RNA level (transcription). 
 
The analysis of pathway inducers and inhibitors upstream of AKT did not reveal a 
differential activity of the PI3K-AKT pathway between tumor tissues and reference 
fibrous tissue. Downstream of AKT, several components of this pathway were found 
to be differentially expressed between fibromatoses and normal fibrous tissue. 
Whereas the overexpression of cyclin D1 (CCND1) and hypoxia-inducible factor 1 α 
subunit (HIF1A), and the downregulation of cyclin / cyclin-dependent kinase complex 
inhibitor 1B (CDKN1B) can be explained by an activated PI3K-AKT signalling 
pathway, the reason for the transcriptional regulation of the other pathway 
components is unknown. However, the net effect of those differentially expressed 
components is an induction of proliferation and an inhibition of apoptosis.  
 
In a recent paper, the authors proved an enhanced activity of the PI3K-AKT pathway 
in superficial fibromatosis as compared to reference fibrous tissue, by demonstrating 
an increased phosphorylation-dependent activation of AKT (Western blot). This may 
lead to an additional amplification of the proliferation inducing and apoptosis 
repressing effects through phosphorylation of the differentially expressed genes 
found in this study.  
 
In the literature, 243 genes are known to be differentially expressed between 
fibromatoses and normal fibrous tissue, whereas only a few of them differentiate the 
two tumors from each other. Most of them were detected by means of gene 
expression microarray experiments. Therefore, the bulk of genes found to be 
transcriptionally regulated in this study are unknown up to date. The functional 
annotation of the regulated genes published in the literature revealed the same 
biological processes as the ones determined by the analysis of the differentially 
expressed genes obtained in this study. The published statements for 93 of those 
genes could be confirmed by our own data, a consensus that is much higher than 
expected when comparing two randomly selected lists of differentially expressed 
genes.  
 
 
Chapter II 
 
For the establishment of primary tumor cell cultures, 7 aggressive fibromatoses (one 
familial adenomatous polyposis (FAP)-associated form carrying a monoallelic 
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mutation in APC, 6 sporadic forms, 5 of them characterized by a monoallelic β-
catenin mutation) and 5 superficial fibromatoses (without any known mutation) were 
taken into culture as small tissue pieces or single cell suspensions after a 
collagenase pre-treatment. Cell cultures of normal fibroblasts from the corium of 
normal dermal tissues were established in the same way. All cell cultures were 
characterized by the outgrowth of fibroblast-like cells (aggressive fibromatosis: 
Aggr1-7, superficial fibromatosis: Super1-5, normal adult dermal fibroblasts: HDF15, 
21 and NHDF).  
 
The cell culture derived from the FAP-associated aggressive fibromatosis (Aggr1) 
carried the same monoallelic APC-mutation as the primary tumor tissue. But since in 
this tissue, an unknown epigenetic alteration is responsible for the inactivation of the 
second APC allele, the tumoral origin of the primary cell culture Aggr1 can not be 
proven. The same accounts for Aggr7 and Super1-5, because the original tumor 
tissues do not carry any known mutations which could be used as markers. Since in 
Aggr2-5, the monoallelic β-catenin mutations present in the original tumor tissues are 
missing, those cells represent normal fibroblasts. On the other hand, the β-catenin 
point mutation at codon 45 (serine → phenylalanine) in the tumor tissue could also be 
found in the corresponding primary cell culture Aggr6, undoubtedly proving its 
tumoral origin. After 23 passages in vitro, this mutation was still present in Aggr6 
cells. However, the cells ceased proliferation (senescence); those cells therefore 
represent a primary cell culture, not an indefinitely proliferating, immortalized cell line.  
 
The endogenous expression of WNT5A was measured in the primary cell cultures 
Aggr2 and Aggr4 (normal fibroblasts), Aggr7 (unknown) and Aggr6 (tumor cells) by 
means of gene expression micoarrays (Agilent), and compared with the expressions 
in the original tumor tissues. There was no correlation between the WNT5A 
expression in vitro and in vivo. The determination of the WNT5A protein content in 
the cytoplasm and the cell culture supernatant (Western blot, IP), although proving a 
correlation with the gene expression, did not reveal the highest values for the tumor 
cell culture Aggr6. The reason for the overexpression of WNT5A in tumor tissues as 
compared to normal fibrous tissues and for the variable expression and secretion of 
WNT5A in vitro, independent of the identity of the culture as a tumor cell or normal 
fibroblast cell culture, is unknown.  
 
Therefore, with Aggr6, an undoubtedly proven primary tumor cell culture is available 
for the functional studies described in Chapter III.   
 
 
Chapter III 
 
Among the abundant possible candidates for subsequent functional studies in cell 
cultures, the Wnt signalling pathway ligand WNT5A was selected based on the 
following reasons: 1) WNT5A is highly overexpressed in aggressive fibromatosis as 
compared to superficial fibromatosis or reference fibrous tissue. This could be 
observed both by the analysis of pooled RNA samples, as well as by the 
measurements in individual tumor tissues. 2) WNT5A is a well-known activator of 
both the canonical Wnt as well as the non-canonical Wnt signalling pathways. The 
latter include the Wnt-planar cell polarity (PCP), the Wnt-Ca2+, the protein kinase A 
(PKA) and the signal transducer and activator of transcription (STAT) signalling 
pathways. 3) WNT5A has been associated both with tumor promoting and tumor 
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suppressing properties, depending on the type of tumor analyzed. Its role in the 
pathogenesis of fibromatoses has not been investigated, yet.  
 
The activity of the canonical Wnt signalling pathway was measured using a TCF-
reporter gene assay (Luciferase assay) and the quantification of the active, 
dephosphorylated form of β-catenin (Western blot). The activity of the PKA pathway 
was determined by the analysis of the phosphorylated, active form of the transcription 
factor CREB (Western blot). To measure the activity of the Wnt-PCP, the Wnt-Ca2+ 
and the STAT pathway, transcription factor assays were used.  
 
In agreement with the classical theory whereupon a monoallelic S45F β-catenin 
mutation leads to the accumulation of dephosphorylated, active β-catenin, the 
baseline activity of Wnt signalling pathway is in Aggr6 tumor cells higher than in cell 
cultures of normal fibroblasts. Whereas endogenously produced WNT5A does not 
exert any effect on the activity of the canonical Wnt pathway, stimulation with 
recombinant WNT5A led to a pronounced increase of its signalling activity in the 
tumor cell culture Aggr6, but not in the cell cultures of normal fibroblasts. Treatment 
with recombinant WNT5A led also to a selective stimulation of the activities of the 
non-canonical Wnt pathways Wnt-PCP and PKA in Aggr6 cells. By means of specific 
activators and inhibitors of those two pathways, a crosstalk with the canonical Wnt 
pathway could be excluded.  
 
A cell proliferation assay revealed that recombinant WNT5A selectively increased the 
proliferation of the tumor cell culture Aggr6, but did not alter the proliferation rate of 
normal fibroblasts. Whereas the inhibition of the canonical Wnt pathway and the Wnt-
PCP pathway by the use of specific pathway inhibitors did not impair WNT5A’s 
positive effect on cellular proliferation, the abrogation of the PKA pathway almost 
completely abolished the proliferative activity of Aggr6 cells. Thus, of the three 
pathways known to be activated by WNT5A, the PKA pathway elucidated to be the 
only one decisively involved in the regulation of proliferation of Aggr6 tumor cells, 
both in terms of their basal proliferation rate and the WNT5A-dependent stimulation 
of proliferation.  
    
A type I collagen Boyden chamber invasion assay was used to measure the invasive 
growth behaviour of the individual cell cultures. Aggr6 tumor cells behaved similarly 
as cell cultures of normal fibroblasts. The addition of recombinant WNT5A did not 
alter the invasive growth behaviour, neither of Aggr6 tumor cells, nor of normal 
fibroblasts.  
 
The numbers of differentially expressed genes obtained by a gene expression 
microarray experiment impressively reflected the above findings concerning a 
selective responsiveness of the tumor cell culture Aggr6 towards recombinant 
WNT5A: it exerted a pronounced effect on the gene expression in Aggr6 cells, but 
hardly affected transcription in normal fibroblasts.  
 
In search of reasons for the differential impact of recombinant WNT5A on Aggr6 
tumor cells and normal fibroblasts, respectively, microarray gene expression data 
were analyzed to detect differentially expressed WNT5A-binding Frizzled (Fzd) 
receptors. It could be shown that Aggr6 tumor cells overexpress Fzd1, Fzd2 and 
Fzd7 as compared to normal fibroblasts. Those Fzd receptors are accordingly 
regulated also in aggressive fibromatosis tissues in comparison to reference fibrous 
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tissue. This led to the suspicion, that Fzd1, Fzd2 and Fzd7 receptors are responsible 
for WNT5A binding on tumor cells. However, downregulation of all three receptors by 
means of siRNAs transfected into Aggr6 cells did not lead to a reduced 
responsiveness of these cells towards recombinant WNT5A.  
 
Another explanation would be that the enhanced basal canonical Wnt pathway 
activity in Aggr6 tumor cells induces the expression of WNT5A receptors. Although 
an overexpression of β-catenin mutated at codon 45 (45-β-catenin) in normal 
fibroblasts led to an increased canonical Wnt pathway activity, it did not allow a 
further stimuation of this pathway by recombinant WNT5A. Therefore, the 
mechanisms being responsible for the observed discrepancy between Aggr6 cells 
and the cell cultures of normal fibroblasts in the responsiveness towards WNT5A 
remain to be elucidated. 
 
In summary, the obtained in vitro results provide the basis for the understanding of 
the mechanisms, by which WNT5A, highly overexpressed in aggressive fibromatosis, 
exerts its proliferation inducing effect.  
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Zusammenfassung 
 
Fibromatosen gehören zu den Weichteiltumoren und entstehen im Bindegewebe. Als 
semimaligne Tumoren sind sie charakterisiert durch ein invasives Wachstum und 
durch die Tendenz zur Bildung von Lokalrezidiven. Metastasen entstehen keine. 
Aggressive Fibromatosen werden wegen ihrer Lokalisation auch als tiefe 
Fibromatosen bezeichnet und den superfiziellen Fibromatosen (Palmar- und 
Plantaraponeurosen) gegenübergestellt. Die Tumorzellen gleichen Myofibroblasten, 
einem Zelltyp mit Merkmalen sowohl von Fibroblasten als auch von glatten 
Muskelzellen. Sie sind eingebettet in eine abundante, kollagenreiche extrazelluläre 
Matrix. Gemeinsam ist den Fibromatosen eine nukleäre Akkumulation der aktiven, 
dephosphorylierten Form des β-catenins. Dieses spielt neben seiner zentralen 
Funktion im Zelladhäsionskomplex eine wichtige aktivierende Rolle im Wnt-
Signaltransduktionsweg als Transkriptions-Cofaktor. Die Akkumulation von β-catenin 
ist in aggressiven Fibromatosen in den meisten Fällen auf eine biallelische Mutation 
des adenomatous polyposis coli (APC) Tumorsuppressor-Gens (familiäre 
adenomatöse Polyposis Coli) oder eine monoallelische Mutation des Onkogens β-
catenin selber (sporadische Formen) zurückzuführen. Der Grund für die 
Anreicherung des β-catenins im Nukleus der superfiziellen Fibromatosen ist 
unbekannt. 
 
Die vorliegende Arbeit umfasst drei Kapitel. Ziel des ersten Kapitels war es, mittels 
der Mikroarray-Genexpressions-Technologie (Agilent) Gene zu identifizieren, die im 
Tumorgewebe der aggressiven und superfiziellen Fibromatose im Vergleich zu 
normalem fibroblastärem Bindegewebe differenziell exprimiert sind. Ausserdem 
wurden die Genexpressions-Unterschiede zwischen den beiden Tumoren untersucht.  
Neu entdeckte differentiell exprimierte Gene können einerseits als Marker für die 
Unterscheidung dieser Weichteiltumoren und anderseits zum Verständnis der für die 
Pathogenese dieser beiden Tumoren verantwortlichen gemeinsamen und 
unterschiedlichen Mechanismen beitragen. Durch die im Kapitel II beschriebene 
Etablierung und Charakterisierung von Primärkulturen von Tumorzellen und 
normalen Fibroblasten sollte die Möglichkeit geschaffen werden, die funktionelle 
Bedeutung differentiell exprimierter Genprodukte zu studieren. Kapitel III befasst sich 
mit der Wirkung des Wnt Liganden WNT5A auf den kanonischen und die nicht-
kanonischen Wnt-Signaltransduktionswege in Tumorzellen der Primärkultur einer 
aggressiven Fibromatose (Aggr6). WNT5A wird im Tumorgewebe aggressiver 
Fibromatoses regelmässig überexprimiert. 
 
 
Kapitel I 
 
Für die Genexpressionsanalyse auf Agilent-Oligonukleotid-Mikroarrays wurde die 
RNS aus dem Tumorgewebe von je 10 aggressiven und 15 superfiziellen Fibromato-
sen sowie aus 5 Exzisaten von normalem Bindegewebe extrahiert und für die Her-
stellung des Genexpressionsprofils gepoolt. Zusätzlich wurden 5 einzelne aggressive 
Fibromatosen und eine weitere superfizielle Fibromatose analysiert. Um Gene zu 
finden, die in ihrer Expression die untersuchten Gewebe am signifikantesten 
voneinander unterscheiden, wurden folgende stringenten Selektionskriterien ange-
wendet: absolute Expressionsstärke ≥ 500, Expressionsverhältnis ≥ 2 oder ≤ 0.5, p-
value ≤ 0.01. Auf diese Weise konnten 2’429 bekannte Gene gefunden werden, die 
zwischen den einzelnen Gewebepools differenziell exprimiert sind: (aggressive 
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Fibromatose / Bindegewebe: 1'113 überexprimiert (↑), 860 herunterreguliert (↓); 
superfizielle Fibromatose / Bindegewebe: 724 ↑, 707 ↓ ; superfizielle Fibromatose / 
aggressive Fibromatose: 226 ↑, 275 ↓). In einer Cluster-Analyse, basierend auf dem 
Verhältnis der Expressionsstärke dieser Gene im Tumorgewebe, verglichen zum 
normalen Bindegewebe, ergab sich eine klare Abgrenzung der aggressiven von der 
superfiziellen Fibromatose. Die differentielle Expression von 30 ausgewählten Genen 
konnte mittels real-time RT-PCR ausnahmslos bestätigt werden. Eines dieser Gene 
ist WNT5A, welches in der aggressiven Fibromatose im Vergleich zur superfiziellen 
Fibromatose und zum normalen Bindegewebe ausnahmslos stark überexprimiert ist. 
 
Mit dem Programm ‚DAVID’ konnte etwa die Hälfte der 2’429 selektierten Gene 
einem biologischen Prozess zugeordnet werden.  
 
Betrachtet man nur die Gene, die die beiden Tumoren gemeinsam vom 
Bindegewebe unterscheiden, so sind folgende biologischen Prozesse statistisch 
signifikant übervertreten: Wnt-Signaltransduktionsweg, TGFβ-Signaltransduktions-
weg, PI3K-AKT-Signaltransduktionsweg, extrazelluläre Matrix- (ECM)-Komponenten, 
ECM-Rezeptor-Interaktion, Zelladhäsionskomplex- und Zelladhäsionsmoleküle, 
Proliferation, Zytoskelett sowie Komplement- und Blutgerinnungs-Kaskaden. 
Während der Wnt-Signaltransduktionsweg in der Pathogenese sowohl der 
aggressiven, wie auch der superfiziellen Fibromatose bekanntermassen eine Rolle 
spielt,  wird der TGFβ-Signaltransduktionsweg in der superfiziellen Fibromatose als 
ursächlich beschrieben. Nur wenig ist bekannt über die Bedeutung des PI3K-AKT-
Signaltransduktionsweges für die Entstehung dieser Tumoren. Eine Akkumulierung 
von ECM-Komponenten ist charakteristisch für beide Fibromatosen. Da es sich bei 
den Tumorzellen um Myofibroblasten handelt, sind auch die Unterschiede in der 
Zusammensetzung des Zytoskeletts, namentlich der 5nm Aktin-Filamente (welche 
das α-SMA glatter Muskelzellen enthalten), verständlich. Veränderte Zell-Zell- und 
Zell-ECM-Interaktionen, wie auch die unterschiedliche Regulation der Proliferation, 
sind allgemein bei der Entstehung von Tumoren von Bedeutung. 
 
Von den Genen, die zwischen der aggressiven und der superfiziellen Fibromatose 
differentiell exprimiert sind, gehören interessanterweise die meisten zu den gleichen  
signifikant übervertretenen biologischen Prozessen. Ausnahmen sind der PI3K-AKT-
Signaltransduktionsweg und die Proliferation, die beide Tumoren in gleicher Weise 
vom Bindegewebe unterscheiden, nicht aber die beiden Tumoren untereinander. 
Solche differentiell exprimierten Gene stellen auf Proteinebene attraktive Kandidaten 
zur immunhistochemischen Unterscheidung der beiden Tumoren dar. Als Beispiele 
können Thrombospondin 4 (THBS4), Amphiregulin (AREG) und WNT5A genannt 
werden. THBS4 ist eine ECM Komponente, die einen aktivierenden Einfluss auf den 
TGFβ-Signaltransduktionsweg ausübt. Dieses Gen ist stark überexprimiert in der 
superfiziellen Fibromatose. AREG (gehört zur Familie der epidermal growth factors 
(EGF)) und WNT5A (Ligand der Wnt-Signaltransduktionskaskaden) sind in aggressi-
ven Fibromatosen stark überexprimiert. 
 
Die Identität der differentiell exprimierten Komponenten der drei Signaltrans- 
duktionswege wurde genauer analysiert. Dazu wurden sie bezüglich ihrer Funktion in 
Aktivatoren, Inhibitoren und Zielgene des Signaltransduktionsweges gruppiert mit 
dem Zweck, Aussagen über die differentielle Aktivität dieser Signalwege in den 
analysierten Geweben machen zu können. Obwohl bei diesem Vorgehen einige 
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Einschränkungen bezüglich der Aussagekraft der erhaltenen Resultate gemacht 
werden müssen, liess sich aus der Analyse der Daten folgendes ableiten:  
 
Die Überexpression von Signalweg-Aktivatoren und Zielgenen deutet darauf hin, 
dass der Wnt- und der TGFβ-Signaltransduktionsweg in beiden Tumoren aktiver ist 
als im normalen Bindegewebe. Ausserdem lässt eine verstärkte Expression von Wnt-
Signalweg-Inhibitoren in beiden Tumoren darauf schliessen, dass diese in einem 
negativen Regelkreis dieser Aktivität entgegenwirken. Zwischen den Tumoren 
besteht eine grosse Übereinstimmung bezüglich der differentiell exprimierten 
Komponenten in beiden Signaltransduktionswegen. 
 
Eine etwas andere Vorgehensweise wurde für die Analyse des PI3K-AKT-
Signaltransduktionswegs angewendet. Die PI3K-AKT Signalkaskade übt unter 
anderem einen induzierenden Effekt auf die Proliferation und einen inhibierenden 
Einfluss auf die Apoptose aus, indem sie via AKT (eine Serin/Threonin-Kinase) 
verschiedenste Proteine in ihrer Funktion durch Phosphorylierung und 
Ubiquitinierung beeinflusst. Andere Komponenten des Signalweges werden aber auf 
Stufe Transkription reguliert. 
  
Eine Analyse der Signaltransduktionsweg-Aktivatoren und -Inhibitoren oberhalb von 
AKT liess auf keine differentielle Aktivität des PI3K-AKT-Signalwegs zwischen den 
Tumorgeweben und normalem Bindegewebe schliessen. Unterhalb von AKT fanden 
sich in der vorliegenden Studie mehrere Komponenten, die zwischen den Tumoren 
und dem Referenzgewebe differentiell exprimiert sind. Die Überexpression von 
Cyclin D1 (CCND1) sowie von hypoxia-inducible factor 1α subunit (HIF1A) und die 
Herunterregulierung von cyclin/cyclin-dependent kinase complex inhibitor 1B 
(CDKN1B) können durch einen aktivierten PI3K-AKT-Signaltransduktionsweg erklärt 
werden, während die Ursache für die differentielle Expression der anderen 
Komponenten unbekannt ist. Der Nettoeffekt dieser differentiell exprimierten 
Komponenten ist eine Induktion der Proliferation und eine Hemmung der Apoptose. 
 
In einer neueren Publikation wird durch den Nachweis von Phospho-AKT die 
Aktivierung dieses Signalweges in der superfiziellen Fibromatose bewiesen. 
Möglicherweise führt dies zu einer weiteren Verstärkung des proliferationsfördernden 
und apoptosehemmenden Effekts der differentiell exprimierten Gene unterhalb AKT.    
 
Aus der Literatur sind 243 Gene bekannt, die zwischen Fibromatosen und normalem 
Bindegewebe differenziell exprimiert sind. Nur sehr wenige dieser Gene unter-
scheiden zwischen aggressiver und superfizieller Fibromatose. Die meisten wurden 
mittels Mikroarray-Genexpressionsstudien entdeckt. Demzufolge war der Grossteil 
der in dieser Studie identifizierten differentiell exprimierten Gene bisher noch nicht 
bekannt. Die differentielle Expression von 93 der 243 bekannten Gene konnte bestä-
tigt werden. Diese Übereinstimmung ist statistisch gesehen um einiges grösser als zu 
erwarten wäre, wenn man zwei beliebige Genlisten miteinander vergleicht. Eine 
Gruppierung der in der Literatur beschriebenen Gene nach biologischen Prozessen 
ergibt ein ähnliches Bild, wie es auch in der vorliegenden Studie erhalten wurde. 
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Kapitel II 
 
Zur Etablierung einer Tumorzellinie wurden 7 aggressive Fibromatosen (eine 
familiäre Form mit monoallelischer APC-Mutation, 6 sporadische Formen, davon 5 
mit und eine ohne β-catenin-Mutation) und 5 superfizielle Fibromatosen (ohne 
bekannte Mutation) als Gewebestückchen oder als Kollagenase isolierte Zellen in 
Kultur genommen. Normale Fibroblastenkulturen wurden auf gleiche Weise aus 
Corium mehrerer normaler Hautexzisate angelegt. In allen Fällen kam es zum 
Wachstum von fibroblastenähnlichen Primärkulturen (aggressive Fibromatosen: 
Aggr1-7, superfizielle Fibromatosen: Super1-5, normale adulte dermale Fibrobasten: 
HDF15, 21 und NHDF). 
 
Die aus der familiären Form der aggressiven Fibromatose ausgewachsenen Zellen 
(Aggr1) wiesen die gleiche monoallelische APC-Mutation auf wie der Ausgangs-
tumor. Da aber schon in diesem eine nicht identifizierte epigenetische Veränderung 
für den Ausfall des zweiten Allels verantwortlich ist, kann nicht entschieden werden, 
ob es sich um eine Tumorzelle oder einen normalen Fibroblasten handelt. Das 
gleiche gilt für Aggr7 und Super1-5, da die Originaltumoren keine bekannten, als 
Marker verwendbare Mutationen aufweisen. Da Aggr2-5 die monoallelische β-
catenin-Mutationen der Ausgangstumoren nicht zeigen, handelt es sich bei diesen 
um normale Fibroblasten. Nur Aggr6 konnte durch die Präsenz der gleichen β-
catenin-Punktmutation im Codon 45 (Serin→Phenylalanin), die auch schon der 
Ausgangstumor trägt, eindeutig als Tumorzelle identifiziert werden. Nach 23 
Generationen findet sich diese Mutation in den Tumorzellen immer noch. Hingegen 
kommt es zu einem Wachstumsstillstand (Seneszenz); es handelt sich also um eine 
Primärkultur und keine permanent wachsende, immortalisierte Zellinie. 
 
Die endogene WNT5A-Expression wurde in den Zellkulturen Aggr2 und Aggr4 
(Fibroblasten), Aggr7 (unklar) und Aggr6 (Tumorzellen) mittels der Microarray-
Technologie (Agilent) gemessen und mit der Expression im Originalgewebe 
verglichen. Es konnte keine Korrelation der Expressionsstärke von WNT5A in vitro 
mit derjenigen in vivo gefunden werden. Die Bestimmung des WNT5A-Proteingehalts 
im Zytoplasma und im Zellkultur-Überstand (Western Blot, IP) zeigte zwar eine 
Übereinstimmung mit der gemessenen Gen-Expression, war aber in Aggr6 nicht am 
höchsten. Der Grund für die WNT5A-Überexpression im Tumorgewebe und für die 
unterschiedliche Expression und Produktion von WNT5A in Zellkulturen (unabhängig 
davon, ob es sich um Tumorzellen oder normale Fibroblasten handelt), ist unbe-
kannt.  
 
Somit steht für funktionelle Studien mit Aggr6 bewiesenermassen eine primäre 
Tumorzellkultur zur Verfügung. 
 
 
Kapitel III 
 
Aus der grossen Fülle möglicher Kandidaten wurde für die anschliessenden 
funktionellen Studien in Zellkulturen der Wnt-Signalisationskaskade-Ligand WNT5A 
aus den folgenden Gründen ausgewählt: 1) Die Expression von WNT5A ist in 
aggressiven Fibromatosen gegenüber superfiziellen Fibromatosen und normalem 
Bindegewebe massiv erhöht. Dies gilt sowohl für die Bestimmung aus gepoolter RNS 
von mehreren Tumoren und Bindegeweben, als auch für die Messung von Einzel-
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geweben. 2) WNT5A ist ein bekannter Aktivator sowohl des kanonischen als auch 
der nicht-kanonischen Wnt-Signaltransduktionswege. Zu den letzteren gehören der 
Wnt-planar cell polarity (PCP)-, der Wnt-Ca2+-, der Protein Kinase A (PKA)- und der 
signal transducer and activator of transcription (STAT)-Signaltransduktionsweg. 3) 
WNT5A wurden in der Literatur sowohl Tumor fördernde als auch Tumor sup-
primierende Eigenschaften zugeschrieben, je nach Typ des untersuchten Tumors. Im 
Zusammenhang mit Fibromatosen wurde WNT5A bisher noch nicht untersucht.  
  
Die Aktivität des kanonischen Wnt-Signalweges wurde mittels des TCF-Reportergen-
Assays (Luciferase Assay) und der Quantifizierung der aktiven, dephosphorylierten 
Form des β-catenins bestimmt  (Western Blot). Die Aktivität des PKA-Signalwegs 
wurde durch den quantitativen Nachweis der phosphorylierten, aktiven Form des 
CREB-Transkriptionsfaktors analysiert (Western Blot). Für die Bestimmung der 
Aktivität des Wnt-PCP-, des Wnt-Ca2+- und des STAT-Signalweges wurden Trans-
kriptionsfaktor Assays verwendet. 
 
Im Einklang mit der Theorie, wonach eine monallelische β-catenin-Mutation im 
Codon 45 zu einer Akkumulierung von aktivem, dephosphoryliertem β-catenin führt, 
zeigt Aggr6 eine höhere basale Aktivität des kanonischen Wnt-Signaltrans-
duktionsweges als die Zellkulturen normaler Fibroblasten. Während die geringe 
Menge des endogen produzierten WNT5A keinen Einfluss auf die Aktivität der 
kanonischen Wnt-Signalkaskade hat, führte die Zugabe von rekombinantem WNT5A 
zu einer deutlichen spezifischen Aktivitätssteigerung in der Tumorzellkultur Aggr6, 
nicht aber in Zellkulturen normaler Fibroblasten. Selektiv in Aggr6 führte die 
Stimulation mit rekombinantem WNT5A auch zu einer Aktivierung der nicht-
kanonischen Wnt-Signaltransduktionswege Wnt-PCP und PKA.  Durch den Einsatz 
entsprechender Inhibitoren und Aktivatoren für beide Signaltransduktionswege 
konnte gezeigt werden, dass  beide Signalwege keinen Einfluss auf die Aktivität der 
kanonischen Wnt-Kaskade nehmen (kein „ Crosstalk“).  
 
Ein Proliferationsassay ergab, dass rekombinantes WNT5A die Proliferationsrate in 
Aggr6 Tumorzellen steigert, auf Zellkulturen normaler Fibroblasten diesbezüglich 
aber keinen Einfluss ausübt. Eine Vorbehandlung der Zellen mit spezifischen 
Inhibitoren gegen den kanonischen Wnt- und die nicht-kanonischen Wnt-PCP- 
respektive PKA-Signalisationskaskaden mit anschliessender WNT5A Stimulation 
machte deutlich, dass der PKA-Signaltransduktionsweg sowohl für die WNT5A-
induzierte Proliferationssteigerung, als auch für die basale Proliferationsrate der 
Aggr6-Tumorzellenellen von entscheidender Bedeutung ist. 
 
Ein Typ I Kollagen-basierter Boyden-Chamber-Invasionsassay wurde für die Mes-
sung des invasiven Wachstumsverhaltens der einzelnen Zellkulturen herangezogen. 
Aggr6-Tumorzellen unterschieden sich in ihrer basalen Invasionsaktivität nicht von 
normalen Fibroblasten. Auch nach Zugabe von rekombinantem WNT5A zeigte sich 
keine Veränderung im Invasionsverhalten von Tumorzellen oder normalen Fibro-
blasten. 
 
Das selektive Ansprechen der Aggr6-Tumorzellen auf eine Stimulation mit rekom-
binantem WNT5A konnte auch eindrücklich deutlich gemacht werden durch eine 
Analyse differentiell exprimierter Gene nach WNT5A-Stimulation mittels der 
Mikroarray-Technologie (Agilent). Die Anzahl der durch WNT5A in ihrer Expression 
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regulierter Gene überstieg in Aggr6 bei weitem diejenige in Kulturen normaler 
Fibroblasten. 
 
Auf der Suche nach Gründen für die unterschiedliche Ansprechbarkeit von Aggr6-
Tumorzellen und normalen Fibroblasten auf rekombinantes WNT5A wurde eine 
Analyse der Mikroarray-Expressions-Daten bezüglich der WNT5A-bindenden 
Frizzled-Rezeptoren vorgenommen. Es zeigte sich, dass Aggr6-Tumorzellen  Fzd1, 
Fzd2 und Fz7 im Vergleich zu normalen Fibroblasten überexprimieren. Diese 
Rezeptoren sind in gleicher Weise auch im Tumorgewebe und in normalem 
Bindegewebe unterschiedlich exprimiert. Dies legte die Vermutung nahe, dass diese 
Rezeptoren für die Bindung von WNT5A an Tumorzellen verantwortlich sein könnten. 
Eine Inhibition der Expression dieser Frizzled-Rezeptoren mittels Transfektion der 
Aggr6-Zellen mit siRNA für alle drei Fzd-Rezeptoren führte aber nicht zu einer 
verminderten Ansprechbarkeit dieser Zellen gegenüber rekombinatem WNT5A. 
 
Eine weitere Möglichkeit wäre, dass  die in Aggr6-Tumorzellen vorhandene basale 
Aktivität der kanonischen Wnt-Signalisationskaskade die Expression von WNT5A-
Rezeptoren induziert.   Die Überexpression von an Codon 45 mutiertem β-catenin in 
normalen Fibroblasten führte zwar zu einer Aktivierung des kanonischen Wnt-
Signaltransduktionswegs, ermöglichte aber keine weitere Aktivitätssteigerung  durch 
anschliessende WNT5A-Stimulation. Der Grund für den unterschiedlichen Einfluss 
von WNT5A auf Tumorzellen aggressiver Fibromatosen gegenüber normalen 
Fibroblasten bleibt also unbekannt. 
 
Zusammengefasst liefern die in vitro-Resultate die Grundlage zum Verständnis der 
Mechanismen, über welche WNT5A, das im Tumorgewebe aggressiver Fibroma-
tosen konstant stark überexprimiert ist, seine proliferationsfördernde Wirkung ausübt.  
 
 
 
.   
 
 
 
 
 
 
 
  Overview 
 
 
The PhD-thesis is divided into three chapters dealing with different aspects of the 
experimental work: 
 
 
Chapter I: Gene expression analysis of aggressive and superficial fibromatoses 
 
Chapter II: Establishment of primary cell cultures derived from fibromatoses 
 
Chapter III:  The impact of WNT5A on cell signalling pathways and biological 
behaviour of aggressive fibromatosis tumor cells 
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Chapter I 
Gene expression analysis of  
aggressive and superficial fibromatoses 
 
 
1. General introduction 
 
The discussions in subsequent sections of this chapter assume that basic signalling 
mechanisms and functions of the canonical Wnt-, the TGFβ- and the PI3K-AKT 
pathway are known, as well as basic principles of the process of wound healing. 
Therefore, those four themes should be introduced in this section.  
 
1.1. Description of the canonical Wnt signalling pathway 
 
1.1.1. Description (Figure 1) 
 
The name “Wnt” is derived from the fusion of the names of two orthologous genes: 
the Drosophila gene Wingless (Wg) (Sharma and Chopra, 1976)  and the mouse 
protooncogene Int-1 (Nusse and Varmus, 1982; Rijsewijk et al., 1987). Wnt genes 
are coding for secreted glycoproteins that have been highly conserved during 
evolution, being expressed in species ranging from Drosophila to human (Giles et al., 
2003; Miller, 2002; van Amerongen et al., 2008). Since their discovery more than 20 
years ago, a plethora of studies has been performed in several organisms aiming to 
elucidate the signalling pathways elicited by the Wnts. The pathway that received by 
far the most attention represents the canonical Wnt pathway with its central 
component β-catenin. The description below is dedicated to this pathway. The non-
canonical pathways will be introduced in Chapter III, Section 1.1. 
 
In the absence of any Wnt-ligand binding to its receptor, newly synthesized β-catenin 
in the cytoplasm is bound by the two scaffold proteins axin (its binding affinity for      
β-catenin is increased after phosphorylation by the glycogene synthase kinase 3 β, 
GSK3β) and adenomatous polyposis coli (APC) (Figure 1, (1)), followed by the 
joining of the serine/threonine kinases GSK3β and casein kinase 1 α (CK1α). This 
multiprotein complex dedicated for the degradation of β-catenin in the cytoplasm is 
termed β-catenin degradation complex (Daugherty and Gottardi, 2007; Kimelman 
and Xu, 2006; Price, 2006; Willert and Jones, 2006). 
 
Within this complex, β-catenin gets phosphorylated by CK1α at codon serine 45 
(S45), followed by phosphorylations at the more N-terminally located residues 
threonine 41 (T41), serine 37 (S37) and serine 33 (S33) by GSK3β, whereby the first 
S45-phosphorylation represents an essential priming step for the subsequent 
phosphorylations at the other three residues (Amit et al., 2002; Liu et al., 2002; 
Yanagawa et al., 2002). This process is accompanied by the simultaneous 
phosphorylations of APC by GSK3β and CK1α,δ,ε, leading to conformational 
changes within the degradation complex, resulting in an enhanced (APC) and 
reduced (axin) binding affinity for β-catenin, respectively (Figure 1 (2)). Consequently, 
N-terminally phosphorylated β-catenin is released from the degradation complex and 
APC acts to ensure its ubiquitination by the transducing repeat-containing protein β 
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(β-TrCP) ubiquitin ligase and its subsequent degradation by the proteasome (Figure 
1 (3)).  
 
In the absence of a functional APC protein, phosphorylated β-catenin is rapidly 
dephosphorylated by the serine/threonine protein phosphatase PP2A (Su et al., 
2008). APC is not essential for N-terminal phosphorylations of β-catenin by CK1α 
and GSK3β, since such phosphorylations can occur in APC mutant colon carcinoma 
cell lines (Yang et al., 2006). 
 
The canonical Wnt-signalling pathway gets activated by binding of a Wnt-ligand to its 
cognate receptor, a member of the Frizzled (Fzd) family of seven-span 
transmembrane receptors (Bhanot et al., 1996; He et al., 1997; Wang et al., 1996), 
and co-receptor low-density lipoprotein receptor-related protein (LRP)-5 or -6 (Wehrli 
et al., 2000). All three components – Wnt, Fzd and LRP – must be bound to each 
other in order to start the signalling pathway (Pinson et al., 2000; Tamai et al., 2000; 
Wehrli et al., 2000) (Figure 1 (4)).  
 
This leads (through a complex and as yet not fully understood mechanism 
(Daugherty and Gottardi, 2007; Kimelman and Xu, 2006; Price, 2006; Willert and 
Jones, 2006) involving the phosphorylations of LRP5/6 through GSK3β, CK1γ and 
CK1ε as well as of Dishevelled (Dsh) (Yanagawa et al., 1995) through CK1ε to the 
sequestration of the β-catenin degradation complex components axin and GSK3β at 
the membrane. This results on one hand to the destabilization of the β-catenin 
degradation complex and a concomitant reduction of its ability to function, on the 
other hand to a direct inhibition and even degradation of components of the β-catenin 
degradation complex (Cselenyi et al., 2008; Piao et al., 2008; Wu et al., 2009)  
(Figure 1 (5)). Whether by these mechanisms both CK1α mediated S45- and GSK3β 
dependent S33, S37, T41-phosphorylations are affected to a similar extent is 
controversially discussed in the literature (Amit et al., 2002; Kimelman and Xu, 2006; 
Liu et al., 2002).  
 
However, as a net result of the activity of the canonical Wnt signalling pathway, N-
terminally dephosphorylated β-catenin – at least at residues S33, S37 and T41 – 
accumulates in the cytoplasm (Figure 1 (6)), translocates into the nucleus and 
activates the transcription of T-cell transcription factor (TCF) / lymphoid enhancer-
binding factor (LEF)-dependent target genes (Figure 1 (7)) (Molenaar et al., 1996; 
Staal et al., 2002; van de Wetering et al., 1997; van Noort et al., 2002). A 
comprehensive, updated overview of the canonical Wnt pathway target genes can be 
found on the Wnt homepage (http:// www.stanford.edu /~rnusse /wntwindow. html).  
 
Whereas N-terminally phosphorylated β-catenin can be detected in the nucleus as 
well (Chung et al., 2001; Clifford et al., 2008; Nakopoulou et al., 2006; Sadot et al., 
2002; Sokolova et al., 2008), it does not contribute to the transactivation of TCF/LEF-
dependent gene expression (Clifford et al., 2008; Sadot et al., 2002; Sokolova et al., 
2008; Staal et al., 2002), since it is unable to form a ternary complex with target gene 
promoter DNA and TCF/LEF, although it is readily able to bind TCF/LEF (Clifford et 
al., 2008; Sadot et al., 2002). Therefore, the N-terminally dephosphorylated form of β-
catenin is often called ‘active’-β-catenin (van Noort et al., 2002). 
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Figure 1: The impact of the canonical Wnt signalling pathway on the degradation of β-catenin.  
A detailed description is provided in the text.  
 
 
β-catenin plays also a fundamental role in cell-cell adhesion, where it connects the 
transmembrane protein cadherin to the actin cytoskeleton (Daugherty and Gottardi, 
2007). In this function, β-catenin is N-terminally dephosphorylated, since 
phosphorylations inhibit the interaction with its binding partners (Bustos et al., 2006; 
Sadot et al., 2002). 
 
The above described mechanisms of phosphorylation and degradation of β-catenin 
form the basis of the ‘classical model’. This view has been challenged by the 
observation that in genetically manipulated colon carcinoma HCT116 cells 
expressing only a S45-deleted β-catenin allele (-/45-HCT116), phosphorylations at 
T41, S37 and S33 can readily occur (Figure 2, red circle), regardless of the missing 
phosphorylation at S45 (Figure 2, blue circle). This finding is clearly contradictory to 
the classical model, whereupon a S45 phosphorylation by CK1α represents an 
essential prerequisite for the subsequent phosphorylations at the other three 
residues by GSK3β (Wang et al., 2003).  
 
A recent paper demonstrated that the observed S33, S37, T41 phosphorylations in    
-/45-HCT116 are not derived from GSK3β (Pai et al., 2008). Nevertheless, 
phosphorylations at these residues are clearly reduced, since active, 
dephosphorylated β-catenin is present in higher amount, leading to an increased 
activity of the TCF/LEF-dependent transcription in the cell line  -/45-HCT116 (Figure 
3, red bars) as compared to the cell line expressing only a wildtype β-catenin (Figure 
3, blue bars) (Chan et al., 2002). The discrepancy between the two models may 
relate to differences in regulation of β-catenin in different species or tissues or to 
different experimental approaches (e.g. exogenously introduced vs. endogenous β-
catenin) (Wang et al., 2003). 
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Figure 2: Observation challenging the classical model of phosphorylation  
and degradation of β-catenin: phosphorylations at T41, S37 and S33 can  
readily occur regardless of the missing phosphorylation at S45.  
W1,W2,M1,M2: different cell clones. Adapted from Wang et al., 2003. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Regardless of the observed phosphorylations at S33, S37, T41, 
-/45-HCT116 cells show an increased activity of TCF/LEF-dependent  
transcription as compared to the cell culture expressing a wild type β-catenin (WT/-). 
W1,W2,M1-M4: different cell clones. Adapted from Chan et al., 2002. 
 
1.1.2. The role of the canonical Wnt signalling pathway in embryogenesis and adult 
organisms 
 
The canonical Wnt-pathway has been implicated in the regulation of virtually every 
aspect of embryonic development in all organisms analyzed, including axis 
specification, patterning, organogenesis, limb formation, adipogenesis and 
angiogenesis (Clevers, 2006; Moon et al., 2002). In some self-renewing tissues in 
mammals, this pathway remains essential throughout life. For instance in the 
absorptive epithelium of the small intestine, in the hair follicle, the hematopoietic 
system or bone (Clevers, 2006).  
 
1.1.3. The role of the canonical Wnt signalling pathway in tumorigenesis 
 
The initial hint that the canonical Wnt signalling pathway leads to tumor formation 
when aberrantly activated came from studies in colorectal cancer cell lines.  
 
The cell line SW480, carrying biallelic inactivating mutations in the tumor-suppressor 
gene APC, was characterized by a constitutively active TCF/LEF-dependent 
transcription that could be abrogated by an exogenous expression of APC (Morin et 
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al., 1997). This constitutive activation was shown to be dependent on the building of 
a β-catenin/TCF-4 complex, since exogenous expression of APC removed β-catenin 
from this complex and interfered with its transcriptional transactivation, indicating that 
inactivating APC-mutations inhibit the degradation process of β-catenin (Korinek et 
al., 1997).  
 
Sequencing of other colon carcinoma cell lines revealed that instead of biallelic 
mutations in APC (SW480), they carried monoallelic mutations in the N-terminal 
region of β-catenin at S45 (45, HCT116) and S33 (S33Y, SW48), thus at those 
residues that are phosphorylated by CK1α and GSK3β in the multiprotein 
degradation complex. Transfection of human embryonic kidney cells (HEK293) with 
plasmids expressing β-catenin mutated at these residues revealed an enhanced 
activity of TCF/LEF-dependent transcription as compared to the activity in those cells 
transfected with a wildtype β-catenin expression plasmid (Morin et al., 1997). Five 
years later, β-catenin mutations at those residues were shown to elicit an 
accumulation of β-catenin (Chan et al., 2002) and active, dephosphorylated β-catenin 
(Staal et al., 2002) in the nuclei of the cells analyzed, proving that mutations at these 
sites interfere with the phosphorylation events needed to target β-catenin for 
proteasomal degradation. 
 
Since these initial findings, the summary of numerous reports analyzing the mutation 
status of APC and β-catenin in colorectal cancer led to the estimation that 90% of 
colorectal cancers are characterized by inactivating mutations in the tumor-
suppressor gene APC (80%) or by activating mutations in the oncogene β-catenin 
(10%). β-catenin and/or APC mutations can also be found in tumors at other organs 
with variable frequency, such as hepatocellular carcinoma, gastric carcinoma or 
ovarian carcinoma (Giles et al., 2003). 
 
With axin, another component of the β-catenin degradation complex has been 
brough into context with the pathogenesis of cancer. Several studies reported 
mutations in this gene in ovarian carcinoma, hepatocellular carcinoma and 
medulloblastoma (Giles et al., 2003).  
 
Interestingly, there are only a few studies describing the involvement of Wnt ligands 
themselves in tumorigenesis. Ectopic expression of WNT1, WNT3A, WNT8 and 
WNT8B leads through accumulation of β-catenin to the transformation of mouse 
C57MG mammary epithelial cells, demonstrating their oncogenic potential in this cell 
culture (Wong et al., 1994). Transgenic mice overexpressing WNT1 develop 
mammary adenocarcinoma (Tsukamoto et al., 1988). In addition, the WNT2 gene 
was reported to be amplified in mammary tumors from mice (Nusse, 1992).  
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1.2. Description of the TGFβ pathway 
 
1.2.1. Description (Figure 4) 
 
The family of transforming growth factors (TGFβs) includes more than 30 factors that 
can be divided into two distinct groups (Figure 4). The first group compromises 
TGFβs themselves (TGFβ1, TGFβ2 and TGFβ3), activins, nodals, and myostatin, 
whereas the second is built up by bone morphogenic proteins (BMPs), anti-
muellerian hormone (AMH) and various growth and differentiation factors (GDFs).  
 
TGFβs are synthesized as a part of larger molecules, the pro-TGFβs, containing 
additionally the latency-associated proteins (LAP) which are cleaved from TGFβs in 
the Golgi apparatus but remain non-covalently bound to them. Extracellularly, latent 
TGFβ-binding proteins 1 and 2 (LTBP1/2) connect LAP-TGFβs to extracellular matrix 
(ECM) proteins. TGFβs can be released from this complex through the proteolytic 
activity of plasmin or matrix-metalloproteinases MMP2 and MMP9, or through 
integrins and thrombospondins (THBS). Two models are proposed how integrins 
contribute to the release of TGFβs: by simultaneously binding to both ECM-bound 
TGFβs and proteases, thereby improving the enzymatic cleavage, or by changing the 
conformation of ECM-bound TGFβ through the transmission of cell contraction 
forces. Thrombospondins associate with ECM-immobilized TGFβs and disrupt 
thereby the interaction between LAP and TGFβ. 
 
Once released, TGFβs activate signalling by bringing together two pairs of receptor 
serine/threonine kinases known as type I and type II receptors. The type III receptor 
(also called betaglycan) is a membrane-anchored proteoglycan that supports the 
binding of TGFβ to the type II receptor. TGFβs themselves bind to TGFβ receptors, 
activins and myostatin to activin receptors, nodals to nodal receptors, whereas 
BMPs, GDFs and AMH bind to BMP receptors. Bound by a TGFβ, the two type II 
receptors phosphorylate and activate the two type I receptors that then propagate the 
signal by phosphorylating mothers against decapentaplegic homolog (Smad) 
transcription factors. Receptors of the first group of TGFβs (TGFβs, activins, 
myostatin, nodals) phosphorylate and activate Smad2 and Smad3, whereas those of 
the second group (receptors for BMPs, AMH, and GDFs) phosphorylate and activate 
Smad1, Smad5 and Smad8. These receptor-activated Smads are called receptor 
substrate Smads (RSmads).  
 
After their activation, RSmads are characterized by a decreased affinity for the 
Smad-anchor for receptor activation (SARA), which in non-stimulated cells mediates 
the retention of the RSmads in the cytoplasm. Simultaneously, their affinity for 
Smad4 increases, leading to the building of a RSmads/Smad4 complex in the 
cytoplasm, its translocation into the nucleus and regulation of the transcription of 
various genes, including fibronectin (FN1), type I and III collagen, cyclin-dependent 
kinase inhibitors 1A (CDKN1A) or paired-like homeodomain transcription factor 2 
(PITX2) (Massague, 2008; Pohlers et al., 2009; Wipff and Hinz, 2008; Young and 
Murphy-Ullrich, 2004). 
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 Figure 4: The TGFβ signalling pathway. A detailed description is provided in the text.  
 
1.2.2. The role of the TGFβ signalling pathway in embryogenesis and adult 
organisms 
 
TGFβ plays a crucial role in the following processes: 
 
- Cell differentiation 
 
TGFβ promotes the differentiation of mesenchymal precursors into fibroblasts and 
myofibroblasts at the expense of adipocytes and osteoblasts. On the other hand, 
BMPs promote the differentiation of mesenchymal precursors toward the osteoblast 
lineage (in bone growth and repair) and of neural precursors into astroglia. BMPs 
also stimulate the self-renewal of embryonic stem cells. Activins, nodals, BMPs, AMH 
and GDFs are important during embryogenesis for proper stem cell differentiation, 
body axis formation, left-right symmetry and organogenesis (Massague, 2008). 
 
- Tissue homeostasis 
 
TGFβ is involved in tissue homeostasis by controlling the secretion of growth factors 
and directly activating cytostatic mechanisms (Massague, 2008). 
 
TGFβ was shown to constrain the secretion of growth factors such as hepatocyte 
growth factor (HGF) in stromal fibroblasts, thus reducing the paracrine stimulation of 
epithelial proliferation and inhibiting an epithelial hyperplasia in the prostate and 
forestomach (Bhowmick et al., 2004).  
 
It also directly exerts cytostatic effects on epithelial cells by inhibiting them to enter 
the synthesis (S)-phase of the cell cycle. TGFβ achieves that through transcriptional 
upregulation of the cyclin-dependent kinase inhibitors 1A (CDKN1A, p21; inhibits 
cyclin E/A – CDK2 complexes) and 2B (CDKN2B, p15; inhibits cyclin D - CDK4/6 
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complexes), the activation of CDKN1B (p27; inhibits inhibits cyclin E/A – CDK2 
complexes), and the transcriptional repression of c-myc (MYC), a key transcriptional 
inducer of cell proliferation (Massague, 2008).  
 
- Suppression of destructive immune and inflammatory reactions, promotion of    
  immune tolerance 
 
TGFβ is a key suppressor of destructive immune and inflammatory reactions, as 
proven by the lethal multifocal inflammatory disease arising in TGFβ1-deficient mice. 
As an immunosuppressive cytokine, TGFβ inhibits the development, proliferation and 
function of CD4+ T helper cells, CD8+ cytotoxic T cells, dendritic cells, natural killer 
cells and macrophages by the same cytostatic mechanism described for epithelial 
cells. In this way, TGFβ promotes immune tolerance that is especially important in 
the intestinal mucosa, where reactions to food antigens must be controlled. TGFβ1-
deficient mice show chronic submucosal inflammatory reactions that frequently lead 
to colon carcinoma (Massague, 2008). 
 
1.2.3. The role of the TGFβ signalling pathway in tumorigenesis 
 
Under normal conditions, the antiproliferative effects of TGFβ described in the 
previous section counter the effects of local mitogenic stimulation to maintain tissue 
homeostasis. In tumors caused by oncogene expression, TGFβ induces proapototic 
mechanisms. These mechanisms include the increased expression of death-
associated protein kinase 1 (DAPK1) and growth arrest and DNA damage inducible 
beta (GADD45B), which trigger apoptosis in a hepatoma cell line, and tumor necrosis 
factor receptor superfamily member 6 (TNFRSF6, FAS) as well as B-cell 
CLL/lymphoma 2 (BCL2)-like 11 (BCL2L11), which triggers apoptosis in gastric 
carcinoma cell lines (Massagué 2008).  
 
Hence, cells must circumvent these tumor-suppressive (cytostatic and apoptotic) 
effects of TGFβ in order to be able to transform into cancer cells. Studies in different 
cancer types revealed that tumor cells can use two alternative ways to achieve that: 
1) completely disrupt the TGFβ-signalling pathway by TGFβ receptor or Smad 
inactivating mutations or 2) selectively abrogate only the tumor-suppressive arm. By 
the latter mode, cancer cells may profit from the tumor promoting functions of TGFβ, 
e.g. its induction of production of mitogenic factors, its stimulating effect on epithelial-
mesenchymal transition (EMT), or using it as a shield against anti-tumor immunity 
(Massague, 2008). 
 
- Complete disruption of the pathway 
 
Biallelic truncating or kinase domain inactivating mutations of the type II TGFβ 
receptor gene (TGFBR2) occur during tumorigenesis of colon, gastric, ovarian, 
esophageal and head and neck carcinomas. Such mutations are highly associated 
with microsatellite instability, pointing towards the occurrence of preceding mutations 
in mismatch repair genes during the progression of disease (Levy and Hill, 2006).  
 
Whereas mutations in RSmads are infrequent in cancer, more than half of sporadic 
colorectal tumors and a high proportion of esophageal tumors carry mutations in 
Smad4 (Sjoblom et al., 2006).  
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In mouse models, tissue specific inactivation of TGFBR2 or Smad4 alone is not 
sufficient to cause malignant epithelial cell transformation, but induces hyperplasia 
(Forrester et al., 2005; Wang et al., 2005). In contrast, mutations in these two genes 
strongly accelerate the malignant progression of tumors initiated by oncogenic 
stimuli. Inactivation of TGFBR2 induces the progression of adenomatous polyps 
initiated by biallelic APC mutations into carcinomas (Biswas et al., 2004). 
 
In addition to its direct growth inhibitory effect on epithelial cells, TGFβ can control 
their proliferation and tumor formation by repressing the production of paracrine 
growth factors in stromal fibroblasts and inflammatory cells. Mice with a deletion in 
the TGFBR2 gene in fibroblasts develop hyperplasia of the adjacent epithelia. This 
effect was accompanied by an increase in the expression of hepatocyte growth factor 
(HGF) in the mutation-carrying fibroblasts (Bhowmick et al., 2004).  
 
- Selective abrogation of the tumor-suppressive arm 
 
Breast cancers, prostate cancers, gliomas, melanomas and hematopoietic 
neoplasias express normal TGFβ receptors and Smads, but are often characterized 
by a loss of function of the tumor-suppressive arm of the TGFβ signalling pathway 
(Massague, 2008).  
 
In a study analyzing cultures of breast cancer cells from pleural fluids of patients with 
metastatic disease, the authors showed that the cells did not respond to the addition 
of TGFβ with an increased expression of CDKN2B and a reduction of the level of c-
myc, despite retaining TGFβ induced growth factor expression. This was due to an 
overexpression of a dominant-negative form of a transcriptional co-activator / 
repressor of Smad that regulates the transcription of CDKN2B and c-myc (Gomis et 
al., 2006).  
 
Glioma cell cultures releaved from the tumor-suppressive effects of TGFβ increase 
their proliferation rate in response to TGFβ through the induction of platelet-derived 
growth factor B (PDGF-B) (Jennings and Pietenpol, 1998).  
 
In another study, cultures of metastatic breast cancer cells did not respond as 
normally to TGFβ with a repressed expression of inhibitor of differentiation/DNA 
binding 1 (ID1), but instead showed an increased expression (Padua et al., 2008). 
ID1 is known as being part of a lung metastasis gene expression signature and as 
being associated with relapse in estrogen receptor negative breast cancer cells (Minn 
et al., 2005). A xenograft model in mice using human breast cancer cell lines showed 
that the expressions of ID1 and ID3 was essential for the successful formation of 
metastases after the cells entered the lung parenchyma (Gupta et al., 2007). 
 
In addition, cells having lost the tumor-suppressive arm of the TGFβ-pathway allow 
TGFβ to function as a potent inducer of the epithelial-mesenchymal transition (EMT), 
a well coordinated process during embryonic development and a pathological feature 
of tumors. Cells undergoing EMT lose the expression of E-cadherin and instead 
express mesechymal markers such as αSMA and vimentin and acquire motility and 
invasive capacity. TGFβ induces EMT by a combination of Smad-dependent 
transcriptional events and transcription-independent effects on cell-adhesion 
complexes (Massague, 2008).  
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1.3. Description of the PI3K-AKT signalling pathway 
 
1.3.1. Description (Figure 5) 
 
The phosphatidylinositol 3-kinase (PI3K) - v-akt murine thymoma viral oncogene 
homolog 1 (AKT) pathway gets activated by binding of growth factors to their cognate 
receptor protein tyrosine kinases (RTKs) (Figure 5). RTKs include the receptors for 
the epidermal growth factor (EGFR and v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, ERBB2), platelet-derived growth factor (PDGFR), fibroblast 
growth factor (FGFR), insulin-like growth factor 1 (IGF1R), vascular endothelial 
growth factor (VEGFR), hepatocyte growth factor (HGFR, MET) and interleukins 
(ILR).  
 
Upon activation, RTKs interact and phosphorylate adapter proteins such as insulin 
receptor substrate (IRS) and growth factor receptor bound protein protein 2 (GRB2)-
associated binding protein (GAB) that in turn activate PI3K. This kinase then 
phosphorylates membrane-bound phosphatidylinositol-3,4-diphosphate (PIP2) to 
produce phosphatidylinositol-3,4,5-triphosphate (PIP3). Phosphatase and tensin 
homologue deleted on chromosome 10 (PTEN) is an antagonist of PI3K that 
removes the phosphate group on PIP3, thus attenuating PI3K/AKT signalling activity. 
PIP3 binds to AKT and phosphoinositol-dependent kinase 1 (PDK1), whereupon 
PDK1 phosphorylates and activates AKT. An additional phosphorylation of AKT by 
PDK2 is required for its full activation.  
 
Upon activation, AKT phosphorylates a number of downstream targets in the 
cytoplasm and the nucleus which regulate various cellular functions. It stimulates 
protein synthesis by phosphorylating the protein tuberin within the tuberous sclerosis 
complex 2 (TSC2) and by inhibiting the activity of the TSC1-TSC2 complex, leading  
to the accumulation and activation of the serine/threonine kinase mechanistic target 
of rapamycin (MTOR), which in turn phosphorylates target genes to enhance protein 
synthesis. It also stimulates glycogen synthesis by the phosphorylation and 
inactivation of GSK3β, known to phosphorylate and repress the activity of the 
glycogen synthase.  
 
On the other hand, AKT stimulates cell proliferation via phosphorylation and inhibition 
of GSK3β and members of the forkhead box (FOXO) family of transcription factors. 
By inactivating GSK3β, AKT reduces GSK3β-mediated phosphorylation and 
inactivation of cyclin D1 (CCND1) and c-myc (MYC), two central components for cell 
cycle progression. In addition, inhibition of GSK3β leads to an accumulation of β-
catenin and an activation of TCF-dependent transcription, whereupon the 
transcription of CCND1 and MYC is increased. Through the phosphorylation and 
inhibition of FOXO transcription factors, the PI3K-AKT pathway represses the 
expression of the cell cycle progression inhibitor cyclin-dependent kinase inhibitor 
CDKN1B (p27, inhibits cyclin E/A – CDK2 complexes), thus further accelerating 
proliferation.  
 
Other target genes of the FOXO transcription factors repressed by the PI3K-AKT 
pathway represent the Fas ligand (FASLG), a member of the tumor necrosis factor 
super family (TNFSF6), and B-cell CLL/lymphoma 2 like 11 (BCL2L11), both known 
for their apoptosis-inducing capacity. Apoptosis gets further repressed by the AKT-
dependent phosphorylation and activation of mouse double minute 2 homolog 
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(MDM2) that binds to and inhibits the key apoptosis-inducing transcription factor p53. 
Additionally, AKT phosphorylates and inhibits BCL2-associated agonist of cell death 
(BAD), an inducer of apoptosis through its inhibitory effect on the anti-apoptotic 
protein BCL2L1 (BCL-XL). Finally, AKT induces the activity of the anti-apoptotic 
signalling pathway nuclear factor of kappa light chain gene enhancer in B-cells 
(NFκB), by phosphorylating and activating the inhibitor of NFκB kinase (IKK) that in 
turn phosphorylates and inhibits the inhibitor of NFκB (NFKBI).  
 
The PI3K-AKT pathway is also a potent inducer of angiogenesis. Hypoxia inducible 
factor 1 α (HIF1A) is the major regulator of vascular endothelial growth factor (VEGF) 
transcriptional activation. AKT induces the transcription of HIF1A via phosphorylation 
and activation of MDM2 and ribosomal protein S6 kinase polypeptide 1 (RPS6KB1) 
(Jiang and Liu, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The PI3K-AKT signalling pathway. A detailed description is provided in the text.  
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1.3.2. The role of the PI3K-AKT pathway in embryogenesis and adult organisms 
 
Due to its impact on central cellular processes such as proliferation, apoptosis, 
angiogenesis, protein synthesis and glycogen synthesis, the PI3K-AKT pathway 
plays a fundamental role in both embryogenesis and adult organisms (Suzuki et al., 
2008).  
 
1.3.3. The role of the PI3K-AKT pathway in tumorigenesis 
 
By positively influencing cell proliferation, angiogenesis and protein synthesis, but 
negatively regulating apoptosis, it is not surprising that a plethora of studies have 
associated a deregulated PI3K-AKT pathway activity with the pathogenesis of 
several cancers.  
Most upstream of the pathway, gene alterations have been reported for EGFR, 
ERBB2 and IGF1R in glioblastoma, lung, ovarian, prostate, cervical endometrial, 
liver, esophageal, and breast cancers. 
 
An amplification of the gene copy number of PI3KCA, the gene encoding the p110α 
catalytic subunit of PI3K, was observed with different frequencies in ovarian, cervical, 
gastric and breast cancers. In addition, somatic constitutively activating mutations of 
the PI3KCA gene were found in colorectal, gastric, breast and lung cancer, and in 
glioblastomas.  
 
PI3K regulatory subunits dimerize with the catalytic subunits and inhibit PI3K activity. 
Deletions and somatic mutations of the gene PIK3R1 coding for the p85α regulatory 
subunit were found in glioblastoma, colon and ovarian cancers.  
 
The antagonist of PI3K, PTEN, is frequently mutated or lost in glioblastomas, breast 
cancer, kidney and uterine endometrioid carcinomas, lung cancer and melanomas.  
 
AKT gene amplification has been observed in a number of human cancers, including 
gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, 
pancreatic, ovarian, and breast cancers (reviewed by Jiang and Liu, 2008). 
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1.4. The process of wound healing 
 
Wound healing is a complex biological process that is dependent on interactions 
between a variety of cells, including fibroblasts, myofibroblasts, smooth muscle cells, 
endothelial cells, keratinocytes and immune cells. These interactions are 
orchestrated by numerous growth factors, including EGF, FGF, IGF, PDGF, TGF, 
VEGF and keratinocyte growth factor (KGF). TGFβ1 and platelet-derived growth 
factor (PDGF), released from platelets at the site of injury, provide the early signals 
for the activation and infiltration of macrophages and neutrophils. These cell types in 
turn secrete the next wave of growth factors essential for the proliferative phase of 
wound healing. This phase is characterized by an increased proliferation of 
fibroblasts, their transformation into myofibroblasts and invasion of the wounded 
tissue. There, they deposit an abundant collagen-rich matrix needed to support 
further cell ingrowth and to stabilize and contract the wound (granulation tissue).  
 
TCF-dependent transcription plays a crucial role in the proliferative phase of wound 
healing. Wounding of a transgenic TCF-reporter mouse (TCF-reporter construct 
containing the lacZ gene downstream of a c-fos minimal promoter and three 
consensus TCF-binding motifs) revealed an increased expression of β-catenin 
(Western blot) and activity of TCF-dependent transcription in the proliferating 
fibroblasts during the proliferative phase of wound healing as compared to fibroblasts 
in unwounded tissues. Wounding of a transgenic mouse expressing a tetracyclin-
inducible N-terminal mutated β-catenin (S33, S37, T41, S45 to A, thus resistant to 
CK1α and GSK3β-mediated phosphorylation and degradation by the proteasome) 
leads to the formation of a larger, hypercellular wound characterized by an excessive 
collagen deposition and a higher fibroblast proliferation rate, as compared to the 
wound in a wildtype-β-catenin animal (Cheon et al., 2002). Analyses of human re-
excision scar tissue after a previous biopsy and samples from hyperplastic cutaneous 
wounds revealed increased levels of α-SMA, type III collagen (RT-PCR) and β-
catenin (Western blot) as compared to normal surrounding tissues. β-catenin was 
shown to be located in the cytoplasm and nucleus (IHC) and correlated with the level 
of S9-phospho-GSK3β, the functionally inhibited form of GSK3β (Western blot). The 
expression of fibronectin and matrix-metalloproteinase 7 (MMP7), two known target 
genes of the canonical Wnt signalling pathway, were elevated as compared to the 
expression in the surrounding normal tissues (RT-PCR) (Cheon et al., 2005).  
 
Dermal fibroblast cell cultures of the TCF-reporter mouse revealed an increased 
expression of β-catenin and S9-phospho-GSK3β (Western blot) and an enhanced 
activity of TCF-dependent transcription after treatment with TGFβ1 or EGF. 
Subcutaneous injection of TGFβ1 or EGF before wounding of the TCF-reporter 
mouse led to an increased activity of TCF-dependent transcription in the proliferating 
fibroblasts during the proliferative phase of wound healing resulting in a larger wound 
as compared to the situation after wounding of an untreated TCF-reporter mouse 
(Cheon et al., 2004). Those data suggest that TGFβ1 and EGF induce the 
proliferative phase of wound healing by transactivating the canonical Wnt signalling 
pathway.  
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2. Introduction 
 
 
In the following section, a general clinical, histological and phenotypical description of 
fibromatoses will be provided, in addition to an introduction into the signalling 
pathways known to be involved in the pathogenesis of these diseases. Finally, some 
results of published gene expression analyses aimed to compare fibromatoses with 
normal fibrous tissues will be presented. 
 
 
2.1. General description 
 
Fibromatoses are invasively growing fibrous lesions lacking the capacity to 
metastasize. Depending on the sites of involvement, they are categorized as 
aggressive and superficial fibromatoses. Aggressive (synonyms: desmoid-type or 
deep) fibromatoses occur extra- and intra-abdominally in the connective tissues 
surrounding muscles, whereas the predilection sites for superficial fibromatoses are 
the palmar and plantar aponeuroses.  
 
The pathogenesis of aggressive fibromatosis is a proven neoplastic process derived 
from a single cell that acquired a growth advantage (Alman et al., 1997b; Li et al., 
1996). In contrast, whether superficial fibromatosis represents a clonal neoplastic 
process or rather a polyclonal reactive process is controversially discussed. Two 
studies report a polyclonal pattern of X chromosome inactivation of the androgen 
receptor gene in tissues from two respectively eight women with superficial 
fibromatosis, thus favoring a polyclonal reactive process (Chansky et al., 1999; Wang 
and Zhu, 2006). Other papers describe clonal chromosomal aberrations at variable 
frequencies in patients suffering from this disease, supporting the notion of a 
neoplastic process (Dal Cin et al., 1999; De Wever et al., 2000).  
 
Histologically, the tumors are characterized by spindle-shaped cells embedded in an 
abundant collagen-rich extracellular matrix (Figure 6). The tumor cells exhibit 
features of myofibroblasts as indicated by the expression of bundles of smooth 
muscle actin (α-SMA) microfilaments similar to those found in smooth muscle cells. 
For the superficial fibromatoses, three distinct histological phases can be 
distinguished. In the proliferative phase, a nodular lesion develops through the 
proliferation of myofibroblasts that express α-SMA. In the involutional phase, the cells 
within the nodule realign themselves with the lines of stress in the tissue, therefore 
building cords. The residual phase corresponds to the complete disappearance of the 
nodules, leaving behind cords of relatively acellular, scar-like tissue (3).        
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   a) 
    
   b) 
  
 
 
 
 
 
 
 
 
 
 
 
   Figure 6: Histology of an aggressive (a) and superficial (b) fibromatosis.  
   Hematoxylin-Eosin (HE)-staining.  
 
Numerous reports in the literature using different experimental techniques such as 
gene expression array, immunohistochemistry, in situ hybridization or Western blot 
describe an overexpression of a vaste array of different components of the 
extracellular matrix (ECM) in fibromatoses.  
 
There are only a few etiologic factors contributing to the pathogenesis of aggressive 
fibromatoses, namely surgical or physiological trauma and radiation. For superficial 
fibromatoses, an association with trauma, alcohol, smoking, manual work, diabetes 
mellitus, epilepsy and rheumatoid disease has been described.  
 
 
2.2. Signalling pathways known to be involved in the pathogenesis of 
fibromatoses 
 
2.2.1. The canonical Wnt signalling pathway 
 
- Data derived  from primary tumors 
 
Aggressive fibromatoses occur as sporadic lesions (80%) or as part of the disease 
familial adenomatous polyposis (FAP, 20%), an inherited disorder characterized by 
the development of adenomatous polyps of the colon (Tejpar et al., 2005). 
Extracolonic manifestations of FAP include, among others, aggressive fibromatosis. 
FAP is caused by a germ-line mutation in the tumor suppressor gene APC (Kinzler et 
al., 1991). The role of APC in the canonical Wnt pathway has been described in 
Section 1.1.1. Polyps and aggressive fibromatosis in FAP patients show a biallelic 
inactivation of the APC gene, by additionally acquiring a somatic mutation on the 
second allele. In sporadic aggressive fibromatoses, biallelic inactivation of the APC 
Blood vessel
Tumor cells
(involutional phase)
Tumor cells
(proliferative phase)
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gene by somatic mutations was found in ~20% of cases (Tejpar et al., 1999). In 
addition, ~52% to ~85% of the reported cases of sporadic aggressive fibromatoses 
demonstrate monoallelic mutations in the oncogene β-catenin (Lazar et al., 2008; 
Tejpar et al., 1999), whereas ~26% of cases remain as yet unexplained (Tejpar et al., 
1999).  
 
Immunohistochemical analysis of β-catenin expression however, revealed increased 
cytoplasmic expression and nuclear accumulation in most if not all aggressive 
fibromatoses analyzed, regardless of their mutation status (Alman et al., 1997a; 
Carlson and Fletcher, 2007; Ferenc et al., 2009; Lazar et al., 2008; Montgomery et 
al., 2001; Saito et al., 2001; Tejpar et al., 1999). Thus the cause for this phenomenon 
in the remaining ~26% of sporadic tumors remains to be elucidated (Figure 7).  
 
Like aggressive fibromatoses, also superficial fibromatoses show increased 
cytoplasmic and nuclear accumulation of β-catenin (Carlson and Fletcher, 2007; 
Montgomery et al., 2001; Varallo et al., 2003), but neither β-catenin (Montgomery et 
al., 2001; Varallo et al., 2003) nor APC (Montgomery et al., 2001) is mutated in these 
tumors. The etiology of this tumor is unknown (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
    
   Figure 7: APC and β-catenin mutation status of fibromatoses 
 
The intensity of nuclear β-catenin expression in sporadic aggressive fibromatoses 
was shown to inversely correlate with the incidence of recurrence after surgical 
resection (Lazar et al., 2008). In sporadic aggressive fibromatoses caused by β-
catenin mutations, ~59% occur at codon 41 (T41A) and ~41% at codon 45 (33%: 
S45F; 8%: S45P), both known target sites for CK1α (S45) and GSK3β (T41) 
mediated phosphorylation. Interestingly, the five-year recurrence-free survival was 
significantly poorer in 45F-mutated desmoids (23%) versus either 41A (57%) or non-
mutated tumors (65%) (Lazar et al., 2008). 
 
- Data derived from cell cultures (aggressive fibromatosis) 
 
That aberrant canonical Wnt signalling pathway activity contributes to the formation 
of aggressive fibromatosis was underlined by experiments performed in primary cell 
cultures derived from this tumor. In the following studies, the authors did not prove 
the tumoral origin of their cell cultures used by mutation analysis. 
 
In a first report, the experiments were based on cell cultures derived from aggressive 
fibromatoses carrying somatic APC mutations. Transient transfection of these cells 
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with an APC expression plasmid led to a decrease of the β-catenin protein level 
(Western blot) and a diminished proliferation rate. A concomitant expression of a 
constitutive active form of β-catenin (N89-β-catenin, missing the N-terminal 
phosphorylation sites) abrogated the negative effect of APC on the cellular 
proliferation, indicating that APC controls the proliferation of these cells through its 
contribution to the degradation process of β-catenin (Li et al., 1998). In a subsequent 
study, 6 primary cell cultures of aggressive fibromatoses (tumor tissues: 3x β-catenin 
mutation, 1x biallelic APC-mutation, 2x no APC/β-catenin mutation) were reported to 
be characterized by a pronounced nuclear accumulation of β-catenin in comparison 
to normal control fibroblasts (Tejpar et al., 1999). In a further study, the authors claim 
that primary cell cultures from aggressive fibromatoses carrying APC- and β-catenin-
T41A-mutations, respectively, are characterized by an increased TCF-dependent 
transcriptional activity as compared to cell cultures of normal fibroblasts. In addition, 
they could show that in aggressive fibromatoses, β-catenin transactivates TCF-
dependent transcription by binding to TCF3, not TCF4, thus contrasts to the situation 
in colon carcinoma (Tejpar et al., 2001). 
 
- Data derived from animal models (aggressive fibromatosis) 
 
Two mouse models further prove the context of a deregulated canonical Wnt-
signalling pathway and the formation of aggressive fibromatoses. In the first, 
heterozygous APC+/APC1638N animals develop aggressive fibromatoses in addition 
to attenuated polyposis (Smits et al., 1998). In the other model, transgenic mice 
expressing a tetracyclin-inducible mutated β-catenin (S33, S37, T41, S45 to A) 
develop in 75% of the cases aggressive fibromatoses after 3 month of transgene 
induction, in addition to gastrointestinal polyps in all mice. Primary fibroblast cultures 
of transgenic mice revealed an increased proliferation, motility and invasiveness as 
compared to normal fibroblasts and are able to form tumors in nude mice (Cheon et 
al., 2002). 
 
2.2.2. The TGFβ signalling pathway (superficial fibromatosis) 
 
In contrast to aggressive fibromatosis a vast literature exists describing the 
involvement of the TGFβ signalling pathway in the pathogenesis of superficial 
fibromatosis.  
 
- Data derived from primary tumors 
 
Immunohistochemical analyses revealed an overexpression of TGFβ1 and TGFβ2 in 
tissues of superficial fibromatoses as compared to normal palmar fasica 
(Badalamente et al., 1996; Berndt et al., 1995), a finding that was confirmed for 
TGFβ2 using microarray gene expression analyses (Lee et al., 2006; Zhang et al., 
2008). 
 
An attempt to correlate single nucleotide polymorphisms (SNPs) in the genes coding 
for the three TGFβ receptors with the risk of superficial fibromatosis formation 
provided no conclusive evidence for their contribution to the pathogenesis of 
superficial fibromatoses (Bayat et al., 2003a). In a subsequent study, the same 
author found a significant correlation between a single SNP (a guanine instead of an 
adenine in the 3’ untranslated region) in the gene coding for the transcription factor 
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kruppel-like factor 6 (KLF6) and an increased risk of developing superficial 
fibromatosis. Since KLF6 is known for its positive impact on the expression of 
TGFβ1, the observed SNP may contribute to a deregulated TGFβ signalling pathway 
activity leading to the formation of superficial fibromatosis (Bayat et al., 2003b). 
 
- Data derived  from cell cultures 
 
In primary cell cultures derived from superficial fibromatoses, the expression of 
TGFβ2 was shown to be upregulated as compared to normal control fibroblasts 
(ELISA) (Kuhn et al., 2002).  
 
A positive effect of TGFβ1 and TGFβ2 on the proliferation of superficial fibromatosis 
cell cultures was also reported, whereas cultures of normal fibroblasts did not react 
(Badalamente et al., 1996). This result was indirectly proven by an experiment 
showing that TGFβ2 increases the DNA and protein synthesis in cultures of 
superficial fibromatoses (Kuhn et al., 2001). 
 
TGFβ1 enhanced the proportion of αSMA-positive myofibroblasts in cultures of 
superficial fibromatoses, whereas normal fibroblast did not respond (IHC) (Bisson et 
al., 2003). In another cell culture experiment, TGFβ1 was shown to induce the 
expression of αSMA, type I collagen and plasminogen activator inhibitor type I (PAI-
1) (Western blot) (Kopp et al., 2006).  
 
Primary tumor cells of superficial fibromatoses contracted fibroblast-populated 
collagen lattices (FPCL) significantly more than control fibroblasts (Kuhn et al., 2002). 
The addition of TGFβ1 (Bisson et al., 2009) and TGFβ2 (Tse et al., 2004) increased 
the generated force in both control and diseased cells.  
 
The above listed results demonstrate that TGFβ is able to induce in normal 
fibroblasts all features that characterize superficial fibromatoses: enhanced 
proliferation, differentiation into myofibroblasts, increased production of extracellular 
matrix proteins and increased contractile force, pointing towards a decisive role of the 
TGFβ signalling pathway in the pathogenesis of superficial fibromatosis.  
 
In all reports describing experiments with primary cell cultures from superficial 
fibromatoses, a formal proof for the tumoral origin of the cell cultures used was not 
provided. 
 
- Data derived from animal models 
 
The TGFβ-dependent induction of extracellular matrix proteins was also analyzed in 
nude rats implanted with human superficial fibromatosis tissue pieces. Explanted 
tissues perfused with TGFβ2 showed an increased synthesis of type-I and type-III 
collagen (IHC) as compared to tissues perfused with a vehicle control (Kuhn et al., 
2001).  
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2.3. Microarray-based gene expression analyses 
 
Some microarray-based gene expression studies have been performed to compare 
the gene expression of aggressive and superficial fibromatoses with the one in 
reference fibrous tissues. An overview of numerously represented biological 
functions of the differentially expressed genes should be provided for each study in 
this section. A more detailed description of these reports will be supplied in Section 
5.2.2. 
 
2.3.1. Aggressive fibromatosis 
 
In one study, the gene expression of four primary cell cultures of aggressive 
fibromatoses was compared with the one in cultures of normal fascia using Affymetrix 
microarrays. They report the differential expression of components of biological 
processes known to be involved in the pathogenesis of cancer, such as the 
overexpression of genes regulating proliferation and proteolysis of extracellular 
matrix (ECM) components (Denys et al., 2004b). 
 
In a second study, 12 tissue samples of aggressive fibromatoses were compared 
with 16 non-neoplastic tissues, including normal adipose, cervix, colon, kidney, liver 
lung, using Affymetrix-based gene expression analysis. Among the upregulated 
genes several ECM components and growth factors could be found (Skubitz and 
Skubitz, 2004).   
 
2.3.2. Superficial fibromatosis 
 
On Atlas microarrays, the gene expression of 6 tissues of palmar superficial 
fibromatoses was compared with the one in 2 unaffected palmar fascia. Some of the 
differentially expressed genes are involved in the ECM and in cell-cell adhesion (Pan 
et al., 2003) (Pan et al., 2003).  
 
Using the same Atlas microarrays, the authors of another study compared tissues of 
9 palmar nodular superficial fibromatoses with adjacent normal tendon. ECM 
components and genes involved in collagen degradation could be found among the 
upregulated genes (Qian et al., 2004). 
 
On cDNA arrays, tissues derived from 4 palmar cord superficial fibromatoses, four 
adjacent control fascia and three control palmar fascia were compared with each 
other. Among the upregulated genes in superficial fibromatoses, some ECM 
components and genes regulating proliferation could be detected (Lee et al., 2006).  
 
The gene expression in 6 primary cell cultures derived from palmar superficial 
fibromatoses was compared with the one in 6 normal palmar fascia fibroblast cell 
cultures using 2 different microarray platforms (GE Code LinkTM and IlluminaTM). 
Some ECM components were downregulated in diseased cultures on both platforms 
(Satish et al., 2008). 
 
Another cDNA microarray analysis compared the gene expression of palmar cord 
superficial fibromatosis tissues with the one in adjacent control fascia. Differentially 
expressed genes represent ECM components and regulators of proliferation (Zhang 
et al., 2008). 
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2.4. Aim of the study 
 
The aim of the experiments described in this chapter was to study the differential 
gene expression between primary tissues of aggressive and superficial fibromatoses 
and reference fibrous tissues using microarray analyses. Whereas microarray-based 
gene expression studies between fibromatoses and reference tissues and between 
corresponding cell cultures have already been published in the literature (Section 
2.3.), a direct comparison between those two phenotypically and histologically similar 
tumors has not been performed, yet. Therefore, this study, in addition to reveal new 
deregulated genes in aggressive and superficial fibromatosis, should contribute to 
the understanding of common and distinctive mechanisms being responsible for the 
pathogenesis of aggressive and superficial fibromatoses.   
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3. Materials and methods 
 
 
3.1. Collection and characterization of fibromatoses and reference fibrous 
tissues 
 
3.1.1. Tissue asservation 
 
Tissue samples used in this study were obtained immediately after surgery or at 
autopsy and flash frozen in liquid nitrogen. They were stored in Hank’s balanced salt 
solution at -80°C. Two types of dense connective tissues were used as samples for 
the reference fibrous tissue pool: fascia lata (1 sample) and patellar ligament (4 
samples). They were derived from patients without fibromatoses. For the preparation 
of paraffin blocks, pieces of tissues were fixed in 4% buffered formalin (pH 7.0) for at 
least 24 hours. Subsequently, they were dehydrated and embedded in paraffin using 
the TBS88 Paraffin Embedding System TBS88 (Medite, Nunningen, Switzerland). 
 
3.1.2. Histology 
 
For histological examination, paraffin sections were cut and stained with hematoxylin-
eosin (H&E) in an automated staining system (Tissue stainer COT20, Medite, 
Nunningen, Switzerland). Histological diagnosis was performed by two independent 
pathologists. Additionally, all cases were reviewed before their use in this study. All 
tumors exhibited the characteristic histological picture of fibromatoses (Section 2.1., 
Figure 6).  
 
 
3.2. Agilent 60mer-oligo microarrays 
 
3.2.1. Total RNA extraction 
 
Total RNA was extracted from cryopreserved tissues using the TriReagent 
(Molecular Research Center, Inc., Cincinnati, OH) protocol. Frozen tissue specimens 
were cut into 100 m sections on a cryostat and maintained on dry ice. A total of ~ 25 
sections were homogenized in 4 ml of TriReagent solution using a Rotor Stator 
homogenizer. The first, the middle and the last section were stained with H&E to 
monitor the composition of the samples (exclusion of those with exuberant 
vascularisation or fat tissue). Resulting total RNA was quantified using the NanoDrop 
ND-1000 spectrophotometer (Agilent Technologies, Santa Clara, CA). 
 
3.2.2. RNA quality control 
 
The integrity and purity of the extracted total RNA was monitored using the RNA 
6000 Nano Kit on the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). 
Only samples characterized by a 28S:18S rRNA ratio of greater than 1.0 and a flat 
baseline on the electropherogram above and below the 18S and 28S rRNA peaks 
were further used. 
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3.2.3. Experimental setup 
 
Equal amounts of total RNA derived from 10 individual aggressive fibromatoses 
(Figure 8, framed red circles) and 15 individual superficial fibromatoses (framed blue 
circles) were pooled to generate an aggressive fibromatosis RNA pool and a 
superficial fibromatosis RNA pool. As a reference, RNA samples from five fibrous 
tissues were pooled (framed black circles). In addition, RNA samples derived from 5 
single aggressive fibromatoses and 1 single superficial fibromatosis were hybridized 
on individual arrays (additional red and blue circles). 
 
 
 
 
 
 
 
 
 
 
Figure 8: Experimental setup for the Agilent microarray  
gene expression analyses 
 
3.2.4. Labelling, hybridization and data processing 
 
44K Agilent 60mer-oligo micorarrays (Agilent Technologies, Santa Clara, CA) were 
used in this study. Instead of annealing the oligos fully synthesized onto the 
microarray surface, they are synthesized base-by-base in microdroplets using 
phosphoramidite chemistry. In phosphoramidite synthesis reactions, the reactive 
sites on the nucleotides are blocked with chemical groups that can be removed 
selectively. This allows to add one base at a time to the oligo chain in a single droplet 
in a very controlled manner. After the first base is printed, the chemical group that 
protects the 5’ hydroxyl group on the nucleotide is removed and oxidized to activate 
it, enabling it to react with the 3’ group on the next nucleotide. In between each step, 
the excess reagents are washed away. This process of ‘printing’ a nucleotide 
followed by washing, the remove of the protecting chemical group and the addition of 
the new nucleotide is repeated 60 times to synthesize the 60mer-oligos present on 
these microarrays. ~41’000 60mer-oligos are synthesized on each array, 
representing over 33’000 known and unknown human genes. 
 
The first round of experiments involving the pooled RNA samples were performed 
using the dual color labelling and competitive hybridization method. This approach 
reduced experimental variability by allowing two biological samples to be directly 
compared with each other on the same microarray.  
 
The second round of experiments aimed to analyze the six individual tumor samples 
was performed after the one color labelling and hybridization technology was 
improved, newly including the RNA Spike-In feature for monitoring the quality of the 
workflow from sample amplification and labelling to the final data processing. For 
each array, a quality control report could be generated based on the Spike-In 
informations. This allows to obtain data that are even more reliable and comparable 
then the ones generated with the dual color method. To be able to compare data 
Aggressive 
fibromatoses
Superficial
fibromatoses
Reference
fibroblastic tissues
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generated by the two different methods, the pooled RNA samples were analyzed by 
the one color approach as well.  
 
- Dual color labelling, competitive hybridization and data processing 
 
The necessary experimental steps for the dual color labelling reaction were 
performed according to the ‘Agilent Low RNA Input Fluorescent Linear Amplification 
Kit, Version 2.0 (August 2003)’ protocol, whereas for the hybridization procedure, the 
instructions were obtained from the ‘Agilent 60-mer oligo microarray processing 
protocol, Version 2.1 (April 2004)’ (Agilent Technologies, Santa Clara, CA). Figure 9 
depicts the relevant experimental steps. Briefly, after the reverse transcription of the 
mRNA (0.75 g total RNA) into cDNA and the production of the second cDNA strand, 
probes were labelled by an in vitro transcription step using different fluorescent dye-
labeled CTPs for the two samples to be compared, namely Cy3-CTPs and Cy5-
CTPs. 1 g of each labelled cRNA was simultaneously hybridized on an Agilent 44K 
60mer oligo microarray. A spot with a light green signal indicates exclusive binding of 
Cy3-labeled cRNA, a light red Cy5-labeled cRNA binding, and a light yellow signal 
arises from an equivalent mixture of the two. Microarrays were scanned using the 
DNA Microarray scanner (Agilent Technologies, Santa Clara, CA). The Feature 
Extraction Software v8.1 (Agilent Technologies, Santa Clara, CA) was used to 
calculate the ratio of the signals Cy5/Cy3 for each spot to detect differentially 
expressed genes between the two samples. Additionally, this software delivers for 
each spot a specific p-value, indicating the trustability of the calculated differential 
gene expression. This p-value is based on the ratio Cy5/Cy3 and on a platform-
specific error model that simulates all the errors that can occur from the initial reverse 
transcription to the final calculations. Further data processing, including selection of 
differentially expressed genes to be further analyzed and hierarchical clustering, was 
performed using the Rosetta Resolver software (Rosetta Inpharmatics LLC, Seattle, 
WA). For functional annotation of selected genes, the software Database for 
Annotation, Visualization and Integrated Discovery (DAVID; http:// david.abcc.ncifcrf. 
gov) was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Work flow for dual color labelling, competitive hybridization,  
and data processing of Agilent 44K 60mer-oligo microarrays 
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- One color labelling, hybridization and data processing 
 
The basic principles for this approach are the same as outlined for the dual color 
method, with the difference, that one color (Cy3)-labelled cRNA of just one single 
sample was hybridized per array. In comparison to arrays used for competitive 
hybridization, these slides contained four single microarrays, therefore their name 
‘4x44K 60mer-oligo microarray’ (Agilent Technologies, Santa Clara, CA). The 
experimental procedure followed the ‘One color microarray-based gene expression 
analysis, Version 1.0.1 (February 2006)’ protocol obtained from the company. 
Instead of the Agilent Feature Extraction Software version 8.1, the new version 8.5 
(Agilent Technologies, Santa Clara, CA) was used, that allows to generate the quality 
control report. Again, the final processing of data was performed on the Rosetta 
Resolver software and the functional annotation of selected genes using the software 
DAVID. 
 
 
3.3. Real-time reverse transcription PCR (RT-PCR) 
 
Total RNA was isolated from cryopreserved tissues as mentioned in Section 3.2.1. 
and its quality determined according to the description in Section 3.2.2. Equal 
amounts (5 g) were reversely transcribed into cDNA with the oligo(dT)18 primer and 
Transcriptor Reverse Transcriptase using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche, Basel, Switzerland). The Roche LightCycler 480 system with 
384 well plates was used (Roche, Basel, Switzerland). Amplification of a selected 
gene was based on the use of the Human Universal Probe Library (Roche, Basel, 
Switzerland) that is build up by 90 different fluorescein-labeled probes. Together with 
two gene specific primers (Mycrosynth GmbH, Balgach, Switzerland) those 90 
probes cover 99% of the human transcriptome. For each gene analyzed, a standard-
curve was calculated first, using 50, 10, 2, 0.4, 0.08 and 0.016 ng input cDNA. Based 
on these standard-curves, their relative expressions to the house-keeping gene 
GAPDH were determined in each sample using 10 ng input cDNA. A reaction (20 l) 
included: 5 l (2 ng/l) cDNA, 0.1 l forward primer (100 M → 0.5 M final 
concentration), 0.1 l reverse primer (100 M → 0.5 M final concentration), 0.2 l 
probe (10 M → 0.1 M final concentration), 10 l LightCycler 480 Probes Master 
(Roche, Basel, Switzerland) and 4.6 l H2O. The probe number and corresponding 
primer sequences for each gene analyzed were derived from the free-access, web-
based ProbeFinder Software (www.universalprobelibrary.com). Table 1 lists up the 
Universal Probe Library number and corresponding forward and reverse primer 
sequences for all genes analyzed by real-time RT-PCR.  
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Gene Probe # Forward primer Reverse primer
ANGPTL7 44 TGTATAAGCTTCCTCCTGATGACTT CGCCTGAAGTCTCCATGTC
APCDD1 90 CACCGAGTTCGTGTTCAAAG TCCCGTTGAAGACGTTGAG
ASPN 72 CATGGTGGATAACTTCTACTTTTAGGA GAAGGGTTTGGCAGAGCAC
CDC73 33 CAAATGCAGCACCTGTGG CCTTTGAATCTTTCCTGATCGT
CTHRC1 57 GGGAGGTGGTGGACCTGTA CAGGTGTACCCGGAATGC
DCD 43 AGCCCTGGTCTGTGCCTAT GCTTCATGGCAAGGGTTC
DKK3 29 TATCACATCTGTGGGAGACGAA TCCTCGTCGATGATGCACT
FGF18 60 ATGAACCGCAAAGGCAAG GAACACACACTCCTTGCTGGT
FRZB 31 TCATGGGCTATGAAGATGAGG CGATCCTTCCACTTCTCAGCTA
FST 69 AAAGCACTCCGGATCTTGC AGGAAAGCTGTAGTCCTGGTCTT
FZD2 1 GGTGTCGGTGGCCTACAT GAGAAGCGCTCGTTGCAC
FZD5 64 CCCAGCCTGTCGCTAAACT GGATTCCAGGGAAAGGACTC
GAPDH 45 TCCACTGGCGTCTTCACC GGCAGAGAGATGACCCTTTT
GJA1 88 GCCTGAACTTGCCTTTTCAT CTCCAGTCACCCATGTTGC
IGFBP6 52 ACCATCGAGGCTTCTACCG CACACCAGCAGGGACCTC
IGFBP7 51 CTGTCCTCATCTGGAACAAGG TGAATGGCCAGGTTGTCC
LRP5 32 GAACCTGCTGACCTGTGGAG CTGTGGCACATGCAAACTG
MMP3 36 CAAAACATATTTCTTTGTAGAGGACAA TTCAGCTATTTGCTTGGGAAA
MT1X 15 CTTCTCCTTGCCTCGAAATG AGGCACAGGAGCCAACAG
NODAL 52 GGCGAGTGTCCTAATCCTGT GCTGGTAACGTTTCAGCAGACT
PITX2 89 CTCCTGAGAGCCGAAAAGAG CCCCTGCTGGCTTTTATCTT
POSTN 41 GAACCAAAAATTAAAGTGATTGAAGG TGACTTTTGTTAGTGTGGGTCCT
PRG4 87 AAGAACTGGCCTGAATCTGTGT CAGGGCACTTCTGTACAGGTT
ROR2 17 CCCCTCATTAACCAGCACAA TTCCCAAACCGGTCCTCT
SFRP4 88 GCCTGAAGCCATCGTCAC CCATCATGTCTGGTGTGATGT
SPARC 85 ACCCGCTTTTTCGAGACC CAAGATCCTTGTCGATATCCTTC
TGFBI 19 TGGTCCATGTCATCACCAAT TGCAAGTTCATCCCCTCTTT
THBS4 57 CTACCGCTGGTTCCTACAGC GAGCCTTCATAAAATCGTACCC
TNMD 35 GATTAAAGTGATTCCTGAATTTTCTGA AAGTTGTGGTAATTTCTTCATTCTCA
WISP2 13 CACCTCCTGGCCTTCTCC GGGGCAGGTACATGGTGT
WNT5A 71 TGGTGCCTGATATCTCAAAGTC GAGAAATAACCCCAGAGTAAACTGTAA
 
Table 1: Universal Probe Library number and sequences of the forward and reverse primers for 
LightCycler real-time RT-PCR of the selected 30 genes 
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4. Results 
 
 
4.1. Selection of differentially expressed genes on Agilent microarrays 
 
Starting with 41’000 oligos present on each Agilent array, about 6’000 showed a 
significant (p-value < 0.01) up- and downregulation in both tumor pools compared to 
the reference tissue pool, whereas roughly only half of them distinguished the two 
tumor pools from each other (Figure 10). Thus the two tumors showed less 
differences in gene expression than the two tumors individually compared to the 
reference tissue. To reduce the number of genes to be further analyzed, more 
stringent criteria were applied, namely, besides the mentioned p-value, a fold-change 
of at least two, an absolute expression level of more than 500, and the selection of 
only known genes. This considerably reduced the numbers of genes in each 
comparison (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Processing of the array data to select for the  
most significant differentially expressed known genes 
 
 
4.2. Verification of microarray results using real-time RT-PCR 
 
To verify microarray results, the differential expression of the following genes was 
analyzed using real-time RT-PCR (Table 2). Their selection based on the criteria 
biological function, ratio and absolute expression level. Some biologically interesting 
genes were selected, although their ratios and absolute expression levels were 
rather low. This allowed to judge the ratio and absolute expression level, over which 
a gene trustworthily can be considered as differentially expressed.  
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Biological function Genes
Wnt signalling
APCDD1, CDC73, DKK3, FGF18, FRZB, 
FZD2, FZD5, GJA1, LRP5, ROR2, SFRP4, 
WISP2
TGFβ signalling FST, NODAL, PITX2, SPARC, TGFBI
PI3K-AKT signalling IGFBP6, IGFBP7
Extracellular matrix associated
ASPN, DCD, MMP3, POSTN, PRG4, 
SPARC, THBS4, TNMD
Angiogenesis ANGTPL7, CTHRC1
 
         Table 2: Selected genes for real-time RT-PCR analysis 
 
The differential expression of all 30 genes tested could be confirmed. Both the 
pooled RNA samples that were used for the microarray experiments, as well as each 
individual tumor sample alone needed to build up these pools were analyzed. As a 
representative example, Figure 11 depicts the results obtained for the Wnt-signalling 
ligand WNT5A. It is highly overexpressed in aggressive fibromatoses compared to 
superficial fibromatoses and reference fibrous tissues, as seen in the microarray 
studies where pooled samples were analyzed (a), as well as in the real-time RT-PCR 
experiments, where additionally the expression in each individual sample alone was 
measured (b). 
 
 
 
 
  
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Expression of WNT5A in aggressive and superficial fibromatoses  
and reference fibrous tissues as measured using Agilent microarrays (a) and  
real-time RT-PCR (b). Aggr pool: aggressive fibromatosis RNA pool, Super pool: 
superficial fibromatosis RNA pool, Ref pool: reference fibrous tissue RNA pool. 
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4.3. Hierarchical clustering of the selected genes 
 
Using the Rosetta Resolver software, the logarithmus of the ratio of tumor (both 
pools and individual samples) to reference fibrous tissue (pool) for the selected 2’429 
genes were hierarchically clustered. This approach allows to detect similarities in the 
profile of selected differentially expressed genes (y-axis) in individual samples (x-
axis) (Figure 12). The color red indicates that the selected gene is overexpressed in 
the corresponding tumor tissue as compared to the reference fibrous tissue, whereas 
the color green signifies the reverse situation. Black corresponds to no differential 
expression of the selected gene between the tumor and the reference fibrous tissue.  
 
The similarities in the gene expression profiles between the different tumors are 
exemplified by the bar-tree on top of the figure, connecting the tumors with each 
other. The lower the level of the horizontal bar that connects two tumors or groups of 
tumors with each other, the higher is the similarity of their gene expression profiles, 
and vice versa. Thus the gene expression profile of the superficial fibromatosis pool 
(Super pool) is most similar to the one of the single individually analyzed superficial 
fibromatosis (Super2). On the other hand, the two samples of superficial 
fibromatoses show the highest divergence in their expression profiles in comparison 
to the six samples of aggressive fibromatoses. Therefore, this clustering analysis 
clearly indicates that the samples of the two tumors can be separated from each 
other by comparing their expression profiles for the 2’429 selected genes. 
 
             
 
Figure 12: Hierarchical clustering of the 2’429 selected genes  
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4.4. Functional annotation of the selected genes 
 
For functional annotation of the selected 2’429 genes, a biostatistical analysis was 
performed using the database DAVID (Database for Annotation, Visualization and 
Integrated Discovery). DAVID generates chart lists of biological processes that are 
statistically overrepresented in the uploaded list of genes. Thus the biological 
processes in the chart list that have a p-value of less then 0.01 are those processes 
that have more representatives in the uploaded gene list then expected by random 
selection, and therefore most likely differentiate the tissues being analyzed from each 
other.  
 
4.4.1. Biological processes commonly differentiating the two tumors from the 
reference fibrous tissue 
 
Figure 13 depicts the biological processes being overrepresented in the list of genes 
commonly differentiating the two fibromatoses from the reference fibrous tissues. 
 
     
 
Chart list of biological processes commonly differentiating  
the two tumors from the reference fibrous tissues
Biological process # genes p-value
ECM-receptor interaction 52 2.81E-04
Focal adhesion 48 0.001
p53 signaling pathway 8 0.001
One carbon pool by folate 11 0.001
Glycolysis / Gluconeogenesis 9 0.001
Insulin signaling pathway 10 0.001
TGF-β-signaling pathway 17 0.003
Fatty acid metabolism 12 0.004
Cell cycle 29 0.004
Glycerolipid metabolism 14 0.005
mTOR signaling pathway 7 0.005
Glycerophospholipid metabolism 11 0.005
Colorectal cancer 10 0.006
ErbB signaling pathway 7 0.006
Wnt signaling pathway 12 0.007
Starch and sucrose metabolism 7 0.007
Complement and coagulation cascades 6 0.008
Glycan structures - biosynthesis 1 5 0.008
Adherens junction 17 0.008
Regulation of actin cytoskeleton 13 0.009
Cell adhesion molecules (CAMs) 9 0.010
 
Figure 13: DAVID-generated chart list of biological processes significantly  
(p-value < 0.01) overrepresented among the uploaded list of genes commonly  
differentiating the two tumors from the reference fibrous tissues. In the  
column “# genes” are the numbers of genes listed that belong to the  
corresponding biological processes. The color codes are explained in the text. 
 
Due to a personal rating of the biological significance of the represented processes in 
context of the pathogenesis of fibromatoses and the fusions of certain processes 
including the same group of genes, some adaptations were performed in this chart 
list. 
 
Both the processes ‘Wnt signalling pathway’ and ‘Colorectal cancer’ (color code blue) 
contain genes involved in the Wnt signalling pathway and were therefore fused in the 
single process ‘Wnt signalling pathway’. In the adapted list of biological processes 
(Figure 14), it is ranked at position 1, due to its crucial role in the pathogenesis of 
fibromatoses (Section 2.2.1.). The TGFβ signalling pathway (color code violet) was 
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moved at position 2, because of its impact on the formation of superficial 
fibromatoses (Section 2.2.2.). The processes categorized using the color code 
orange (p53 signalling pathway, Glycolysis/Gluconeogenesis, Insulin signalling 
pathway, mTOR signalling pathway, ErbB signalling pathway) have one feature in 
common: the PI3K-AKT pathway (Section 1.3.). Therefore, their genes were 
summarized in one process and named after this pathway that is mainly unknown so 
far concerning a contribution to the pathogenesis of fibromatoses. It was set at 
position 3. The extracellular matrix components present among the genes belonging 
to the two processes standing up most in the list (color code pink: ECM-receptor 
interaction, Focal adhesion) were fused in the separate new process ‘Extracellular 
matrix (ECM)’ at position 4, since the DAVID-based functional categorization does 
not contain the separate process ‘ECM’. The prominent appearance of ECM 
components in histological sections of fibromatoses has been pointed at in Section 
2.1. All genes listed among the two pink processes were unified in the process ‘ECM-
receptor interaction’ at position 5. These genes play a central role in the regulation of 
migration and invasion of tumor cells. The same holds true for the two processes in 
red (Adherens junction, Cell adhesion molecules (CAMs)) at the bottom of the list. 
Their genes were joined under the process name ‘Adherens junction and cell 
adhesion molecules (CAMs)’ at position 6. The process ‘Cell cycle’ in dark green, 
fundamental in context of tumorigenesis, was renamed into the more general term 
‘Proliferation’ and set at position 7. The process ‘Regulation of actin cytoskeleton’ 
(color code brown) represents an important process in the pathogenesis of 
fibromatoses, since tumor cells show features of myofibroblasts, expressing bundles 
of smooth muscle actin (α-SMA) microfilaments similar to those found in smooth 
muscle cells (Section 2.1.). It was renamed into ‘Cytoskeleton’ and listed at position 
8. The process ‘complement and coagulation cascades’ (light green) was ordered 
under the same term at position 9. In addition, the category ‘Others’ at position 10 
includes all those selected differentially expressed genes that could not be assigned 
to a biological process but were characterized by high differential expressions and/or 
high absolute expression levels. The processes listed in Figure 13 in grey (One 
carbon pool by folate, Fatty acid metabolism, Glycerolipid metabolism, Starch and 
sucrose metabolism, Glycan structures – biosynthesis 1) are all in context of 
metabolism/anabolism, known to be specifically enhanced in tumors. Since our focus 
of interest was laid on the processes mentioned before, they were excluded from 
Figure 14. 
 
The numbers of genes belonging to those ten biological processes were expanded 
by the manual addition of differentially expressed genes that were not recognized by 
the automated DAVID-based functional annotation.  
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Adapted chart list of biological processes commonly differentiating the two tumors from
the reference fibrous tissues
upregulated downregulated
1) Wnt signalling pathway 18 6
2) TGFβ signaling pathway 15 8
3) PI3K-AKT signalling pathway 5 10
4) Extracellular matrix (ECM) 53 14
5) ECM-receptor interaction 46 7
6) Adherens junction and cell adhesion molecules (CAMs) 20 14
7) Proliferation 58 59
8) Cytoskeleton 21 5
9) Complement and coagulation cascades 5 10
10) Others 23 22
# of genes in the tumors Biological process
 
Figure 14: Adapted list of biological processes significantly overrepresented among the uploaded list 
of genes commonly differentiating the two tumors from the reference fibrous tissues. The numbers of 
genes being commonly upregulated and downregulated in the two tumors as compared to the 
reference fibrous tissues are indicated for each biological process. The color codes are explained in 
the text. 
 
Comprehensive informations about all differentially expressed genes (name, ratio, p-
value, absolute expressions) categorized into the ten biological processes can be 
found in Gene list A in the Appendix.  
 
4.4.2. Biological processes differentiating the two tumors from each other 
 
Figure 15 depicts the biological processes being overrepresented in the list of genes 
differentiating the two tumors from each other. 
 
     
Chart list of biological processes differentiating  
the two tumors from each other
Biological process # genes p-value
Focal adhesion 28 2.53E-05
ECM-receptor interaction 27 6.43E-05
Complement and coagulation cascades 10 1.59E-04
Wnt signaling pathway 11 0.001
Colorectal cancer 7 0.003
Regulation of actin cytoskeleton 12 0.004
TGFβ-signaling pathway 7 0.007
Cell adhesion molecules (CAMs) 5 0.009
 
Figure 15: DAVID-generated chart list of biological processes significantly  
(p-value < 0.01) overrepresented among the uploaded list of genes differentiating  
the two tumors from each other. In the column “# genes” are the numbers  
of genes listed that belong to the corresponding biological processes.  
The color codes are explained in the text in Section 4.4.1. 
 
A comparison of the colors representing the biological processes in Figure 13 and 
Figure 15 demonstrates that all biological processes that are significantly 
overrepresented in the list of genes differentiating the two tumors from each other 
(Figure 15), are also significantly overrepresented in the list of genes commonly 
differentiating the two tumors from the reference fibrous tissue (Figure 13). On the 
other hand, unique among the processes commonly differentiating the two tumors 
from the reference fibrous tissue (Figure 13) are the two processes PI3K-AKT 
signalling pathway and proliferation. This indicates that most differentially expressed 
genes belonging to these two processes and differentiating aggressive fibromatosis 
from reference fibrous tissue are identical to the ones distinguishing superficial 
fibromatosis from reference fibrous tissue. In addition, it suggests that those genes 
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must be regulated in a quantitatively (concerning ratio value) similar way in both 
tumors.  
 
The chart list in Figure 15 was adapted according to approach described in Section 
4.4.1. Afterwards, the numbers of genes belonging to those processes were 
expanded by manual addition. The resulting adapted chart list is depicted in Figure 
16. To allow a direct comparison with Figure 14, Figure 16 includes the processes 
PI3K-AKT signalling pathway and proliferation as well, although they are not 
statistically overrepresented in the list of genes differentiating the two tumors from 
each other.  
 
       
Adapted chart list of biological processes differentiating the two tumors from each other
Super > Aggr Super < Aggr
1) Wnt signalling pathway 8 21
2) TGFβ signaling pathway 10 9
3) PI3K-AKT signalling pathway 6 3
4) Extracellular matrix (ECM) 22 17
5) ECM-receptor interaction 20 16
6) Adherens junction and cell adhesion molecules (CAMs) 10 6
7) Proliferation 31 25
8) Cytoskeleton 14 19
9) Complement and coagulation cascades 15 7
10) Others 14 24
Biological process # of genes  
 
Figure 16: Adapted list of biological processes significantly overrepresented among the uploaded list 
of genes differentiating the two tumors from each other. The numbers of genes being upregulated in 
their expressions in superficial fibromatosis as compared to aggressive fibromatosis (Super > Aggr) 
and vice versa (Super < Aggr) are indicated for each biological process. The color codes are 
explained in the text in Section 4.4.1. 
 
Comprehensive informations about all differentially expressed genes (name, ratio, p-
value, absolute expressions), categorized according to the biological processes, can 
be obtained from Gene list B in the Appendix.  
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4.4.3. Single genes differentiating the two tumors from each other 
 
Within Gene list B in the Appendix, those genes where selected that outstandingly 
differentiate the two tumors from each other by a high ratio and a highly significant p-
value. 16 candidate genes that fulfil these selection criteria are presented in Figure 
17. The proteins encoded by those genes represent attractive candidates for marker 
proteins differentiating the two tumors using immunohistochemical analysis. 
 
a) Upregulated in superficial fibromatosis
Gene Name Ratio p-value Super Aggr
ANGPTL7 Angiopoietin-like 7 66.9 0 12779 192
TNMD Tenomodulin 24.0 0 5597 233
DCD Dermcidin 22.7 0 12859 566
PRG4 Proteoglycan 4 18.7 0 4629 246
DMRT2 Doublesex and mab-3 related transcription factor 2 12.3 0 1886 154
MYOC Myocilin, trabecular meshwork inducible glucocorticoid response 10.5 0 3158 300
NOV Nephroblastoma overexpressed gene 8.9 0 9069 1018
THBS4 Thrombospondin 4 8.0 2.8026E-45 67565 8263
b) Upregulated in aggressive fibromatosis
Gene Name Ratio p-value Aggr Super
FGA Fibrinogen, A alpha polypeptide 29.0 2.51E-15 1879 94
ACTN2 Actinin, alpha 2 18.0 0 1129 64
AREG Amphiregulin (schwannoma-derived growth factor) 14.7 0 8751 598
APCDD1 Adenomatosis polyposis coli down-regulated 1 13.2 0 26641 2023
TTN Titin 9.2 0 5824 633
PITX2 Paired-like homeodomain transcription factor 2 8.4 0 3142 373
GREM1 Gremlin 1 homolog, cysteine knot superfamily 7.1 9.75E-30 5990 823
WNT5A Wingless-type MMTV integration site family, member 5A 7.0 0 5937 849
Absolute expression
Absolute expression
 
Figure 17: Single genes outstandingly differentiating the two tumors from each other. a) 8 genes 
upregulated in superficial fibromatosis, b) 8 genes upregulated in aggressive fibromatosis. The color 
code categorizes the genes into the following biological processes: dark green = proliferation, pink = 
extracellular matrix (ECM), black = others, brown = cytoskeleton, violet = TGFβ signalling pathway, 
light green = complement and coagulation cascades, orange = PI3K-AKT signalling pathway, blue = 
Wnt signalling pathway. The genes are ordered according to the ratio tumor vs. tumor.  
 
ANGPTL7, TNMD and DCD are coding for secreted proteins known to induce 
proliferation of certain cell types. PRG4 and NOV are components of the extracellular 
matrix (ECM). DMRT2 encodes a transcription factor of uncertain function. MYOC, 
ACTN2 and TTN are components of the cytoskeleton. The ECM component THBS4 
and the transcription factor PITX2 are involved in the TGFβ signalling pathway. FGA 
is a major component in the process of blood coagulation. AREG is a member of the 
epidermal growth factor (EGF) family known to activate the PI3K-AKT signalling 
pathway. The Wnt-ligand WNT5A activates the Wnt signalling pathway, whereas 
GREM1 and APCDD1 represent two target genes of this pathway.   
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4.5. Detailed analysis of signalling pathways 
 
Since besides the Wnt, the TGFβ and the PI3K-AKT pathway, no other signalling 
pathway proved to be significantly overrepresented among the lists of differentially 
expressed genes, the following detailed analyses in this section will focus on these 
three pathways.  
 
The individual differentially expressed components within each pathway were 
grouped according to their functions into pathway activity inducers, inhibitors and 
pathway target genes. This approach aimed to deduce informations about differential 
activities within these pathways between the tissues analyzed. The restrictions of this 
approach are discussed in Section 5.4. 
 
The presented data are based on the analysis of pooled tissue samples.  
 
4.5.1. The canonical Wnt signalling pathway 
 
The components of the canonical Wnt signalling pathway were introduced in detail in 
Section 1.1., whereas its involvement in the pathogenesis of fibromatoses was 
explained in Section 2.2.1. 
 
- Aggressive fibromatosis vs. reference fibrous tissue 
 
Figure 18 depicts the components of the canonical Wnt signalling pathway being 
differentially expressed between aggressive fibromatosis and reference fibrous 
tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Between aggressive fibromatosis (Aggr) and reference fibrous tissue (Ref) differentially 
expressed genes of the Wnt signalling pathway. Components represented as yellow rectangles are 
overexpressed, whereas those symbolized as red rectangles are downregulated in the tumor.  
(+) pathway activity inducer, (-) pathway activity inhibitor, (*) FZD2 is repressed in its expression by an 
active Wnt pathway, (°) target genes that have not been established in human tissues, yet.  
 
In the tumor tissue, more pathway activity inducers are overexpressed (10) than in 
the reference tissue (6). On the other hand, 8 pathway activity inhibitors are 
upregulated in their expression in the tumor, whereas no inhibitors at all could be 
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found to be overexpressed in the reference tissue. This could reflect the 
establishment of a negative feedback loop. The number of differentially expressed 
target genes reflecting an increased activity of this pathway in the tumor (21) is 
clearly higher than in the reference fibrous tissue (9).  
 
- Superficial fibromatosis vs. reference fibrous tissue 
 
Figure 19 shows the same approach, but applied on the comparison between 
superficial fibromatosis and reference fibrous tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Between superficial fibromatosis (Super) and reference fibrous tissue (Ref) differentially 
expressed genes of the Wnt signalling pathway. Components represented as yellow rectangles are 
overexpressed, whereas those symbolized as red rectangles are downregulated in the tumor.  
(+) pathway activity inducer, (-) pathway activity inhibitor, (°) target genes that have not been 
established in human tissues, yet.  
 
In superficial fibromatosis and reference tissue, similar numbers of pathway inducers 
are overexpressed (4 and 3, respectively), whereas more inhibitors are upregulated 
in the tumor (5 vs. 1). Again, the overexpressed inhibitors may indicate a negative 
feedback loop. An analysis of differentially expressed target genes reveals that more 
of them are upregulated in the tumor tissue (14) as compared to the reference fibrous 
tissue (7), suggesting an increased activity of this pathway in superficial fibromatosis 
as compared to the reference tissue.  
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- Aggressive and superficial fibromatosis vs. reference fibrous tissue 
 
The analysis of canonical Wnt pathway components commonly deregulated between 
the two tumors and the reference fibrous tissue is summarized in Figure 20.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Genes of the Wnt signalling pathway commonly differentiating aggressive and superficial 
fibromatoses from reference fibrous tissue. Components represented as yellow rectangles are 
overexpressed, whereas those symbolized as red rectangles are downregulated in both tumors.  
(+) pathway activity inducer, (-) pathway activity inhibitor, (°) target genes that have not been 
established in human tissues, yet.  
 
48% (24/50) of the pathway components found to be deregulated in aggressive 
fibromatosis are also deregulated in superficial fibromatosis. On the other hand, even 
77% (24/31) of the differentially expressed genes detected in superficial fibromatosis 
behave in the same way in aggressive fibromatosis. This reflects prominent 
similarities in the deregulation of the Wnt signalling pathway in both aggressive and 
superficial fibromatosis. 
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- Hierarchical clustering of the canonical Wnt pathway target genes 
 
Figure 21 depicts a hierarchical clustering of the 35 canonical Wnt signalling pathway 
target genes found to be differentially expressed between the three tissue pools. All 
gene expression arrayed samples, also the six individually analyzed tumors (Aggr1, 
Aggr2, Aggr4, Aggr6, Aggr7, Super2), were included in this clustering. The dominant 
color red indicates that the majority of the target genes are overexpressed in the 
tumors in comparison to the reference fibrous tissue. Whereas in Figure 12, the 
analysis of all 2’429 selected genes delivered two clusteres separating aggressive 
fibromatosis from the superficial fibromatosis samples, such a strict separation 
disappears when clustering just the 35 Wnt pathway target genes. 
                             
                                
Figure 21: Hierarchical clustering of canonical Wnt target genes  
differentially expressed between the three tissue pools 
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4.5.2. The TGFβ signalling pathway 
 
The components of the TGFβ signalling pathway were introduced in detail in Section 
1.2., whereas its involvement in the pathogenesis of superficial fibromatosis was 
explained in Section 2.2.2. 
 
- Aggressive fibromatosis vs. reference fibrous tissue 
 
Figure 22 depicts the components of the TGFβ signalling pathway being differentially 
expressed between aggressive fibromatosis and reference fibrous tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Between aggressive fibromatosis (Aggr) and reference fibrous tissue (Ref) differentially 
expressed genes of the TGFβ signalling pathway. Components represented as yellow rectangles are 
overexpressed, whereas those symbolized as red rectangles are downregulated in the tumor.  
(+) pathway activity inducer, (-) pathway activity inhibitor, (*) MYC is repressed in its expression by an 
active TGFβ signalling pathway. 
 
More pathway activity inducers are overexpressed in aggressive fibromatosis (10) 
than vice versa (6).  In the tumor and the reference fibrous tissue, similar numbers of 
pathway inhibitors (4 vs. 3) are upregulated. The number of differentially expressed 
TGFβ signalling target genes reflecting an increased activity of this pathway is higher 
in the tumor (10) than in the reference tissue (2).  
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- Superficial fibromatosis vs. reference fibrous tissue 
 
Figure 23 presents the TGFβ pathway components that are transcriptionally 
deregulated between superficial fibromatosis and reference fibrous tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Between superficial fibromatosis (Super) and reference fibrous tissue (Ref) differentially 
expressed genes of the TGFβ signalling pathway. Components represented as yellow rectangles are 
overexpressed, whereas those symbolized as red rectangles are downregulated in the tumor.  
(+) pathway activity inducer, (-) pathway activity inhibitor, (*) MYC is repressed in its expression by an 
active TGFβ signalling pathway. 
 
Among the differentially expressed pathway activity inducers, 8 are upregulated in 
superficial fibromatosis, whereas only 4 of them in the reference fibrous tissue. In 
both tissues, an equal number of pathway inhibitors (2) are overexpressed. The 
number of differentially expressed TGFβ signalling target genes reflecting an 
increased activity of this pathway in the tumor (9) is higher than in the reference 
tissue (5). 
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- Aggressive and superficial fibromatosis vs. reference fibrous tissue 
 
Between both tumors and the reference fibrous tissue commonly deregulated 
components of the TGFβ pathway are presented in Figure 24.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
Figure 24: Genes of the TGFβ signalling pathway commonly differentiating aggressive and superficial 
fibromatoses from reference fibrous tissue. Components represented as yellow rectangles are 
overexpressed, whereas those symbolized as red rectangles are downregulated in both tumors.  
(+) pathway activity inducer, (-) pathway activity inhibitor, (*) MYC is repressed in its expression by an 
active TGFβ signalling pathway. 
 
66% (23/35) of the genes found to be deregulated in aggressive fibromatosis are 
accordingly deregulated in superficial fibromatosis. And even 77% (23/30) of the 
differentially expressed genes detected in superficial fibromatosis behave in the 
same way in aggressive fibromatoses. This reflects prominent similarities in the 
deregulation the TGFβ signalling pathway in both aggressive and superficial 
fibromatosis. 
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4.5.3. The PI3K-AKT signalling pathway 
 
The components of the PI3K-AKT signalling pathway were introduced in detail in 
Section 1.3. There, it is explained that the central component of this pathway, AKT, is 
not a transcription factor, but a serine/threonine-kinase modulating the activities of a 
plethora of downstream targets on the protein level by phosphorylation. These 
proteins in turn transmit the signal on the protein level to other target proteins or 
regulate the transcription of target genes (in the case of transcription factors), 
resulting in an increasing branching and expansion of the downstream signalling 
pathways. There exists no defined, central transcription factor in the PI3K-AKT 
pathway, as it is the case in the Wnt (TCF) or the TGFβ (Smad) signalling pathways, 
but a crosstalk to a complex network of individual signal transduction routes. 
Therefore, informations about differential activities in the PI3K-AKT pathway between 
different tissues can not be deduced by simply enumerating a limited number of 
differentially expressed target genes. For this reason, the examination of the pathway 
activity was restricted in this study to the enumeration of differentially expressed 
pathway activity inducers and inhibitors upstream of AKT. Downstream of AKT, the 
focus was laid on the analysis of the biological functions of the differentially 
expressed pathway components in terms of a possible contribution of these genes to 
the pathogenesis of fibromatoses.  
 
- Aggressive fibromatosis vs. reference fibrous tissue 
 
Figure 25 depicts the components of the PI3K-AKT pathway that are differentially 
expressed between aggressive fibromatosis and reference fibrous tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Between aggressive fibromatosis (Aggr) and reference fibrous tissue (Ref) differentially 
expressed genes of the PI3K-AKT signalling pathway. Components represented as yellow rectangles 
are overexpressed, whereas those symbolized as red rectangles are downregulated in the tumor.  
(+) pathway activity inducer, (-) pathway activity inhibitor.  
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in the tumor as compared to the reference fibrous tissue. Therefore, a differential 
activation of the PI3K-AKT pathway in aggressive fibromatosis can not be deduced. 
 
Downstream of AKT, three components known for their apoptosis-inducing activity 
are downregulated in aggressive fibromatosis as compared to the reference fibrous 
tissue, namely an inhibitor of NFκB (NFKBIA), the transcription factor forkhead box 
O1A (FOXO1A) and the tumor protein p53 (TP53). 
 
In addition, some genes involved in the regulation of proliferation are differentially 
expressed in aggressive fibromatosis. Cyclin / cyclin-dependent kinase complex 
inhibitor 1B (CDKN1B), an inhibitor of cell cycle progression, is downregulated, 
whereas cyclin D1 (CCND1) and β-catenin, two inducers of proliferation, are 
upregulated in the tumor. On the other hand, c-myc (MYC), another stimulator of 
proliferation, is downregulated in aggressive fibromatosis as compared to the 
reference fibrous tissue.  
 
The major inducer of angiogenesis, hypoxia-inducible factor 1 α subunit (HIF1α), is 
more highly expressed in the tumor. 
 
- Superficial fibromatosis vs. reference fibrous tissue 
 
The differentially expressed pathway components between superficial fibromatosis 
and reference fibrous tissue are shown in Figure 26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Between superficial fibromatosis (Super) and reference fibrous tissue (Ref) differentially 
expressed genes of the PI3K-AKT signalling pathway. Components represented as yellow rectangles 
are overexpressed, whereas those symbolized as red rectangles are downregulated in the tumor.  
(+) pathway activity inducer, (-) pathway activity inhibitor.  
 
Upstream of AKT, similar numbers of pathway activity inducers and inhibitors are 
overexpressed in the tumor (6 inducers, 1 inhibitor) and the reference fibrous tissue 
(5 inducers, 2 inhibitors).  
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Most of the genes found to be deregulated downstream of AKT in aggressive 
fibromatosis behave equally in superficial fibromatosis. The exceptions represent β-
catenin and HIF1α that do not appear any more in the list of deregulated genes in 
superficial fibromatosis. Instead, the HIF1α target gene VEGF is downregulated in 
superficial fibromatosis as compared to the reference fibrous tissue. 
 
- Aggressive and superficial fibromatosis vs. reference fibrous tissue 
 
Between both tumors and the reference fibrous tissue commonly deregulated 
components of the PI3K-AKT pathway are presented in Figure 27.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Genes of the PI3K-AKT signalling pathway commonly differentiating aggressive and 
superficial fibromatoses from reference fibrous tissue. Components represented as yellow rectangles 
are overexpressed, whereas those symbolized as red rectangles are downregulated in both tumors.  
(+) pathway activity inducer, (-) pathway activity inhibitor.  
 
15 of the 23 (65%) PI3K-AKT components found to be deregulated in their 
expressions in aggressive fibromatosis were in the same direction modulated in 
superficial fibromatosis. On the other hand, 15 out of 21 (71%) components that 
proved to be differentially expressed in superficial fibromatosis behaved in the same 
way in aggressive fibromatosis. This demonstrates a pronounced overlap of the 
differentially expressed PI3K-AKT pathway components in aggressive and superficial 
fibromatosis. 
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5. Discussion 
 
 
5.1. Summary of the results 
 
Using Agilent microarray gene expression analysis, 2’429 genes could be determined 
differentiating aggressive and superficial fibromatoses from reference fibrous tissue 
or the two tumors from each other.  
 
A hierarchical clustering analysis of those genes built two clusters, separating the 
samples of aggressive fibromatosis from the ones of superficial fibromatosis.  
 
Functional annotation of selected genes commonly differentiating the two tumors 
from the reference fibrous tissue revealed the following biological processes to be 
statistically overrepresented: Wnt signalling pathway, TGFβ signalling pathway, PI3K-
AKT signalling pathway, extracellular matrix (ECM), ECM-receptor interaction, 
adherens junction and cell adhesion molecules (CAMs), proliferation, cytoskeleton, 
complement and coagulation cascades.  
 
Interestingly, with the exceptions of the PI3K-AKT signalling pathway and 
proliferation, all the biological processes being overrepresented in the list of genes 
commonly differentiating the two tumors from the reference tissue, are also 
significantly overrepresented in the list of genes differentiating the two tumors from 
each other.   
 
The differentially expressed components of the Wnt, TGFβ and PI3K-AKT signalling 
pathways were analyzed in detail. Although some restrictions of the validity of the 
resulting statements must be considered, some interesting hints could be deduced 
from these analyses.  
 
The numbers of regulated pathway activity inducers and/or pathway target genes 
indicated that aggressive and superficial fibromatoses are characterized by increased 
signalling activities in the Wnt and TGFβ pathways as compared to the reference 
fibrous tissue.  
 
In addition, the overexpression of numerous Wnt pathway activity inhibitors in 
fibromatoses suggests that a negative feedback loop mechanism may try to 
counterbalance an excessive Wnt signalling pathway activity in both tumors. 
 
Concerning the PI3K-AKT pathway upstream of AKT, the analysis of pathway 
inducers and inhibitors did not reveal a differential activity of this pathway between 
the tissues. Vast branching and expansion of the PI3K-AKT pathway downstream of 
AKT make an analysis of a limited number of pathway target genes impossible. 
Nevertheless, the analysis of the biological processes the differentially expressed 
components downstream of AKT are involved in revealed some findings relevant for 
the pathogenesis of fibromatoses. In both fibromatoses, genes inducing apoptosis 
were found to be downregulated, whereas differentially expressed genes regulating 
proliferation favour an induction of proliferation. Therefore, differentially expressed 
PI3K-AKT components downstream of AKT may contribute to the pathogenesis of 
fibromatoses.    
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For all three pathways, there is an extensive overlap of differentially expressed 
components in aggressive and superficial fibromatoses. 
 
 
5.2. Comparison of own results with data published in the literature 
 
A literature screen was performed to find genes that are reported to be differentially 
expressed between fibromatoses and reference fibrous tissues or – very rarely – 
between aggressive and superficial fibromatoses.  
 
5.2.1. Consensus with published data 
 
Overall, 234 genes could be gathered. The statements for 93 (40%) of them could be 
confirmed by our own data. Those 93 genes are summarized in the Gene list C in the 
Appendix. There, a link to the corresponding literature, a short description of the 
experiment and a comparison to the own results can also be obtained. That the 
differential expression of 93 out of 234 genes could be confirmed is much more than 
expected when comparing two randomly selected lists of differentially expressed 
genes: our 2’429 selected genes represent roughly only 10% of all known genes 
present on the Agilent microarray used. Therefore, a random selection would yield an 
overlap of 10% at maximum. This high agreement with literature data is even more 
astonishing, when thinking about the different techniques that were applied to 
produce these data, ranging from analyses on the mRNA level (Microarray, RT-PCR, 
Northern blot), through studies done on protein extracts (Western blot, 2D-gel-
electrophoresis and mass-spectrometry), to experiments using cell culture 
supernatants (ELISA). The high consensus to the literature data therefore underlines 
the trustworthiness of our data.  
 
The published results of expression analyses for 141 genes could not be confirmed 
by our own data. They are summarized in the Gene list D in the Appendix, including 
a link to the corresponding literature, a short description of the experiment and a 
comparison to the own results. 
 
5.2.2. Genes belonging to nine biological processes 
 
In Section 4.4.1., the functional annotation of selected genes commonly 
differentiating the two tumors from the reference fibrous tissue revealed that nine 
biological processes are statistically overrepresented (Figure 28, Own data.). Most of 
the genes reported in the literature to differentiate aggressive or superficial 
fibromatosis from reference fibrous tissue belong to these nine biological processes 
as well (Figure 28, Literature, total).  
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total Denys Skubitz Pan Qian Lee Satish Zhang
1) Wnt signalling pathway 24 13 3 2 0 1 1 0 0
2) TGFβ signaling pathway 23 23 0 5 0 2 2 0 3
3) PI3K-AKT signalling pathway 15 12 2 0 0 0 0 0 0
4) Extracellular matrix (ECM) 67 56 11 16 3 7 5 3 5
5) ECM-receptor interaction 53 28 2 11 2 3 5 1 3
6) Adherens junction and cell adhesion molecules 34 12 2 1 2 1 0 0 2
7) Proliferation 117 49 15 7 1 2 3 1 5
8) Cytoskeleton 26 15 6 0 1 0 1 0 0
9) Complement and coagulation cascades 15 5 1 0 0 0 1 0 0
Biological process Own data Literature
 
Figure 28: Comparison of own results with literature data by means of the numbers of genes 
belonging to the nine biological processes determined in Section 4.4.1. Total: summary of all 
expression studies. Microarray expression studies are listed individually.  
 
Of those genes, numerous are derived from microarray gene expression 
experiments: 
 
- Aggressive fibromatosis 
 
In one study (Figure 28, Literature, Denys), the gene expression of four primary cell 
cultures of aggressive fibromatoses (no proof of tumoral origin was provided) was 
compared with the one in cultures of normal fascia using Affymetrix microarrays. The 
authors found 69 genes to be differentially expressed (33 genes upregulated, 36 
genes downregulated). The most numerously represented biological processes are 
the ECM (e.g. type VI collagen, proteoglycan 1, ADAM metallopeptidase domain 19 
(ADAM19), matrix metalloproteinases 3 and 7 (MMP3, MMP7)) and proliferation, 
including cyclin D2, insulin-like growth factor 2 (IGF2), insulin-like growth factor-
binding protein 6 (IGFBP6) and neurite growth-promoting factor 2 (MDK).  
.  
In a second study (Figure 28, Literature, Skubitz), 12 samples of aggressive 
fibromatosis tissues were compared with 16 non-neoplastic tissues, including normal 
adipose, cervix, colon, kidney, liver and lung, using Affymetrix-based gene 
expression analysis. 30 genes were found to be significantly upregulated in 
aggressive fibromatosis, most of them belonging to the biological processes ECM / 
ECM-receptor interaction, proliferation and TGFβ signalling pathway. The ECM-
components include type I, III, V, VI, XI, XII, XIV collagen, spondin 2 (SPON2), 
biglycan (BGN), cartilage oligomeric protein (COMP) and versican (CSPG2). Genes 
involved in the process of proliferation represent TGFβ3 (TGFB3), angiopoietin-like 2 
(ANGPTL2), tumor necrosis factor ligand superfamily member 4 (TNFSF4) or stem-
cell growth factor (CLEC11A). In context of TGFβ-signalling pathway, TGFβ3, asporin 
(ASPN), COMP, type I and type II collagen could be found.  
  
- Superficial fibromatosis 
 
Comparing the gene expression of 6 palmar superficial fibromatosis tissues with the 
one in 2 unaffected palmar fascia using Atlas microarrays (Figure 28, Literature, 
Pan), 23 genes were reported to be differentially expressed. Three of them belong to 
the extracellular matrix (laminin, beta 3 (LAMB3), tetranectin (CLEC3B) and amyloid 
A4 precursor (APP)), two to the biological process adherens junction (intercellular 
adhesion molecule 2 (ICAM2), erythrocyte membrane protein band 4.9 (EPB49)) and 
one each to the processes proliferation (tumor necrosis factor superfamily member 
12 (TNFSF12)) and cytoskeleton (tubulin alpha 3 (TUBA3). 
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Using the same Atlas microarrays, the authors of another study (Figure 28, 
Literature, Qian) compared tissues of 9 palmar nodular superficial fibromatoses with 
adjacent normal tendon. 16 genes were upregulated, whereas 3 genes showed a 
reduced expression in diseased tissues. Most of them are involved in the 
extracellular matrix, including type II alpha collagen (COL2A), decorin (DCN), 
periostin (POSTN), matrix metalloproteinase 2 (MMP2), amyloid A4 precursor (APP), 
thymosin, beta 4, X-linked (TMSB4X) and thymosin, beta 10 (TMSB10).  
 
In another study done on cDNA arrays (Figure 28, Literature, Lee), tissues derived 
from 4 palmar cord superficial fibromatoses, four adjacent control fascia and three 
control palmar fascia were compared with each other. Among the upregulated genes 
in superficial fibromatoses, the ECM components type V and type VIII collagen, 
fibronectin (FN), tenascin C (TNC) and serine (or cysteine) proteinase inhibitor, clade 
H (SERPINH1) were detected. Genes belonging to the biological process of 
proliferation included maf musculoaponeurotic fibrosarcoma oncogene homolog B 
(MAFB), TGFβ2 and tenascin.  
 
The gene expression in 6 primary cell cultures derived from palmar superficial 
fibromatoses was compared with the one in 6 normal palmar fascia fibroblast cell 
cultures using 2 different microarray platforms (GE Code LinkTM and IlluminaTM). 
Among the 11 genes detected to be downregulated in diseased cultures on both 
platforms, the ECM componets type XV collagen, proteoglycan 4 (PRG4) and fibulin-
1 (FBLN1) could be found. PRG4 has also been implicated in the regulation of 
proliferation (Figure 28, Literature, Satish). 
 
Another cDNA microarray analysis was performed with the emphasis to detect 
differentially expressed TGFβ isoforms between palmar cord superficial fibromatosis 
tissues and adjacent control fascia (Figure 28, Literature, Zhang). A dominant 
increase of TGFβ2 (TGFB2) expression was seen in the diseased tissues, whereas 
TGFβ1 (TGFB1) and TGFβ3 (TGFB3) were not found to be differentially expressed. 
In addition, 20 novel differentially expressed genes could be detected. Most of them 
belong to the ECM, including fibroblast activation protein (FAP), secreted protein, 
acidic, cysteine-rich (SPARC), thrombospondin 2 (THBS2), type V and VIII collagen, 
or to the biological process proliferation (ras oncogene family member 31 (RAB31), 
protein regulator of cytokinesis (PRC1), FAP, MAFB, SPARC). 
 
 
5.3. Single genes differentiating the two tumors from each other 
 
16 genes that outstandingly differentiate the two tumors from each other by a high 
ratio and a highly significant p-value were presented in Figure 17 (Section 4.4.3.). In 
this section, their cellular functions, if known in context with tumorigenesis, should be 
discussed. 
 
5.3.1. Genes overexpressed in superficial fibromatosis 
 
ANGPTL7 is a promoter of angiogenesis by enhancing the proliferation of endothelial 
cells. Its expression can be induced by TGFβ. In turn, it increases the expression of 
type I collagen. ANGPTL7 has been brought into context with the pathogenesis of 
glaucoma (Kuchtey et al., 2008). TNMD is related to chondromodulin, which is a 
cartilage-specific protein that functions to stimulate chondrocyte growth and to inhibit 
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tube formation of endothelial cells, thus possesses angiogenesis inhibiting properties. 
A role for this protein in tumorigenesis has not been described to date. DCD is a 
secreted protein that acts as a proliferation and survival factor in a variety of cancer 
cell lines under hypoxia or oxidative stress (Stewart et al., 2008). PRG4 is a 
proteoglycan synthesized by chondrocytes located at the surface of articular 
cartilage. It functions as a boundary lubricant. Its expression is found in various 
sarcomas including low grade fibromyxoid sarcoma, malignant fibrous histiocytoma, 
synovial sarcoma, Ewing tumors and extraskeletal myxoid chondrosarcomas 
(Panagopoulos et al., 2004). DMRT2 is a transcription factor playing essentials roles 
during embryonic somite patterning. Recently, it has been brought into context with a 
translocation occurring in B-cell chronic lymphocytic leukemia (Russel et al., 2009; 
Seo et al., 2006). As ANGPTL7, MYOC has been associated with the formation of 
glaucoma (Kim et al., 2001). Normally, it is expressed in many occular tissues and 
exerts cytoskeletal functions. The secreted protein NOV associates with the 
extracellular matrix and plays an important role in cardiovascular and skeletal 
development, as well as fibrosis. In context of tumorigenesis, this protein has been 
investigated as a potential tumor suppressor in Ewing sarcoma (Perbal et al., 2009), 
chronic myeloid leukemia (McCallum et al., 2009), and melanoma (Fukunaga-Kalabis 
et al., 2008). There’s a review article about its function in cancer (Perbal, 2006). 
THBS4 is a secreted glycoprotein that mediates cell-to-cell and cell-to-matrix 
interactions. It positively influences the TGFβ signalling pathway by associating with 
ECM-immobilized TGFβ and disrupting the connection between the ECM and TGFβ 
(Young and Murphy-Ullrich, 2004). Its function in tumorigenesis has not been 
analyzed, yet. In a recent report, thrombospondins, including THBS4, were shown to 
activate EGFR in a MMP9-dependent manner, leading to increased epidermal cell 
migration (Liu et al., 2009). 
 
5.3.2. Genes upregulated in aggressive fibromatosis 
 
The protein encoded by the FGA gene is the alpha component of the blood-borne 
glycoprotein fibrinogen. Following injury, fibrinogen is cleaved by thrombin to form 
fibrin which is the most abundant component of blood clots. Mutations in this gene 
are associated with several disorders including dysfibrinogenemia, 
hypofibrinogenemia and renal amyloidosis. The gene ACTN2 encodes a muscle-
specific form of the cytoskeletal protein actinin. In non-muscle cells, actinins are 
involved in connecting actin to the cell membrane, whereas in muscle cells, they help 
to anchor the myofibrillar actin filaments to the Z-disc. A link to tumorigenesis hasn’t 
been published, yet. AREG is a member of the epidermal growth factor (EGF) family 
that binds to and activates EGFR and is therefore also an activator of the PI3K-AKT 
pathway. Its contribution to tumorigenesis has been discussed in breast cancer 
(Sternlicht and Sunnarborg, 2008). APCDD1 was found to be upregulated in colon 
cancer cell lines and downregulated by APC. Therefore, it was proposed to be 
involved in the pathogenesis of this disease (Takahashi et al., 2002). The protein 
encoded by the gene TTN, Titin, is highly expressed in striated muscle cells where it 
is involved as an adhesion template in the assembly of the contractile machinery. 
There is no literature available concerning its association with cancer. The 
transcription factor PITX2 is downstream of the NODAL-signalling route within the 
TGFβ signalling pathway and has important functions during embryogenesis (left-
right axis determination, mesoderm and endoderm induction). Its promoter 
hypermethlyation has proven to be a marker of poor prognosis in prostate cancer 
(Weiss et al., 2009) and breast cancer (Nimmrich et al., 2008), thus indicating its 
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tumor suppressive capabilities. GREM1 is a secreted protein that binds to BMPs and 
inhibits the association with their receptors, therefore functions as an inhibitor of the 
BMP-induced TGFβ signalling pathway. In addition, it is a target gene of the 
canonical Wnt signalling pathway. It is believed that GREM1 is an important 
constituent of tumor stroma, by providing a favourable microenvironment for cancer 
cell survival and proliferation in many cancers (Sneddon et al., 2006). WNT5A is an 
activating ligand for both the canonical and non-canonical Wnt signalling pathways. It 
has been associated with the pathogenesis of many cancers, by acting both as a 
tumor promoter and tumor repressor, depending on the type of cancer. The 
introduction to Chapter III is dedicated to the discussion of this protein. 
 
 
5.4. Detailed analysis of signalling pathways and comparison with published 
data 
 
In this study, the functional annotation of the selected 2’429 genes differentiating 
aggressive and superficial fibromatoses from reference fibrous tissue and 
distinguishing the two tumors from each other revealed that components of the 
canonical Wnt, the TGFβ, and the PI3K-AKT signalling pathway are statistically 
overrepresented. In the subsequent detailed analyses of those components, they 
were grouped according to their functions within the pathways into pathway activity 
inducers, inhibitors and pathway target genes. This approach aimed to deduce 
informations about differential activities within these pathways between the tissues 
analyzed. Applying such an approach, the following restrictions of the validity of the 
resulting informations must be considered.  
 
1) The numerical analysis of differentially expressed pathway inducers and 
inhibitors does not necessarily lead to a conclusive statement about the 
differential activity within the pathway, because the single components may 
exert variable impacts.  
2) The activity of single components is often regulated on a post-translational 
level, e.g. through phosphorylations.  
3) The expression level of a certain target gene is mostly the result of a crosstalk 
between several different signalling pathways and therefore gives a hint at the 
differential activity of this pathway, but does not proof it. 
4) Even though carefully selected by light microscopy, surgically removed tumor 
tissue also contains other tissue components, e.g. the tumor stroma, that 
might contribute to the expression profile. 
5) Genome wide expression profiling yields only a momentary picture of a 
continuously changing spectrum of transcriptional activiy. 
 
5.4.1. The canonical Wnt signalling pathway 
 
A hallmark in the diagnosis of fibromatoses represents the nuclear accumulation of β-
catenin in the nucleus, indicating an increased TCF-dependent transcription in these 
tumors (Section 2.2.1.). In this study, the functional annotation of the selected genes 
differentiating aggressive and superficial fibromatoses from reference fibrous tissue 
and distinguishing the two tumors from each other revealed a statistically significant 
overrepresentation of components of the canonical Wnt signalling pathway. Gene 
lists A and B in the Appendix allow to compare those results with findings published 
in the literature. The subsequent analysis of the identities of the differentially 
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expressed components point towards a higher activity of this pathway in 
fibromatoses as compared to reference fibrous tissues, the existence of a negative 
feedback loop mechanism established in fibromatoses to try to counterbalance an 
excessive pathway activity, and reveals a high overlap of deregulated pathway 
components between aggressive and superficial fibromatoses. 
 
- Higher activity in fibromatoses as compared to reference fibrous tissues 
 
In aggressive fibromatosis, more pathway activity inducers are overexpressed (10) 
than in the reference fibrous tissue (6). In addition, the number of differentially 
expressed canonical Wnt signalling target genes reflecting an increased activity of 
this pathway in aggressive (21) and superficial fibromatoses (14) is clearly higher 
than in the reference fibrous tissue (9 and 7, respectively). Findings that support the 
current view, that fibromatoses are characterized by an increased activity in this 
pathway (Section 2.2.1.).  
 
Such a comprehensive analysis of differentially expressed canonical Wnt signalling 
pathway components in fibromatoses in comparison to reference fibrous tissues has 
not been published, yet.  
 
Among the pathway activity inducers, only a few of them have already been 
mentioned in the literature to be differentially expressed in fibromatoses. For 
example, among the several Wnt ligands and Frizzled receptors found to be 
differentially expressed in this study, only WNT5A has ever been found to be 
overexpressed in aggressive fibromatosis. In a microarray study comparing the gene 
expression in primary cell cultures of aggressive fibromatoses with the one in 
reference fibroblast cultures (Denys et al., 2004b). 
 
In several independent studies, the overexpressions of the canonical Wnt signalling 
target genes MMP3 (Denys et al., 2004a; Denys et al., 2004b; Kong et al., 2004), 
MMP7 (Denys et al., 2004b), PTGS2 (Poon et al., 2001), CCND1 (Saito et al., 2002; 
Saito et al., 2001), CCND2 (Denys et al., 2004b), EPHB3 (Skubitz and Skubitz, 2004) 
and WISP1 (Skubitz and Skubitz, 2004) have been determined in aggressive 
fibromatosis, whereas in superficial fibromatosis, an increased expression of FN1 
(Kosmehl et al., 1995; Tomasek et al., 1986), MMP2 (Qian et al., 2004) and MYC 
(Jemec et al., 1999) was observed. In our study, an overexpression of MMP3 and 
MYC (downregulated in both types of fibromatoses) could not be verified, whereas 
the results for the other target genes could be confirmed. A downregulation of MYC 
may reflect the dominant effect of an active TGFβ signalling pathway in these tissues, 
since the TGFβ signalling pathway exerts its negative impact on cell proliferation in 
part through a downregulation of MYC (Section 1.2.2.).  
 
- A negative feedback loop mechanism established in fibromatoses may try to   
   counterbalance an excessive pathway activity 
 
The study revealed that there is a bias in the regulation of pathway activity inhibitors 
towards their higher expressions in fibromatoses. 8 pathway activity inhibitors are 
upregulated in aggressive fibromatosis, whereas none could be found to be 
overexpressed in the reference tissue. In superficial fibromatosis, 5 inhibitors are 
overexpressed, but only 1 in the reference fibrous tissue. This may reflect the 
existence of a negative feedback loop mechanism established in fibromatoses to try 
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to counterbalance a canonical Wnt signalling activity that ran out of control. Indeed, 
the pathway activity inhibitors AXIN2 and SFRP2 are established canonical Wnt 
signalling target genes, but have not been described to be upregulated in 
fibromatoses, yet. The same accounts for the other activity inhibitors found to be 
enhanced in their expressions in fibromatoses (DKK2, DKK3, APC, APC2, SFRP4, 
SOX17, WIF1).  
 
- High overlap of deregulated pathway components between tumors 
 
Half of the pathway components found to be deregulated in aggressive fibromatosis 
are in the same way regulated in superficial fibromatosis. And even three fourth of 
the differentially expressed components detected in superficial fibromatosis are 
equally regulated in aggressive fibromatosis. This finding suggests common 
mechanisms being responsible for this outcome. Whereas for aggressive 
fibromatosis, APC and β-catenin mutations are accountable for a deregulation of the 
canonical Wnt signalling pathway in most of the cases, the causing mechanisms in 
superficial fibromatoses remain to be elucidated (Section 2.2.1.).  
 
5.4.2. The TGFβ signalling pathway 
 
The results of several studies suggest a contribution of a deregulated TGFβ 
signalling pathway activity to the pathogenesis of superficial fibromatosis (Section 
2.2.2.). The functional annotation of the selected genes in this study revealed that a 
statistically significant high number of TGFβ signalling pathway components are 
differentially expressed between fibromatoses and reference fibrous tissues, as well 
as between the two tumors. Gene lists A and B in the Appendix allow to compare 
those results with findings published in the literature. The examination of the 
identities of the deregulated components supports the notion that the TGFβ signalling 
pathway shows a higher activity in both types of fibromatoses as compared to 
reference fibrous tissues and demonstrates that there is a high overlap of 
deregulated pathway components between the two tumors. 
 
- Higher activity in fibromatoses as compared to reference fibrous tissues 
 
In both aggressive (10) and superficial fibromatosis (8), more TGFβ pathway activity 
inducers are overexpressed as compared to the reference fibrous tissue (6 and 4, 
respectively).  
 
The impression of an enhanced activity of the TGFβ signalling pathway in 
fibromatoses is further underlined by the analysis of differentially expressed pathway 
target genes. The number of target genes reflecting an increased activity of this 
pathway in aggressive (10) and superficial fibromatosis (9) is higher than in the 
reference fibrous tissue (2 and 5, respectively). 
 
Concerning the upstream pathway inducers, our data confirm findings published in 
the literature whereupon TGFB3 is more highly expressed in both types of 
fibromatoses as compared to reference fibrous tissues (Berndt et al., 1995; Skubitz 
and Skubitz, 2004; Zhang et al., 2008). In addition, an overexpression of TGFB2 
(Badalamente et al., 1996; Berndt et al., 1995; Kuhn et al., 2002; Lee et al., 2006; 
Zhang et al., 2008) and MMP2 (Qian et al., 2004) in superficial fibromatosis could be 
verified. Contradictory to data in the literature (Locci et al., 2001), our data reveal a 
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downregulation of TGFBR2 in aggressive fibromatosis and of TGFBR3 in both 
fibromatoses. In addition, the determined overexpression of BMP7 in both 
fibromatoses and of MMP2 in aggressive fibromatosis is not in agreement with data 
published in the literature (Denys et al., 2004a; Kong et al., 2004; Shin et al., 2004). 
All other pathway inducers found to be differentially expressed in our study have not 
been mentioned in the literature in context with fibromatoses so far, namely anti-
Mullerian hormone (AMH), BMP8A, thrombospondins 2 (THBS2) and 4 (THBS4), 
galectin 3 (LGALS3), inhibin β A and B (INHBA, INHBB), nodal, activin A receptor 
type IB (ACVR1B), mothers against decapentaplegic homolog 3 (SMAD3) and early 
growth response 1 (EGR1).   
 
Concerning the ECM component target genes of this pathway, an overexpression in 
both fibromatoses has been reported for COL1A1 (Kopp et al., 2006; Skubitz and 
Skubitz, 2004) and COL3A1 (Howard et al., 2003; Skubitz and Skubitz, 2004), 
whereas an enhanced expression of COL1A2 (Kopp et al., 2006), fibronectin (FN1) 
(Berndt et al., 1995; Tomasek et al., 1986) and TGFβ-induced (TGFBI) (Kraljevic 
Pavelic et al., 2009) has been specifically associated with superficial fibromatoses. 
The overexpressions of osteoglycin (OGN), osteonectin (SPARC) and collagen triple 
helix repeat containing 1 (CTHRC1) have not been described in the literature, yet.  
The single ECM target gene found to be upregulated in the reference tissue is TGFβ 
inducible nuclear protein 1 (TINP1) that has not been brought into context with 
fibromatoses, yet.   
 
The TGFβ signalling pathway achieves its negative effect on proliferation by inhibiting 
the expression of c-myc (MYC) and inducing the expression of the cyclin / cyclin-
dependent kinase complex inhibitor 1B (CDKN1B). In both fibromatoses, those two 
proteins were found to be downregulated. The observed downregulation of CDKN1B 
may reflect a crosstalk with another pathway that exerts a dominant inhibiting effect. 
There exist no data concerning the expression of CDKN1B in fibromatoses. MYC has 
been described to be upregulated in superficial fibromatosis as compared to normal 
fascia (Jemec et al., 1999), a finding that is therefore contradictory to our data.  
 
Another target gene found to be upregulated specifically in aggressive fibromatosis 
represents the transcription factor PITX2. Its promoter hypermethylation has been 
associated with poor prognosis in prostate cancer (Weiss et al., 2009) and breast 
cancer (Nimmrich et al., 2008), thus indicating its tumor suppressive capabilities in 
these tumors. Up to now, is has not been described in relation to the pathogenesis of 
fibromatosis.  
 
The TGFβ signalling pathway induces apoptosis in part through the upregulation of 
growth arrest and DNA damage inducible (GADD45), whose expression is found to 
be downregulated in superficial fibromatosis, therefore indicating another possible 
crosstalk with unknown pathways. In the literature, it has not been discussed in 
context with fibromatoses so far.  
 
Two other target genes of the TGFβ signalling pathway that are specifically 
downregulated in superficial fibromatosis are inhibitor of DNA binding 2 (ID2) and 4 
(ID4). Other members of this family of transcription factors, ID1 and ID3, were shown 
to be essential for the successful formation of breast cancer metastases after the 
cells entered the lung parenchyma (Gupta et al., 2007). Therefore, the 
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downregulation of ID2 and ID4, by whatever pathway, may contribute to the inability 
of superficial fibromatosis to form metastases.  
 
- The differential expressions of pathway activity inhibitors do not indicate the   
    establishment of a negative feedback loop in fibromatoses  
 
In both tumors and the reference fibrous tissue, similar numbers of pathway inhibitors 
are overexpressed (Aggr vs. Ref = 4:3 ; Super vs. Ref = 2:2). This suggests that 
there exists no negative feedback loop in fibromatoses trying to counteract an 
exaggerated TGFβ signalling pathway activity. 
 
Of the those differentially expressed pathway inhibitors, only asporin (ASPN) (Skubitz 
and Skubitz, 2004), cartilage oligomeric matrix protein (COMP) (Skubitz and Skubitz, 
2004) and decorin (DCN) (Qian et al., 2004) have ever been mentioned in 
publications to be regulated in their expressions in fibromatoses. Whereas the 
statements for ASPN and DCN could be confirmed, the overexpression of COMP in 
aggressive fibromatosis was not verified by our data. The remaining genes found to 
be differentially expressed in our study are so far unknown for being regulated in 
fibromatoses: gremlin 1 homolog (GREM1), cartilage intermediate layer protein 
(CILP), follistatin (FST), follistatin-like 3 (FSTL3) and BMP and activin membrane-
bound inhibitor homolog (BAMBI).  
 
- High overlap of deregulated pathway components between tumors 
 
Similarly to the picture obtained analyzing the canonical Wnt pathway, the 
examination of the differentially expressed TGFβ pathway genes revealed a 
pronounced overlap between the deregulated components in the two tumors. Two 
thirds of the pathway components found to be deregulated in aggressive fibromatosis 
are in the same way regulated in superficial fibromatosis. And even three fourth of 
the differentially expressed components detected in superficial fibromatosis are 
equally regulated in aggressive fibromatosis. The reason for this outcome is 
unknown, but it suggests a common deregulation inducing mechanism.  
 
5.4.3. The PI3K-AKT signalling pathway 
 
The PI3K-AKT signalling pathway plays a central role in the pathogenesis of diverse 
cancers by representing an effector pathway for several important growth factors 
such as EGF, IGF, HGF or PDGF to regulate proliferation, apoptosis, angiogenesis, 
protein synthesis and glycogen synthesis (Section 1.3.).  
 
The DAVID-based functional annotation of the differentially expressed genes in our 
study associated this pathway with a possible role in the pathogenesis of 
fibromatoses, since it is overrepresented in the list of genes commonly differentiating 
the two tumors from the reference fibrous tissue. Gene lists A and B in the Appendix 
allow to compare those results with findings published in the literature. 
 
The central component of this pathway, AKT, is not a transcription factor, but a 
serine/threonine-kinase modulating the activities of a plethora of downstream targets 
on the protein level by phosphorylation (Section 1.3.1., Figure 5). These proteins in 
turn transmit the signal on the protein level to other target proteins or regulate the 
transcription of target genes (in the case of transcription factors), resulting in an 
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increasing branching and expansion of the downstream signalling pathways. The 
PI3K-AKT pathway does not contain one major, central transcription factor that alters 
the transcription of a limited number of target genes, but induces crosstalks to 
several individual signal transduction routes. Therefore, informations about 
differential activities in the PI3K-AKT pathway between different tissues can be 
deduced by enumerating differentially expressed inducers and inhibitors only 
upstream of AKT. Downstream of AKT, the focus was laid on the analysis of the 
biological functions of the differentially expressed pathway components in terms of a 
possible contribution of these genes to the pathogenesis of fibromatoses. The reason 
for the up- or downregulation of these genes is unknown. 
 
- The analysis of components upstream of AKT reveals no differences in the activity  
  of the PI3K-AKT pathway between fibromatoses and reference fibous tissue 
   
The differential expressions of pathway inducers and inhibitors upstream of AKT do  
not point towards a differential activity of this pathway between fibromatoses and 
reference fibrous tissue. Similar numbers of inducers and inhibitors are 
overexpressed in tumors and in reference tissue. 
 
Of all deregulated components upstream of AKT, only the downregulated insulin-like 
growth factor-binding protein 6 (IGFBP6) has ever been brought into context with the 
pathogenesis of fibromatoses (Denys et al., 2004b). Comparing the gene expression 
of four primary cell cultures of aggressive fibromatoses (no proof of tumoral origin 
was provided) with the one in cultures of normal fascia using Affymetrix microarrays, 
the authors of the mentioned study found 69 genes to be differentially expressed. 
IGFBP6 was highly downregulated in all aggressive fibromatosis cell cultures 
analyzed, a finding that was confirmed using RT-PCR, Northern and Western blot. 
IGFBP6 preferentially binds and inhibits insulin-like growth 2 (IGF2) from binding to 
the insulin-like growth factor 1 receptor (IGF1R). Cell culture proliferation assays 
revealed that exogenous IGF2 acts as a mitogen in aggressive fibromatoses. This 
effect could be abrogated by the concomitant treatment with recombinant IGFBP6 or 
an antibody against IGF1R, indicating that the missing expression of IGFBP6 in 
aggressive fibromatosis may contribute to their pathogenesis through a deregulated 
IGF2-IGF1R-dependent proliferation activity. Whether the PI3K-AKT pathway is 
activated through this proposed mechanism was not analyzed (Denys et al., 2004b). 
 
Even though our approach did not reveal any differential activity in the PI3K-AKT 
pathway between the tissues analyzed, a direct proof of a deregulated PI3K-AKT 
pathway activity has recently been delivered in a study done in superficial 
fibromatosis. An integrated proteomics approach (combining two-dimensional gel 
electrophoresis (2-DE) and mass spectrometry (MS) with a bioinformatic tool to 
depict protein-protein interactions (interactome)) was applied to detect new molecular 
mechanisms involved in the pathogenesis of superficial fibromatosis. Starting from a 
list of 28 proteins (involved in biological processes such as extra- and intracellular 
signalling, metabolism, cytoskeleton and oxidative stress) determined to be 
overexpressed in tissues from superficial fibromatoses as compared to reference 
tissues using 2-DE/MS, the in silico interactome map suggested a functional link of v-
erb-b2 erythroblastic leukaemia viral oncogene homologue 2 (ERBB2) and insulin-
like growth factor receptor 1 (IGFR1) to the 28 in vitro detected differentially 
expressed proteins. Western blot analysis and immunohistochemistry confirmed their 
overexpression in superficial fibromatosis. In addition, the interactome approach 
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indicated an involvement of the PI3K-AKT signalling pathway in the pathogensis of 
superficial fibromatosis. Western blot analyses approved an overexpression of AKT 
and its activated form, phospho-AKT, in diseased tissues, pointing towards a higher 
activity of the PI3K-AKT pathway in superficial fibromatosis as compared to reference 
tissues (Kraljevic Pavelic et al., 2009). Therefore, at least in superficial fibromatosis, 
the PI3K-AKT pathway is activated. Of those 28 differentially expressed proteins, four 
could be verified on the expression level in our study, namely type VI collagen 
(COL6A3), galectin 1 (LGALS1), TGFβ-induced (TGFBI) and triosephosphate 
isomerise (TPI1).  
 
- Differentially expressed genes downstream of AKT inhibit apoptosis in both  
   fibromatoses 
 
The PI3K-AKT pathway inhibits apoptosis through the AKT-dependent modulation of 
the function of diverse downstream proteins, both on the protein (phosphorylation, 
ubiquitination) and the RNA level (transcription) (Section 1.3.1., Figure 5).   
 
AKT represses apoptosis by phosphorylating and activating mouse double minute 2 
homolog (MDM2) that binds to and inhibits the key apoptosis-inducing transcription 
factor p53 (TP53). Additionally, AKT induces the activity of the anti-apoptotic 
signalling pathway nuclear factor of kappa light chain gene enhancer in B-cells 
(NFκB), by phosphorylating and activating the inhibitor of NFκB kinase (IKK) that in 
turn phosphorylates and inhibits the inhibitor of NFκB (NFKBI). Finally, it 
phosphorylates and inhibits forkhead box (FOXO) family transcription factors, known 
for their transcriptional induction of apoptosis-inducing genes. 
 
Key components on the above described AKT-dependent apoptosis repressing 
routes are accordingly regulated on the transcriptional level in both fibromatoses as 
compared to the reference fibrous tissue. NFKBIA, FOXO1A and TP53, all potent 
inducers of apoptosis, are downregulated in both fibromatoses. Their transcriptional 
inhibition, induced by whatever mechanism, may contribute to the pathogenesis of 
fibromatoses. Perhaps, the function of those three proteins is further repressed on 
the protein level by an increased activity of the PI3K-AKT pathway in fibromatoses, 
as it is described in the above mentioned paper for superficial fibromatosis (Kraljevic 
Pavelic et al., 2009). 
 
A differential expression of NFKB1A and FOXO1A in fibromatoses in comparison to 
reference tissues has not been mentioned in the literature, yet. In one report, the 
authors describe the analysis of the expression of TP53 both on the protein (IHC) 
and the mRNA level (RT-PCR) in aggressive and superficial fibromatoses. They 
could not find a differential expression, confirming our results (Muller et al., 1996).. 
 
- Differentially expressed genes downstream of AKT induce proliferation in both  
   fibromatoses 
 
The PI3K-AKT pathway induces induces proliferation through the AKT-dependent 
modulation of the function of diverse downstream proteins, both on the protein 
(phosphorylation, ubiquitination) and the RNA level (transcription) (Section 1.3.1., 
Figure 5).   
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AKT stimulates cell proliferation via phosphorylation and inhibition of GSK3β and 
members of the FOXO family of transcription factors. By inactivating GSK3β, AKT 
reduces GSK3β-mediated phosphorylation and inactivation of cyclin D1 (CCND1) 
and c-myc (MYC), two central components for cell cycle progression. In addition, 
inhibition of GSK3β leads to an accumulation of β-catenin and an activation of TCF-
dependent transcription, whereupon the transcription of CCND1 and MYC is 
increased. Through the phosphorylation and inhibition of FOXO transcription factors, 
the PI3K-AKT pathway represses the expression of the cell cycle progression 
inhibitor cyclin-dependent kinase inhibitor CDKN1B (p27, inhibits cyclin E/A – CDK2 
complexes), thus further accelerates proliferation.  
 
Three genes involved in the above described regulation of proliferation are 
differentially expressed in both fibromatoses, namely CDKN1B, CCND1 and MYC. 
CDKN1B was found to be downregulated, whereas CCND1 was upregulated, 
reflecting the effect of an active PI3K-AKT pathway on their transcription. In addition, 
an active PI3K-AKT-pathway in fibromatoses may increase the function of CCND1 on 
the protein level, by releaving it from the GSK3β-mediated phosphorylation and 
inhibition. In contrast, the inducer of proliferation MYC was found to be 
downregulated in its expression in both tumors as compared to the reference fibrous 
tissue. This may reflect the result of an inhibiting effect of the TGFβ signalling 
pathway on the expression of MYC (Section 1.2.2.). Another inducer of proliferation, 
β-catenin, was shown to be specifically upregulated on the transcriptional level in 
aggressive fibromatosis. Its observed overexpression, together perhaps with an 
active PI3K-AKT signalling-dependent repression of its degradation, may contribute 
to an increased proliferation of aggressive fibromatosis tumor cells. Overall, the 
differential expressions of those PI3K-AKT pathway components involved in 
regulating proliferation, induced by unknown mechanisms, indicate a proliferation 
enhancing effect in fibromatoses. Therefore, they may play a role in the pathogenesis 
of fibromatoses. 
 
β-catenin is known for its nuclear accumulation in both fibromatoses (Alman et al., 
1997a; Carlson and Fletcher, 2007; Ferenc et al., 2009; Lazar et al., 2008; 
Montgomery et al., 2001; Saito et al., 2001; Tejpar et al., 1999; Varallo et al., 2003), 
On the mRNA level, an overexpression has been described in aggressive 
fibromatoses carrying β-catenin mutations as compared to those without mutations 
(Saito et al., 2002). CCND1 is known to be overexpressed in aggressive 
fibromatoses (Saito et al., 2002; Saito et al., 2001). MYC was shown to be 
upregulated in superficial fibromatoses (Jemec et al., 1999), a finding that is in 
disagreement with our results. The differential expression of CDKN1B has not been 
mentioned in the literature in context of fibromatoses, yet.  
 
- The major inducer of angiogenesis, HIF1α, is upregulated in aggressive  
    fibromatosis 
 
The PI3K-AKT pathway induces angiogenesis by upregulating the transcription of 
hypoxia-inducible factor 1 α subunit (HIF1α) (Section 1.3.1., Figure 5).   
 
In our study, HIF1α was found to be more highly expressed in aggressive 
fibromatosis as compared to reference fibrous tissue, indicating its role in the 
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pathogenesis of this tumor. In context of fibromatosis, this protein has not been 
mentioned in the literature up to date.  
 
In contrast, a target gene of HIF1α, vascular endothelial growth factor (VEGF), is 
downregulated in superficial fibromatosis as compared to the reference fibrous 
tissue. Its relevance for the pathogenesis of fibromatoses has not been discussed in 
the literature, yet.  
 
- High overlap of deregulated pathway components between tumors 
 
The PI3K-AKT pathway is characterized by a high number of differentially expressed 
components between fibromatoses and normal fibrous tissues, and concurrently by a 
pronounced overlap of the deregulated pathway components between the two 
fibromatoses. Two thirds of the pathway components found to be deregulated in 
aggressive fibromatosis are in the same way regulated in superficial fibromatosis. 
And even nearly three fourth of the differentially expressed components detected in 
superficial fibromatosis are equally regulated in aggressive fibromatosis. The high 
similarity in the way of deregulation of this pathway in the two tumors suggests that 
common, so far unknown mechanisms are responsible for this outcome.  
 
 
5.5. The process of wound healing 
 
In Section 1.4., a brief introduction in the process of wound healing was given. During 
the proliferative phase of wound healing, fibroblasts are involved in the formation of 
the granulation tissue, by increasing their proliferation rate, transforming into 
myofibroblasts and invading into the wound space. There, they deposit an abundant 
collagen matrix needed to support further cell ingrowth and to stabilize and contract 
the wound. Increased TCF-dependent transcription, transactivated by TGFβ- and 
EGF-induced signalling pathways, was shown to be involved in this process. These 
parallels concerning histology, cellular basis and involved signalling pathways 
between fibromatoses and the process of wound healing led to the theory that the 
pathogenesis of aggressive (Cheon et al., 2005; Cheon et al., 2002; Tejpar et al., 
2005) and superficial fibromatosis (Cordova et al., 2005; Kloen, 1999) is based on 
mechanisms being responsible for normal wound healing. Whereas in normal wound 
healing, a negative feed-back loop controls an exaggerated process, molecular 
alterations in tumor cells of fibromatoses may account for its continuous action. 
 
Our data point towards a higher activity of both the canonical Wnt and the TGFβ 
signalling pathway in fibromatoses as compared to reference fibrous tissues. In 
addition, they suggest the establishment of a negative feedback loop in fibromatoses 
to try to counterbalance an exaggerated canonical Wnt signalling pathway activity. 
Altogether, our data therefore underline the proposed parallels between fibromatoses 
and the process of wound healing. 
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5.6. Differentially expressed genes belonging to the other biological 
processes 
 
The differentially expressed genes belonging to the functional process extracellular 
matrix (ECM) can be be found in the Appendix, Gene lists A and B. There, a 
comparison with literature data can also be obtained. Numerous reports using 
different experimental techniques such as gene expression array, 
immunohistochemistry, in situ hybridization or Western blot describe an 
overexpression of ECM components in fibromatoses. Collagen type I (Kopp et al., 
2006; Naito et al., 1998; Skubitz and Skubitz, 2004; Zamora et al., 1994), type III 
(Howard et al., 2003; Naito et al., 1998; Skubitz and Skubitz, 2004), type V (Lee et 
al., 2006; Skubitz and Skubitz, 2004) and type VI (Denys et al., 2004b; Kraljevic 
Pavelic et al., 2009; Magro et al., 1995a; Thurston, 2003; Zhang et al., 2008) were 
shown to be overexpressed in both types of fibromatoses as compared to reference 
fibrous tissues. Collagen type XI, XII, XIV, spondin 2, biglycan, cartilage oligomeric 
protein (COMP) and versican were found to be upregulated in aggressive 
fibromatosis (Skubitz and Skubitz, 2004), whereas superficial fibromatoses were 
characterized by an overexpression of type II (Qian et al., 2004), type IV (Berndt et 
al., 1994; Kosmehl et al., 1995; Magro et al., 1997), and type VIII collagen (Lee et al., 
2006), fibronectin (Berndt et al., 1995; Halliday et al., 1994; Howard et al., 2004; 
Kosmehl et al., 1995; Lee et al., 2006; Tomasek et al., 1986), laminin β1, β2 
(Kosmehl et al., 1995) and tenascin C (Lee et al., 2006; Shih et al., 2009).  
 
The differentially expressed genes belonging to the remaining functional processes, 
including ECM-receptor interaction, adherens junction and cell adhesion molecules 
(CAMs), proliferation, cytoskeleton and complement and coagulation cascades can 
be found in the Appendix, Gene lists A and B as well. In addition, the genes 
categorized as ‘others’, including those that could not be associated with a biological 
process. Genes that have been mentioned in the literature as being differentially 
expressed between the tissues analysed, are marked with the corresponding 
informations in the first column.  
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Chapter II 
Establishment of primary cell cultures  
derived from fibromatoses 
 
 
1. General introduction 
 
 
Cells directly cultured from a tissue biopsy are known as primary cultures. Two 
barriers prevent cultured cells from proliferating indefinitely in culture: senescence 
and crisis.  
 
Senescence is characterized by the cessation of proliferation after a certain number 
of replicative doublings (~50-60), depending on the species from which the cells were 
derived, on the tissue of origin, and on the age of the donor organism. Cells in the 
stadium of senescence normally retain viability for a prolonged time. Senescence is 
provoked by physiologic stresses that cells are faced to in vitro, such as fluctuations 
of oxygen tension leading to cumulative oxidative damage. In the great majority of 
human tumors, the tumor suppressor genes tumor protein p53 (TP53) and 
retinoblastoma 1 (RB1) are inactivated through mutations. This allows tumor cells in 
vivo to adapt to a variety of physiologic stresses normally leading to cessation of 
proliferation and even apoptosis. Likewise, these mutations help tumor cells taken 
into culture to resist to many of the stresses imposed by in vitro culture conditions. 
Senescence of cultured human fibroblasts and epithelial cells can be avoided if the 
large T oncoprotein of the simian virus SV40 is expressed in these cells. By 
sequestering both the TP53 and RB1 tumor suppressor proteins, the large T 
oncoprotein is able to neutralize the key cellular signalling pathways leading to 
senescence in response to stress. 
 
While cultured cells being mutated at TP53 and RB1 or expressing the large T 
oncoprotein succeed in bypassing senescence, they still will not be immortalized. 
After an additional number of replicative doublings (~10-20) beyond the number at 
which they would usually senesce, the cells enter into crisis and exhibit widespread 
apoptosis. Crisis is provoked by the erosion of telomeres, which results in end-to-end 
chromosomal fusions and karyotypic chaos. The telomeres are located at the ends of 
the chromosomes and act to prevent the end-to-end fusion of chromosomal DNA 
molecules. While the replication machinery that operates during the S phase of the 
cell cycle is highly effective at copying the sequences in the middle of linear DNA 
molecules, this machinery has great difficulty in copying sequences at the very ends 
of these molecules. This end-replication problem provides a molecular explanation 
for the observed shortening of telomeric DNA each time a normal human cell passes 
through a cell cycle. Telomere regeneration can be accomplished through the action 
of the telomerase enzyme, which functions specifically to elongate telomeric DNA. 
Telomerase activity is clearly detectable in 85-90% of human tumor cell samples, 
while being present at very low levels in the lysates of most types of normal human 
cells. The telomerase enzyme is a complex composed of a number of distinct 
subunits. The core contains two subunits: a reverse transcriptase and a RNA 
template. The reverse transcriptase is encoded by the gene human telomerase 
reverse transcriptase (hTERT) that needs a short segment of the RNA template, 
encoded by the telomerase-associated RNA molecule gene (hTR), to accomplish 
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telomere regeneration. Before entering crisis, human cells are essentially telomerase 
activity negative and do not express appreciable levels of the hTERT mRNA. 
Exogenous expression of hTERT in cells just before they are destined to enter crisis 
confers telomerase activity to these cells, causes elongation of their greatly shorted 
telomeres, prevents entrance into crisis, and allows such cells to grow indefinitely. In 
fact, cell immortalization is thought to be a step that governs the development of all 
human cancers. The mechanisms that lead to the de-repression of hTERT 
transcription during tumor progression are complex and still not fully understood. 
Multiple transcription factors appear to collaborate to activate the hTERT promoter. c-
myc (MYC) that exerts a central role in the activation of the cell cycle, also 
contributes to the transcription of hTERT. Therefore, activating mutations within the 
MYC gene that can be often found in human tumors, may contribute to a constitutive 
expression of hTERT leading to immortalization.  
 
Cells that can be passaged indefinitely in culture and therefore are able to prevent 
both senescence and crisis, constitute a cell line. Nevertheless, cancer cells often fail 
to adapt to culture, because in vivo they strongly depend on several other cell types, 
the so called tumor stroma, supporting their viability and proliferation (Weinberg, The 
Biology of Cancer, 2007, Garland Science, New York).  
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2. Introduction 
 
 
An essential step after the establishment of a primary tumor cell culture is to formally 
prove the derivation from the original tumor in vivo. This can often be done by the 
analysis of a certain mutation present in the tumor cells of the original tumor tissue 
which should be present in the primary tumor cell culture as well. Alternatively, 
certain marker proteins may exist that distinguish the tumor cells from tumor-
associated cells.  
 
 
2.1. Markers applicable to aggressive and superficial fibromatoses 
 
Aggressive fibromatosis is a monoclonal proliferartion of myofibroblast-like tumor 
cells (Alman et al., 1997b; Li et al., 1996). Aggressive fibromatoses are in most of the 
cases characterized by a monoallelic mutation in the β-catenin or a biallelic mutation 
in the APC-gene (Lazar et al., 2008; Tejpar et al., 1999) (Chapter I, Section 2.2.1.). 
The derivation of primary cell cultures from tumor cells can therefore be proven by 
the detection of identical mutations as present also in the tumor tissue.   
 
In superficial fibromatoses, causing mutations have not been found, yet (Montgomery 
et al., 2001; Varallo et al., 2003). Whether they represent a true neoplastic 
proliferation or rather a polyclonal reactive process is controversially discussed. Two 
studies report a polyclonal pattern of X chromosome inactivation of the androgen 
receptor gene in superficial fibromatosis tissues from two and eight women, 
respectively, thus favouring a polyclonal reactive process (Chansky et al., 1999; 
Wang and Zhu, 2006). Others describe clonal chromosomal aberrations at variable 
frequencies in patients suffering from this disease, supporting the notion of a 
neoplastic process (Dal Cin et al., 1999; De Wever et al., 2000).  
 
In vivo, the tumor cells of fibromatoses exhibit features of myofibroblasts as indicated 
by the expression of bundles of smooth muscle actin (α-SMA) microfilaments (similar 
to those found in smooth muscle cells), differentiating them from tumor-associated 
normal fibroblasts. But in vitro, α-SMA is not useful as tumor cell marker, because 
normal fibroblasts are characterized by α-SMA positive stress fibres as well.   
 
Since no reliable genetic or phenotypic markers exist in superficial fibromatoses, the 
derivation of primary cell cultures from the original tumor tissue can not be proven to 
date.  
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2.2. Published studies using primary cultures of aggressive and superficial 
fibromatoses 
 
Several studies published in the literature report the establishment of primary tumor 
cell cultures derived from fibromatoses for the use in functional studies.  
 
2.2.1. Aggressive fibromatosis 
 
In the following three reports, the authors claimed that primary cell cultures derived 
from aggressive fibromatoses are characterized by an increased activity of the Wnt 
signalling pathway. In the first study, the experiments were based on cell cultures 
derived from tumors carrying somatic APC mutations. Transient transfection of these 
cells with an APC expression plasmid led to a decrease of the β-catenin protein level 
(Western blot) and a diminished proliferation rate. A concomitant expression of a 
constitutive active form of β-catenin (N89-β-catenin, missing the N-terminal 
phosphorylation sites) abrogated the negative effect of APC on the cellular 
proliferation, indicating that APC controls the proliferation of these cells through its 
contribution to the degradation process of β-catenin (Li et al., 1998). In a subsequent 
study, primary cell cultures of aggressive fibromatoses were reported to be 
characterized by a pronounced nuclear accumulation of β-catenin in comparison to 
normal control fibroblasts (Tejpar et al., 1999). In a further study, the authors claim 
that primary aggressive fibromatosis cell cultures are characterized by an increased 
TCF-dependent transcriptional activity as compared to cell cultures of normal 
fibroblasts. In addition, they could show that in aggressive fibromatosis, β-catenin 
transactivates TCF-dependent transcription by binding to TCF3, not TCF4 as in colon 
carcinoma (Tejpar et al., 2001). 
 
Using primary cell cultures of FAP-associated aggressive fibromatoses and cell 
cultures of normal fibroblasts, the authors of another study found an overexpression 
of TGFβ1 (ELISA, Northern blot) and its type I and II receptors (TGFBR1, TGFBR2), 
(SDS-PAGE and fluorography) in the tumor cells. Tumor cell derived TGFβ1 was 
shown to induce the secretion of TNFα in monocytes, that in turn stimulates the 
tumor cells to produce the extracellular matrix (ECM) component glycosaminoglycan 
(GAG). Treatment of the tumor cells with Tamoxifen reduced their secretion of 
TGFβ1 and GAG. In addition, it inhibited the secretion of tumor necrosis factor α 
(TNFα) in monocytes. Therefore, the authors propose that a TGFβ1-induced 
crosstalk between tumor cells and infiltrating monocytes may contribute to the 
pathogenesis of aggressive fibromatosis, by stimulating the tumor cells to produce 
ECM components (Locci et al., 2001).  
 
In another study, insulin-like growth factor-binding protein 6 (IGFBP6) was shown to 
be highly downregulated in aggressive fibromatosis cell cultures as compared to cell 
cultures of normal fibroblasts (Microarray, RT-PCR, Northern and Western blot). 
IGFBP6 preferentially binds and inhibits insulin-like growth 2 (IGF2) from binding to 
the insulin-like growth factor 1 receptor (IGF1R). Cell culture proliferation assays 
revealed that exogenous IGF2 acts as a mitogen in aggressive fibromatoses. This 
effect could be abrogated by the concomitant treatment with recombinant IGFBP6 or 
an antibody against IGF1R, indicating that the missing expression of IGFBP6 in 
aggressive fibromatosis may contribute to their pathogenesis through a deregulated 
IGF2-IGF1R-dependent proliferation activity (Denys et al., 2004b).  
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Using a type I collagen cell invasion assay, it was reported that cell cultures derived 
from aggressive fibromatoses show an invasive capacity that could be further 
stimulated by the addition of conditioned medium. The invasion of tumor cells into the 
collagen gel could be partly inhibited by a synthetic matrix metalloproteinase (MMP) 
inhibitor, suggesting a critical role for MMPs in this locally invasive tumor (Denys et 
al., 2004a). 
 
The authors of another study report the overexpression of the Wilms’ tumor gene 1 
(WT1) in primary cell cultures of aggressive fibromatoses as compared to cell 
cultures of normal fibroblasts (RT-PCR, Western blot, Immunohistochemistry) (Amini 
Nik et al., 2005). 
 
2.2.2. Superficial fibromatosis 
 
Most experiments with primary cell cultures derived from superficial fibromatoses 
were aimed to analyze the impact of TGFβ stimulation. A positive effect of TGFβ1 
and TGFβ2 on the proliferation of superficial fibromatosis tumor cells was reported, 
whereas cultures of normal fibroblasts did not react (Badalamente et al., 1996). This 
result was indirectly proven by an experiment showing that TGFβ2 increases the 
DNA and protein synthesis in cultures of superficial fibromatoses (Kuhn et al., 2001). 
TGFβ1 enhanced the proportion of α-SMA-positive cells in cultures of superficial 
fibromatoses, whereas normal fibroblasts did not respond (IHC) (Bisson et al., 2003). 
In another cell culture experiment, TGFβ1 was shown to induce the expression of α-
SMA, type I collagen and plasminogen activator inhibitor type I (PAI-1) (Western blot) 
(Kopp et al., 2006). Primary tumor cells of superficial fibromatoses contracted 
fibroblast-populated collagen lattices significantly more than control fibroblasts (Kuhn 
et al., 2002). The addition of TGFβ1 (Bisson et al., 2009) and TGFβ2 (Tse et al., 
2004) increased the generated force in both control and diseased cells.  
 
In another study, treatment of superficial fibromatosis tumor cells with 5α-
dihydrotestosterone increased their proliferation and expression of α-SMA (Pagnotta 
et al., 2003).  
 
Tumor cells derived from superficial fibromatoses and normal palmar fascia 
fibroblasts were analyzed for mRNA expression of bone morphogenetic proteins 
(BMPs) and their receptors (BMPRs) using RT-PCR. The expression levels of BMP4, 
BMP6, BMP8, BMPR1A, BMPR1B and BMPR2 were found to be reduced in tumor 
cells as compared to normal fibroblasts. The differential expressions of BMP4 and 
BMP8 could be confirmed on the protein level (Western blot, immunocytochemistry) 
(Shin et al., 2004). 
 
Two important wound-healing-associated proteins – heat shock protein 47 (HSP47), 
fibronectin (FN1) and its oncofetal splice variant – were determined to be 
overexpressed in superficial fibromatosis primary tissues and cell cultures as 
compared to reference normal tissues and cultures (Western blot, 
immunocytochemistry) (Howard et al., 2004). 
 
The gene expression in 6 primary cell cultures derived from palmar superficial 
fibromatoses was compared with the one in 6 normal palmar fascia fibroblast cell 
cultures using 2 different microarray platforms (GE Code LinkTM and IlluminaTM). 
Among the 11 genes detected to be downregulated in primary cultures on both 
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platforms, the ECM componets type XV collagen, proteoglycan 4 (PRG4) and fibulin-
1 (FBLN1) could be found. PRG4 has also been implicated in the regulation of 
proliferation (Satish et al., 2008). 
 
Bioinformatic analytical techniques on existing, published gene expression data were 
employed in another study to identify candidate genes differentiating superficial 
fibromatoses from normal reference tissue. The following six genes, reported to be 
overexpressed in diseased tissues, could be found: a disintegrin and 
metalloproteinase domain 12 (ADAM12), aldehyde dehydrogenase 1 (ALDH1), 
iroquois homeobox protein 6 (IRX6), proteoglycan 4 (PRG4), tenascin C (TNC) and 
periostin (POSTN). The expression of these 6 genes was analyzed in tissues and 
corresponding cell cultures of superficial fibromatoses as compared to normal fascia 
(real-time RT-PCR). In tissues, the overexpression of ADAM12, IRX6, POSTN and 
TNC could be confirmed. In contrast, these genes were not differentially expressed in 
the corresponding cell cultures (Shih et al., 2009). 
 
 
2.3. Aim of the study 
 
Agilent microarray and real-time RT-PCR analyses described in Chapter I, Section 
4.2. revealed an overexpression of WNT5A in aggressive fibromatosis as compared 
to superficial fibromatosis and reference fibrous tissue. Functional cell culture 
experiments should bring light into the impact of WNT5A on cell signalling pathways, 
proliferation and invasive behaviour of fibromatosis tumor cells (Chapter III). 
Therefore, the aim of the experiments described in this chapter was the 
establishment and characterization of primary tumor cell cultures derived from 
fibromatoses. In addition, their endogenous expression and secretion of WNT5A 
should be analyzed. 
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3. Materials and methods 
 
 
3.1. Techniques applied for the establishment of primary tumor cell cultures 
derived from fibromatoses 
 
The collection and characterization of tissues is described in Chapter I, Section 3.1. 
 
1) Outgrowth of cells from small tissue pieces 
2) Pre-treatment of small tissue pieces with collagenase to obtain a single cell 
suspension 
 
3.1.1. Outgrowth of cells from small tissue pieces 
 
Biopsies of 7 aggressive fibromatoses (Aggr1-7) and 5 superficial fibromatoses 
(Super1-5) were cut with a razor blade in a petri-dish containing Mg2+/Ca2+-free 
phosphate-buffered saline (PBS, Invitrogen, Carlsbad, CA) and 2.8 g/ml 
Amphotericin B (Sigma-Aldrich, Saint Louis, MI)  into small, ~ 1 mm3 pieces, washed 
several times in the same solution, and then transferred into cell culture flasks. A 
limited amount of cell culture growth medium (Section 3.5.) was added to cover the 
tissue pieces, but allowing them to adhere on the bottom of the flasks. After a few 
days of cultivation, first cells growing out of the tissue pieces could be observed. As 
soon as the outgrowing cells reached a certain density, the tissue pieces were 
transferred into other flasks, whereas the cells were trypsinized (1xTrypsin-EDTA, 
Invitrogen, Carlsbad, CA) and splitted into new cell culture flasks.  
 
3.1.2. Pre-treatment of small tissue pieces with collagenase 
 
Primary tissues were cut with a razor blade in a petri-dish containing Mg2+/Ca2+-free 
phosphate-buffered saline (PBS, Invitrogen, Carlsbad, CA) and 2.8 g/ml 
Amphotericin B (Sigma-Aldrich, Saint Louis, MI) into pieces as small as possible. 
They were incubated in 1.5 ml PBS-Solution ‘nach Kreis’ (8 g NaCl, 0.2 g KCl, 1.435 
g Na2HPO4, 0.2g KHPO4 per liter H2O), containing 0.25 g/l CaCl2 and 2 mg/ml 
Collagenase A (Roche, Basel, Switzerland) on a overhead shaker at 37°C for 2-12 
hours, depending of the amount of tissue and the content and composition of the 
extracellular matrix (ECM) to be degraded. The resulting cell suspension was 
pelleted through a centrifugation step (160 g, 3 minutes) and resuspended into 
growth medium (Section 3.5.) for further cultivation. 
 
 
3.2. Mutation analysis 
 
β-catenin sequence analysis was performed on a 3130x Genetic Analyzer (Applied 
Biosystems, Norwalk, CT) at the Laboratory for Molecular Diagnostics, University 
Hospital, Zürich (Prof. Zimmermann) using the following primers: forward: 
CATTTCCAATCTACTAATGCT, reverse: CTGCATTCTGACTTTCAGTAA (Tejpar et 
al., 1999). APC sequence analysis was done by the Research Group Human 
Genetics at the Center for Biomedicine DKBW, University of Basel (Prof. Heinimann). 
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3.3. Digital pictures 
 
Pictures of cell cultures were taken on the Axiovert 40 CFL microscope (Zeiss, Jena, 
Germany) at a magnification of 10, using the digital Powershot A650 IS camera 
(Canon, Tokyo, Japan) at a zoom of 3.8. 
 
 
3.4. Cell cultures of normal adult human dermal fibroblasts 
 
The cell culture of normal human dermal fibroblasts (NHDF) was purchased from 
PromoCell (Heidelberg, Germany). The normal human dermal fibroblast cell cultures 
HDF15 and HDF21 were established from normal adult human skin using the 
technologies described above. 
 
 
3.5. Growth medium 
 
All cell cultures  were grown in endothelial cell medium 2 (EGM2) basal medium 
supplemented with insulin-like growth factor (IGF), fibroblast growth factor (FGF) and 
ascorbic acid (Lonza, Basel, Switzerland), 20% fetal calf serum (FCS), 1% 
penicillin/streptomycin (Invitrogen, Carlsbad, CA) and 2.8 g/ml Amphotericin B 
(Sigma-Aldrich, Saint Louis, MI) in a cell culture incubator at 37°C, 5% CO2.  
 
 
3.6. Cytoplasmic protein extraction 
 
The description of the method used to obtain cytoplasmic protein extracts from cell 
cultures can be found in Chapter III, Section 3.1.2. 
 
 
3.7. SDS-PAGE and Western blot 
 
Details about this technique to analyze the synthesis of WNT5A in different cell 
cultures using cytoplasmic protein extracts can be obtained in Chapter III, Section 
3.2. 
 
 
3.8. Immunoprecipitation of WNT5A and subsequent SDS-PAGE / Western 
blot 
 
Immunoprecipitation of secreted WNT5A in cell culture supernatants of NHDF, 
HDF15, HDF21, Aggr2, Aggr4, Aggr7 and Aggr6 was performed according to the 
technical bulletin of the Protein G Immunoprecipitation Kit (Sigma-Aldrich, Saint 
Louis, MI). WNT5A was precipitated in 600 l of conditioned medium (3 day culture) 
using 5 g of WNT5A-antibody (R&D Systems, Minneapolis, USA). Equal volumes of 
precipitated WNT5A (12 l) were loaded on denaturing gels and resolved using SDS-
PAGE as described in Chapter III, Section 3.2. Afterwards, Western blotting was 
performed according to the technical manual of the One-step Complete IP-Western 
Kit (GeneScript Corporation, Piscataway, NJ), to reduce the detection of the WNT5A-
antibody used for Immunoprecipitation, since the same antibody was applied for the 
Western blot. After exposure of the membrane to a Hyperfilm ECL high performance 
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chemiluminescence film (GE Healthcare, Waukesha, WI), the film was processed as 
described in Chapter III, Section 3.2. 
 
 
3.9. Agilent 60mer-oligo microarrays 
 
For the analysis of RNA samples derived from tissue, details about this technique 
can be obtained from Chapter I, Section 3.2.  
 
For the analysis of RNA samples derived from cell cultures NHDF, HDF15, HDF21, 
Aggr2, Aggr4, Aggr6 and Aggr7, the day before the experiment, cells were splitted 
into 25 cm2 cell culture flasks at a density to reach ~80-90% confluency over night. 
Then, after washing in Mg2+/Ca2+-free phosphate-buffered saline (PBS), cells were 
trypsinized (1xTrypsin-EDTA, Invitrogen, Carlsbad, CA), centrifuged (160 g, 3 
minutes) and the pelleted cells (~1x106) resuspended in 1 ml of TriReagent 
(Molecular Research Center, Inc., Cincinnati, OH) for subsequent total RNA 
extraction according to the protocol supplied by the company. Resulting total RNA 
was quantified using the NanoDrop ND-1000 spectrophotometer (Agilent 
Technologies, Santa Clara, CA). RNA quality control was performed as described in 
Chapter I, Section 3.2.2. Equal amounts of total RNA derived from cell cultures 
NHDF, HDF15 and HDF21 were pooled to generate a normal human dermal 
fibroblast RNA pool. The samples were single color (Cy3)-labelled, hybridized, and 
the resulting data processed according to the descriptions in Chapter I, Section 3.2.4. 
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4. Results 
 
 
4.1. Mutation analysis of the established primary cell cultures 
 
Figure 29 summarizes the results obtained from the β-catenin- and APC-mutation 
analyses to verify the tumoral origin of the different established primary cell cultures.  
 
Aggr1 is derived from a Familial Adenomatous Polyposis (FAP) patient, thus its 
primary tumor is characterized by a biallelic inactivation of the APC gene. APC-
mutation analysis revealed a germline mutation in one allele, but no somatic mutation 
in the second, indicating that an epigenetic promoter hypermethylation inactivated 
the second allele in this tumor. Accordingly, only the monoallelic germline APC-
mutation was found in the corresponding cell culture.  Therefore, the tumoral origin of 
the cell culture Aggr1 remains uncertain. 
 
All other cell cultures from aggressive fibromatoses (Aggr2-7) are derived from 
sporadic cases. Aggr2-6 tumor tissues are characterized by a monoallelic β-catenin 
mutation at codon 45 (S45F) or codon 41 (T41A), whereas for Aggr7, no β-catenin 
mutation could be detected.  In the corresponding cell cultures, a congruent mutation 
could only be found in Aggr6, proving its tumoral origin. Aggr2-5 did not show the β-
catenin mutation their original tumors are characterized by. Therefore, they represent 
cultures of normal fibroblasts. The tumoral origin of Aggr7 remains uncertain, 
because its primary tumor lacks any β-catenin mutation.  
 
Since tumor tissues of superficial fibromatoses are not affected by genetic alterations 
in the β-catenin- or APC-gene, their tumoral origin could not be determined.  
 
               
Tumor Primary cell culture
Aggr1 (FAP-assoc.) APC (mut/?) APC (mut/?)
Aggr2 (sporadic) β-catenin (S45F/WT) no β-catenin mutation
Aggr3 (sporadic) β-catenin (S45F/WT) no β-catenin mutation
Aggr4 (sporadic) β-catenin (T41A/WT) no β-catenin mutation
Aggr5 (sporadic) β-catenin (T41A/WT) no β-catenin mutation
Aggr6 (sporadic) β-catenin (S45F/WT) β-catenin (S45F/WT)
Aggr7 (sporadic) no β-catenin mutation no β-catenin mutation
Super1 no β-catenin mutation no β-catenin mutation
Super2 no β-catenin mutation no β-catenin mutation
Super3 no β-catenin mutation no β-catenin mutation
Super4 no β-catenin mutation no β-catenin mutation
Super5 no β-catenin mutation no β-catenin mutation
color code: Tumoral origin of cell culture proven
Tumoral origin of cell culture uncertain
Tumoral origin of cell culture excluded
Mutation status (first allele / second allele)
 
Figure 29: Mutation status of the different established cell cultures and their tumor tissues of origin 
 
In order to verify that the initially proven tumor cell culture Aggr6 does not get 
overgrown by tumor-associated normal fibroblasts during repeated passaging in 
culture, the β-catenin sequencing was repeated after its passage 4, 6, 10, 14 and 21. 
The tumoral origin could be proven in each of the samples analyzed. 
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4.2. Growth characteristics of the established primary cell cultures 
 
A prerequisite of cell growth is the addition of 20% FCS, IGF, FGF and ascorbic acid 
to the endothelial cell medium 2 (EGM2) basal medium. 
 
After 23 passages, cells go into senescence. This stadium is characterized by the 
cessation of proliferation, an enormous expansion of the cell body’s surface and the 
development of stress fibres (Figure 30: b) (p23) vs. a) (p8)). Therefore, the cells do 
not represent an immortalized cell line. 
 
                      
Figure 30: Pictures of Aggr6 after different numbers of passages in culture. 
a) 8 passages (p8) b) 23 passages (p23). Pictures were done at the same 
magnification. 
 
 
4.3. Analysis of the endogenous WNT5A-expression 
 
The endogenous expression of WNT5A was measured in tissues of aggressive 
fibromatoses on the mRNA level using Agilent microarray analysis and in the 
corresponding primary cell cultures on the mRNA level (Agilent microarray) as well as 
on the protein level using Western blot analyses on cytoplasmic protein extracts and 
cell cultures supernatants by immunoprecipitation. For comparison, the reference 
fibrous tissue RNA pool from dense connective tissues and the three cell cultures of 
normal human dermal fibroblasts NHDF, HDF15 and HDF21 were used accordingly. 
Figure 31 a) summarizes the results of all different analyses: WNT5A RNA 
expression levels (Agilent microarray), cytoplasmic WNT5A content (Western blot, 
Figure 31 b)) and WNT5A content in cell culture supernatants (immunoprecipitation, 
Figure 31c)). 
 
WNT5A is highly overexpressed in tissues of aggressive fibromatoses as compared 
to reference fibrous tissues (Figure 31 a), red columns 5,9,13,17 vs. red column 1). 
This confirms the results obtained by comparing pools of aggressive fibromatoses 
and reference fibrous tissues (Chapter I, Section 4.2.).  
 
Cell cultures of normal fibroblasts express more (Aggr4; blue columns 10,11,12 ) or 
similar amounts (Aggr2; blue columns 6,7,8) of WNT5A in comparison to the sole 
tumor cell culture Aggr6 (blue columns 18,19,20), whereas Aggr7 (blue columns 
14,15,16) expresses less, comparable to the level expressed in the reference dermal 
fibroblasts (blue columns 2,3,4). These differences can be observed on the mRNA-
level (blue columns 2,6,10,14,18), on the protein level in the cytoplasm (blue columns 
3,7,11,15,19), as well as on the level of WNT5A secreted into the supernatant (blue 
columns 4,8,12,16,20).  
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Figure 31: Endogenous WNT5A-expression in tumor tissues of aggressive fibromatoses 
as compared to reference fibrous tissues and in corresponding primary cell cultures. 
a) WNT5A-expression measured on the mRNA level (RNA) using Agilent microarrays 
and on the protein level on Western blots using cytoplasmic protein extracts (Cytopl) 
and cell culture supernatants (Supernat). Aggr2, Aggr4, Aggr7, Aggr6 tumor tissues 
(red bars TT) and the reference fibrous tissue pool (red bar RT) were analyzed using 
Agilent microarrays, whereas the corresponding cell cultures (blue bars Culture) were 
examined using both Agilent microarrays and Western blots. The three values for the 
Culture Ref pool represent the means of the values obtained analyzing the single cell 
cultures of normal human dermal fibroblasts NHDF, HDF15 and HDF21. 
b) WNT5A-expression measured on the protein level on a Western blot using 
cytoplasmic protein extracts of cell cultures of normal human dermal fibroblasts 
NHDF, HDF15 and HDF21 and of aggressive fibromatoses Aggr2, Aggr4, Aggr7, and 
Aggr6. The intensity of the bands was quantified and the resulting values integrated 
as columns (Cytopl) into Figure 31 a). β-tubulin: loading control.  
c) WNT5A-expression measured on the protein level on a Western blot using 
immunoprecipitated supernatants of cell cultures of normal human dermal fibroblasts 
NHDF, HDF15 and HDF21 and of aggressive fibromatoses Aggr2, Aggr4, Aggr7, and 
Aggr6. The intensity of the bands was quantified and the resulting values integrated 
as columns (Supernat) into Figure 31 a). Different amounts of recombinant WNT5A 
were added to estimate the amount of endogenously produced WNT5A secreted by 
the cell cultures. Ig heavy chain: Immunoglobulin heavy chain of the WNT5A-antibody 
used to immunoprecipitate WNT5A. 
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In several experiments described in Chapter III, primary cell cultures of aggressive 
fibromatoses and reference normal fibroblasts will be treated with recombinant 
WNT5A to analyze its impact on cellular signalling pathways and behaviour. The aim 
of the addition of three different amounts of recombinant WNT5A on the gel analyzing 
WNT5A-immunoprecipitated cell culture supernatants (Figure 31c) was it therefore to 
approximately quantify the amount of WNT5A secreted by these cell cultures. This 
allows then to estimate the proportion of secreted WNT5A in comparison to the 
added recombinant WNT5A. The calculations yielded the following result: The cell 
culture Aggr4, producing the highest amount of WNT5A (Figure 31c), secrets ~ 60 ng 
WNT5A during 72 hours, per 1.5 millions of cells into 36 ml of medium. In a typical 
experiment presented in Chapter III, 150 ng/ml recombinant WNT5A was added to 
~1 million of cells in 4 ml of medium, thus an amount (600ng), that is 15 times higher 
then the WNT5A secreted by 1 million of Aggr4 cells during 72 hours (40ng). Aggr6 
and the other cell cultures analyzed secrete even less.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter II 
  14 
5. Discussion 
 
 
5.1. Summary of the results 
 
Of the five cell cultures (Aggr2-6) being derived from β-catenin mutated aggressive 
fibromatosis tumors, only one (Aggr6) undoubtedly proved to represent a tumor cell 
culture, whereas the others certainly are cultures of normal fibroblasts. Concerning 
Aggr1, Aggr7 and all the superficial fibromatosis cell cultures, their tumoral origin 
could not be determined using mutation analyses due to a missing mutation in the 
second APC-allele (Aggr1), or due to missing mutations in the β-catenin gene (Aggr7, 
all Supers) in the tumor tissues.  
 
The established primary cell cultures do not represent immortalized cell lines, since 
they go into the stadium of senescence after 23 passages. 
 
Aggressive fibromatosis tumor tissues highly overexpress WNT5A as compared to 
reference fibrous tissues. In contrast, the sole tumor cell culture Aggr6 is not 
characterized by an increased expression or secretion of WNT5A as compared to cell 
cultures of normal fibroblasts. There is a pronounced correlation between WNT5A 
mRNA synthesis, WNT5A protein expression and WNT5A protein secretion in the cell 
cultures analyzed. The amount of endogenously secreted WNT5A by these cell 
cultures represents just a small portion of the amount of recombinant WNT5A usually 
added to the cells in a typical experiment described in Chapter III.  
 
 
5.2. Published studies using primary cultures of aggressive and superficial 
fibromatoses 
 
Several papers published in the literature report about the use of primary tumor cell 
cultures derived from fibromatoses in functional studies (Section 2.2.). 
 
The papers dealing with primary cell cultures of aggressive fibromatoses are 
summarized in Figure 32. It is striking that the mutation status of the tumor tissues is 
in most of the cases properly annotated (column 2), whereas the one for the 
corresponding primary cell cultures is always missing (column 3). Therefore, the 
formal proof that these cell cultures represent primary tumor cell cultures and not 
cultures of tumor-associated fibroblasts is lacking in all these studies. Instead, the 
authors try to prove the tumoral origin of their cell cultures in the following ways:  
 
In one study, the authors used instead an immunohistochemical approach, showing 
that an antibody raised against the C-terminal part of APC detects this protein in 
cultures of normal fibroblasts, but not of aggressive fibromatoses, due to their biallelic 
C-terminal truncating mutations in the gene coding for this protein (Li et al., 1998). 
 
In addition, the same authors report about an accumulation of β-catenin in these 
tumor cells (Western blot, whole cell protein extracts) that can be repressed by an 
exogenous expression of wildtype APC (Li et al., 1998). Two other papers report 
about an enhanced accumulation of nuclear β-catenin in the cell cultures of 
aggressive fibromatoses as compared to cultures of control fibroblasts, using 
immunhistochemistry (Amini Nik et al., 2005; Denys et al., 2004b). A similar 
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argument for the tumoral origin of their cell cultures provide the authors of another 
report, showing an increased nuclear β-catenin staining in tumoral cell cultures using 
confocal immunofluorescence microscopy (Tejpar et al., 1999). 
 
The authors of three studies argue for a tumoral origin of their cell cultures used by 
describing their increased TCF-LEF-dependent transcriptional activity (Luciferase-
reporter assay) as compared to the one of normal fibroblasts (Amini Nik et al., 2005; 
Denys et al., 2004b; Tejpar et al., 2001). 
 
In two further papers, the authors do not tell anything about the ‘tumoral origin’ of 
their cell cultures (Denys et al., 2004a; Locci et al., 2001). 
 
Thus, since in all these studies mutation analyses to prove the tumoral origin of the 
primary cell cultures used are missing, it is at least questionable whether all the 
reported cultures in the literature truly represent tumor cell cultures.   
 
Primary cell culture Paper
Number and type Mutation status Prove of tumoral origin
Antibody C-terminus APC (IHC)
Increased β-catenin (Western, whole cell)
1 x FAP-assoc. APC: biallelic
3 x Sporacic β-catenin: monoallelic
2 x Sporadic β-catenin: no mutation
? x FAP-assoc. APC: biallelic No prove provided Locci et al ., 2001
2 x FAP-assoc. APC: biallelic
6 x Sporadic β-catenin: monoallelic
2 x Sporadic β-catenin: no mutation
2 x FAP-assoc. APC: biallelic Increased nuclear β-catenin accum. (IHC)
2 x Sporadic β-catenin: monoallelic Increased TCF-LEF-reporter assay activity
7 x not described No prove provided Denys et al. , 2004a
2 x FAP-assoc. APC: biallelic Increased nuclear β-catenin accum. (IHC)
3 x Sporacic β-catenin: monoallelic Increased TCF-LEF-reporter assay activity
Li et al ., 1998
Increased TCF-LEF-reporter assay activity
Aggressive fibromatosis tumor tissue
Denys et al ., 2004b
Tejpar et al. , 2001
Tejpar et al ., 1999
Amini Nik et al ., 2005
Increased nuclear β-catenin                      
(Confocal microscopy)
4 x FAP-assoc. APC: biallelic
 
Figure 32: Studies published in the literature describing the use of primary tumor cell cultures of 
aggressive fibromatoses and the approach to prove their tumoral origin. Number and type: number of 
sporadic or familial adenomatous polyposis (FAP)-associated aggressive fibromatosis tumor tissues 
taken into culture. 
 
The situation is even more questionable, when looking at the publications reporting 
the use of primary tumor cell cultures derived from superficial fibromatoses (Section 
2.2.2.). In those papers, the authors do not tell anything about a characterization of 
their cell cultures used.   
 
 
5.3. Endogenous WNT5A expression 
 
The primary cell culture Aggr6 represents the only established primary aggressive 
fibromatosis tumor cell culture. Therefore, a similar overexpression of WNT5A in this 
verified tumor cell culture would be expected in comparison to all the other cultures of 
normal fibroblasts, if the differences observed on the tissue level are transferable into 
primary cell cultures. Our data demonstrate that such a correlation between tissues 
and cell cultures does not exist for the expression of WNT5A. Two explanations may 
come up with this result.  
 
First, both tumor cells and tumor-associated fibroblasts are responsible for the 
observed overexpression of WNT5A in tissues of aggressive fibromatoses. An 
immunohistochemistry (IHC) and in-situ hybridization (ISH) approach was attempted 
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to help to clarify this issue. But due to a missing specificity of the WNT5A-antibody 
(IHC) and an unsatisfying reproducibility of the ISH-results, this attempt had to be 
abandoned.  
 
The second explanation for the missing correlation between WNT5A-expression in 
tumor tissues and cell cultures is the completely modified microenvironment tumor 
cells are faced to in artificial in vitro cell cultures as compared to the highly complex 
cell-cell- and cell-extracellular matrix (ECM)-interactions tumor cells are involved in in 
vivo. Missing influences of neighbouring cells and/or ECM-proteins may therefore be 
responsible for the observed reduced WNT5A-expression in the tumor cell culture 
Aggr6. In fact, several studies published in the literature claim that the expression of 
WNT5A in different cell cultures is inducible after the addition of certain stimuli.  
 
Human umbilical venous endothelial cells (HUVEC) react to inflammatory mediators 
with an increased expression of WNT5A, leading to their enhanced proliferation and 
migration (Cheng et al., 2008). Stimulation of human T-lymphocyte cultures with the 
chemokine CXCL12 induces their secretion of WNT5A that in turn exerts a positive 
autocrine effect on their migratory behaviour (Ghosh et al., 2009). Cell cultures of 
human macrophages respond to the addition of LPS or interferon gamma with an 
enhanced expression of WNT5A that induces their secretion of proinflammatory 
cytokines (Pereira et al., 2008). Rat neonatal heart myocyte cell cultures show an 
enhanced expression of WNT5A after the interleukin-6-dependent activation of the 
transcription factor STAT3. This leads to a stabilization of N-cadherin and an 
enhanced cell adhesion (Fujio et al., 2004). In cell cultures of human papillary thyroid 
cancer, pancreatic cancer and cutaneous melanoma, the expression of WNT5A is 
dependent on the activation of the Toll-like receptor 3 (TLR3) that in turn activates 
STAT3 through the upregulation of interleukin-6. Through this mechanism, the 
proliferation and migration of those tumor cells gets enhanced (McCall et al., 2007; 
Schwartz et al., 2009). In human pancreatic cancer cell cultures, TGFβ was shown to 
activate the transcription factor CUTL1 that upregulates the transcription of WNT5A, 
leading to increased migration, invasion, proliferation, and expression of marker 
genes associated with epithelial-mesenchymal transition (EMT) (Ripka et al., 2007). 
In human cutaneous melanoma cell cultures, the expression of WNT5A gets 
enhanced after the addition of heparan sulfate proteoglycans (HSPGs), components 
of the ECM that induce in this way the invasive capacity of those cells (O'Connell et 
al., 2009).  
 
On the other hand, genetic alterations of the WNT5A gene, such as amplifications, 
leading to an enhanced expression of WNT5A in tumor cells, have not been 
described in the literature up to date.  
 
 
5.4. Possible approaches to improve the rate of success for the 
establishment of primary tumor cell cultures 
 
The experiments done to establish primary cell cultures of aggressive and superficial 
fibromatoses impressively demonstrated that this approach is a tricky task. Of the five 
cell cultures (Aggr2-6) being derived from β-catenin-mutated aggressive fibromatosis 
tumors, only one undoubtedly proved to represent a tumor cell culture, whereas the 
others certainly are cultures of normal fibroblasts. Concerning Aggr1, Aggr7 and all 
the superficial fibromatosis cell cultures, their tumoral origin could not be determined 
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using mutation analyses due to a missing mutation in the second APC-allele (Aggr1), 
or due to missing mutations in the β-catenin gene (Aggr7, all Supers) in the tumor 
tissues.  
 
The question therefore raises, whether there may be some technical improvements 
feasible to specifically enrich the number of fibromatosis tumor cells before taking 
them into culture in order to increase the likelihood for establishing a primary tumor 
cell culture.  
 
One approach would be to transfect the cells with a TCF-reporter construct and sort 
for the positive cells using fluorescence-activated cell sorting (FACS) analysis, since 
a hallmark of all fibromatoses is an accumulation of β-catenin in the nucleus and 
therefore an increased TCF-dependent transcription (Alman et al., 1997a; 
Montgomery et al., 2001; Tejpar et al., 1999; Varallo et al., 2003). Two aspects impair 
the usefulness of this approach. First of all, our study revealed that tumor-associated 
fibroblasts of aggressive fibromatoses are characterized by an enhanced – although 
reduced in comparison to tumor cells – activity of TCF-dependent transcription as 
well (Chapter III, Section 4.2.1.). Therefore, the setting of the threshold-level for the 
sorting process may be difficult. Secondly, there is no study published so far 
describing the activity of TCF-dependent transcription in tumor cell cultures of 
fibromatoses lacking any β-catenin or APC-mutation. It is unknown whether these 
cells retain their constitutive activation when taken into culture, since the dogma of 
constitutive activation of TCF-LEF-dependent transcription in all fibromatoses, 
independent of any APC- or β-catenin mutation background, is derived from β-
catenin immunohistochemical analyses on tissue sections. Therefore, whereas such 
a FACS approach may be appropriate for tumors carrying APC- or β-catenin-
mutations, it may not be feasible for superficial fibromatoses and aggressive 
fibromatoses without β-catenin/APC-mutations.  
 
Another approach would be to sort the cells prior cultivation using a cell membrane 
marker that is specifically overexpressed in fibromatoses tumor cells as compared to 
tumor-associated normal fibroblast. Unfortunately, such a marker has not been 
found, yet.  
 
Aggressive and superficial fibromatoses are characterized by their capability to 
invade into neighbouring tissues (Chapter I, Section 2.1.). Primary tumor cells may 
show an enhanced invasive growth in an in vitro invasion assay. Selection and 
further culturing of the first cells being able to invade through the ECM-barrier in such 
an assay may therefore be a possible approach to specifically enrich tumor cells.  
 
A selection for those cells that show a higher proliferation rate may be another 
possibility.  
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Chapter III 
The impact of WNT5A on cell signalling pathways and biological 
behaviour of aggressive fibromatosis tumor cells  
 
 
1. General introduction 
 
 
In this chapter, the focus is laid on the analysis of WNT5A’s impact on cell signalling 
pathways and biological behaviour of aggressive fibromatosis tumor cells. Since 
WNT5A is known to activate both canonical and non-canonical Wnt pathways, the 
latter will be introduced in the following general introduction. A comprehensive 
description of the canonical Wnt pathway can be found in Chapter I, Section 1.1. 
Subsequently, published studies analyzing the role of WNT5A in the pathogenesis of 
cancer will be reviewed.  
 
 
1.1. The non-canonical Wnt pathways 
 
In this section, the non-canonical – meaning β-catenin-independent – Wnt signalling 
pathways should be introduced on the basis of their components. In addition, their 
crosstalks with the canonical Wnt signalling pathway should be demonstrated.  
 
1.1.1. The Wnt-Ca2+ signalling pathway 
 
The idea that there are multiple Wnt signalling pathways came up with experiments in 
Xenopus embryos and mouse C57MG mammary epithelial cells showing that 
vertebrate Wnts can be divided into two groups according to their biological activities. 
Ectopic expression of the first group of Wnts (including WNT1, WNT3A, WNT8 and 
WNT8B) induces a secondary axis in Xenopus embryos (Du et al., 1995) and 
morphologically transforms C57MG mammary epithelial cells (Wong et al., 1994) 
through the activation of the canonical Wnt pathway. In contrast, the expression of 
the second group of Wnts (WNT4, WNT5A, WNT11) neither induces a second axis in 
Xenopus, nor transforms C57MG cells. However, these Wnts are biologically active, 
since they are important for convergent extension movements (directed migrations of 
cells driving the mediolateral convergence and anteroposterior extension of the body) 
during Xenopus embryogenesis (Du et al., 1995; Moon et al., 1993; Torres et al., 
1996).  
 
Further experiments, mainly done using WNT5A, supported the hypothesis that there 
is more than one signalling pathway induced by the Wnts. In contrast to the first 
group of Wnts that transform C57MG cells after ectopic expression, loss of function 
of WNT5A by antisense RNA is also transforming (Olson and Gibo, 1998). WNT5A 
induces a secondary axis in Xenopus via the canonical Wnt pathway when 
coexpressed with the Frizzled (Fzd) receptors Fzd4, Fzd5, Fzd7 or Fzd8 (Deardorff 
et al., 1998; He et al., 1997; Itoh et al., 1998; Umbhauer et al., 2000). WNT5A blocks 
the ability of WNT8 to induce a secondary axis (Torres et al., 1996). These 
experiments led to the assumption, that the different cellular responses elicited by the 
various Wnts in Xenopus and C57MG cells are derived from multiple pathways 
induced by the signalling specificities of each single Wnt-Fzd receptor interaction. 
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This point of view got further support by a recent study in human embryonic kidney 
cells, demonstrating that WNT5A activates the canonical Wnt pathway when 
coexpressed with Fzd4 and LRP5, but inhibits the same when coexpressed with 
ROR2 (Mikels and Nusse, 2006).  
 
Subsequent experiments were dedicated to elucidate the details of the so far 
unknown Wnt signaling pathway (Figure 33). WNT5A, but not the axis-inducing 
WNT8, triggers an intracellular Ca2+ release (Slusarski et al., 1997b). Ectopic 
expression of a serotonin receptor, known for its induction of intracellular Ca2+ 
release, blocks the ability of WNT8 to induce a secondary axis, thus phenocopies the 
effect of WNT5A, showing that WNT5A inhibits the canonical Wnt pathway in a Ca2+-
dependent manner (Slusarski et al., 1997b). The intracellular Ca2+ release induced 
by WNT5A is dependent upon heterotrimeric G proteins, since this effect can be 
blocked by the addition of the specific G protein inhibitor Pertussis toxin. 
Heterotrimeric G proteins are so named because of their three distinct subunits Gα, 
Gβ, Gγ, and because the activity of Gα is dependent on the binding of guanosine 
triphosphate (GTP). In its inactive state, Gα binds guanosine diphosphate (GDP). In 
addition, an inositol monophosphatase inhibitor blocks the intracellular Ca2+ efflux as 
well, an effect that can be avoided by concomitant treatment with myoinositol 
(Slusarski et al., 1997a), indicating that Gα activates phospholipase C β (PLCβ), that 
in turn induces the intracellular Ca2+ release through the cleavage of 
phosphatidylinositol diphosphate (PIP2) to yield diacylglycerol (DAG) and inositol 
triphosphate (IP3). Thus, WNT5A inhibits the canonical Wnt pathway by the activation 
of the phosphatidylinositol pathway in a G protein-dependent manner leading to an 
intracellular Ca2+ efflux. Subsequently, it was shown that WNT5A activates the 
downstream, Ca2+-sensitive enzymes calcium-calmodulin-dependent protein kinase II 
(CamKII) (Kuhl et al., 2000a) and protein kinase C (PKC) (Sheldahl et al., 1999). In 
contrast, WNT8, that activates the canonical Wnt pathway, does not activate either 
CamKII or PKC. After these findings, the newly detected Wnt pathway was termed 
Wnt-Ca2+ pathway (Kuhl et al., 2000b). Further components of Wnt-Ca2+-pathway 
could also be found, namely the transcription factor nuclear factor of activated T cells 
(NFAT) that gets dephosphorylated and activated through the calmodulin-dependent 
phosphatase calcineurin (PP2B) (Saneyoshi et al., 2002) and Dishevelled (Dsh), that 
is also involved in the canonical Wnt pathway (Sheldahl et al., 2003).  
 
In other studies, the components of the canonical Wnt and Wnt-Ca2+ pathway were 
determined that are responsible for the observed crosstalk between these two 
pathways. It turned out that the canonical Wnt pathway is absolutely necessary for 
convergent extension movements during Xenopus gastrulation, but that the Wnt-Ca2+ 
pathway exerts an important modulating effect on it, by inhibiting Dsh through PKC 
and LEF via CamKII and therefore inhibiting the activity of the canonical Wnt pathway 
(Kuhl et al., 2001). Working with human embryonic kidney cells, the authors of 
another study report that the CamKII induced inhibition of the canonical Wnt pathway 
is dependent upon a downstream activation of the MAPKs TAK1 and NLK (Ishitani et 
al., 2003).  
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Figure 33: The components of the canonical Wnt  
and the Wnt-Ca2+ pathway and their crosstalk 
 
 
1.1.2. The Wnt-PCP signalling pathway 
 
A series of experiments indicated that the observed modulation of convergent 
extension movements in Xenopus embryogenesis is not solely dependent upon the 
Wnt-Ca2+ signalling pathway, but at least in part upon another non-canonical Wnt 
pathway that shows similarities to the planar cell polarity (PCP) pathway in 
Drosophila and is therefore termed Wnt-PCP pathway. In Drosophila, the PCP 
pathway is needed to control the orientation of hairs, bristles and ommatidia during 
embryogenesis.  
 
In the following review of the literature, the components of the Wnt-PCP pathway will 
briefly be introduced (Figure 34). Whereas the DIX-domain of Dsh is needed to 
activate the canonical Wnt pathway, its DEP-domain is absolutely required for the 
induction of both Drosophila PCP and vertebrate Wnt-PCP pathway (convergent 
extension movements) (Axelrod et al., 1998; Boutros et al., 1998; Heisenberg et al., 
2000; Tada and Smith, 2000). A Dsh-construct lacking the DIX-domain – thus 
activating the Wnt-PCP pathway but not the canonical Wnt pathway – was shown to 
be a strong inducer of the Wnt-Ca2+ pathway as well (Sheldahl et al., 2003). These 
findings indicate that the canonical Wnt pathway diverges from the non-canonical 
pathways at the level of Dsh, whereas the Wnt-Ca2+ pathway diverges from the Wnt-
PCP pathway more downstream (Veeman et al., 2003). Further mediators of the 
Drosophila PCP and vertebrate Wnt-PCP pathway include members of the Rho 
family of small GTPases, namely Rho, Rac and Cdc42. In Drosophila, Rho acts 
downstream of Dsh (Strutt et al., 1997), whereas a function for Cdc42 has also been 
proposed (Eaton et al., 1996). Rho, Rac and Cdc42 have all been implicated in 
vertebrate Wnt-PCP signalling (Choi and Han, 2002; Habas et al., 2003; Habas et al., 
2001; Penzo-Mendez et al., 2003), whereupon a parallel induction of Rho and Rac by 
Dsh has been shown to be essential (Habas et al., 2003). More downstream of the 
small GTPases, the c-jun-N-terminal kinase (JNK) comes into play. It is essential for 
the PCP pathway in Drosophila (Boutros et al., 1998). Which small GTPases are 
responsible for JNK-activation in the vertebrate Wnt-PCP pathway is controversially 
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discussed, with one report stating that JNK is activated through Dsh and Rac, but not 
Rho or Cdc42 (Habas et al., 2003), the other study showing that JNK induction 
requires both Rac and Cdc42 (Moriguchi et al., 1999). 
 
In addition, there’s a plethora of studies reporting that WNT5A activates JNK through 
binding to the receptor tyrosine kinase-like orphan receptor 2 (ROR2). In a recent 
study describing this connection, the authors claim that the resulting modulation of 
convergent extension movements in Xenopus embryos should be considered as a 
novel non-canonical Wnt pathway, since it functions independent of Dsh, known to 
be essential for the Wnt-PCP pathway (Schambony and Wedlich, 2007). However, 
the authors of another study working with human osteosarcoma cell cultures report 
that WNT5A signals via ROR2 and Dsh2 to activate JNK, leading to increased 
invasion and migration, suggesting that ROR2 represents an alternative receptor for 
WNT5A to activate the Wnt-PCP pathway (Enomoto et al., 2009). This view is 
supported by the work demonstrating that ROR2 functions as a coreceptor for Fzd 
receptors, similar to the LRP5/6 coreceptors, but with different downstream activation 
characteristics. After WNT5A-binding to ROR2, its intracellular domain gets 
phosphorylated by certain kinases, leading to the activation of ROR2 and the 
inhibition of the canonical Wnt pathway through the involvement of unknown 
downstream components (Winkel et al., 2008). On the other hand, after binding of a 
‘canonical’ Wnt, such as WNT1, ROR2 does not get phosphorylated and activated. In 
contrast, this interaction leads to a potentiation of the canonical Wnt-signalling 
pathway activation, probably because ROR2 supports the binding of the canonical 
Wnt to its cognate receptor. Thus, depending on the Wnt binding, ROR2 functions as 
a Fzd coreceptor to potentiate or repress canonical Wnt-signalling. The authors of 
another study draw the same conclusion, demonstrating that ROR2 functions as a 
Fzd coreceptor important to activate the Wnt-PCP pathway, but suppressing the 
canonical Wnt pathway (Yamamoto et al., 2008). This opinion is further underlined by 
two studies showing that WNT5A, but not the canonical WNT3A, induces the 
dimerization of ROR2, leading to the activation of the tyrosine kinase SRC 
(Akbarzadeh et al., 2008) or the serine/threonine kinases GSK3α/β (Liu et al., 
2008b), that in turn phosphorylate and activate the intracellular domain of ROR2. 
Further studies are needed to elucidate the function of ROR2 in context of Wnt-PCP 
signalling. However, whether it functions as a Fzd-independent or a Fzd coreceptor, 
whether it induces the Wnt-PCP pathway or a Dsh-independent, novel non-canonical 
pathway: most studies published report that it represents the relay station between 
Wnt and JNK. Therefore, to simplify matters, ROR2-dependent JNK-activation is 
going to be considered as an activated Wnt-PCP signalling pathway in the following 
presentation of the literature.  
 
JNK functions as a mitogen-activated protein kinase (MAPK), phosphorylating and 
activating among others components of the dimeric activator protein (AP-1) 
transcription factor complex such as the c-jun, junB and junD. AP-1 is composed of 
several different heterodimeric complexes of proteins derived from the fos and jun 
families including c-fos, fosB, fra-1, fra-2, c-jun, junB and junD. Upon phosphorylation 
by JNK or other MAPKs and subsequent dimerization, the AP-1 transcription factor 
complexes translocate into the nucleus and activate the transcription of AP-1-
dependent target genes (Eferl and Wagner, 2003; Vogt, 2001).  
 
A vast literature describes an inhibitory crosstalk between the Wnt-PCP pathway and 
the canonical Wnt pathway: in Xenopus embryogenesis modulating convergent 
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extension movements (Schambony and Wedlich, 2007; Yamanaka et al., 2002), in 
human osteosarcoma cell lines (Enomoto et al., 2009), in human embryonic kidney 
cells (Mikels et al., 2009; Mikels and Nusse, 2006; Winkel et al., 2008; Yamamoto et 
al., 2008) and in an axin-LacZ-canonical Wnt pathway reporter mouse model (Mikels 
et al., 2009). Nevertheless, the identification of the exact components of these two 
pathways being involved in this crosstalk has not been described, yet.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Figure 34: The components of the canonical Wnt  
and the Wnt-PCP pathway and their crosstalk 
 
1.1.3. The cAMP-dependent protein kinase (PKA) pathway 
 
The cAMP-dependent protein kinase (PKA) pathway has not been categorized as a 
‘real’ non-canonical Wnt pathway, since only two studies involving WNT5A proved its 
activation through Wnts, yet (Hansen et al., 2009; Torii et al., 2008).  
 
Normally, the activity of this pathway is started upon binding of ligands, such as 
growth factors or neurotransmitters, to G protein-coupled receptors (GPCR) (Figure 
35). These receptors then activate a heterotrimeric G protein, so named because it 
consists of three distinct subunits (Gα, Gβ, Gγ), and because the activity of Gα is 
dependent on the binding of guanosine triphosphate (GTP). In its inactive state, Gα 
binds guanosine diphosphate (GDP).  Upon stimulation through the GPCR, Gα 
switches into its active state, allowing its dissociation from the two other partners and 
its activation of the adenylyl cyclase (AC). The AC produces the ubiquitous 
intracellular messenger cyclic adenosine monophosphate (cAMP) by converting 
adenosine triphosphate (ATP). The major function of cAMP is activating the cAMP-
dependent protein kinase (PKA), a tetramer protein consisting of two catalytic 
subunits and two regulatory subunits that upon cAMP binding dissociate from the 
catalytic subunits. The free activated PKA catalytic subunits then translocate into the 
nucleus and phosphorylate the cAMP response element binding protein (CREB) at 
serine 133, rendering it active to bind to the promoters of target genes and induce 
their transcription (Chiaradonna et al., 2008). 
 
Upon activation through WNT5A, PKA was reported to phosphorylate and inactivate 
GSK3β at serine 9, leading to the accumulation of β-catenin and its translocation into 
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the nucleus, therefore inducing an activating crosstalk between the PKA-pathway 
and the canonical Wnt-pathway (Torii et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: The components of the canonical Wnt  
and the PKA pathway and their crosstalk 
 
 
1.1.4. The signal transducer and activator of transcription (STAT) pathway 
 
As the PKA pathway, the STAT pathway has only recently been described to be 
induced by WNT5A and therefore is not considered as an established non-canonical 
Wnt pathway (Dissanayake et al., 2008) (Figure 36).  
 
The signal transducer and activator of transcription (STAT) family of transcription 
factors are activated by virtually every cytokine and growth factor and therefore are 
essential components in the immune system. Their activity is induced through 
tyrosine phosphorylation by ligand-activated receptor tyrosine kinases (such as 
epidermal growth factor receptor, EGFR) or by receptors that lack intrinsic tyrosine 
kinase activity but to which janus kinases (JAK) are associated (such as receptors for 
interferon-α or interleukin-13). The STAT family consists of seven members. After 
tyrosine phosphorylation, STAT dimers and heterodimers, but not monomers, are 
competent to bind to the promoters of target genes (Aaronson and Horvath, 2002). In 
the study describing an activation of the STAT pathway by WNT5A, JAK was not 
involved. Instead, WNT5A activated STAT3 in a PKC-dependent manner.  
 
No crosstalk with the canonical Wnt signalling pathway was reported.  
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Figure 36: The components of the STAT pathway  
 
 
1.2. The role of WNT5A in the pathogenesis of cancer 
 
In the following two sections, studies published in the literature should be presented 
that brought WNT5A into context with the pathogenesis of a diverse array of human 
cancers. The first section deals with functional studies in cell cultures and animal 
models, whereas the second section is dedicated to the discussion of studies linking 
the expression of WNT5A to clinical data.  
 
1.2.1. Functional studies in cell cultures and animal models 
 
The results discussed in this section are summarized in Figure 37. 
 
- Breast cancer 
 
The role of WNT5A in the pathogenesis of breast cancer is controversially discussed 
in the literature.  
 
In one study using the human immortalized mammary epithelial cell line HC11, 
WNT5A was shown to increase the proliferation rate by transactivating the receptor 
tyrosine kinase EGFR through the canonical Wnt pathway leading to the expression 
of matrix metalloproteinases (MMPs) and the resultant increase of the availability of 
EGFR ligands (Civenni et al., 2003). This study indicates therefore that WNT5A might 
exert tumor-promoting capabilities in the pathogenesis of breast cancer through the 
activation of the canonical Wnt pathway. This finding is supported by a report stating 
that macrophages-derived WNT5A promotes the invasive capacity of the human 
breast cancer cell line MCF-7 by activating the Wnt-PCP pathway (Pukrop et al., 
2006).  
 
All the other studies analyzing the role of WNT5A in the pathogenesis of breast 
cancer favour a tumor-suppressing function for this protein. In the first study ever that 
brought WNT5A into context with tumorigenesis, it was reported that the inhibition of 
its expression through the use of antisense RNA in mouse mammary epithelial 
C57MG cells leads to their transformation (Olson and Gibo, 1998). Working with the 
human breast cancer cell line MCF-7 that was used in the study reported before 
(Pukrop et al., 2006), the authors came to the conclusion, that WNT5A inhibits the 
migration of the cells by activating the PKA pathway (Hansen et al., 2009). An 
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inhibiting impact on both migration and invasion by WNT5A through the activation of 
the Wnt-Ca2+ pathway was reported for the human immortalized mammary epithelial 
cell line HB2 (Dejmek et al., 2006). The remaining studies report a tumor-suppressive 
function of WNT5A as well, but do not demonstrate the exact signalling pathway by 
which WNT5A achieves its effect. An inhibiting effect on the canonical Wnt pathway 
was reported in mouse mammary cell cultures, leading to an increased differentiation 
of the cells (Roarty et al., 2009). In human breast cancer cell lines, WNT5A was 
shown to suppress invasion by increasing intercellular adhesion (Medrek et al., 
2009). In estrogen receptor-α (ERα)-negative human breast cancer cell lines, the 
addition of WNT5A led to an increased ERα expression through a reduction of its 
promoter methylation. Consequently, these cells regain their responsiveness to 
Tamoxifen (Ford et al., 2009a). Finally, there are two studies analyzing the impact of 
WNT5A in a mouse model: Mouse 4T1 breast cancer cells inoculated in mouse fat 
pad generated less metastases to lungs and liver when mice were treated with 
WNT5A (Safholm et al., 2008). In a mouse ERα-negative breast cancer model, the 
injection of WNT5A led a reduction of liver and lung metastases, and an upregulation 
of ERα (Ford et al., 2009b). 
 
- Cutaneous melanoma 
 
Concerning cutaneous melanoma, there is a consensus in the literature that WNT5A 
exerts a tumor promoting effect. Working with human cutaneous melanoma cell 
cultures, the authors of several studies report an activation of the Wnt-Ca2+ and Wnt-
PCP pathway by WNT5A, leading to an increased migration and invasion of the cells 
(O'Connell et al., 2009a; Weeraratna et al., 2002; Witze et al., 2008). In the same cell 
cultures, an activation of the STAT pathway probably through the Wnt-Ca2+ pathway 
was described, leading to a suppression of the expression of tumor-associated 
antigens MITF, MART-1 (Dissanayake et al., 2008). Heparan sulfate proteoglycans 
(HSPGs) were shown to exert an expression inducing effect on WNT5A, leading to 
an increased invasive behaviour of cultured human cutaneous melanoma cells 
(O'Connell et al., 2009b). WNT5A was shown to increase the intracellular Ca2+ 
mobilization in cutaneous melanoma cell cultures, through the activation of Fzd2 and 
cGMP-phosphodiesterase 6 (PDE6) (Bazhin et al., 2009). Additionally, a positive 
effect of WNT5A on proliferation and migration via an unknown signalling pathway 
was reported (Schwartz et al., 2009). Using in vitro and in vivo metastasis assays, 
the authors of another study showed that the Wnt-PCP pathway (ROR2) is necessary 
for the WNT5A-mediated metastasis of cutaneous melanoma cells (O'Connell et al., 
2009c). 
 
- Hematopoietic neoplasia 
 
In the pathogenesis of hematopoietic neoplasia, the data in the literature favour a 
tumor suppressive role for WNT5A. In mouse B lymphocytes from fetal liver, WNT5A 
activated the Wnt-Ca2+ pathway with a subsequent reduction in the expression level 
of cyclin D1 and a diminished proliferation rate, indicating an inhibitory crosstalk 
between the Wnt-Ca2+ and the canonical Wnt pathway in these cells, initiated by 
WNT5A (Liang et al., 2003). This study got further support by a paper showing that 
the WNT5A promoter is hypermethylated in all human acute lymphoblastic leukemia 
cell lines analyzed and that the hypermethylation in primary tissues of this disease 
correlates with an upregulation of cyclin D1 (Roman-Gomez et al., 2007). WNT5A 
promoter hypermethylations were also found in cell cultures of human nasal NK/T-
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cell lymphoma, leukemia and Burkitt lymphoma, further supporting the view of a 
tumor suppressive role for WNT5A in hematopoietic neoplasia (Ying et al., 2007). 
 
- Gastric cancer 
 
Two studies analyzing the role of WNT5A in the formation of gastric cancer led to the 
conclusion that it promotes carcinogenesis of this tumor. In the first report, the 
authors describe that WNT5A induces cell adhesion and migration of gastric cancer 
cells in vitro by the activation of the Wnt-Ca2+ pathway (Kurayoshi et al., 2006). In the 
other report, human gastric cancer cells with and without expressing WNT5A siRNA 
were injected in spleens of nude mice and the resulting liver metastases were 
counted. The authors could show that WNT5A increased the number of liver 
metastases due to its positive effect on the expression Laminin γ2, a component of 
the basement membrane, essential for cell migration and adhesion. In vitro, they 
showed that this effect is dependent on the Wnt-Ca2+ and Wnt-PCP pathway 
(Yamamoto et al., 2009). 
 
- Neuroblastoma 
 
In human neuroblastoma cell cultures, WNT5A was shown to induce differentiation 
and repress invasion through the Wnt-Ca2+ pathway. It therefore acts as a tumor 
suppressive protein (Blanc et al., 2005). 
 
- Cholangiocarcinoma 
 
WNT5A inhibits the proliferation of human cholangiocarcinoma cell cultures through 
the activation of the non-canonical Wnt-PCP pathway (DeMorrow et al., 2008). 
 
- Prostate cancer 
 
In human prostate cancer cell lines, WNT5A was shown to induce the expression of 
BMPs in a Wnt-PCP pathway-dependent manner, leading to osteoblast differentiation 
and excessive bone production, thus contributing to the pathogenesis of this disease 
(Dai et al., 2008). On the other hand, WNT5A inhibits androgen receptor (AR) 
transcriptional activity in human prostate cancer cell lines, supporting a tumor-
suppressive function for WNT5A in the pathogenesis of this disease (Kawano et al., 
2009). 
 
- Lung cancer 
 
Tobacco smoke condensate (TSC)-induced expression of WNT5A may contribute to 
the pathogenesis of lung cancer through the activation of the Wnt-PCP pathway 
(Hussain et al., 2009). 
 
- Osteosarcoma 
 
A study in human osteosarcoma cell lines showed that WNT5A increased invasion 
and migration through the Wnt-PCP pathway-dependent upregulation of MMP13 and 
a concomitant inhibition of the canonical Wnt pathway (Enomoto et al., 2009). 
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- Papillary thyroid cancer 
 
Via an unknown signalling pathway, WNT5A was shown to promote proliferation and 
migration in human papillary thyroid cancer cell cultures (McCall et al., 2007). 
 
- Pancreatic cancer 
 
The two studies published in the context of pancreatic cancer lead to the conclusion 
that WNT5A promotes the formation of this cancer, but via an unknown pathway. The 
first study showed that TGFβ leads to an increased expression of WNT5A which in 
turn induces migration, invasion and proliferation and modulates expression of 
marker genes associated with epithelial-mesenchymal transition (EMT) (Ripka et al., 
2007). In the second study, the authors provide evidence that WNT5A induces the 
proliferation and migration of human pancreatic cancer cell cultures (Schwartz et al., 
2009). 
 
- Glioblastoma 
 
WNT5A promotes proliferation of human glioblastoma-derived tumor cells in vitro and 
induces infiltrating tumors when injected in nude mice (Yu et al., 2007). 
 
- Non-small-cell lung cancer 
 
WNT5A induces proliferation in human cell cultures of non-small-cell lung cancer 
(Huang et al., 2009). 
 
- Hepatocellular carcinoma 
 
In a study using well-differentiated and poorly-differentiated human hepatocellular 
carcinoma cell lines, WNT5A was shown to induce the poor-differentiated subtype by 
inhibiting the canonical Wnt pathway. The authors propose that Wnt pathways have 
complementary roles in the pathogenesis of hepatocellular carcinomas: a 
deregulated canonical Wnt pathway contributes to tumor initiation, whereas a non-
canonical Wnt pathway induced by WNT5A is essential for tumor progression 
(Yuzugullu et al., 2009). 
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Figure 37: The role of WNT5A in the pathogenesis of cancer based on functional studies in cell 
cultures and animal models 
 
 
1.2.2. Expression studies in human tumor tissues 
 
Figure 38 lists the WNT5A expression studies performed in various tumor tissues to 
correlate its expression with clinical data.  
 
- Studies that confirmed the results obtained from cell culture experiments and animal   
  models 
 
Expression data from breast cancer tissues favour a role for WNT5A as a tumor 
suppressor in this disease (Jonsson et al., 2002; Leris et al., 2005). This confirms 
most of the data obtained from functional studies.  
 
Studies done using tissues of cutaneous melanoma also verify the in vitro findings 
that WNT5A acts as a tumor promoter in cutaneous melanoma (Da Forno et al., 
2008; Dissanayake et al., 2008; Weeraratna et al., 2002).  
 
Expression and promoter-methylation studies performed in tissues of hematopoietic 
neoplasias reflect the results obtained in vitro using cell cultures (Liang et al., 2003; 
Roman-Gomez et al., 2007; Ying et al., 2007).  
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For gastric cancer, its role as a tumor promoter in cell cultures and mouse model 
could be confirmed performing expression studies in tumor tissues (Kurayoshi et al., 
2006; Yamamoto et al., 2009). 
 
A positive correlation between the results of in vitro studies and expression analyses 
in tumor tissues could also be obtained for neuroblastoma, pointing towards a tumor 
suppressive role of WNT5A in the pathogenesis of this disease (Blanc et al., 2005).  
 
In vivo analyses of prostate cancer revealed a hypomethylation of the WNT5A 
promoter leading to its increased expression as compared to reference cells, thus 
indicating a tumor promoting function of WNT5A (Wang et al., 2007). This outcome 
verifies the result of a study performed in vitro (Dai et al., 2008; Kawano et al., 2009).  
 
The proposed role of WNT5A as a tumor promoter in pancreatic cancer cell culture 
experiments was confirmed by expression studies in tumor tissues (Crnogorac-
Jurcevic et al., 2001; Ripka et al., 2007).  
 
Also glioblastoma cell culture and mouse model data could be confirmed in vivo, 
whereupon WNT5A acts as a tumor promoter in this disease (Yu et al., 2007). 
 
- Studies that did not confirm the results obtained from cell culture experiments and  
  animal models 
 
Whereas the in vitro study using cell cultures of non-small-cell lung cancers favoured 
a tumor-promoting role for WNT5A in the pathogenesis of this type of cancer, the 
interpretation of in vivo data are not conclusive (Campioni et al., 2008; Huang et al., 
2005).  
 
A contradictory result to the one obtained in vitro (tumor promoter) yielded the 
expression study in hepatocellular carcinoma, favouring a tumor suppressive role for 
WNT5A (Liu et al., 2008a). 
 
- Studies performed in tumors that have not been analyzed in vitro or in animal  
   models so far 
 
Studies in ovarian cancer (Badiglian Filho et al., 2009) and head and neck squamous 
cell carcinoma (Diaz Prado et al., 2009), both proposing a tumor promoting role for 
WNT5A, can not be compared with functional experiments.  
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Figure 38: The role of WNT5A in the pathogenesis of cancer based on expression studies in human 
tumor tissues and their correlation with clinical data 
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2. Introduction 
 
 
2.1. WNT5A is highly overexpressed in aggressive fibromatoses 
 
The microarray gene expression study comparing pooled aggressive fibromatosis 
tumor tissues with pooled superficial fibromatosis and reference fibrous tissues 
revealed that WNT5A is highly overexpressed in aggressive fibromatoses (Chapter I, 
Section 4.2.). Real-time RT-PCR (Chapter I, Section 4.2.) and additional microarray 
experiments (Chapter II, Section 4.3) on individual tumor tissue samples confirmed 
an upregulation of WNT5A in aggressive fibromatoses.   
 
 
2.2. WNT5A has been implicated in the pathogenesis of many types of cancer 
 
Numerous studies published in the literature brought WNT5A into context with the 
pathogenesis of different types of cancer. Experiments based on functional studies in 
cell cultures and animal models are reviewed in Section 1.2.1., whereas reports 
linking the expression of WNT5A with clinical data are summarized in Section 1.2.2. 
of this chapter.  
 
Aggressive fibromatoses and colon carcinoma are both characterized by β-catenin 
and APC mutations in most of the cases (Chapter I, Sections 1.1.3. and 2.2.1.). 
Studies have been done in colon carcinoma to elucidate the functional role of 
WNT5A. They all suggest that WNT5A exerts a tumor-suppressive role in the 
pathogenesis of this disease. An initial report described that WNT5A-expression was 
missing in several colon cancer cell lines analyzed (Smith et al., 1999). This finding 
was confirmed by a later study showing that the WNT5A promoter is hypermethylated 
in the cancer cell lines HCT116, HT29, SW620, Caco2 and LoVo (Ying et al., 2008). 
Two studies provided evidence that WNT5A achieves its tumor suppressive function 
in colon cancer through the inhibition of the canonical Wnt pathway activity: in the 
first, it was shown that WNT5A leads to an increased degradation of β-catenin in a 
ROR2- and Siah2-dependent manner in the colon cancer cell line HT-29 (MacLeod et 
al., 2007). The second study reports about an inhibitory effect of WNT5A on the 
canonical Wnt-signalling pathway in the cell line HCT116, resulting in a suppressed 
tumor cell colony formation of these cells (Ying et al., 2008). Finally, by an unknown 
mechanism, WNT5A suppressed migration of the colon carcinoma cell line SW480 
(Dejmek et al., 2005). Expression and promoter methylation studies performed in 
tissues of colon carcinoma reflect the results obtained in vitro using cell cultures: the 
WNT5A promoter is often hypermethylated, leading to a reduced expression of 
WNT5A in these tumors as compared to normal epithelia (Dejmek et al., 2005; Smith 
et al., 1999; Ying et al., 2008). 
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2.3. The signalling pathways activated by WNT5A 
 
WNT5A is known to activate both canonical and non-canonical Wnt pathways. The 
canonical Wnt pathway has comprehensively been introduced in Chapter I, Section 
1.1., whereas the non-canonical pathways Wnt-Ca2+, Wnt-PCP, PKA and STAT, 
including their crosstalks with the canonical Wnt pathway, have been described in 
Section 1.1. of this chapter. Figure 39 summarizes those signalling pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: The signalling pathways activated by WNT5A. A plus-sign in a circle indicates that the non-
canonical pathway is known to exert a stimulating effect on the activity of the canonical pathway, 
whereas the inverse is true for a minus-sign. 
 
 
2.4. Widely used methods to measure the activities of WNT5A-stimulated 
signalling pathways 
 
Some methods often described in the literature to measure the activity of WNT5A-
stimulated signalling pathways are summarized in Figure 40.  
 
The canonical Wnt pathway was analyzed by measuring the accumulation of the 
active, N-terminally dephosphorylated form of β-catenin in the cytoplasm using 
Western blot analysis on cytoplasmic protein extracts, since the process of β-catenin 
phosphorylation and degradation and its inhibition by the canonical Wnt pathway 
occurs in this cell compartment. Additionally, a TCF reporter-gene assay (Luciferase 
assay) was often used to measure the activity of the TCF-dependent transcription, 
known to be induced by an activated canonical Wnt pathway.  
 
The activities of the non-canonical Wnt-Ca2+, Wnt-PCP, and STAT pathways can be 
monitored using transcription factor (TF)-activity assays for NFAT (Wnt-Ca2+), AP-1 
(Wnt-PCP), and STAT3 (STAT), that are all based on nuclear protein extracts. 
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The activity of the PKA pathway was described to be measured on Western blots 
using nuclear protein extracts and an antibody that is specific for the active, serine 
133-phosphorylated form of CREB.  
 
In addition, WNT5A-induced crosstalks between the non-canonical and the canonical 
pathways can be analyzed by a specific inhibition of a central component of a non-
canonical pathway, followed by WNT5A-treatment and the measurement of the 
canonical Wnt pathway activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: Often used methods to measure the activities of WNT5A-stimulated signalling pathways. A 
plus-sign in a circle indicates that the non-canonical pathway is known to exert a stimulating effect on 
the activity of the canonical pathway, whereas the inverse is true for a minus-sign. 
 
 
2.5. Aim of the study 
 
Our microarray gene expression analysis on pooled RNA samples revealed that 
WNT5A is highly overexpressed in aggressive fibromatosis as compared to 
superficial fibromatosis and reference fibrous tissue (Chapter I, Section 4.2.). This 
finding could be verified on individual tumor tissue samples using real-time RT-PCR 
(Chapter I, Section 4.2.) and additional microarray experiments (Chapter II, Section 
4.3). 
 
Therefore, the aim of the experiments described in this chapter was to analyze the 
impact of WNT5A on the activity of canonical- and non-canonical Wnt pathways, as 
well as on proliferation and invasive behaviour in the primary aggressive fibromatosis 
tumor cell culture Aggr6 in comparison to cultures of normal fibroblasts. In addition, a 
gene expression analysis using Agilent microarrays should bring light into the 
differential gene expression induced by WNT5A in those cell cultures. 
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3. Materials and methods 
 
 
3.1. Protein extractions  
 
All protein extracts were quantified following the protocol of the bicinchoninic acid 
(BCA) Protein Assay Kit (Pierce, Rockford, IL). The absorbance of the colorimetric 
reaction within the wells was measured on an ELX800NB spectrophotometer 
(BioTec, Winooski, VT) at 570 nm. Prior to quantification, the whole cell protein 
extracts were heated at 95°C for 5 minutes, followed by centrifugation at 21’000 g for 
5 min. The supernatants were transferred into new tubes, whereas the pellets were 
discarded. 
 
3.1.1. Whole cell protein extracts 
 
After washing in Mg2+/Ca2+-free phosphate-buffered saline (PBS, Invitrogen, 
Carlsbad, CA), cells were scrabbed from the flask using 1 ml 2x sample buffer 
(100mM Trizma acid (TrisHCl) pH 6.8, 4% SDS, 10% Glycerol) per 75 cm2 flask and 
stored at -20°C. Those extracts were used for the analysis of the subcellular protein 
fractionation process performance (Section 4.1.).   
 
3.1.2. Subcellular phospho-protein fractions 
 
Subcellular phospho-protein fractions were extracted according to the instruction 
manual of the Nuclear Extract Kit (Active Motif, Carlsbad, CA). An overview of the 
experimental steps is given in Figure 41. The cells were opened in a hypotonic buffer 
containing a weak detergent (1). After a centrifugation step (2), the supernatant 
contained the soluble cytoplasmic protein extract, whereas in the pellet, the intact 
nuclei and fragments of the cytoplasm membrane were concentrated. The nuclei 
were then lysed by a strong detergent in lysis buffer (3) and a final centrifugation step 
(4) differentiated the soluble nuclear extract from the pellet containing cytoplasm- and 
nuclear membrane fragments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Principle working steps needed to perform  
subcellular phospho-protein fractionation according to  
the protocol of the Nuclear Extract Kit (Active Motif) 
 
1)       Hypotonic buffer
weak detergent
2)          Centrifugation
14‘000 g Soluble cytoplasmic protein extract
3)            Lysis buffer
strong detergent
4)         Centrifugation
14‘000 g Soluble nuclear protein extract
Intact nuclei + cytoplasm membrane fragments
Cytoplasm- and nuclear membrane fragments
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The soluble nuclear and cytoplasmic phospho-protein fractions represent the basis 
for subsequent Western blot experiments and transcription factor activity assays 
depicted in Section 4 of this chapter. They were stored at -80°C. For the analysis of 
the subcellular protein fractionation process performance (Section 4.1.), membranous 
protein fractions, usually generated as pellets to be discarded during the process of 
protein fractionation, were used as well. They were resolved in 2x sample buffer 
(100mM Trizma acid (TrisHCl) pH 6.8, 4% SDS, 10% Glycerol) and stored at -20°C. 
 
 
3.2. SDS-PAGE and Western blot 
 
Proteins were resolved by sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis (PAGE) on Precast Gels 4-20% Tris-HCl (BIORAD, Hercules, CA) 
using a BIORAD apparatus. Per lane, 5 g of protein in a volume of 15 l was 
loaded, including 3 l 5x sample buffer containing bromophenol blue plus β-
mercaptoethanol (250mM Trizma acid (TrisHCl) pH 6.8, 10% SDS, 25% Glycerol, 
0.25% bromophenol blue, 10% β-mercaptoethanol). Accordingly, the samples were 
diluted in 1x sample buffer containing bromophenol blue (50mM Trizma acid 
(TrisHCl) pH 6.8, 2% SDS, 5% Glycerol, 0.05% bromophenol blue). Prior to loading, 
the samples were heated at 95°C for 5 minutes. A mixture of the SeeBlue Plus2 Pre-
Stained Standard and the MagicMark XP Western Protein Standard (Invitrogen, 
Carlsbad, CA) was always loaded to evaluate the molecular size of the resolved 
proteins. The SDS-PAGE was run at 200 V and 0.05 A using the Pac 200 power 
supply (BIORAD, Hercules, CA). The proteins were transferred onto Whatman 
Protran Nitrocellulose Transfer Membranes (GE Healthcare, Waukesha, WI) at 60 V 
and 0.4 A for 45 minutes. Membranes were blocked for 1 hour at room temperature 
(RT) by gentle shaking in 5% non-fat milk powder containing blocking buffer 1xTBS, 
0.1% Tween (3 g TrisHCl pH 7.4, 8 g NaCl, 0.2 g KCl, 1 ml Tween 20 per liter H2O). 
Membranes were incubated in primary antibody solution overnight at 4°C by gentle 
shaking. The next day, membranes were washed 3 times 30 min in 1xTBS, 0.1% 
Tween, before incubating them in secondary antibody solution for 1 hour at RT under 
gentle shaking.  Primary and secondary (horseradish peroxidase-labelled) antibodies 
are cited in Table 3. Membranes were washed as above and incubated in 
SuperSignal West Dura Extended Duration Substrate Solutions (Pierce, Rockford, IL) 
for detecting the active-β-catenin and active-CREB antibodies and in Amersham ECL 
Western Blotting Analysis System Detection Reagents (GE Healthcare, Waukesha, 
WI) for the detection of the other antibodies. After exposure of the membranes to 
Hyperfilm ECL high performance chemiluminescence films (GE Healthcare, 
Waukesha, WI), the films were developed on a FILM FPM 800A Medical Film 
Processor (FUJI, Tokyo, Japan). They were scanned on a Perfection 4870 Photo 
Scanner (Epson, Long Beach, CA) and the bands of interest quantified on the 
Quantitiy One software (BIORAD, Hercules, CA).  
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Antibodies Dilution
1) active (S37,T41-dephospho)-β-catenin (mouse, monoclonal, A) 1:500 TBS/T, 5% MP
    2nd horse anti-mouse IgG (B) 1:5'000 TBS/T, 1% MP
2) active (S133-phospho)-CREB (rabbit, monoclonal, B) 1:1'000 TBS/T, 5% BSA 
    2nd goat anti-rabbit IgG (A) 1:2'000 TBS/T, 5% MP
3) β-tubulin (mouse, monoclonal, C) 1:1'000 TBS/T, 0.5% MP 
    2nd horse anti-mouse IgG (B) 1:5'000 TBS/T, 0.5% MP
4) HDAC1 (mouse, monoclonal, D) 1:100 TBS/T, 0.5% MP 
    2nd horse anti-mouse IgG (B) 1:5'000 TBS/T, 0.5% MP
5) Lamin A/C (mouse, monoclonal, E) 1:500 TBS/T, 0.5% MP 
    2nd horse anti-mouse IgG (B) 1:5'000 TBS/T, 0.5% MP
6) GLUT1 (rabbit, polyclonal, A) 1:1'000 TBS/T, 5% MP 
    2nd goat anti-rabbit IgG (A) 1:3'000 TBS/T, 0.5% MP
7) WNT5A (goat, polyclonal, F) 1:1'000 TBS/T, 5% MP 
    2nd donkey-anti-goat IgG (B) 1:5'000 TBS/T, 5% MP
 
Table 3: Primary and secondary antibody solutions used for Western blots. Abbreviations: TBS/T = 
1xTBS, 0.1% Tween (see text for details); MP = non-fat milk powder; BSA = bovine serum albumin. 
Companies providing the antibodies: A = Millipore, Billerica, MA; B = Cell Signalling, Danvers, MA; C = 
Sigma-Aldrich, Saint Louis, MI; D = Abcam, Cambridge, UK; E = BD Transduction Laboratories, 
Franklin Lakes, NJ; F = R&D Systems, Minneapolis, USA. 
 
A detailed description of the kinetics and treatment concentrations applied in the 
Western blot experiments depicted in Section 4 can be obtained in Section 3.4., 
Table 4.  
 
 
3.3. TCF-reporter gene assay (Luciferase assay) 
 
Cells were transfected using the Amaxa Basic Nucleofector Kit for Primary 
Mammalian Fibroblasts on the Amaxa Nucleofector electroporation system (Lonza, 
Basel, Switzerland). The constructs needed to measure the activity of the canonical 
signalling pathway in transfected cells were kindly provided by Dr. van der Flier 
(Aglaia Biomedical Ventures, Utrecht Area, Netherlands): the ‘TOP’-construct 
containing unmutated TCF responsive elements and minimal TATA box upstream of 
the firefly luciferase reporter gene, and the ‘FOP’-construct being mutated in the TCF 
responsive elements and therefore unable to bind TCF and respond to canonical Wnt 
signalling activity. To normalize differences from transfection to transfection 
concerning transfection efficiency and numbers of cells used, the pRL-SV40-renilla 
luciferase reporter vector ‘Renilla’ (Promega, Madison, WI) was always cotransfected 
with TOP and FOP, respectively.  
 
The day before transfection, cells were splitted to reach 80-90% confluency at 
transfection. That day, 1x106 cells were resuspended in 100 l of Amaxa 
Supplemented Nucleofector Solution (Lonza, Basel, Switzerland). To the suspension, 
1 g of TOP or FOP was added, in addition to 0.5 g of Renilla. The cells were 
electroporated on the Amaxa Nucleofector using protocol A-34. After transfection, the 
cells were transferred back into cell culture flasks to recover for at least 8 hours. 
Firefly- and Renilla-luciferase activity in the transfected cells were measured 
according to the technical manual of the Dual-Luciferase Reporter Assay System on 
the Glomax apparatus (Promega, Madison, WI). The activity of the canonical Wnt 
signalling pathway was defined as follows: Ratio TOP/Renilla (Transfection 1) divided 
by Ratio FOP/Renilla (Transfection 2). A resulting value of 1 indicates that the 
canonical Wnt signalling pathway is not active in the corresponding cells, whereas 
values greater than 1 reflect activated canonical Wnt signalling.  
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A comprehensive description of the kinetics and treatment concentrations applied in 
the Luciferase assays depicted in Section 4 can be obtained in the following Section 
3.4. (Table 4). 
 
The 45-β-catenin expression plasmid used to activate the canonical Wnt signalling 
pathway in cell cultures of normal fibroblasts NHDF and Aggr2 was kindly provided 
by Prof. Vogelstein (The Johns Hopkins Oncology Center, Baltimore, MD). In those 
experiments, the construct was cotransfected with TOP and FOP, respectively. The 
cells were treated 16 hours and 40 hours after transfection, respectively, with 
150ng/ml recombinant WNT5A (R&D Systems, Minneapolis, USA) for 8 hours, before 
Luciferase activity measurements were performed.  
 
 
3.4. Detailed kinetics and treatment concentrations in experiments using 
Western blots and Luciferase assays 
 
Treatment Start Luciferase measurement/ Duration 
treatment Protein extraction treatment (h)
control Luciferase no 23
Western β-catenin no 32
WNT5A Luciferase 150ng/ml 15 23 8
Western β-catenin 150ng/ml 24 32 8
DKK1+WNT5A Luciferase 150ng/ml + 150ng/ml 8 + 24 32 24 + 8
Western β-catenin 150ng/ml + 150ng/ml 8 + 24 32 24 + 8
DKK1 Luciferase 150ng/ml 8 32 24
Western β-catenin 150ng/ml 8 32 24
Antibody+WNT5A Luciferase  2g/ml + 150ng/ml 15 23 8
Western β-catenin  2g/ml + 150ng/ml 24 32 8
Antibody Luciferase 2g/ml 15 23 8
Western β-catenin 2g/ml 24 32 8
control Luciferase no 23
Western β-catenin no 23
WNT5A Luciferase 150ng/ml 15 23 8
Western β-catenin 150ng/ml 15 23 8
JNKI1+WNT5A Luciferase 10M + 150ng/ml 14.5 + 15 23 8.5 + 8
Western β-catenin 10M + 150ng/ml 14.5 + 15 23 8.5 + 8
JNKI1 Luciferase 10M 14.5 23 8.5
Western β-catenin 10M 14.5 23 8.5
control Western CREB no 23
Bt2cAMP Western CREB 1mM 21 23 2
H-89+Bt2cAMP Western CREB 10M+1mM 20.5 + 21 23 2.5 + 2
WNT5A Western CREB 150ng/ml 15 23 8
H-89+WNT5A Western CREB 10M + 150ng/ml 14.5 + 15 23 8.5 + 8
H-89 Western CREB 10M 14.5 23 8.5
control Luciferase no 23
Western β-catenin no 23
Bt2cAMP Luciferase 1mM 15 23 8
Western β-catenin 1mM 21 23 2
H-89+Bt2cAMP Luciferase 10M+1mM 14.5 + 15 23 8.5 + 8
Western β-catenin 10M+1mM 20.5 + 21 23 2.5 + 2
WNT5A Luciferase 150ng/ml 15 23 8
Western β-catenin 150ng/ml 15 23 8
H-89+WNT5A Luciferase 10M + 150ng/ml 14.5 + 15 23 8.5 + 8
Western β-catenin 10M + 150ng/ml 14.5 + 15 23 8.5 + 8
H-89 Luciferase 10M 14.5 23 8.5
Western β-catenin 10M 14.5 23 8.5
Hours after transfection/last splitting
Experiment
 
Table 4: Detailed kinetics and treatment concentrations in experiments using Western blots and 
Luciferase assays. Yellow: canonical Wnt pathway (Section 4.2.1.), green: crosstalk Wnt-PCP and 
canonical Wnt pathway (Section 4.2.3.), pink: PKA pathway (Section 4.2.4.), grey: crosstalk PKA and 
canonical Wnt pathway (Section 4.2.4.). Recombinant WNT5A, WNT5A antibody and recombinant 
DKK1 were obtained from R&D Systems, Minneapolis, USA. The JNK inhibitor 1 (JNKI1) was 
purchased from Axxora, LLC (San Diego, CA), whereas dihydrochloride hydrate (H-89) and dibutyryl 
cAMP sodium salt (Bt2cAMP) were from Sigma-Aldrich, Saint Louis, MI. 
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3.5. Transcription factor activity assay 
 
The following TransAM transcription factor activity assays from Active Motif 
(Carlsbad, CA) were used: NFATc1 (NFAT2), AP-1 for c-jun, JunB and JunD and 
STAT family for STAT1α and STAT3. They are based on 96-well-plates, where the 
consensus binding DNA-sequences for the relevant transcription factors are spotted 
on the bottom of the single wells. Only activated phosphorylated (AP-1, STAT) and 
dephosphorylated (NFAT), respectively, transcription factors are able to bind to these 
sequences.  After the addition of a specific primary antibody and a horseradish 
peroxidase-conjugated secondary antibody, the absorbance of the colorimetric 
reaction within the wells was read on an ELX800NB spectrophotometer (BioTec, 
Winooski, VT) at 450 nm. The assays were performed according to the 
corresponding manufacturer’s instructions: 2 g of soluble nuclear phospho-protein 
extract was loaded per well. The specificity of the signals obtained were confirmed by 
the addition of wildtype and mutated consensus oligonucleotide sequences aligning 
(wildtype) or not aligning (mutated) to the spotted sequences at the bottom of the 
wells. Hybridized wildtype sequences hinder active transcription factors from binding 
to their spotted consensus sequences and therefore no signal should be obtained 
from those wells. 
 
If applicable, the cells were treated for 10 min, 1 hour, 4 hours and 8 hours with 150 
ng/ml recombinant WNT5A (R&D Systems, Minneapolis, USA), before soluble 
nuclear phospho-protein extracts were generated (Section 3.1.2.). For the activity 
measurement of c-jun in Aggr6, cells were additionally pre-treated for 30 minutes with 
10M JNK inhibitor 1 (JNKI1, Axxora LLC, San Diego, CA), before recombinant 
WNT5A was added.  
 
 
3.6. BrdU-incorporation assay 
 
The 5-Bromo-2’-deoxy-uridine (BrdU) Labelling and Detection Kit III (Roche, Basel, 
Switzerland) was used to measure proliferation. It is based on the principle that cells 
being engaged in the DNA-synthesis (S)-phase of the cell cycle incorporate 5-bromo-
2-deoxy-uridine (BrdU) in place of thymidine into the newly synthesized DNA. These 
cells are then detected using an enzyme-conjugated antibody against BrdU. The 
higher the signal in a well, the more cells are involved in the S-phase of the cell cycle. 
It therefore reflects the proliferation rate of the cells within the corresponding well and 
inversely correlates with their doubling time.   
 
The assay was performed according to the protocol provided by the company. 3’000 
cells were seeded in 100 l medium per well. After 48 hours of incubation, 10 l of 
BrdU labelling solution was added to the cells for incorporation during 6 hours. 
Thereafter, the cells were fixed and treated with a peroxidase-conjugated antibody 
directed against BrdU. After the addition of peroxidase substrate, the absorbance of 
the colorimetric reaction within the wells was read on an ELX800NB 
spectrophotometer (BioTec, Winooski, VT) at 450 nm.  
 
Before starting the experiment, all cells were cultivated for 16 hours in EGM2 basal 
medium and 10% FCS. Where necessary, cultured cells were pre-treated for the 
same period of time with DKK1 (150ng/ml), JNKI1 (10M), H-89 (10M), or a mixture 
of the three inhibitors. Cells were trypsinized and seeded into the wells for the BrdU-
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assay. There, new medium was added, again containing the appropriate inhibitors. If 
applicable, cells were treated with recombinant WNT5A (600ng/ml) and an antibody 
against WNT5A (2 g/ml).  
 
 
3.7. Collagen type I cell invasion assay 
 
The invasive capacity of the cell cultures Aggr6, Aggr2, and NHDF after stimulation 
with WNT5A was determined using the Boyden-chamber based Cultrex Collagen I 
Cell Invasion Assay (R&D Systems, Minneapolis, USA) (Figure 40). Such a collagen 
based assay was favoured over the extensively used matrigel based approach, since 
the matrigel represents a basement membrane model and is therefore convenient to 
study the invasive behaviour of epithelial cells, but not of fibroblasts. In vivo, 
fibroblasts are not forced to pass a basement membrane in order to be able to invade 
adjacent tissues.  
 
Cells were serum starved for 24 hours before seeding into the inserts of the invasion 
chamber (4’500 cells in 50 l serum- and supplement-free EGM2 basal medium). In 
the appropriate inserts, different concentrations of recombinant WNT5A was added 
(none, 300ng/ml or 600ng/ml). The bottom chambers were filled with 150 l EGM2 
basal medium supplemented with different concentrations of FCS (1% vs. 10% vs. 
20%) and the same concentrations of WNT5A as applied in the upper inserts. 48 
hours after seeding, invaded cells were labelled with calcein, a fluorescent compound 
that permeates cells, according to the manufacturer’s protocol. The resulting signals 
were measured on a Tecan Genious apparatus (Tecan, Männedorf, Switzerland) at 
485 nm excitation and 520 nm emission.   
 
 
 
 
 
 
 
 
 
 
Figure 42: Assembly of a well in a Boyden invasion chamber assay used to analyze  
the invasive capacity of Aggr6, Aggr2, and NHDF cells with and without the addition  
of different concentrations of recombinant WNT5A in both the insert and the bottom chamber 
 
 
3.8. Agilent 60mer-oligo microarrays 
 
The day before the experiment, Aggr2, Aggr4, Aggr6 and NHDF cells were splitted 
into 25 cm2 cell culture flasks at a density to reach ~80-90% confluency over night. 
Then, 600 ng/ml recombinant WNT5A (R&D Systems, Minneapolis, USA) was added 
and cells incubated for 8 hours. Control cells remained untreated. After washing in 
Mg2+/Ca2+-free phosphate-buffered saline (PBS), cells were trypsinized (1xTrypsin-
EDTA, Invitrogen, Carlsbad, CA), centrifuged (160 g, 3 minutes) and the pelleted 
cells (~1x106) resuspended in 1 ml of TriReagent (Molecular Research Center, Inc., 
Cincinnati, OH) for subsequent total RNA extraction according to the protocol 
Cell suspension in
serum-free medium +/- WNT5A
Insert
Bottom chamber
Invaded cells at the bottom
of the membrane
8 m pore size
membrane
Collagen I matrix
Serum-containing
medium +/- WNT5A
Assembly of a well in a Boyden invasion chamber
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supplied by the company. Resulting total RNA was quantified using the NanoDrop 
ND-1000 spectrophotometer (Agilent Technologies, Santa Clara, CA). 
 
RNA quality control was performed as described in Chapter I, Section 3.2.2. 
 
The samples were single color (Cy3)-labelled, hybridized, and the resulting data 
processed according to the descriptions in Chapter I, Section 3.2.4. 
 
 
3.9. siRNA-experiments 
 
Aggr6 cells were cotransfected using the Amaxa Basic Nucleofector Kit for Primary 
Mammalian Fibroblasts on the Amaxa Nucleofector electroporaton system (Lonza, 
Basel, Switzerland) with the TOP- or FOP-plasmid, the Renilla-construct (all 
introduced in Section 3.3.), and a mix of the following Dharmacon On-target plus 
siRNA SMARTpools (Thermo Scientific, Lafayette, CO) at different concentrations 
(0nM, 20nM, 200nM, 2M), targeting Fzd1, Fzd2 and Fzd7 receptors: 
 
Fzd1 (target sequences): GUUCUACCCUCUAGUGAAA, UUACGUACCUGGUGGA 
CAU, GAAGCCAACUCACAGUAUU, GCAAGACCCUCAACUCCUG 
 
Fzd2 (target sequences): CCACGUACUUGGUAGACAU, GAACUGCGCUUCUUCC 
UGU, GGAGGAAGUUCUACACUCG, GCUACAAGUUUCUGGGCGA 
 
Fzd7 (target sequences): UCAAGUACCUGAUGACCAU, GUUCGUCUACCUCUUC 
AUA, UGAUGUACUUUAAGGAGGA, AGGCAUAACUGUGACGAA 
 
As a negative control, the On-target plus non-targeting pool of four non-specified, 
non-targeting siRNAs was transfected at the highest concentration (2M).  
 
16 hours, 40 hours, and 64 hours after transfection, the cells were treated with 
150ng/ml recombinant WNT5A for 8 hours, before the luciferase activity 
measurement was performed.  
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4. Results 
 
 
4.1. Analysis of the performance of subcellular protein fractionation  
 
Since the analyses of the activities of the signalling pathways induced by WNT5A 
described in this chapter are partly dependent on subcellular protein fractions 
(Western blots, TF-activity assays), the following section describes the results of 
experiments dedicated to investigate the performance of the kit used to separate 
nuclear from cytoplasmic protein fractions. The subcellular protein fractions obtained 
through the different steps described in Section 3.1.2. were tested for their purity on 
Western blots by means of antibodies against the following marker proteins: β-tubulin 
(soluble cytoplasmic protein), histone deacetylase 1 (HDAC1, soluble nuclear 
protein), lamin A/C (largely a insoluble nucear membrane protein) and glucose 
transporter 1 (GLUT1, a membrane bound protein). 
   
Figure 43 shows the results obtained in a typical separation experiment. HDAC1 was 
present in the whole cell extract (lane 1) and prominently in the soluble nuclear 
protein fraction (lane 2). It was also detectable in the fraction that includes the whole 
nuclei plus the cytoplasmic membrane fragments but, due to the dilution effect, in a 
lower concentration (lane 4). Nevertheless, the soluble cytoplasmic extract also 
contained low amounts of this soluble nuclear protein (lane 3). β-tubulin could only be 
found in the whole cell protein extract (lane 1) and in a high concentration in the 
soluble cytoplasmic fraction (lane 3). Finally, GLUT1 and lamin A/C are present only 
in the membrane-containing fractions (lane 4 and 5).  
                                 
  
  Figure 43: Distribution of the marker proteins β-tubulin (cytoplasm),  
HDAC1 (nucleus), GLUT1 (cytoplasmic membrane) and lamin A/C 
(nuclear membrane) in the different protein fractions 
 
In summary, the soluble nuclear protein fraction is free from any contaminations 
derived from the other protein fractions. A substantial contamination of the soluble 
cytoplasmic protein fraction by soluble nuclear proteins can also be excluded. 
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4.2. Analysis of the impact of WNT5A on cellular signalling pathways in 
Aggr6 and cell cultures of normal fibroblasts 
 
In the following section, the influence of WNT5A on the activation of the canonical 
and non-canonical Wnt signalling pathways as well as the induction of possible 
crosstalks between these pathways will be described. Aggressive fibromatosis tumor 
cells (Aggr6) and normal human fibroblasts are used as model system. 
 
4.2.1.  The effect of WNT5A stimulation on the canonical Wnt signalling pathway 
 
- Baseline activity of canonical Wnt signalling in Aggr6 cells and normal fibroblasts 
 
Using the TCF-reporter gene assay (Luciferase assay), the baseline activity of Wnt 
signalling in Aggr6 tumor cells and normal fibroblasts was determined (Figure 44). 
The canonical Wnt signalling pathway in cell cultures of normal dermal fibroblasts 
NHDF, HDF15 and HDF21 is almost inactive (1.0 on the scale of the y-axis indicates 
no measurable activity). On the other hand, the tumor-associated fibroblasts derived 
from aggressive fibromatoses Aggr2 and Aggr4 are characterized by a slight increase 
of canonical Wnt signalling activity as compared to the normal dermal fibroblasts. 
Since in Aggr2 and Aggr4, both alleles of the β-catenin gene are unmutated, the 
observed faint activation of this pathway may be derived from an endogenous 
paracrine/autocrine signalling induced by secreted canonical Wnt ligands. In contrast, 
a pronounced activity of the canonical Wnt signalling pathway can be measured in 
Agg6 tumor cells carrying a monoallelic β-catenin mutation at codon serine 45 
(S45F).  This is in agreement with the classical theory whereupon a monoallelic S45F 
mutation impedes phosphorylation at this residue by CK1α and subsequently also 
the phosphorylation at the other three residues by GSK3β, leading to the 
accumulation of dephosphorylated, active β-catenin. After translocation into the 
nucleus, it activates TCF-LEF-dependent transcription (Chapter I, Sections 1.1.1. and 
1.1.3.). 
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  Figure 44: Baseline activity of the canonical Wnt signalling pathway  
in normal dermal fibroblasts NHDF, HDF15, HDF21, aggressive  
fibromatosis-associated normal fibroblasts Aggr2 and Aggr4 and  
aggressive fibromatosis tumor cells Aggr6 (Luciferase assay). 
The mean and standard deviation of three independent tests is 
demonstrated.  
  
 
 
  
  Chapter III 
  28 
- The impact of endogenous Wnts on canonical Wnt signalling in Aggr6 cells 
 
As demonstrated in the last section, Luciferase assay data revealed that Aggr6 tumor 
cells are characterized by a pronounced baseline activity of the canonical Wnt 
signalling pathway. The most obvious explanation for this finding is the monoallelic 
S45F-mutation in β-catenin carried by these cells. Another reason for this finding 
could be that secreted Wnt ligands lead to an increased canonical Wnt signalling 
activity. To test for this possibility, Aggr6 cells were treated with Dickkopf-1 (DKK1), a 
selective inhibitor of canonical Wnt signalling. DKK1 binds to the Frizzled (Fzd) 
coreceptor low density lipoprotein receptor-related protein 5 and 6 (LRP5/6) and thus 
inhibits receptor activation through Wnt ligands. The effect of DKK1-treatment was 
measured both with Luciferase-assay (Figure 45, L) as well as with Western blot 
(Figure 45, W), using cytoplasmic protein extracts and an antibody against active, 
dephosphorylated β-catenin. DKK1-treatment of Aggr6 cells led to a reduction in the 
activity of the canonical Wnt pathway, demonstrated by both methods (4), as 
compared to untreated cells (1). This result reflects a measurable effect of 
endogenously produced Wnt ligands on the canonical Wnt signalling pathway activity 
in Aggr6 cells via wildtype β-catenin. Nevertheless, the level of activity is still clearly 
higher than in normal fibroblasts NHDF (7) and Aggr2 (9). This demonstrates a clear 
contribution of the mutated S45F-β-catenin to the increased canonical Wnt signalling 
activity in Aggr6 cells as well. In Figure 46 this situation is graphically illustrated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: The impact of endogenous Wnts, WNT5A and recombinant WNT5A 
on the activity of the canonical Wnt pathway.  
a) The activity of the canonical Wnt signalling was measured by Luciferase  
assays (L; mean and standard deviation of three independent experiments)  
and Western blots (W) in Aggr6 tumor cells (Aggr6) and normal human  
fibroblasts (NHDF, Aggr2). The different treatments are indicated.  
Control, C: untreated cells. 
b) Western blot for active β-catenin, aligned to Figure 45 a). The intensity  
of the bands was quantified and the resulting numbers integrated as  
columns (W) into Figure 45 a). β-tubulin: loading control. 
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Figure 46: In Aggr6, both a monoallelic S45F-mutation in β-catenin 
  and an endogenous Wnt signalling activity mediated by Wnt ligands 
contribute to the activation of TCF-LEF-dependent transcription  
 
- The impact of endogenous WNT5A on canonical Wnt signalling in Aggr6 cells 
 
To analyze whether endogenous WNT5A alone exerts a stimulating effect on the 
baseline canonical Wnt signalling activity in Aggr6, the cells were additionally treated 
with an antibody against WNT5A. Figure 45 demonstrates that the WNT5A antibody 
did not affect the canonical Wnt signalling activity in Aggr6 cells (6), as compared to 
untreated cells (1). The increased activity determined using Western blot analysis (6, 
W) represents a technical artefact, since three independent Luciferase experiments 
(6, L) statistically prove that the antibody exerts no effect. Therefore, the 
endogenously produced WNT5A has no measurable effect on the canonical Wnt 
signalling pathway activity in Aggr6. 
 
- The impact of recombinant WNT5A on canonical Wnt signalling in Aggr6 cells and   
  in normal fibroblasts 
 
Having shown that endogenous WNT5A does not exert any impact on canonical Wnt-
signalling in Aggr6 cells, the question raises whether exogenous WNT5A is able to 
activate this pathway. Therefore, the cells were treated with recombinant WNT5A 
alone, or together with DKK1 to examine, whether WNT5A signals via the canonical 
Wnt pathway. The results depicted in Figure 45 clearly demonstrate that recombinant 
WNT5A had indeed an inducing effect on the canonical Wnt signalling pathway (2), 
because its impact could be abrogated by the simultaneous addition of the canonical 
Wnt inhibitor DKK1 (3). The observed induction was specific, since the simultaneous 
addition of anti-WNT5A antibodies abolished the effect of WNT5A (5).  
 
In contrast to the results obtained for Aggr6 cells, normal fibroblasts did not show any 
increase in the activity of the canonical Wnt signalling pathway after WNT5A 
stimulation (NHDF: 8, Aggr2: 10) as compared to untreated controls (NHDF: 7, 
Aggr2: 9).  
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4.2.2. The impact of recombinant WNT5A on the Wnt-Ca2+ pathway in Aggr6 cells 
 
To determine, whether WNT5A signals via the Wnt-Ca2+ pathway, the activity of the 
downstream transcription factor NFAT2 was compared between WNT5A-treated and 
untreated Aggr6 cells. As Figure 47 demonstrates, WNT5A does not influence the 
activity of this pathway in Aggr6 cells. 
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  Figure 47: The impact of recombinant WNT5A on the activity of the  
Wnt-Ca2+ pathway in Aggr6, determined using a transcription factor- 
activity assay from Active Motif for NFAT2. Cells were treated with  
recombinant WNT5A for the indicated periods of time. As a positive 
control, a nuclear protein extract of phytohaemagglutinin (PHA)- 
treated Jurkat cells was used, whereas the value for the negative 
control is derived from a well containing no nuclear protein extract.  
Control: untreated cells. 
 
4.2.3. The effect of WNT5A stimulation on the Wnt-PCP signalling pathway 
 
- The impact of recombinant WNT5A on Wnt-PCP signalling in Aggr6 cells and in   
  normal fibroblasts 
 
The activities of the downstream transcription factors c-jun, junB and junD were 
compared between WNT5A-treated and untreated Aggr6 cells. WNT5A activated 
those transcription factors, showing a peak effect after ~ 1 hour of incubation (Figure 
48, blue, brown and red curves). That WNT5A mediates this effect via the activation 
of the Wnt-PCP pathway was proven by pre-treating the cells with a specific inhibitor 
of JNK, JNK-inhibitor 1 (JNKI1), resulting in an abrogation of WNT5A’s stimulating 
effect on c-jun (pink curve).  
 
In contrast, recombinant WNT5A did not modulate the activity of the Wnt-PCP 
pathway in cell cultures of normal fibroblasts Aggr2 and NHDF, as proven by the 
analysis of the activity of c-jun in these cells (green and grey curves). 
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  Figure 48: The impact of recombinant WNT5A on the activity of the  
Wnt-PCP pathway in Aggr6 and the cell cultures of normal fibroblasts  
Aggr2 and NHDF, determined using transcription factor-activity assays  
from Active Motif for c-jun, junD and junB. Cells were treated with  
recombinant WNT5A for the indicated periods of time. Control: untreated 
cells. 
 
- Analysis of the WNT5A-induced crosstalk between the Wnt-PCP and the canonical  
  Wnt pathway in Aggr6 cells 
 
Having shown that recombinant WNT5A is able activate the canonical Wnt (Section 
4.2.1.) and the non-canonical Wnt-PCP pathway in Aggr6 cells, it remains to be 
elucidated whether there is a WNT5A-induced crosstalk between these two 
pathways. To accomplish this purpose, Aggr6 cells were treated with recombinant 
WNT5A alone or with WNT5A after a pre-treatment with JNKI1 to selectively inhibit 
its impact on the Wnt-PCP pathway. Subsequently, the activity of the canonical Wnt 
pathway was measured both with Luciferase-assay (Figure 49, L) as well as with 
Western blot (Figure 49, W), using cytoplasmic protein extracts and an antibody 
against active, dephosphorylated β-catenin. Whereas the sole treatment with 
recombinant WNT5A increased the canonical Wnt pathway activity, demonstrated by 
both methods (2), as compared to untreated cells (1), the pre-treatment with JNKI1 
did not alter WNT5A’s effect (3). The somewhat reduced activity determined using 
Western blot analysis (3, W) represents a technical artefact, since three independent 
Luciferase experiments (3, L) statistically prove that the JNKI1 pre-treatment does 
not affect WNT5A’s impact. This finding demonstrates that the selective inhibition of 
the Wnt-PCP pathway does not modulate the effect of WNT5A on the canonical Wnt 
pathway, indicating that a WNT5A-induced crosstalk between these two pathways in 
Aggr6 cells does not exist. In addition, the sole treatment of Aggr6 cells with JNKI1 
(4) shows no measurable impact on canonical Wnt signalling in comparison to 
untreated cells (1), revealing that the baseline canonical Wnt signalling activity in 
Aggr6 cells is not influenced by any Wnt-PCP signalling activity.  
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Figure 49: The analysis of the WNT5A-induced crosstalk between the Wnt-PCP  
and the canonical Wnt pathway in Aggr6 cells.  
a) The activity of the canonical Wnt signalling was measured by Luciferase assays 
(L; mean and standard deviation of three independent experiments) and Western 
blot (W) in Aggr6 tumor cells. The different treatments are indicated. Control: 
untreated cells.  
b) Western blot for active β-catenin, aligned to Figure 49 a). The intensity of the 
bands was quantified and the resulting numbers integrated as columns (W) into 
Figure 49 a). β-tubulin: loading control. 
 
4.2.4. The effect of WNT5A stimulation on the PKA signalling pathway 
 
- The impact of recombinant WNT5A on PKA signalling in Aggr6 cells and in normal  
  fibroblasts 
 
Western blot analysis on nuclear protein extracts using an antibody specific for the 
active, serine 133-phosphorylated form of CREB was performed to investigate 
whether recombinant WNT5A activates the PKA pathway in Aggr6 cells and normal 
fibroblasts. This antibody crossreacts with the phosphorylated form of activating 
transcription factor 1 (ATF1), another phosphorylation target of PKA. Treatment of 
Aggr6 cells with recombinant WNT5A (Figure 50, 4)  or dibutyryl cAMP sodium salt 
(Bt2cAMP), a cell-permeable cAMP analog that activates PKA (2), led to an 
accumulation of both phosphorylated active CREB and ATF1, as compared to 
untreated cells (1). This demonstrates that WNT5A is able to phosphorylate and 
activate those two PKA target proteins. On the other hand, pre-treatment of Aggr6 
cells with a selective potent inhibitor of PKA, dihydrochloride hydrate (H-89), 
abrogated the effects of both WNT5A (5) and Bt2cAMP (3), proving that WNT5A 
stimulates the phosphorylation of CREB and ATF1 through the activation of the PKA 
pathway. The addition of H-89 alone (6) and in combination with WNT5A (5) or 
Bt2cAMP (3) reduced the phosphoylation status of CREB and ATF1 slightly below the 
level found in untreated cells (1), demonstrating a certain baseline activity of the PKA 
pathway in Aggr6 cells.  
 
In contrast, a pronounced activation of CREB and ATF1 could not be observed in the 
cell cultures of normal fibroblasts NHDF and Aggr2, neither through recombinant 
WNT5A (NHDF: 9, Aggr2: 12), nor after the addition of Bt2cAMP (NHDF: 8, Aggr2: 
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11), in comparison to untreated cells (NHDF: 7, Aggr2: 10), suggesting an impaired 
functional linkage between PKA and CREB/ATF1 in these cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Figure 50: The impact of recombinant WNT5A on the activity of the  
PKA pathway. The activity of the PKA pathway was measured by  
Western blot for active, phospho-CREB and phospho-ATF1 in Aggr6  
tumor cells (Aggr6) and normal human fibroblasts (NHDF, Aggr2). 
The different treatments are indicated. Control: untreated cells. 
The intensity of the bands below was quantified and the resulting  
numbers depicted as columns in the upper diagram. HDAC1:  
loading control. 
 
- Analysis of the WNT5A-induced crosstalk between the PKA and the canonical Wnt  
  pathway in Aggr6 cells 
 
In the last section, WNT5A was shown to activate the PKA pathway specifically in the 
tumor cell culture Aggr6. In a next step it should be investigated, whether there is a 
crosstalk between the WNT5A-induced PKA and canonical Wnt signalling pathways. 
Aggr6 cells were treated with recombinant WNT5A alone or with WNT5A after a pre-
treatment with the PKA-inhibitor H-89 to selectively inhibit its impact on the PKA 
pathway. Subsequently, the activity of the canonical Wnt pathway was measured 
both with Luciferase-assay (Figure 51, L) as well as with Western blot (Figure 51, W), 
using cytoplasmic protein extracts and an antibody against active, dephosphorylated 
β-catenin. Using both techniques, WNT5A was shown to increase the canonical Wnt 
signalling pathway activity (4) as compared to the activity in untreated cells (1). A pre-
treatment with the PKA-inhibitor H-89, whereas completely abolishing the effect of 
WNT5A on the PKA pathway (Figure 50), did not modulate WNT5A’s inducing impact 
on the canonical Wnt pathway (Figure 51, 5), demonstrating a lacking crosstalk 
between these two signalling pathways. This finding was further confirmed by the 
results obtained when treating the cells with the PKA pathway inducer Bt2cAMP (2) or 
its inhibitor H-89 (6). Neither of the two had any effect on the canonical Wnt signalling 
pathway as compared to the activity in untreated cells (1). Consequently, the same is 
true for combined treatment with both inducer and inhibitor (3). 
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Figure 51: The analysis of the WNT5A-induced crosstalk between the PKA and the  
canonical Wnt pathway in Aggr6 cells.  
a) The activity of the canonical Wnt signalling was measured by Luciferase assays 
(L; mean and standard deviation of three independent experiments) and Western 
blot (W) in Aggr6 tumor cells. The different treatments are indicated. Control: 
untreated cells.  
b) Western blot for active β-catenin, aligned to Figure 51 a). The intensity of the 
bands was quantified and the resulting numbers integrated as columns (W) into 
Figure 51 a). β-tubulin: loading control. 
 
4.2.5. The effect of WNT5A stimulation on the STAT signalling pathway 
 
To determine, whether WNT5A signals via the STAT pathway, the activities of the 
downstream transcription factors STAT1α and STAT3 were compared between 
WNT5A-treated and untreated Aggr6 cells. As Figure 52 demonstrates, WNT5A does 
not influence the activity of this pathway in Aggr6 cells. 
 
                       
 
 
 
 
 
 
 
 
          
             Figure 52: The impact of recombinant WNT5A on the activity of the  
STAT pathway in Aggr6 cells, determined using transcription factor- 
activity assays from Active Motif for STAT1α and STAT3. Cells were  
treated with recombinant WNT5A for the indicated periods of time.  
As a positive control, a nuclear protein extract of prolactin stimulated 
Nb2 cells (rat lymphoma cell line) was used for both antibodies,  
whereas the values for the negative controls are derived from wells  
containing no nuclear protein extract. Control: untreated cells.  
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4.2.6. Summary of the signalling pathway analyses 
 
Figure 53 summarizes the results obtained in Sections 4.2.1. – 4.2.5. In the 
aggressive fibromatosis derived primary tumor cell culture Aggr6, recombinant 
WNT5A elicits the activity of the canonical Wnt, the Wnt-PCP, and the PKA pathway. 
No crosstalks between the latter two and the canonical Wnt pathway could be 
observed. In contrast, cell cultures of normal fibroblasts NHDF and Aggr2 show no 
signalling response in these pathways after stimulation with recombinant WNT5A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 53: WNT5A activates the canonical Wnt, the Wnt-PCP and 
  the PKA pathway in the aggressive fibromatosis derived tumor cell  
culture Aggr6. No crosstalks between the pathways could be observed. 
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4.3. The impact of WNT5A stimulation on proliferation and invasive 
behaviour of Aggr6 cells and cell cultures of normal fibroblasts 
 
4.3.1. Proliferation 
 
Figure 54 demonstrates that treatment of Aggr6 cells and cell cultures of normal 
fibroblasts Aggr2, NHDF and HDF15 with recombinant WNT5A led to an increase of 
the proliferation rate in Aggr6, whereas the other cell cultures remain unaffected. 
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  Figure 54: The impact of WNT5A on the proliferation rate in Aggr6  
cells and cell cultures of normal fibroblasts Aggr2, NHDF and HDF15, 
  measured using a BrdU-incorporation assay. Cells were treated with  
recombinant WNT5A for 48 hours. Measurements were performed in  
triplicates and demonstrated in the diagram as mean value and standard  
deviation. Control: untreated cells. Medium: negative control (the background  
signal obtained from wells containing growth medium but no cells).  
 
To demonstrate the specificity of the observed effect in Aggr6, cells were 
simultaneously treated with recombinant WNT5A and a specific antibody against this 
protein. Doing so, the proliferation stimulating impact of WNT5A could mostly be 
abrogated (Figure 55).  
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  Figure 55: The specificity of the proliferation inducing effect of WNT5A  
in Aggr6 cells, determined using a BrdU-incorporation assay. Cells were  
treated with recombinant WNT5A without (WNT5A) or with the addition  
of its specific antibody (Antibody+WNT5A) for 48 hours. Measurements  
were performed in triplicates and demonstrated in the diagram as mean  
value and standard deviation. Control: untreated cells. Medium: negative  
control (the background signal obtained from wells containing growth medium 
but no cells).  
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Analyses summarized in Section 4.2.6. revealed that recombinant WNT5A induces in 
Aggr6 cells the activity of three different pathways: the canonical Wnt, the Wnt-PCP, 
and the PKA pathway. Therefore, the following experiment was intended to explore, 
which of these three pathways are involved in the regulation of proliferation of Aggr6 
cells. The cells were treated with WNT5A alone or in combination with a specific 
inhibitor of the particular pathway: DKK1 for the canonical Wnt, JNKI1 for the Wnt-
PCP and H-89 for the PKA pathway. In addition, these inhibitors were added to the 
cells alone to investigate whether the activities of the corresponding pathways are 
relevant for the baseline proliferation of Aggr6. WNT5A proved again to be able to 
increase the proliferation rate of Aggr6 cells (Figure 56, 2) as compared to untreated 
cells (1). Whereas the inhibitor of the canonical Wnt (DKK1, 3) and the Wnt-PCP 
pathway (JNKI1, 4) alone did not influence the proliferation rate of Aggr6 cells, the 
inhibitor of the PKA pathway (H-89, 5) reduced the emitted signal near to the level of 
the background signal of the medium (10). This finding demonstrates that an active 
PKA signalling pathway is essential for the baseline proliferation activity of Aggr6 
cells. Whereas the specific inhibition of the canonical Wnt pathway (DKK1+WNT5A, 
6) and the Wnt-PCP pathway (JNKI1+WNT5A, 7) did not impair WNT5A’s positive 
effect on cellular proliferation, the abrogation of WNT5A’s impact on the PKA 
pathway (H-89+WNT5A, 8) almost completely abolished the proliferation activity of 
Aggr6 cells. Consequently, the combined treatment with the three inhibitors and 
recombinant WNT5A (9) led to a similar outcome. Thus, of the three pathways known 
to be activated by WNT5A, the PKA pathway elucidated to be the only one decisively 
involved in the regulation of proliferation of Aggr6 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 56: Analysis of the involvement of the three WNT5A-induced pathways  
in the regulation of proliferation of Aggr6 cells using a BrdU-incorporation assay.  
The cells were treated for 48 hours with the indicated compounds. Measurements  
were performed in triplicates and demonstrated in the diagram as mean value and 
standard deviation. Control: untreated cells. Medium: negative control (the background 
signal obtained from wells containing growth medium but no cells).  
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4.3.2. Invasion 
 
For the analysis of the invasive behaviour of the cell cultures Aggr6, Aggr2 and 
NHDF in response to WNT5A, a type I collagen cell invasion assay was used. The 
results are depicted in Figure 57. If attracting the cells with 1% FCS in the bottom 
chambers (A, D, G), the cells do not invade at all, reflected by the emitted 
fluorescence signals that were equal to the ones obtained from the negative control 
wells (K) containing no cells. The invasive behaviour of all three cell cultures then 
steadily increased with higher concentrations of serum in the media of the bottom 
chambers (10% FCS: B, E, H vs. 20% FCS: C, F, I), since the emitted fluorescence 
signals in the corresponding wells increasingly differed from the ones in the negative 
control wells (10% FCS: L, 20% FCS: M). Whereas Aggr6 and Aggr2 cells showed 
overall a very similar invasive behaviour in response to serum attraction, NHDF cells 
proved to be more responsive, since their emitted fluorescence signals in the wells 
containing 10% (H) and 20% FCS (I) were above the levels emitted in the 
corresponding wells of Aggr6 (10% FCS: B, 20% FCS: C) and Aggr2 cells (10% FCS: 
E, 20% FCS: F). For Agg6, Aggr2 and NHDF cells, the addition of different 
concentrations of WNT5A (300 ng/ml vs. 600 ng/ml) into the media of both the inserts 
and the bottom chambers did not influence their invasive behaviour.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57: Invasive behaviour of the cell cultures Aggr6, Aggr2 and NHDF in response to 
serum attraction (1% vs. 10% vs. 20% FCS containing media in the bottom chambers) and 
addition of recombinant WNT5A (300ng/ml vs. 600ng/ml in both the inserts and the bottom 
chambers), analyzed using a type I collagen cell invasion assay. Cells were allowed to invade 
for 48 hours. Measurements were performed in triplicates and demonstrated in the diagram as 
mean value and standard deviation. neg.: negative control (the background signals obtained 
from wells containing growth medium, but no cells). W: WNT5A. 
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4.4. The differential gene expression induced by WNT5A stimulation in Aggr6 
cells and cell cultures of normal fibroblasts  
 
Agilent microarray analyses were performed to study the differential gene expression 
induced by recombinant WNT5A stimulation in the tumor cell culture Aggr6 and the 
cell cultures of normal fibroblasts Aggr2, Aggr4 and NHDF.  
 
4.4.1. Selection of differentially expressed sequences to be further analyzed 
 
Starting with 41’000 sequences present on each Agilent array, the following selection 
criteria were applied to reduce to number of sequences to be further analyzed: a fold-
change of at least two, a p-value of less than 0.01 and an absolute expression level 
of more than 0.1 in at least one sample to be compared. Applying those selection 
criteria, the remaining numbers of differentially expressed sequences in the four cell 
cultures reflected the findings obtained in Sections 4.2. and 4.3. concerning a 
selective responsiveness of the tumor cell culture Aggr6 towards recombinant 
WNT5A: it exerted a pronounced effect on the gene expression in Aggr6 cells, but 
hardly effected the cell cultures of normal fibroblasts Aggr2, Aggr4 and NHDF (Figure 
58).  
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  Figure 58: Numbers of differentially expressed sequences in the  
tumor cell culture Aggr6 and the cell cultures of normal fibroblasts  
Aggr2, Aggr4 and NHDF (Agilent microarray analysis).  
 
 
4.4.2. Functional annotation of the selected sequences 
 
For functional annotation of the selected 3’931 sequences found to be differentially 
expressed in Aggr6 cells after WNT5A stimulation, the biostatistical software GeneGo 
Metacore was used. Results in previous Sections 4.2. and 4.3.1. demonstrated that 
WNT5A exerts a stimulating impact on signalling pathways and proliferation in Aggr6 
cells. Therefore, the focus of the analysis was laid on genes involved in the biological 
processes cell signalling cascades and proliferation. In addition, genes coding for 
components of the extracellular matrix (ECM) and for proteins involved in cell-cell 
and cell-ECM adhesion were also selected, due to their relevance in the 
pathogenesis of aggressive fibromatoses (Chapter I, Sections 2.1. and 4.4.1.). Figure 
59 summarizes the numbers of genes belonging to these 3 biological processes. In 
addition, two examples are given.  
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# of genes upregulated Examples downregulated Examples
Proliferation 184 127 CCND1, MYC 57 IGF1R, E2F6
Signalling pathway components 76 42 SMAD3, MAP3K5 34 CSNK1D, NR4A2
ECM / Cell adhesion 69 25 ITGA6, MMP3 44 ADAMTS1, HAS1
 
 
Figure 59: Numbers of genes belonging to the biological processes proliferation, signalling pathway 
components, and ECM/cell adhesion found to be differentially expressed in Aggr6 cells after the 
addition of WNT5A. Abbreviations: CCND1 = cyclin D1, MYC = c-myc, SMAD3 = mothers against 
decapentaplegic homolog (central transcription factor in TGFβ signalling pathway), MAP3K5 = 
mitogen-activated protein kinase kinase kinase 5, ITGA6 = integrin, alpha 6, MMP3 = matrix 
metalloproteinase 3, IGF1R = insulin-like growth factor 1 receptor, E2F6 = E2F transcription factor 6 
(central role in the regulation of cell cycle), CSNK1D = casein kinase 1 delta, NR4A2 = nuclear 
receptor subfamily 4, group A, member 2 (member of the steroid-thyroid hormone-retinoid receptor 
superfamily), ADAMTS1 = ADAM metallopeptidase with thrombospondin type 1 motif, 1, HAS1 = 
hyaluronan synthase 1 
 
Remarkable is the finding that 69% (127 out of 184) of the deregulated genes 
involved in the regulation of proliferation are induced in their expression after the 
addition of WNT5A. This indicates the prominent impact of WNT5A on the induction 
of proliferation in these cells. On the other hand, 64% (44/69) of the genes involved 
in ECM/Cell adhesion are downregulated in Aggr6 cells after treatment with WNT5A, 
suggesting that an overexpression of WNT5A in aggressive fibromatosis is not 
responsible for the observed accumulation of ECM proteins in this tumor.  
 
The names, ratios, p-values and absolute expression levels of all genes listed in the 
figure above can be found in Gene list E in the Appendix.  
 
 
4.5. Analysis of the reason for the differential responsiveness of tumor cells 
and normal fibroblasts towards WNT5A stimulation 
 
Having shown that recombinant WNT5A activates the canonical Wnt, the Wnt-PCP 
and the PKA pathway (Section 4.2) and stimulates proliferation (Section 4.3.1.) in the 
tumor cell culture Aggr6, but not in the cell cultures of normal fibroblasts, the question 
raises what could be the reason for this discrepancy.  
 
4.5.1. Analysis of Fzd receptor expression in tumor tissues and corresponding cell 
cultures 
  
One possible explanation would be that Aggr6 cells express the relevant WNT5A 
receptors, whereas normal fibroblasts do not. Agilent microarray data revealed that 
all the aggressive fibromatosis tumor tissues analyzed in Chapter I (pool of 10 
individual aggressive fibromatoses (Aggr pool) and 5 individually analyzed tumors 
Aggr1, Aggr2, Aggr4, Aggr6, Aggr7) overexpress the mRNAs coding for the Wnt 
receptors Fzd1, Fzd2, Fzd7, Fzd10 and ROR2 in comparison to the pool of reference 
fibrous tissues (Figure 60 a). Analysis of Agilent microarray data derived from cell 
culture RNA samples (Chapter II) revealed that of these five receptors, Fzd1, Fzd2 
and Fzd7 (red in Figure 60) were also found to be overexpressed in the tumor cell 
culture Aggr6 as compared to the pool of normal human dermal fibroblasts, but 
mostly not in the other aggressive fibromatosis-derived cell cultures Aggr1, Aggr2, 
Aggr4 and Aggr7 (Figure 60 b).  
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Figure 60: Ratios of Wnt receptor expressions in tissues of aggressive  
fibromatoses vs. pooled reference fibrous tissues (a) and in primary cell  
cultures of aggressive fibromatoses vs. pooled normal human dermal  
fibroblast cell cultures (b), determined using Agilent microarray analysis.  
Presented are those receptors that are differentially expressed in at least  
one comparison tumor tissue vs. reference pool and of primary cell culture vs.  
normal human dermal fibroblasts pool, respectively.  
 
These findings suggest that aggressive fibromatosis tumor cells overexpress Fzd1, 
Fzd2 and Fzd7, what renders them responsive to the impact of WNT5A on cellular 
signalling pathways and proliferation.  
 
4.5.2. Activation of the canonical Wnt pathway in cell cultures of normal fibroblasts 
 
A possible reason for the higher expression of those Fzd receptors in the tumor cell 
culture Aggr6 may be the increased activity of the canonical Wnt signalling pathway 
as compared to the cell cultures of normal fibroblasts (Figure 44). A certain level of 
activity within this pathway may be a prerequisite for WNT5A to be able to execute its 
function, since it may lead to the expression of those receptors. To substantiate this 
theory, NHDF and Aggr2 cells were transfected with a plasmid expressing β-catenin 
carrying a deletion at codon 45 (45-β-catenin). This mutation protects it from 
degradation by the β-catenin degradation complex and therefore leads to a 
constitutive activation of the canonical Wnt signalling pathway. Figure 61 illustrates 
that an activation indeed occurred, since both cell cultures are characterized by 
increased canonical Wnt signalling on the Luciferase assay 24 hours (NHDF: 2, 
Aggr2: 7) and 48 hours (NHDF: 4, Aggr2: 9) after transfection, as compared to the 
activities in untransfected cells (NHDF: 1, Aggr2: 6). However, WNT5A was still not 
able to further activate this pathway, neither in the cell culture NHDF (24h: 3, 48h: 5), 
nor in Aggr2 cells (24h: 8, 48h: 10), demonstrating that the above presented theory 
did not prove to be true.  
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Figure 61: Activity of the canonical Wnt signalling pathway in cell cultures of normal 
fibroblasts NHDF and Aggr2 after transfection with a 45-β-catenin expression plasmid  
and subsequent (16 h or 40 h after transfection) treatment with 150ng/ml recombinant  
WNT5A for 8 hours (Luciferase assay). The mean and standard deviation of three 
independent tests is demonstrated. Control: untransfected and untreated cells.  
 
4.5.3. Downregulation of Fzd1, Fzd2 and Fzd7 in the tumor cell culture Aggr6 
 
To further investigate the functional relevance of the observed overexpression of 
Fzd1, Fzd2 and Fzd7 in Aggr6 cells, their expressions were inhibited by transfecting 
Aggr6 cells with different concentrations (20nM, 200nM, 2M) of a pool of siRNAs 
directed against the mRNAs of those Fzd receptors. 16 hours, 40 hours and 64 hours 
after transfection, the cells were treated with recombinant WNT5A for 8 hours to 
explore whether its inducing impact on the canonical Wnt signalling pathway was 
abrogated or not (Luciferase assay). Figure 62 illustrates that WNT5A’s stimulating 
effect on the activity of the canonical Wnt signalling pathway in Aggr6 cells was not 
diminished by the transfection with siRNAs against Fzd1, Fzd2 and Fzd7.  
 
                       
 
 
 
 
 
 
 
 
 
 
 
Figure 62: Activity of the canonical Wnt signalling pathway in Aggr6 cells 
after transfection with a pool of siRNAs against the Wnt receptors Fzd1,  
Fzd2 and Fzd7 (concentrations: 20 nM vs. 200 nM vs. 2 M) and subsequent  
(16 h, 40 h, and 64 h after transfection) treatment with 150ng/ml recombinant  
WNT5A for 8 hours, determined using Luciferase assay. Control: untreated cells. 
control siRNA: negative control (a pool of four non-specified, non-targeting siRNAs)
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5. Discussion 
 
 
5.1. Summary of the results 
 
Agg6 tumor cells carrying a monoallelic β-catenin mutation at codon serine 45 (S45F) 
are characterized by an enhanced activity of the canonical Wnt signalling pathway as 
compared to cell cultures of normal fibroblasts. This is in agreement with the classical 
theory whereupon a monoallelic S45F mutation impedes phosphorylation at this 
residue by CK1α and subsequently also the phosphorylation at the other three 
residues by GSK3β, leading to the accumulation of dephosphorylated, active β-
catenin. 
 
There is a measurable effect of endogenously produced Wnt ligands on the 
canonical Wnt signalling pathway activity in Aggr6 cells via wildtype β-catenin, 
contributing to the impact of mutated β-catenin on this pathway.  
 
Whereas the endogenously produced WNT5A exerted no measurable effect on the 
canonical Wnt signalling pathway activity in Aggr6 tumor cells, recombinant WNT5A 
had an inducing impact on this pathway, because it could be abrogated by the 
simultaneous addition of the canonical Wnt inhibitor DKK1. The observed induction 
was specific, since the concomitant treatment with anti-WNT5A antibodies abolished 
the effect of recombinant WNT5A. In contrast to the results obtained for Aggr6 cells, 
normal fibroblasts did not show any increase in the activity of the canonical Wnt 
signalling pathway after WNT5A stimulation. 
 
Recombinant WNT5A activates the non-canonical Wnt-PCP and PKA pathways in 
Aggr6 tumor cells as well, whereas a crosstalk of those pathways to the canonical 
Wnt signalling cascade could not be observed. Cell cultures of normal fibroblasts did 
not respond to the addition of WNT5A with an increased activity of the Wnt-PCP or 
PKA pathway. The non-canonical Wnt-Ca2+ pathway as well as the STAT signalling 
pathway were not affected by the addition of WNT5A.  
 
A cell proliferation assay revealed that recombinant WNT5A selectively increased the 
proliferation rate of the tumor cell culture Aggr6. Whereas the specific inhibition of the 
canonical Wnt pathway and the Wnt-PCP pathway did not impair WNT5A’s positive 
effect on cellular proliferation, the abrogation of WNT5A’s impact on the PKA 
pathway almost completely abolished the proliferative activity of Aggr6 cells. Thus, of 
the three pathways known to be activated by WNT5A, the PKA pathway elucidated to 
be the only one decisively involved in the regulation of proliferation of Aggr6 tumor 
cells.  
 
For the analysis of the invasive behaviour of the tumor cell culture Aggr6 and the cell 
cultures of normal fibroblasts Aggr2 and NHDF in response to WNT5A, a type I 
collagen cell invasion assay was used. Neither of them responded to the addition of 
recombinant WNT5A with an altered invasive behaviour.  
 
The numbers of differentially expressed sequences obtained by a microarray 
experiment reflected the above findings concerning a selective responsiveness of the 
tumor cell culture Aggr6 towards recombinant WNT5A: it exerted a pronounced effect 
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on the gene expression in Aggr6 cells, but hardly affected the cell cultures of normal 
fibroblasts Aggr2, Aggr4 and NHDF. 
 
Fzd1, Fzd2 and Fzd7 receptors were found to be overexpressed in the tumor cell 
culture Aggr6 as compared to the pool of normal human dermal fibroblasts, but 
mostly not in the other aggressive fibromatosis-derived cell cultures Aggr1, Aggr2, 
Aggr4 and Aggr7. Those Fzd receptors are also upregulated in aggressive 
fibromatosis tumor tissues in comparison to the reference fibrous tissues, providing a 
possible explanation for the selective responsiveness of Aggr6 tumor cells towards 
recombinant WNT5A. However, WNT5A’s stimulating effect on the activity of the 
canonical Wnt signalling pathway in Aggr6 cells could not abrgated by the 
transfection with siRNAs against Fzd1, Fzd2 and Fzd7. 
 
 
By the transfection of a β-catenin expression plasmid into cell cultures of normal 
fibroblast, the activity of the canonical Wnt pathway could be enhanced in normal 
fibroblasts, simulating the situation in Aggr6 tumor cells. However, recombinant 
WNT5A was still not able to further activate this pathway, demonstrating that an 
activated canonical Wnt pathway is not responsible for an overexpression of relevant 
WNT5A receptors.  
 
 
5.2. Analysis of the performance of subcellular protein fractionation 
 
Western blot analyses presented in Section 4.1. were aimed to reveal the accuracy of 
the subcellular protein fractionation process performed by the Nuclear Extract Kit 
from Active Motif, since these protein extracts represent the basis for the cell 
signalling activity experiments depicted in Section 4.2.  
 
The soluble nuclear protein fraction that was used for the transcription factor-activity 
assays and the CREB Western blot experiment was shown to be free from any 
contaminations derived from the other protein fractions, therefore represents a 
trustable basis for those experiments. In addition a substantial contamination of the 
soluble cytoplasmic protein fraction, used for β-catenin Western blot analyses, by 
soluble nuclear proteins could be excluded as well, demonstrating its justified use for 
those studies. 
 
 
5.3. Analysis of the impact of WNT5A on cellular signalling pathways in 
Aggr6 and cell cultures of normal fibroblasts 
 
 
5.3.1. The effect of WNT5A stimulation on the canonical Wnt signalling pathway 
 
Our observation, that the aggressive fibromatosis tumor cell culture Aggr6 is 
characterized by an increased endogenous activity of the canonical Wnt signalling 
pathway as compared to the activity in normal fibroblast cell cultures, is in agreement 
with findings published in the literature reporting the same (Amini Nik et al., 2005; 
Denys et al., 2004; Tejpar et al., 2001) and also confirmes the prevalent theory 
whereupon a monoallelic mutation at serine 45 makes impossible a phosphorylation 
at this residue by CK1α and subsequently impedes the phosphorylation at the other 
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three residues by GSK3β, leading to the accumulation of dephosphorylated, active β-
catenin (Amit et al., 2002; Liu et al., 2002; Yanagawa et al., 2002). 
 
In the tumor cell culture Aggr6, the enhanced activity of the canonical Wnt signalling 
pathway was shown to be derived from both an activating mutation in the oncogene 
β-catenin and an endogenous stimulation through secreted Wnt ligands. A finding, 
that have not been described for tumor cell cultures of aggressive fibrombatoses, yet.  
 
It was also observed for the first time, that cell cultures of normal fibroblasts derived 
from aggressive fibromatoses are characterized by a higher activity of the canonical 
Wnt signalling pathway in comparison to normal human dermal fibroblast cultures, 
pointing towards the existence of an endogenous stimulation through secreted Wnt 
ligands in these cell cultures as well.  
 
Whereas endogenously produced WNT5A does not exert any impact on the 
canonical Wnt pathway activity in Aggr6 cells, recombinant WNT5A was shown to 
selectively induce the activity of this pathway in the tumor cell culture Aggr6, whereas 
all the cell cultures of normal fibroblasts did not respond. As pointed out in Chapter II, 
section 4.3, the amounts of WNT5A used for stimulation were 15 times higher than 
the quantity of endogenous WNT5A present in the culture supernatant of Aggr 6 
cells. Historically, WNT5A was categorized as a ‘non-canonical’ Wnt ligand, since it 
was not able to induce a secondary axis in Xenopus, or to transform mouse 
mammary epithelial C57MG cells (Du et al., 1995; Wong et al., 1994), both 
processes depending on the activity of the canonical Wnt pathway. But meanwhile, 
this strict categorization has been abandoned after the observations that WNT5A can 
activate the canonical Wnt pathway as well, depending on the context of Fzd 
receptors expressed (Deardorff et al., 1998; He et al., 1997; Itoh et al., 1998; Mikels 
and Nusse, 2006; Umbhauer et al., 2000; Yang et al., 2009). However, in context of 
tumorigenesis, a contribution of WNT5A to the pathogenesis through the activation of 
the canonical Wnt pathway has been published only once, so far. In a study done in 
the human immortalized mammary epithelial cell line HC11, WNT5A was shown to 
increase the proliferation rate by transactivating the receptor tyrosine kinase EGFR 
through the canonical Wnt-pathway leading to the expression of matrix 
metalloproteinases (MMPs) and the resultant increase of the availability of EGFR 
ligands (Civenni et al., 2003). All other functional studies performed to reveal its 
impact on the pathogenesis a diverse array of cancers came to the conclusion that it 
signals via a non-canonical pathway (Section 1.2.1.).  
 
5.3.2. The impact of recombinant WNT5A on the Wnt-Ca2+ pathway in Aggr6 cells 
 
NFAT is a transcription factor downstream of calmodulin (CaM) and the protein 
phosphatase calcineurin (PP2B) and has been shown to be involved in the Wnt-Ca2+ 
pathway (Saneyoshi et al., 2002). In Aggr6 cells, a transcription factor-activity assay 
for the family member NFATC1 (NFAT2) revealed that recombinant WNT5A does not 
lead to its dephosphorylation and activation, indicating that it does not signal through 
the Wnt-Ca2+ pathway. 
 
In the literature, several publications report about the relevance of a WNT5A-induced 
Wnt-Ca2+ pathway activity in the pathogenesis of different types of cancer. Via this 
pathway, it exerts tumor-suppressing activities in breast cancer (Dejmek et al., 2006), 
hematopoietic neoplasia (Liang et al., 2003), and neuroblastoma (Blanc et al., 2005), 
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whereas tumor-promoting abilities in cutaneous melanoma (Dissanayake et al., 2008; 
O'Connell et al., 2009b; Weeraratna et al., 2002; Witze et al., 2008) and gastric 
cancer (Kurayoshi et al., 2006; Yamamoto et al., 2009). 
 
Additionally, a study using mouse B-cells reports about an inhibitory effect of WNT5A 
on the canonical Wnt signalling pathway and cellular proliferation via the activation of 
the Wnt-Ca2+-pathway (Liang et al., 2003). 
 
5.3.3. The effect of WNT5A stimulation on the Wnt-PCP signalling pathway 
 
Transcription factor activity assays for c-jun, junB and junD, in combination with a 
pre-treatment of the cells with a specific JNK-inhibitor, JNKI1, led to the conclusion 
that WNT5A selectively activates the Wnt-PCP pathway in the tumor cell culture 
Aggr6, but not in the cultures of normal fibroblasts.  
 
In the literature, an activation of this pathway by WNT5A has been brought into 
context with an increased invasive capacity of the human breast cancer cell line 
MCF-7 (Pukrop et al., 2006), an increased migration and invasion behaviour of 
human cutaneous melanoma (O'Connell et al., 2009a; Weeraratna et al., 2002; Witze 
et al., 2008) and osteosarcoma cell cultures (Enomoto et al., 2009) and an increased 
number of liver metastases after injection of human gastric cancer cells into the 
spleens of nude mice (Yamamoto et al., 2009). Therefore, the observed 
overexpression of WNT5A in aggressive fibromatoses may contribute to their 
characteristic invasive growth behaviour through the activation the Wnt-PCP 
pathway. However, the addition of recombinant WNT5A to Aggr6 cells did not 
improve their invasive capacity (Section 4.3.2.), suggesting that in aggressive 
fibromatoses other mechanisms are responsible for this behaviour.  
 
In a study using human cholangiocarcinoma cells, WNT5A was reported to inhibit 
their proliferation by the activation of the Wnt-PCP pathway (DeMorrow et al., 2008), 
a finding that contrasts our results in Aggr6 cells, whereupon WNT5A exerts no 
influence on cellular proliferation via the Wnt-PCP pathway (Section 4.3.1.). 
 
In addition, two reports using human osteosarcoma cell lines (Enomoto et al., 2009), 
and human colon carcinoma cell lines (MacLeod et al., 2007) describe an inhibition of 
the canonical Wnt pathway through the activation of the Wnt-PCP pathway by 
WNT5A, leading to increased invasion and migration of the osteosarcoma cells 
(Enomoto et al., 2009). In contrast to the results of these studies, our data in 
aggressive fibromatosis tumor cells Aggr6 did not show up any crosstalk between 
these two WNT5A-induced pathways.  
. 
5.3.4. The effect of WNT5A stimulation on the PKA signalling pathway 
 
In agreement with results of a study based on the human breast cancer cell line 
MCF-7 (Hansen et al., 2009), our study revealed that WNT5A activates in Aggr6 cells 
the transcription factor CREB in a PKA-dependent manner, indicating that it activates 
the PKA pathway in these cells. In contrast, cell cultures of normal fibroblasts did not 
respond to the addition of recombinant WNT5A with an increased phosphorylation of 
CREB. Hansen’s study is the only one so far published in the literature describing an 
activation of the PKA pathway by WNT5A in cancerous cells. The authors of another 
publication (Torii et al., 2008) worked with primary human dermal fibroblast cultures 
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and report their reduced serum starvation induced apoptosis after WNT5A-dependent 
activation of the PKA pathway. In our study, fibroblast cell cultures, including the 
normal dermal fibroblast cell culture NHDF, did not show an increased activation of 
CREB, neither after WNT5A-treatment, nor the addition of the PKA-inducer Bt2cAMP, 
indicating that there is no functional linkage between PKA and CREB in these cells. 
This discrepancy might be due to the fact that the fibroblasts in Torii’s study were 
cultivated in serum-free medium prior to their treatment with WNT5A. Under serum-
starvation conditions, they report also a crosstalk between PKA and GSK3β, leading 
to its Ser9-phosphorylation-dependent inhibition and subsequent activation of TCF-
dependent transcription. The addition of WNT5A to Aggr6 cells after their pre-
treatment with the PKA-inhibitor H-89 did not influence the observed stimulating 
effect of WNT5A on the canonical Wnt pathway, demonstrating that under the growth 
conditions applied in our study, there is no crosstalk between the PKA and the 
canonical Wnt signalling pathway.    
 
5.3.5. The effect of WNT5A stimulation on the STAT signalling pathway 
 
In human cutaneous melanoma cell cultures, WNT5A was reported to activate the 
transcription factor STAT3 in a PKC-dependent manner leading to a suppressed 
expression of tumor-associated antigens (Dissanayake et al., 2008). Our approach to 
study in Aggr6 cells the impact of WNT5A on the activation of STAT1α and STAT3 
using transcription factor activity assays did not reveal an influence of WNT5A on the 
activity of the STAT pathway in these cells.   
 
 
5.4. The impact of WNT5A stimulation on proliferation and invasive 
behaviour of Aggr6 cells and cell cultures of normal fibroblasts 
 
5.4.1. Proliferation 
 
The BrdU-proliferation assay demonstrated that Aggr6 cells respond to the addition 
of recombinant WNT5A with an increased proliferation rate, whereas the cell cultures 
of normal fibroblasts Aggr2, NHDF and HDF15 did not respond.  
 
A positive effect of WNT5A on proliferation has been described in the literature in 
context with diverse types of human cell cultures, including immortalized mammary 
epithelial cells (Civenni et al., 2003), cutaneous melanoma cells (Schwartz et al., 
2009), papillary thyroid cancer cells (McCall et al., 2007), pancreatic cancer cells 
(Schwartz et al., 2009), glioblastoma-derived tumor cells (Yu et al., 2007), and non-
small-cell lung cancer cells (Huang et al., 2009), therefore demonstrating WNT5A’s 
tumor-promoting effect in these types of cancers. But the exact mechanism by which 
WNT5A contributes to this effect, has not been investigated in all these studies, with 
the exception of the report by Civenni, describing an involvement of the canonical 
Wnt pathway.  
 
With the aim to elucidate the mechanisms of the WNT5A-dependent proliferation 
stimulation in Aggr6, the cells were pre-treated with inhibitors of the three pathways 
known to be activated after WNT5A stimulation (canonical Wnt, Wnt-PCP and PKA). 
The results of these experiments revealed that the PKA pathway is the only one 
decisively involved in the regulation of proliferation of Aggr6 cells. 
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The PKA pathway has been reported to stimulate cell growth in many cell types while 
inhibiting it in others (Stork and Schmitt, 2002). It has been proposed, that PKA 
regulates cell proliferation through its phosphorylation and activation of myosine 
phosphatase targeting subunit 1 (MYPT1) and phosphorylation and inactivation of 
the tumor suppressor protein neurofibromin 2 (NF2, merlin), an important inhibitor of 
cell proliferation in many cell and tissue types (Alfthan et al., 2004; Umeda et al., 
2008). On the other hand, MYPT1 was shown to dephosphorylate and activate NF2 
itself (Jin et al., 2006). Therefore, PKA exerts its proliferation inducing effect by 
directly inhibiting NF2 and its proliferation inhibiting effect by indirectly activating NF2 
through MYPT1. The PKA-inhibitor H-89 was reported to inhibit cell proliferation in 
human cell cultures of hepatocellular carcinoma (HepG2), breast cancer (MCF-7), 
lung adenocarcinoma (A549) and squamous cell carcinoma (A431), findings that 
confirm our observation in Aggr6 cells. Knockdown of MYPT1 in the human cervical 
cancer cell line HeLa attenuated their H-89-induced cell growth inhibition, further 
suggesting that the phosphorylation level of NF2 regulated by both PKA and MYPT1 
is critically involved in the regulation of cell proliferation (Umeda et al., 2008). At 
higher concentrations (25M), H-89 was reported to compromise the viability of HeLa 
cells, whereas at 10M (the concentration that was used in our study) this effect was 
less pronounced, still allowing cell growth, but significantly retarded as compared to 
untreated cells (Umeda et al., 2008).  
 
In addition, PKA was shown to stimulate proliferation through the phosphorylation 
and activation of the MAP3K BRAF (v-raf murine sarcoma viral oncogene homolog 
B1), leading to the activation of MAPK-pathways, known to be involved in the 
regulation of cell proliferation (Chiaradonna et al., 2008). CREB itself also influences 
proliferation, since among its targets, numerous cell cycle promoting genes can be 
found, including cyclins D1 (CCND1) and A2 (CCNA2), cyclin-dependent kinase 5 
(CDK5), FBJ murine osteosarcoma viral oncogene homolog (FOS), fibroblast growth 
factor 6 (FGF6) and JUND, just to name a few (Mayr and Montminy, 2001).  
 
That the activation of the canonical Wnt pathway does not contribute to the 
proliferation stimulating effect of WNT5A in Aggr6 cells is somehow surprising, 
considering the central role of this pathway in the pathogenesis of aggressive 
fibromatoses and other cancers (Chapter I, Section 1.1.3. and 2.2.1.). In addition, it 
has been reported that primary cell cultures of aggressive fibromatoses derived from 
FAP-patients, therefore carrying biallelic inactivating mutations in the tumor 
suppressor gene APC and being characterized by an increased activity in the 
canonical Wnt pathway, show an increased proliferation rate in comparison to the 
same cultures ectopically expressing a wildtype APC-construct, and therefore being 
characterized by a reduced canonical Wnt signalling activity (Li et al., 1998). 
However, the tumor cell culture Aggr6, that shows an increased endogenous 
canonical Wnt signalling pathway activity as compared to cell cultures of normal 
fibroblasts Aggr2, NHDF and HDF15, does not proliferate faster than those three cell 
cultures, confirming that in our cell cultures used and under our growth conditions 
applied, the canonical Wnt signalling pathway activity does not influence cellular 
proliferation. 
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5.4.2. Invasion 
 
The type I collagen cell invasion assay demonstrated that neither the primary tumor 
cell culture Aggr6, nor Aggr2 or NHDF normal fibroblasts respond to the addition of 
recombinant WNT5A with an alteration of their invasive behaviour.  
 
WNT5A was reported to promote the invasion of tumor cells in several types of 
cancer, including breast cancer (Pukrop et al., 2006), cutaneous melanoma 
(O'Connell et al., 2009b; Weeraratna et al., 2002), osteosarcoma (Enomoto et al., 
2009), pancreatic cancer (Ripka et al., 2007) and glioblastoma (Yu et al., 2007). On 
the other hand, WNT5A was shown to inhibit the invasive behaviour of breast cancer 
(Dejmek et al., 2006; Medrek et al., 2009; Safholm et al., 2008) and neuroblastoma 
(Blanc et al., 2005) tumor cells.  
 
 
5.5. The differential gene expression induced by WNT5A stimulation in Aggr6 
cells and cell cultures of normal fibroblasts 
 
The selective impact of WNT5A on the tumor cell culture Aggr6 is impressively 
demonstrated by looking at the simple numbers of sequences differentially expressed 
after WNT5A stimulation of Aggr6 cells and cell cultures of normal fibroblasts using 
Agilent microarray gene expression analysis. Whereas nearly 4’000 sequences were 
found to be differentially expressed in Aggr6 cells, not even 100 were regulated in 
Aggr2, Aggr4 and NHDF normal fibroblasts.  
 
The functional annotation of the selected differentially expressed genes in Aggr6 
identified 184 genes to be involved in the regulation of proliferation, whereas 127 of 
them (69%) were found to be induced in their expression after WNT5A-treatment. 
Just to name a few examples, the upregulated genes include cyclins such as A2, B1, 
B2, D1 and G2, growth factors such as fibroblast growth factor 2 (FGF2) or platelet-
derived growth factor A (PDGFA) and oncogenes like c-myc and epidermal growth 
factor receptor (EGFR).  
 
The other focus was laid on intracellular components of signalling pathways. Also in 
this biological process, a lot of genes (76) were found to be differentially expressed, 
including among the upregulated genes the transcription factors of the TGFβ 
signalling pathway SMAD1, SMAD3 and SMAD4. Therefore, an increased 
expression of WNT5A in aggressive fibromatosis may lead to a transactivation of the 
TGFβ signalling pathway through the upregulation of these three critical components. 
However, looking at the gene expression data presented in Chapter I reveals that 
those transcription factors are not upregulated in tissues of aggressive fibromatosis 
as compared to reference fibrous tissues. SMAD3 was even shown to be 
downregulated.  
 
69 genes belonging to the biological processes extracellular matrix (ECM), cell-cell 
and cell-ECM adhesion were found to be regulated in their expressions by WNT5A 
stimulation. Only 25 (36%) of them were upregulated, lacking any collagens, 
demonstrating that an increased expression of WNT5A in aggressive fibromatosis 
does not contribute to the characteristic accumulation of ECM proteins (Chapter I, 
Section 2.1.).  
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5.6. Analysis of the reason for the differential responsiveness of tumor cells 
and normal fibroblasts towards WNT5A stimulation 
 
The analyses of the WNT5A-reguated signalling pathways and cellular behaviour 
demonstrated the selective impact of this protein on the tumor cell culture Aggr6. The 
missing responsiveness of the cell cultures of normal fibroblasts led to the suspicion, 
that they may lack the relevant receptors. An analysis of microarray gene expression 
data performed both on tissues and primary cell cultures revealed that the tumor cell 
culture Aggr6 selectively overexpresses the Wnt receptors Fzd1, Fzd2 and Fzd7 as 
compared to primary cell cultures of normal fibroblasts, and that these receptors are 
also overexpressed in aggressive fibromatosis tumor tissues as compared to 
reference fibrous tissues.  
 
A downregulation of those receptors by the means of siRNAs transfected into Aggr6 
cells did not lead to the expected effect of an abrogated WNT5A impact on these 
cells. Because of the very low transfection efficiency of primary cell cultures of 
aggressive fibromatosis, that is in the range of 15% at best, a confirmation of a 
successful downregulation of the targets on the protein level without any previous cell 
sorting approach could not be performed. Therefore, we do not know whether an 
inhibition of the expressions of Fzd1, Fzd2 and Fzd7 in the transfected cells indeed 
occurred.  
 
The other approach, transfecting cell cultures of normal fibroblasts Aggr2 and NHDF 
with a 45-β-catenin expression plasmid, did not induce the expression of those Fzd 
receptors.. Although an increase of TCF-dependent transcription both in Aggr2 and 
NHDF could be observed, recombinant WNT5A was still not able to further activate it.  
 
In conclusion, WNT5A activates the canonical Wnt as well as the non-canonical Wnt-
PCP and PKA pathways. No crosstalk between the latter and the canonical pathway 
coud be observed. WNT5A stimulates the proliferation in a PKA pathway dependent 
manner, but does not affect the invasive behaviour of Aggr6 cells. In an attempt to 
investigarte the reason for the differential responsiveness of tumor cells and normal 
fibroblasts towards recombinant WNT5A, candidate Fzd receptors were repressed in 
their expressions by siRNA. This did not abolish WNT5A’s effect on the activation of 
the canonical Wnt pathway. In order to investigate the possibility of an induction of 
relevant Fzd receptors by an active canonical Wnt pathway, normal fibroblasts were 
transfected with a β-catenin expression plasmid. Although an increased pathway 
activity could be observed, WNT5A was still not able to exert its stimulating effect. 
 
Therefore, the mechanisms being responsible for the observed discrepancy between 
Aggr6 cells and the cell cultures of normal fibroblasts in the responsiveness towards 
WNT5A remain to be elucidated. 
     
Taken together, the in vitro results provide a basis for the understanding of the 
mechanisms, by which WNT5A exerts its tumor promoting effects also in vivo.  
 
 
 
 
 
 
Appendix Gene list A
Gene list A: Genes commonly differentiating both tumors from the 
reference fibrous tissue or solely differentiating one tumor from 
the reference fibrous tissue
Aggr, Super > Ref
Aggr, Super < Ref
Aggr ≠ Ref or Super ≠ Ref
Genes whose differential expression between fibromatoses and reference tissue has been described in the 
literature are marked with the according informations in the first column. Abbreviations: 
A Aggressive fibromatosis
S Superficial fibromatosis
R Reference fibrous tissue
√ Differential expression described in the literature could be confirmed by own results
no √ Differential expression described in the literature could not be confirmed, 
the result published in the literature is indicated, e.g. A = R
IHC. Result published in the literature obtained by immunohistochemical analysis
M Result published in the literature obtained by microarray gene expression analysis
W Result published in the literature obtained by Western blot analysis
N Result published in the literature obtained by Northern blot analysis
ELISA Result published in the literature obtained by ELISA analysis
2D-GE Result published in the literature obtained by two-dimensional gel electrophoresis, 
followed by mass spectrometry (MS) analysis
PCR Result published in the literature obtained by RT-PCR or real-time RT-PCR
1) Wnt signalling pathway
ratio pvalue aggr ref ratio pvalue superfic ref
APC  adenomatosis polyposis coli (APC), mRNA [NM_00003 2.16 1.20E-07 802 377
AXIN2  axin 2 (conductin, axil) (AXIN2), mRNA [NM_004655] 2.32 0.00002 711 312 2.18 0.00006 1179 564
5.54 5.43E-33 3650 661
A√ IHC,M CCND1  cyclin D1 (PRAD1: parathyroid adenomatosis 1) (CCN 3.06 1.22E-37 2463 802 2.41 2.61E-23 2102 867
A√ M CCND2  cyclin D2 (CCND2), mRNA [NM_001759] 2.10 6.80E-12 1014 479 2.72 1.20E-11 913 346
CCND2 5.16 5.81E-31 1799 350
CREBBP  CREB binding protein (Rubinstein-Taybi syndrome) (C 0.49 2.94E-10 405 830
A√ IHC. CTNNB1  catenin (cadherin-associated protein), beta 1, 88kDa (C 2.74 2.21E-21 3650 1324
EDN1  endothelin 1 (EDN1), mRNA [NM_001955] 0.13 0 628 5007 0.26 0 1125 4354
EGFR  epidermal growth factor receptor (erythroblastic leukem 0.41 0.00052 257 658
A√ M EPHB3  EPH receptor B3 (EPHB3), mRNA [NM_004443] 3.91 1.60E-14 1113 289 2.87 4.10E-13 857 291
S√ IHC,ISH,W,M FN1  fibronectin 1 (FN1), transcript variant 7, mRNA [NM_05 2.14 7.8E-09 1306 617 5.86 0 9319 1582
FN1 6.26 0 101623 16237 5.97 0 92627 15302
FOSL1  FOS-like antigen 1 (FOSL1), mRNA [NM_005438] 2.13 7.5E-10 1587 736
FRAT1  frequently rearranged in advanced T-cell lymphomas ( 3.54 4.48E-36 1557 441 2.58 1.14E-13 955 378
FZD1  frizzled homolog 1 (Drosophila) (FZD1), mRNA [NM_0 3.65 1.90E-27 15258 4131 2.42 7.85E-16 9305 3796
FZD10  frizzled homolog 10 (Drosophila) (FZD10), mRNA [NM 2.10 4.41E-10 2552 1196
FZD4  frizzled homolog 4 (Drosophila) (FZD4), mRNA [NM_0 0.39 0 2230 5650
FZD5  frizzled homolog 5 (Drosophila) (FZD5), mRNA [NM_0 0.46 6.92E-16 573 1260
GJA1  gap junction protein, alpha 1, 43kDa (connexin 43) (GJ 14.32 0 51266 3499 4.75 6.31E-08 1048 239
GJA1 7.27 0 1444 200 6.75 0 25739 3798
ID2  inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2), mRNA [NM_002 0.28 0 3698 13227
JUN  v-jun sarcoma virus 17 oncogene homolog (avian) (JUN), mRNA [NM_002228] 0.46 0 19284 42331
A=R  PCR LEF1  lymphoid enhancer-binding factor 1 (LEF1), mRNA [NM 7.67 0 3569 467 3.11 1.69E-13 1260 392
S√ IHC,ELISA,M MMP2  matrix metalloproteinase 2 (gelatinase A, 72kDa gelati 2.05 9.59E-09 5162 2507 3.31 2.63E-31 7670 2317
A=R  PCR
A>R  M,PCR MMP3  matrix metalloproteinase 3 (stromelysin 1, progelatinas 0.01 0 3050 286788 0.01 0 3432 279991
aggressive / reference superficial / reference
Appendix Gene list A
ratio pvalue aggr ref ratio pvalue superfic ref
S>R IHC. MYC  v-myc myelocytomatosis viral oncogene homolog (avia 0.23 0 901 3971 0.29 1.77E-21 1390 4801
PTTG1  pituitary tumor-transforming 1 (PTTG1), mRNA [NM_00 6.60 3.18E-37 25146 3703 4.53 1.38E-19 14803 3078
RHOU  ras homolog gene family, member U (RHOU), mRNA [ 0.30 4.59E-13 216 703 0.35 2.59E-09 244 672
RUNX2  runt-related transcription factor 2 (RUNX2), transcript v 5.72 0 3228 562 3.91 0 1565 398
SFRP2  secreted frizzled-related protein 2 (SFRP2), mRNA [NM10.58 0 26378 2490 3.66 0 1964 537
10.13 0 7482 740 2.91 0 3466 1192
5.73 0 7945 1388 5.98 0 11575 1934
SFRP4  secreted frizzled-related protein 4 (SFRP4), mRNA [NM16.57 0 29554 1781 30.97 0 73816 2390
SMAD3  SMAD, mothers against DPP homolog 3 (Drosophila) ( 0.32 0 695 2149 0.41 1.24E-20 927 2249
SMAD3 0.28 1.33E-29 1180 4180 0.47 7.25E-26 2007 4272
SOX17  SRY (sex determining region Y)-box 17 (SOX17), mRN 2.03 9.57E-20 2761 1360 2.09 4.30E-29 3075 1473
TCF4  transcription factor 4 (TCF4), mRNA [NM_003199] 2.23 2.64E-36 14206 6354
TNFRSF19  tumor necrosis factor receptor superfamily, member 19 20.61 3.90E-28 3316 158 6.43 2.25E-16 866 127
TNFRSF19  tumor necrosis factor receptor superfamily, member 19 2.38 0.0823 178 77
TWIST1  twist homolog 1 (acrocephalosyndactyly 3; Saethre-Ch 3.54 0 2351 664
A√ M WISP1  WNT1 inducible signaling pathway protein 1 (WISP1), 3.03 0 9133 3017 2.57 0.00001 4174 1751
A√ M WNT5A  wingless-type MMTV integration site family, member 5 14.40 0 5461 378 2.27 4.47E-09 657 295
WNT6  wingless-type MMTV integration site family, member 6 2.54 6.10E-19 17815 6961
WNT11  wingless-type MMTV integration site family, member 1 0.43 2.61E-37 1585 3710 0.40 0 1249 3114
2) TGFβ signalling pathway
ratio pvalue aggr ref ratio pvalue superfic ref
ACVR1B  activin A receptor, type IB (ACVR1B), transcript varian 2.23 4.12E-37 44664 19989
AMH  anti-Mullerian hormone (AMH), mRNA [NM_000479] 2.11 3.39E-07 870 407
A√ M ASPN  asporin (LRR class 1) (ASPN), mRNA [NM_017680] 14.89 0 36546 2424 27.27 0 91077 3308
S√ PCR BMP1  bone morphogenetic protein 1 (BMP1), transcript varia 2.04 3.6E-07 720 355
2.01 4.1E-08 626 310
S=R  PCR BMP7  bone morphogenetic protein 7 (osteogenic protein 1) (B16.33 0 2205 136 5.36 9.92E-13 552 99
BMP8A  bone morphogenetic protein 8a (BMP8A), mRNA [NM_ 2.90 8.89E-17 47854 16023 2.31 3.31E-12 36604 15440
CILP  cartilage intermediate layer protein, nucleotide pyropho 0.04 0 3778 87300 0.17 2.75E-22 12084 74050
CDKN1B  cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN 0.26 2.80E-45 863 3382 0.31 1.77E-39 986 3235
S√ IHC,W COL1A1  collagen, type I, alpha 1 (COL1A1), mRNA [NM_00008 12.42 4.8E-44 434853 32173 13.40 0 377400 28676
A√ PCR,M
S√ IHC,W COL1A2  collagen, type I, alpha 2 (COL1A2), mRNA [NM_00008 8.36 1.1E-44 3978 468 25.72 0 360611 14122
COL1A2 21.97 1.4E-45 438794 18042 5.50 0 2176 396
SvR √ COL3A1  collagen, type III, alpha 1 (Ehlers-Danlos syndrome typ 15.12 0 338160 21395 22.10 0 418071 18917
AvR √ M,PCR 19.81 0 439519 20690 33.25 0 66275 1999
40.43 0 117501 2996 13.65 0 329376 24085
CTHRC1  collagen triple helix repeat containing 1 (CTHRC1), mR 13.13 0 62754 4696 7.61 0 40183 5219
S√ M DCN  decorin (DCN), transcript variant A1, mRNA [NM_0019 0.39 1.34E-11 60964 157385 0.40 1.90E-15 54925 139728
S√ IHC,ISH,W,M FN1  fibronectin 1 (FN1), transcript variant 7, mRNA [NM_05 2.14 7.8E-09 1306 617 5.86 0 9319 1582
FN1 6.26 0 101623 16237 5.97 0 92627 15302
GADD45B  growth arrest and DNA-damage-inducible, beta (GADD45B), mRNA [NM_015675] 0.34 1.29E-23 10475 31156
ID2  inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2), mRNA [NM_002 0.28 0 3698 13227
INHBB  inhibin, beta B (activin AB beta polypeptide) (INHBB), m 0.39 6.61E-31 1704 4376 0.30 3.39E-27 1254 4220
S√ IHC,ELISA,M MMP2  matrix metalloproteinase 2 (gelatinase A, 72kDa gelati 2.05 9.59E-09 5162 2507 3.31 2.63E-31 7670 2317
A=R  PCR
S>R  IHC. MYC  v-myc myelocytomatosis viral oncogene homolog (avia 0.23 0 901 3971 0.29 1.77E-21 1390 4801
NODAL  nodal homolog (mouse) (NODAL), mRNA [NM_018055 2.23 7.82E-07 1184 539 2.14 4.05E-13 871 413
OGN  osteoglycin (osteoinductive factor, mimecan) (OGN), tr 16.59 0 8686 524 7.88 0 3775 480
SMAD3  SMAD, mothers against DPP homolog 3 (Drosophila) ( 0.32 0 695 2149 0.41 1.24E-20 927 2249
SMAD3 0.28 1.33E-29 1180 4180 0.47 7.25E-26 2007 4272
S√ M SPARC  secreted protein, acidic, cysteine-rich (osteonectin) (SP12.85 1.1E-44 440326 31435 13.33 0 433979 31064
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Appendix Gene list A
ratio pvalue aggr ref ratio pvalue superfic ref
A√ M TGFB3  transforming growth factor, beta 3 (TGFB3), mRNA [NM 9.31 0 6452 684 8.77 0 6492 736
S√ IHC. TGFB3 5.77 0.0002 305 64
S√ 2D-GE TGFBI  transforming growth factor, beta-induced, 68kDa (TGF 4.56 1.2E-33 162242 35015 7.27 0 289821 39235
S√ IHC, ELISA,M TGFB2  transforming growth factor, beta 2 (TGFB2), mRNA [NM_003238] 3.06 1.82E-11 703 238
A>R  W TGFBR2  transforming growth factor, beta receptor II (70/80kDa) 0.44 4.88E-15 382 861
A=R  W TGFBR3  transforming growth factor, beta receptor III (betaglyca 0.35 2.62E-32 744 2148 0.27 0 558 2087
THBS2  thrombospondin 2 (THBS2), mRNA [NM_003247] 6.57 1.21E-33 18698 2782 5.36 0 12664 2355
TINP1  TGF beta-inducible nuclear protein 1 (TINP1), mRNA [ 0.46 2.38E-18 5486 12150 0.48 9.30E-20 4510 9552
3) PI3K-AKT signalling pathway
ratio pvalue aggr ref ratio pvalue superfic ref
A√ IHC,M CCND1  cyclin D1 (PRAD1: parathyroid adenomatosis 1) (CCN 3.06 1.22E-37 2463 802 2.41 2.61E-23 2102 867
CDKN1B  cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN 0.26 2.80E-45 863 3382 0.31 1.77E-39 986 3235
A√ IHC. CTNNB1  catenin (cadherin-associated protein), beta 1, 88kDa (C 2.74 2.21E-21 3650 1324
EGFR  epidermal growth factor receptor (erythroblastic leukem 0.41 0.00052 257 658
FGF1  fibroblast growth factor 1 (acidic) (FGF1), transcript va 4.24 0 1627 384 3.49 1.67E-27 1720 495
FGF7  fibroblast growth factor 7 (keratinocyte growth factor) ( 0.46 1.54E-27 766 1683 0.32 1.40E-45 510 1616
FGF7  fibroblast growth factor 7 (keratinocyte growth factor) ( 0.29 2.64E-22 3824 13118 0.19 0 2448 12905
FOXO1A  forkhead box O1A (rhabdomyosarcoma) (FOXO1A), m 0.28 0 3545 12921 0.28 0 3417 12156
HIF1A  hypoxia-inducible factor 1, alpha subunit (basic helix-lo 2.27 1.37E-43 9240 4072
A √ M,W,N IGFBP6  insulin-like growth factor binding protein 6 (IGFBP6), m 0.09 0 380 4180 0.25 6.62E-35 1172 4684
IL6R  interleukin 6 receptor (IL6R), transcript variant 1, mRN 0.27 8.10E-26 401 1497 0.25 4.75E-30 391 1540
IL20RA  interleukin 20 receptor, alpha (IL20RA), mRNA [NM_01 2.66 7.34E-11 1032 381
IRS1  insulin receptor substrate 1 (IRS1), mRNA [NM_00554 3.33 0 2352 706 2.85 2.80E-45 1796 632
IRS2  insulin receptor substrate 2 (IRS2), mRNA [NM_00374 0.29 0 656 2298 0.25 0 574 2252
S>R IHC. MYC  v-myc myelocytomatosis viral oncogene homolog (avia 0.23 0 901 3971 0.29 1.77E-21 1390 4801
NFKBIA  nuclear factor of kappa light polypeptide gene enhance 0.37 0 11092 29643 0.25 0 8082 32193
PDGFC  platelet derived growth factor C (PDGFC), mRNA [NM_ 2.19 6.40E-20 3513 1597 2.44 0 3722 1522
PDK1  pyruvate dehydrogenase kinase, isoenzyme 1 (PDK1), 0.45 3.84E-11 557 1224 0.45 2.21E-26 663 1459
A=S√  IHC,PCR TP53  tumor protein p53 (Li-Fraumeni syndrome) (TP53), mR 0.21 0 614 2968 0.27 0 726 2711
S>R  W
PIK3CD  phosphoinositide-3-kinase, catalytic, delta polypeptide 4.87 0 5856 1202 4.62 0 5517 1192
PIK3R3  phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) (PIK3R3), mRNA [NM_00362 0.48 8.45E-06 322 707
VEGF  vascular endothelial growth factor, mRNA (cDNA clone MGC:70609 IMAGE:6006890), com 0.48 5.79E-16 1188 2446
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4) Extracellular matrix (ECM)
ratio pvalue aggr ref ratio pvalue superfic ref
A√ M ADAM12  a disintegrin and metalloproteinase domain 12 (meltrin 3.52 7.16E-40 6058 1722 3.05 0 5308 1737
S√  PCR
ADAMTSL3  ADAMTS-like 3 (ADAMTSL3), mRNA [NM_207517] 0.11 9.31E-07 67 574 0.18 1.59E-12 120 615
ADAMTS5  a disintegrin-like and metalloprotease (reprolysin type) 0.19 0 2709 14432 0.34 7.66E-20 5514 16061
AGRN  agrin (AGRN), mRNA [NM_198576] 2.00 1.58E-32 5920 2949
ANGPTL7  angiopoietin-like 7 (ANGPTL7), mRNA [NM_021146] 0.005 0 1284 274406 0.05 0 11741 233940
S√ M APP  amyloid beta (A4) precursor protein (protease nexin-II, 4.67 1.64E-27 1801 387 3.80 2.09E-22 1778 472
A√ M ASPN  asporin (LRR class 1) (ASPN), mRNA [NM_017680] 14.89 0 36546 2424 27.27 0 91077 3308
CHI3L1  chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), 0.10 0 550 5400 0.14 0 711 4990
CHI3L1  chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), 0.18 5.72E-14 152 829
CHI3L2  chitinase 3-like 2 (CHI3L2), mRNA [NM_004000] 0.09 0 362 4237 0.13 0 485 3719
CILP  cartilage intermediate layer protein, nucleotide pyropho 0.04 0 3778 87300 0.17 2.75E-22 12084 74050
COL10A1  collagen, type X, alpha 1(Schmid metaphyseal chondro 2.61 6.42E-39 5005 1922
A√ M COL11A1  collagen, type XI, alpha 1 (COL11A1), transcript varian 16.45 0 11610 708 5.43 0 3027 556
COL11A2  collagen, type XI, alpha 2 (COL11A2), transcript varian 0.55 3.6E-13 2073 3787
A√ M COL12A1  collagen, type XII, alpha 1 (COL12A1), transcript varian 2.32 0 5029 2168
COL13A1  collagen, type XIII, alpha 1 (COL13A1), transcript varia 7.79 0 3009 383 9.53 0 3369 351
A√ M COL14A1  collagen, type XIV, alpha 1 (undulin) (COL14A1), mRN 5.93 0 9815 1652 6.47 0 11169 1727
COL14A1 8.62 0 15418 1794 12.96 0 28779 2173
COL14A1 2.83 0 12313 4344
COL16A1  collagen, type XVI, alpha 1 (COL16A1), mRNA [NM_00 9.20 1.29E-29 151140 15768 5.84 2.36E-22 84214 13909
COL18A1  collagen, type XVIII, alpha 1 (COL18A1), transcript var 2.57 0 31927 12408 3.17 0 38523 12135
S√ IHC,W COL1A1  collagen, type I, alpha 1 (COL1A1), mRNA [NM_00008 12.42 4.8E-44 434853 32173 13.40 0 377400 28676
A√ PCR,M
S√ IHC,W COL1A2  collagen, type I, alpha 2 (COL1A2), mRNA [NM_00008 8.36 1.1E-44 3978 468 25.72 0 360611 14122
COL1A2 21.97 1.4E-45 438794 18042 5.50 0 2176 396
COL25A1  collagen, type XXV, alpha 1 (COL25A1), transcript vari 2.20 1.15E-17 1223 558
SvR √ COL3A1  collagen, type III, alpha 1 (Ehlers-Danlos syndrome typ 15.12 0 338160 21395 22.10 0 418071 18917
AvR √ M,PCR 19.81 0 439519 20690 33.25 0 66275 1999
40.43 0 117501 2996 13.65 0 329376 24085
S√ IHC. COL4A1  collagen, type IV, alpha 1 (COL4A1), mRNA [NM_0018 2.87 1.20E-12 762 263 2.05 0.00081 596 268
S√ IHC. COL4A5  collagen, type IV, alpha 5 (Alport syndrome) (COL4A5) 2.30 3.38E-13 805 351 4.00 0 2598 649
2.32 9.87E-21 1315 564
7.93 0 7045 883
A√ M COL5A1  collagen, type V, alpha 1 (COL5A1), mRNA [NM_0000 12.82 0 53506 4187 7.85 0 23475 3005
28.83 0 5889 206 15.60 0 2091 134
A,S√ M COL5A2  collagen, type V, alpha 2 (COL5A2), mRNA [NM_0003 18.18 0 18974 1044 16.16 0 20278 1262
COL5A2 6.34 0 73717 11539 5.79 0 69785 11871
COL5A2 4.17 4.40E-43 1473 354 4.08 5.96E-38 1443 357
COL5A3  collagen, type V, alpha 3 (COL5A3), mRNA [NM_0157 2.12 6.86E-12 816 386
S√ IHC. COL6A1  collagen, type VI, alpha 1 (COL6A1), mRNA [NM_0018 4.13 0 2438 588 7.52 0 366939 48166
A√ M COL6A1 7.50 4.68E-29 384091 47253 3.34 3.63E-34 1405 425
S√ IHC. COL6A2  collagen, type VI, alpha 2 (COL6A2), transcript variant 10.68 0 4702 440 9.25 0 3564 384
A√ M COL6A2 2.55 3.22E-18 3551 1388 2.03 1.22E-13 2717 1334
S√ IHC,2D-GE COL6A3  collagen, type VI, alpha 3 (COL6A3), transcript variant 2.22 0 76955 34656 2.71 1.17E-17 94430 34605
A√ M
S√ M COL8A1  collagen, type VIII, alpha 1 (COL8A1), transcript varian 3.10 7.17E-23 8420 2674 2.47 0 5304 2144
COL8A2  collagen, type VIII, alpha 2 (COL8A2), mRNA [NM_005 2.20 5.66E-15 4848 2176 5.85 0 14811 2511
CTHRC1  collagen triple helix repeat containing 1 (CTHRC1), mR 13.13 0 62754 4696 7.61 0 40183 5219
S√ M DCN  decorin (DCN), transcript variant A1, mRNA [NM_0019 0.39 1.34E-11 60964 157385 0.40 1.90E-15 54925 139728
ECM1  extracellular matrix protein 1 (ECM1), transcript varian 4.14 0 2572 621 4.59 0 3023 658
EFEMP2  EGF-containing fibulin-like extracellular matrix protein 2.52 0 3065 1215
A,S√ M FAP  fibroblast activation protein, alpha (FAP), mRNA [NM_ 52.70 0 56300 1063 40.41 0 41456 1023
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FBN1  fibrillin 1 (Marfan syndrome) (FBN1), mRNA [NM_0001 3.72 0 16665 4470 2.53 9.42E-43 10616 4188
FIBL-6  hemicentin (FIBL-6), mRNA [NM_031935] 4.52 0 5522 1221 2.85 3.12E-10 2444 876
S√ IHC,ISH,W,M FN1  fibronectin 1 (FN1), transcript variant 7, mRNA [NM_05 2.14 7.8E-09 1306 617 5.86 0 9319 1582
FN1 6.26 0 101623 16237 5.97 0 92627 15302
FN1 6.90 0 14416 2083
LAMA1  laminin, alpha 1 (LAMA1), mRNA [NM_005559] 2.21 4.92E-08 626 281 2.36 4.13E-07 554 228
LAMA2  laminin, alpha 2 (merosin, congenital muscular dystrop 0.46 0 3377 7359 0.46 4.12E-31 3706 8078
LAMA4  laminin, alpha 4 (LAMA4), mRNA [NM_002290] 3.81 1.56E-23 14402 3748 3.17 4.53E-23 10314 3223
S√ IHC. LAMB1  laminin, beta 1 (LAMB1), mRNA [NM_002291] 3.56 0 25964 7281 2.85 0 19914 6971
S√ 2D-GE LGALS1  lectin, galactoside-binding, soluble, 1 (galectin 1) (LGA 4.86 0 37051 7543 5.12 0 39357 7656
LUM  lumican (LUM), mRNA [NM_002345] 6.17 0 82530 13378 3.76 1.21E-30 43130 11393
MFAP5  microfibrillar associated protein 5 (MFAP5), mRNA [NM 4.90 3.39E-40 6723 1352
MGP  matrix Gla protein (MGP), mRNA [NM_000900] 0.37 5.92E-30 29059 78907
S√ IHC,ELISA,M MMP2  matrix metalloproteinase 2 (gelatinase A, 72kDa gelati 2.05 9.59E-09 5162 2507 3.31 2.63E-31 7670 2317
A=R  PCR
MMP10  matrix metalloproteinase 10 (stromelysin 2) (MMP10), 0.29 0 1013 3514 0.24 0 832 3401
A√ PCR MMP11  matrix metalloproteinase 11 (stromelysin 3) (MMP11), 18.57 0 21077 1139 8.93 0 6272 693
A,S√  PCR MMP14  matrix metalloproteinase 14 (membrane-inserted) (MMP14), mRNA [NM_004995] 2.29 1.56E-15 4216 1826
MMP19  matrix metalloproteinase 19 (MMP19), transcript varian 10.78 0 3898 362 3.43 4.58E-21 1259 360
MMP23B  matrix metalloproteinase 23B (MMP23B), mRNA [NM_ 6.09 0 4386 719 2.75 1.54E-42 1210 439
MMP27  matrix metalloproteinase 27 (MMP27), mRNA [NM_02 2.07 1.87E-17 1608 774
A>R  M,PCR MMP3  matrix metalloproteinase 3 (stromelysin 1, progelatinas 0.01 0 3050 286788 0.01 0 3432 279991
A<R  M NID2  nidogen 2 (osteonidogen) (NID2), mRNA [NM_007361 7.30 0 2909 396 12.24 0 5659 460
OGN  osteoglycin (osteoinductive factor, mimecan) (OGN), tr 16.59 0 8686 524 7.88 0 3775 480
P4HA2  procollagen-proline, 2-oxoglutarate 4-dioxygenase (pro 12.03 0 25382 2106 7.78 0 15322 1960
P4HA3  procollagen-proline, 2-oxoglutarate 4-dioxygenase (pro 3.04 1.21E-18 975 323 10.32 0 6331 612
P4HA3 7.21 0 3635 504 4.29 5.01E-29 1302 309
P4HB  procollagen-proline, 2-oxoglutarate 4-dioxygenase (pro 3.61 0 11836 3279 2.70 0 7759 2870
P4HB 2.41 5.50E-09 49702 20517
PCOLCE  procollagen C-endopeptidase enhancer (PCOLCE), m 5.17 0 11955 2298 3.13 0 6771 2171
PCOLCE2  procollagen C-endopeptidase enhancer 2 (PCOLCE2) 0.03 0 1250 46252 0.05 0 2015 44588
PLG  plasminogen (PLG), mRNA [NM_000301] 5.56 0 43311 7793 3.39 0 24010 7092
PLOD1  procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 ( 2.29 7.21E-27 6001 2614 2.39 1.53E-20 6111 2543
S√ IHC,M,PCR POSTN  periostin, osteoblast specific factor (POSTN), mRNA [N53.68 0 36596 691 60.23 0 85449 1436
PRG2  proteoglycan 2, bone marrow (natural killer cell activat 2.28 2.54E-18 4001 1749
S√  M PRG4  proteoglycan 4 (PRG4), mRNA [NM_005807] 0.01 0 482 44080 0.12 0 4826 40787
SERPINA3  serine (or cysteine) proteinase inhibitor, clade A (alpha 0.08 0 526 6291 0.09 0 544 5783
SERPINA3 0.15 0 426 2793 0.21 0 477 2342
SERPINA5  serine (or cysteine) proteinase inhibitor, clade A (alpha 4.73 4.20E-16 3499 728 2.80 9.34E-08 1838 668
SERPINA10 serine (or cysteine) proteinase inhibitor, clade A (alpha 2.59 3.16E-31 1487 575
SERPING1  serine (or cysteine) proteinase inhibitor, clade G (C1 in 0.26 0 1289 4950 0.34 3.82E-39 1445 4214
S√ M,W SERPINH1  serine (or cysteine) proteinase inhibitor, clade H (heat 9.87 0 4017 406 5.35 2.61E-38 2103 395
SMOC2  SPARC related modular calcium binding 2 (SMOC2), m 3.45 8.2E-13 12678 3473 3.71 3.23E-15 13922 3652
S√ M SPARC  secreted protein, acidic, cysteine-rich (osteonectin) (SP12.85 1.1E-44 440326 31435 13.33 0 433979 31064
SPON1  spondin 1, extracellular matrix protein (SPON1), mRNA 35.89 0 41573 1161 18.04 0 18125 1001
A√ M SPON2  spondin 2, extracellular matrix protein (SPON2), mRNA 9.59 1.19E-41 103308 10375 23.98 0 278300 11395
THBS2  thrombospondin 2 (THBS2), mRNA [NM_003247] 6.57 1.21E-33 18698 2782 5.36 0 12664 2355
S√ IHC. TIMP2  tissue inhibitor of metalloproteinase 2 (TIMP2), mRNA 2.27 1.28E-08 6918 3005 2.04 1.74E-10 6273 3038
A=R  PCR
A√  PCR TIMP3  tissue inhibitor of metalloproteinase 3 (Sorsby fundus d 0.46 9.58E-23 4559 9945
TIMP4  tissue inhibitor of metalloproteinase 4 (TIMP4), mRNA 0.35 0 1165 3367 0.31 2.46E-32 916 2958
S√ M, PCR TNC  tenascin C (hexabrachion) (TNC), mRNA [NM_002160 2.48 0 5955 2403 8.99 0 41901 4677
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5) ECM-receptor interaction
ratio pvalue aggr ref ratio pvalue superfic ref
AGRN  agrin (AGRN), mRNA [NM_198576] 2.00 1.58E-32 5920 2949
ACTB  actin, beta (ACTB), mRNA [NM_001101] 2.11 2.8E-19 35553 16645 2.01 0 53091 26364
ACTN1  actinin, alpha 1 (ACTN1), mRNA [NM_001102] 2.20 1.46E-15 3378 1532 2.14 2.18E-26 3488 1626
ACTN3  actinin, alpha 3 (ACTN3), mRNA [NM_001104] 2.29 3.01E-06 701 312 2.05 0.00036 531 274
BIRC3  baculoviral IAP repeat-containing 3 (BIRC3), transcript 0.20 1.31E-33 238 1208 0.22 4.44E-35 269 1236
BIRC7  baculoviral IAP repeat-containing 7 (livin) (BIRC7), tran 0.36 1.48E-08 504 1430 0.35 2.14E-15 504 1447
CAPN1  calpain 1, (mu/I) large subunit (CAPN1), mRNA [NM_0 2.19 4.97E-08 635 291
CAPN5  calpain 5 (CAPN5), mRNA [NM_004055] 2.95 0 4144 1406
CAPN6  calpain 6 (CAPN6), mRNA [NM_014289] 3.97 1.05E-32 2581 651 4.95 4.42E-30 2975 599
CAST  calpastatin (CAST), transcript variant 2, mRNA [NM_17 0.41 3.27E-07 5187 12975 0.49 2.15E-06 6167 12760
CAV1  caveolin 1, caveolae protein, 22kDa (CAV1), mRNA [N 0.38 0 3179 8358
CAV2  caveolin 2 (CAV2), transcript variant 1, mRNA [NM_00 0.49 1.14E-06 401 823
CD36  CD36 antigen (collagen type I receptor, thrombospond 0.29 4.39E-37 722 2495 0.27 0 584 2225
CLK1  CDC-like kinase 1 (CLK1), mRNA [NM_004071] 0.29 0 1087 3737 0.30 0 1107 3715
CLK1 0.32 8.92E-22 2024 6304 0.35 5.48E-21 2077 6045
COL10A1  collagen, type X, alpha 1(Schmid metaphyseal chondro 2.61 6.42E-39 5005 1922
A√ M COL11A1  collagen, type XI, alpha 1 (COL11A1), transcript varian 16.45 0 11610 708 5.43 0 3027 556
COL11A2  collagen, type XI, alpha 2 (COL11A2), transcript varian 0.55 3.6E-13 2073 3787
A√ M COL12A1  collagen, type XII, alpha 1 (COL12A1), transcript varian 2.32 0 5029 2168
COL13A1  collagen, type XIII, alpha 1 (COL13A1), transcript varia 7.79 0 3009 383 9.53 0 3369 351
A√ M COL14A1  collagen, type XIV, alpha 1 (undulin) (COL14A1), mRN 5.93 0 9815 1652 6.47 0 11169 1727
COL14A1 8.62 0 15418 1794 12.96 0 28779 2173
COL14A1 2.83 0 12313 4344
COL16A1  collagen, type XVI, alpha 1 (COL16A1), mRNA [NM_00 9.20 1.29E-29 151140 15768 5.84 2.36E-22 84214 13909
COL18A1  collagen, type XVIII, alpha 1 (COL18A1), transcript var 2.57 0 31927 12408 3.17 0 38523 12135
S√ IHC,W COL1A1  collagen, type I, alpha 1 (COL1A1), mRNA [NM_00008 12.42 4.8E-44 434853 32173 13.40 0 377400 28676
A√ PCR,M
S√ IHC,W COL1A2  collagen, type I, alpha 2 (COL1A2), mRNA [NM_00008 8.36 1.1E-44 3978 468 25.72 0 360611 14122
COL1A2 21.97 1.4E-45 438794 18042 5.50 0 2176 396
COL25A1  collagen, type XXV, alpha 1 (COL25A1), transcript vari 2.20 1.15E-17 1223 558
S√ COL3A1  collagen, type III, alpha 1 (Ehlers-Danlos syndrome typ 15.12 0 338160 21395 22.10 0 418071 18917
A√ M,PCR 19.81 0 439519 20690 33.25 0 66275 1999
40.43 0 117501 2996 13.65 0 329376 24085
S√ IHC. COL4A1  collagen, type IV, alpha 1 (COL4A1), mRNA [NM_0018 2.87 1.20E-12 762 263 2.05 0.00081 596 268
S√ IHC. COL4A5  collagen, type IV, alpha 5 (Alport syndrome) (COL4A5) 2.30 3.38E-13 805 351 4.00 0 2598 649
2.32 9.87E-21 1315 564
7.93 0 7045 883
A√ M COL5A1  collagen, type V, alpha 1 (COL5A1), mRNA [NM_0000 12.82 0 53506 4187 7.85 0 23475 3005
28.83 0 5889 206 15.60 0 2091 134
A,S√ M COL5A2  collagen, type V, alpha 2 (COL5A2), mRNA [NM_0003 18.18 0 18974 1044 16.16 0 20278 1262
COL5A2 6.34 0 73717 11539 5.79 0 69785 11871
COL5A2 4.17 4.40E-43 1473 354 4.08 5.96E-38 1443 357
COL5A3  collagen, type V, alpha 3 (COL5A3), mRNA [NM_0157 2.12 6.86E-12 816 386
S√ IHC. COL6A1  collagen, type VI, alpha 1 (COL6A1), mRNA [NM_0018 4.13 0 2438 588 7.52 0 366939 48166
A√ M COL6A1 7.50 4.68E-29 384091 47253 3.34 3.63E-34 1405 425
S√ IHC. COL6A2  collagen, type VI, alpha 2 (COL6A2), transcript variant 10.68 0 4702 440 9.25 0 3564 384
A√ M COL6A2 2.55 3.22E-18 3551 1388 2.03 1.22E-13 2717 1334
S√ IHC,2D-GE COL6A3  collagen, type VI, alpha 3 (COL6A3), transcript variant 2.22 0 76955 34656 2.71 1.17E-17 94430 34605
A√ M
S√ M COL8A1  collagen, type VIII, alpha 1 (COL8A1), transcript varian 3.10 7.17E-23 8420 2674 2.47 0 5304 2144
COL8A2  collagen, type VIII, alpha 2 (COL8A2), mRNA [NM_005 2.20 5.66E-15 4848 2176 5.85 0 14811 2511
CRKL  v-crk sarcoma virus CT10 oncogene homolog (avian)- 10.01 0 2999 300 6.22 0 1946 311
A√ IHC. CTNNB1  catenin (cadherin-associated protein), beta 1, 88kDa (C 2.74 2.21E-21 3650 1324
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DIAPH1  diaphanous homolog 1 (Drosophila) (DIAPH1), mRNA 0.31 4.57E-20 8246 27359
DIAPH3  diaphanous homolog 3 (Drosophila) (DIAPH3), mRNA 4.72 3.32E-34 1884 401 3.05 8.92E-18 1248 416
DYRK2  dual-specificity tyrosine-(Y)-phosphorylation regulated 3.12 0 1863 596 2.61 7.19E-20 1513 571
EDIL3  EGF-like repeats and discoidin I-like domains 3 (EDIL3 8.77 0 8573 968 20.14 0 18664 922
EGFR  epidermal growth factor receptor (erythroblastic leukem 0.41 0.00052 257 658
FLNC  filamin C, gamma (actin binding protein 280) (FLNC), m 3.04 0.00033 752 260 2.76 0.00018 681 277
FLRT2  fibronectin leucine rich transmembrane protein 2 (FLR 4.42 1.83E-10 709 156 4.22 3.18E-19 981 240
FLRT2 3.04 1.22E-14 807 268 6.29 0 1540 244
S√ IHC,ISH,W,M FN1  fibronectin 1 (FN1), transcript variant 7, mRNA [NM_05 2.14 7.8E-09 1306 617 5.86 0 9319 1582
FN1 6.26 0 101623 16237 5.97 0 92627 15302
FN1 6.90 0 14416 2083
GPC1  glypican 1 (GPC1), mRNA [NM_002081] 3.40 0 34796 10218
ITGAV  integrin, alpha V (vitronectin receptor, alpha polypeptid 3.14 6.26E-22 1077 344 4.90 8.06E-32 1832 378
2.94 0 10769 3662 5.04 0 19513 3872
S√ IHC, M ITGB1  integrin, beta 1 (fibronectin receptor, beta polypeptide, 2.59 6.32E-24 5992 2307 3.98 3.05E-32 9727 2446
ITGB1 2.64 0 18176 6883 3.61 0 25574 7102
ITGB1 2.82 5.61E-13 53401 18303 4.51 2.48E-23 92904 19961
ITGB5  integrin, beta 5 (ITGB5), mRNA [NM_002213] 3.10 1.38E-17 7018 2197
JUN  v-jun sarcoma virus 17 oncogene homolog (avian) (JUN), mRNA [NM_002228] 0.46 0 19284 42331
LAMA1  laminin, alpha 1 (LAMA1), mRNA [NM_005559] 2.21 4.92E-08 626 281 2.36 4.13E-07 554 228
LAMA2  laminin, alpha 2 (merosin, congenital muscular dystrop 0.46 0 3377 7359 0.46 4.12E-31 3706 8078
LAMA4  laminin, alpha 4 (LAMA4), mRNA [NM_002290] 3.81 1.56E-23 14402 3748 3.17 4.53E-23 10314 3223
S√ IHC. LAMB1  laminin, beta 1 (LAMB1), mRNA [NM_002291] 3.56 0 25964 7281 2.85 0 19914 6971
MFAP5  microfibrillar associated protein 5 (MFAP5), mRNA [NM 4.90 3.39E-40 6723 1352
A<R  M NID2  nidogen 2 (osteonidogen) (NID2), mRNA [NM_007361 7.30 0 2909 396 12.24 0 5659 460
NLGN1  neuroligin 1 (NLGN1), mRNA [NM_014932] 0.15 3.13E-14 123 791 0.21 1.23E-43 235 1118
PDGFC  platelet derived growth factor C (PDGFC), mRNA [NM_ 2.19 6.40E-20 3513 1597 2.44 0 3722 1522
PIK3CD  phosphoinositide-3-kinase, catalytic, delta polypeptide 4.87 0 5856 1202 4.62 0 5517 1192
S√ IHC,M,PCR POSTN  periostin, osteoblast specific factor (POSTN), mRNA [N53.68 0 36596 691 60.23 0 85449 1436
PPP1CB  protein phosphatase 1, catalytic subunit, beta isoform 2.16 2.92E-07 2033 935
RAPGEF1  Rap guanine nucleotide exchange factor (GEF) 1 (RAP 4.70 0 13411 2853 2.78 7.29E-44 7895 2853
SDC1  syndecan 1 (SDC1), transcript variant 1, mRNA [NM_0 9.81 0 6976 700 4.68 3.17E-24 2507 533
SDC4  syndecan 4 (amphiglycan, ryudocan) (SDC4), mRNA [ 3.38 1.59E-42 108824 32179 2.11 1.40E-45 57062 27002
SGCE  sarcoglycan, epsilon (SGCE), mRNA [NM_003919] 3.33 0 22127 6649
SHC1  SHC (Src homology 2 domain containing) transforming 2.15 4.28E-24 3620 1681
A√ M SPON2  spondin 2, extracellular matrix protein (SPON2), mRNA 9.59 1.19E-41 103308 10375 23.98 0 278300 11395
SV2A  synaptic vesicle glycoprotein 2A (SV2A), mRNA [NM_0 3.05 0 62284 20411 2.36 0 37972 16114
THBS2  thrombospondin 2 (THBS2), mRNA [NM_003247] 6.57 1.21E-33 18698 2782 5.36 0 12664 2355
S√ M, PCR TNC  tenascin C (hexabrachion) (TNC), mRNA [NM_002160 2.48 0 5955 2403 8.99 0 41901 4677
VASP  vasodilator-stimulated phosphoprotein (VASP), transcr 2.65 1.87E-14 6738 2501 2.29 3.40E-13 5901 2538
VAV3  vav 3 oncogene (VAV3), mRNA [NM_006113] 5.48 0 2197 401 2.21 1.07E-09 649 289
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AEBP1  AE binding protein 1 (AEBP1), mRNA [NM_001129] 2.79 6.98E-16 8323 2947 2.85 2.02E-16 8270 2829
AGRN  agrin (AGRN), mRNA [NM_198576] 2.00 1.58E-32 5920 2949
S√ M APP  amyloid beta (A4) precursor protein (protease nexin-II, 4.67 1.64E-27 1801 387 3.80 2.09E-22 1778 472
ASTN2  astrotactin 2 (ASTN2), transcript variant 1, mRNA [NM 2.18 0 3932 1803
CASK  calcium/calmodulin-dependent serine protein kinase (M 3.37 1.31E-41 1100 326 2.24 2.24E-07 719 309
CCR1  chemokine (C-C motif) receptor 1 (CCR1), mRNA [NM 0.32 0 1666 5273 0.42 0 1849 4415
CD226  CD226 antigen (CD226), mRNA [NM_006566] 2.52 1.40E-10 682 269
CD36  CD36 antigen (collagen type I receptor, thrombospond 0.29 4.39E-37 722 2495 0.27 0 584 2225
CDH11  cadherin 11, type 2, OB-cadherin (osteoblast) (CDH11 3.86 7.05E-37 19002 4897 3.21 5.52E-39 16289 5038
CDH19  cadherin 19, type 2 (CDH19), mRNA [NM_021153] 0.12 2.87E-41 121 1038 0.09 7.42E-42 83 923
CDH19 0.49 0.55828 38 75
CDH24  cadherin-like 24 (CDH24), mRNA [NM_022478] 2.23 2.28E-13 4982 2230
CHL1  cell adhesion molecule with homology to L1CAM (clos 3.70 2.78E-12 511 138
CHST4  carbohydrate (N-acetylglucosamine 6-O) sulfotransfera 0.42 8.15E-41 1639 3862 0.45 1.28E-27 1917 4238
CRTAC1  cartilage acidic protein 1 (CRTAC1), mRNA [NM_0180 0.07 0 190 2558 0.20 0 539 2753
A√ IHC. CTNNB1  catenin (cadherin-associated protein), beta 1, 88kDa (C 2.74 2.21E-21 3650 1324
CX3CL1  chemokine (C-X3-C motif) ligand 1 (CX3CL1), mRNA [ 0.32 0 1437 4539 0.25 0 1041 4250
CXCR3  chemokine (C-X-C motif) receptor 3 (CXCR3), mRNA [ 2.58 9.20E-32 5252 2029
DCBLD2  discoidin, CUB and LCCL domain containing 2 (DCBLD 2.12 8.96E-14 3810 1780 2.02 7.98E-14 3823 1879
DPT  dermatopontin (DPT), mRNA [NM_001937] 9.96 0 2257 226 9.95 0 2923 293
EDG1  endothelial differentiation, sphingolipid G-protein-coup 0.27 1.06E-11 194 716 0.38 4.81E-08 235 598
EMILIN1  elastin microfibril interfacer 1 (EMILIN1), mRNA [NM_0 2.15 6.22E-26 10251 4755
FAT  FAT tumor suppressor homolog 1 (Drosophila) (FAT), 2.89 1.40E-45 4138 1430 3.28 0 4241 1294
FIBL-6  hemicentin (FIBL-6), mRNA [NM_031935] 4.52 0 5522 1221 2.85 3.12E-10 2444 876
FLRT2  fibronectin leucine rich transmembrane protein 2 (FLR 4.42 1.83E-10 709 156 4.22 3.18E-19 981 240
FLRT2 3.04 1.22E-14 807 268 6.29 0 1540 244
GJA1  gap junction protein, alpha 1, 43kDa (connexin 43) (GJ 14.32 0 51266 3499 4.75 6.31E-08 1048 239
GJA1 7.27 0 1444 200 6.75 0 25739 3798
HNT  neurotrimin (HNT), mRNA [NM_016522] 3.31 7.91E-17 971 296 4.05 1.86E-34 1397 348
KAL1  Kallmann syndrome 1 sequence (KAL1), mRNA [NM_0 10.21 1.53E-26 698 68 6.53 9.23E-14 539 80
A=R  PCR LEF1  lymphoid enhancer-binding factor 1 (LEF1), mRNA [NM 7.67 0 3569 467 3.11 1.69E-13 1260 392
LOXL2  lysyl oxidase-like 2 (LOXL2), mRNA [NM_002318] 3.16 0 22483 7028 3.95 0 28934 7237
LRRN5  leucine rich repeat neuronal 5 (LRRN5), transcript vari 2.62 0 17464 6662
LU  Lutheran blood group (Auberger b antigen included) (L 3.03 4.68E-15 33840 10984
MMRN1  multimerin 1 (MMRN1), mRNA [NM_007351] 2.49 2.68E-22 1628 657
NEO1  neogenin homolog 1 (chicken) (NEO1), mRNA [NM_00 2.52 5.87E-25 2826 1123 2.14 3.75E-33 2427 1136
NLGN1  neuroligin 1 (NLGN1), mRNA [NM_014932] 0.15 3.13E-14 123 791 0.21 1.23E-43 235 1118
PCDH7  BH-protocadherin (brain-heart) (PCDH7), transcript var 2.66 4.57E-23 938 353 2.75 2.98E-30 1160 423
19.74 8.38E-25 740 40
2.29 0.11056 140 60
PC-LKC  protocadherin LKC (PC-LKC), mRNA [NM_017675] 2.28 1.71E-30 26944 11742
PECAM1  platelet/endothelial cell adhesion molecule (CD31 antig 0.33 0 2059 6308
PKP1  plakophilin 1 (ectodermal dysplasia/skin fragility syndro 2.07 4.80E-18 1346 648
S√ IHC,M,PCR POSTN  periostin, osteoblast specific factor (POSTN), mRNA [N53.68 0 36596 691 60.23 0 85449 1436
PROS1  protein S (alpha) (PROS1), mRNA [NM_000313] 0.37 3.66E-09 298 785
PROS1  protein S (alpha) (PROS1), mRNA [NM_000313] 0.32 0 1388 4315
RDS  retinal degeneration, slow (RDS), mRNA [NM_000322] 3.92 8.08E-09 666 165
ROBO1  roundabout, axon guidance receptor, homolog 1 (Dros 3.11 7.35E-31 1534 495 3.22 4.31E-24 1656 518
ROM1  retinal outer segment membrane protein 1 (ROM1), mR 0.37 5.75E-15 955 2618 0.40 2.83E-40 1015 2526
SAA1  serum amyloid A1 (SAA1), transcript variant 1, mRNA 0.03 0 2033 78668 0.03 0 1919 72560
SAA2  serum amyloid A2 (SAA2), mRNA [NM_030754] 0.05 0 2594 49704 0.05 0 2220 41872
SAA4  serum amyloid A4, constitutive (SAA4), mRNA [NM_00 0.02 0 213 8743 0.02 0 211 9224
aggressive / reference superficial / reference
Appendix Gene list A
ratio pvalue aggr ref ratio pvalue superfic ref
SLIT3  slit homolog 3 (Drosophila) (SLIT3), mRNA [NM_00306 3.95 0 14124 3576 2.49 1.51E-26 8137 3237
STIM2  stromal interaction molecule 2 (STIM2), mRNA [NM_02 0.40 1.57E-06 1223 3239 0.46 2.51E-06 1256 2808
TAOK2  TAO kinase 2 (TAOK2), mRNA [NM_016151] 2.07 0 58320 28140
THBS2  thrombospondin 2 (THBS2), mRNA [NM_003247] 6.57 1.21E-33 18698 2782 5.36 0 12664 2355
XLKD1  extracellular link domain containing 1 (XLKD1), mRNA 0.07 0 654 9823 0.21 0 1845 8662
7) Proliferation
ratio pvalue aggr ref ratio pvalue superfic ref
ANAPC1  anaphase promoting complex subunit 1 (ANAPC1), mR 0.47 2.30E-18 684 1454
ALS2CR19  amyotrophic lateral sclerosis 2 (juvenile) chromosome 0.46 0.00019 337 704 0.50 2.96E-08 304 599
ANGPTL7  angiopoietin-like 7 (ANGPTL7), mRNA [NM_021146] 0.005 0 1284 274406 0.05 0 11741 233940
BCAT1  branched chain aminotransferase 1, cytosolic (BCAT1) 0.39 1.90E-18 2824 7216 0.35 1.76E-29 2542 7317
BCL3  B-cell CLL/lymphoma 3 (BCL3), mRNA [NM_005178] 0.48 7.85E-17 5337 11201
BCL6  B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6) 0.05 0 1735 35683 0.10 0 3027 30979
BCL11B  B-cell CLL/lymphoma 11B (zinc finger protein) (BCL11 3.03 0 8619 2849
BCR  breakpoint cluster region (BCR), transcript variant 2, m 4.99 0 3447 688 3.58 1.52E-21 1876 508
BCR 3.60 0 10584 2943
BIN1  bridging integrator 1 (BIN1), transcript variant 4, mRNA 2.00 2.82E-10 1450 728
S=R  PCR BMP7  bone morphogenetic protein 7 (osteogenic protein 1) (B16.33 0 2205 136 5.36 9.92E-13 552 99
BMP8A  bone morphogenetic protein 8a (BMP8A), mRNA [NM_ 2.90 8.89E-17 47854 16023 2.31 3.31E-12 36604 15440
CCL23  chemokine (C-C motif) ligand 23 (CCL23), transcript va 0.28 3.52E-09 225 794 0.43 1.35E-09 354 839
CCNB2  cyclin B2 (CCNB2), mRNA [NM_004701] 3.27 0 2719 832 2.56 3.48E-42 1908 746
A√ IHC,M CCND1  cyclin D1 (PRAD1: parathyroid adenomatosis 1) (CCN 3.06 1.22E-37 2463 802 2.41 2.61E-23 2102 867
A√ M CCND2  cyclin D2 (CCND2), mRNA [NM_001759] 2.10 6.80E-12 1014 479 2.72 1.20E-11 913 346
CCND2 5.16 5.81E-31 1799 350
CCNDBP1  cyclin D-type binding-protein 1 (CCNDBP1), transcript 0.30 4.55E-25 1804 5998 0.44 1.71E-10 2675 6135
CCNG2  cyclin G2 (CCNG2), mRNA [NM_004354] 0.49 2.75E-16 3246 6722 0.41 2.62E-26 2393 5814
CCNI  cyclin I (CCNI), mRNA [NM_006835] 0.45 5.96E-41 13757 30362
CCNL1  cyclin L1 (CCNL1), mRNA [NM_020307] 0.33 0 967 2924 0.33 5.61E-45 818 2498
CCNL1 0.31 1.74E-34 2178 7150 0.32 1.09E-43 1962 6094
CD248  CD248 antigen, endosialin (CD248), mRNA [NM_0204 4.03 1.10E-31 24947 6051 3.30 2.05E-34 18407 5512
CDC14B  CDC14 cell division cycle 14 homolog B (S. cerevisiae 0.49 2.32E-11 2935 6114
CDC91L1  CDC91 cell division cycle 91-like 1 (S. cerevisiae) (CD 2.08 5.70E-21 7106 3401
CDK2AP1  CDK2-associated protein 1 (CDK2AP1), mRNA [NM_0 3.49 0 9509 2726 3.44 0 10106 2930
CDK6  cyclin-dependent kinase 6 (CDK6), mRNA [NM_00125 2.14 1.82E-09 626 293 6.99 0 3144 447
CDK6 6.46 0 3321 515
CDKN1B  cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN 0.26 2.80E-45 863 3382 0.31 1.77E-39 986 3235
CENPB  centromere protein B, 80kDa (CENPB), mRNA [NM_00 2.27 2.36E-16 1123 497
CGREF1  cell growth regulator with EF hand domain 1 (CGREF1 4.57 0 1635 359 3.48 8.90E-24 1287 375
CKS1B  CDC28 protein kinase regulatory subunit 1B (CKS1B), 0.49 1.68E-11 4803 9878
CLK1  CDC-like kinase 1 (CLK1), mRNA [NM_004071] 0.29 0 1087 3737 0.30 0 1107 3715
CLK1 0.32 8.92E-22 2024 6304 0.35 5.48E-21 2077 6045
CMIP  c-Maf-inducing protein (CMIP), transcript variant C-mip 3.31 3.53E-27 2456 736 4.07 2.43E-41 50177 12410
CMIP 5.61 0 105445 18435
A√ M CRLF1  cytokine receptor-like factor 1 (CRLF1), mRNA [NM_00 0.27 0 4269 15813 0.31 0 4492 14588
A√ M CSRP2  cysteine and glycine-rich protein 2 (CSRP2), mRNA [N 5.68 0 23708 4138 6.02 0 26372 4366
S√ M DCN  decorin (DCN), transcript variant A1, mRNA [NM_0019 0.39 1.34E-11 60964 157385 0.40 1.90E-15 54925 139728
DCTN1  dynactin 1 (p150, glued homolog, Drosophila) (DCTN1 2.52 1.90E-40 51651 20421
DLC1  deleted in liver cancer 1 (DLC1), transcript variant 3, m 4.19 0 7643 1822 2.27 4.16E-39 3105 1368
DOCK9  dedicator of cytokinesis 9 (DOCK9), mRNA [NM_0152 0.34 6.82E-36 448 1313 0.49 7.88E-11 728 1478
ECRG4  esophageal cancer related gene 4 protein (ECRG4), m 0.09 0 95 1070 0.12 1.91E-29 140 1100
EDN1  endothelin 1 (EDN1), mRNA [NM_001955] 0.13 0 628 5007 0.26 0 1125 4354
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EDNRA  endothelin receptor type A (EDNRA), mRNA [NM_0019 2.31 8.13E-06 772 326
EGFL6  EGF-like-domain, multiple 6 (EGFL6), mRNA [NM_015 3.02 2.72E-30 1099 365
EGFR  epidermal growth factor receptor (erythroblastic leukem 0.41 0.00052 257 658
A√ PCR ELN  elastin (supravalvular aortic stenosis, Williams-Beuren 2.53 3.22E-37 4214 1662
ELN 2.00 3.12E-43 78634 39240
EPS8  epidermal growth factor receptor pathway substrate 8 ( 0.26 1.37E-31 2022 7828 0.61 3.38E-06 4557 7430
EREG  epiregulin (EREG), mRNA [NM_001432] 3.05 1.18E-15 629 205 3.45 7.21E-16 537 155
5.93 2.27E-14 1257 215
ERG  v-ets erythroblastosis virus E26 oncogene like (avian) 0.48 7.79E-22 656 1369
ERK8  mitogen-activated protein kinase 15 (MAPK15), mRNA 3.34 4.17E-38 1494 446
ERK8 2.98 0 4360 1460
ERN1  endoplasmic reticulum to nucleus signalling 1 (ERN1), 2.02 1.70E-20 1991 987
F2R  coagulation factor II (thrombin) receptor (F2R), mRNA 3.01 5.57E-13 871 292 2.68 6.69E-23 963 361
FABP3  fatty acid binding protein 3, muscle and heart (mamma 0.50 0.02468 248 528
A,S√ M FAP  fibroblast activation protein, alpha (FAP), mRNA [NM_ 52.70 0 56300 1063 40.41 0 41456 1023
FAT  FAT tumor suppressor homolog 1 (Drosophila) (FAT), 2.89 1.40E-45 4138 1430 3.28 0 4241 1294
FGF1  fibroblast growth factor 1 (acidic) (FGF1), transcript va 4.24 0 1627 384 3.49 1.67E-27 1720 495
FGF7  fibroblast growth factor 7 (keratinocyte growth factor) ( 0.46 1.54E-27 766 1683 0.32 1.40E-45 510 1616
FGF7 0.29 2.64E-22 3824 13118 0.19 0 2448 12905
FGFR1OP  FGFR1 oncogene partner (FGFR1OP), transcript varia 2.34 9.56E-13 697 297
FOSL1  FOS-like antigen 1 (FOSL1), mRNA [NM_005438] 2.13 7.5E-10 1587 736
G0S2  putative lymphocyte G0/G1 switch gene (G0S2), mRNA 0.04 0 987 27098 0.05 0 1454 27317
GHR  growth hormone receptor (GHR), mRNA [NM_000163] 0.16 0 525 3281 0.15 0 422 2862
GHR 0.44 1.68E-13 748 1658
GMNN  geminin, DNA replication inhibitor (GMNN), mRNA [NM 0.27 7.45E-24 763 2837 0.33 9.32E-15 869 2711
HK2  hexokinase 2 (HK2), mRNA [NM_000189] 0.43 5.64E-17 798 1863 0.28 0 503 1804
HMGB2  high-mobility group box 2 (HMGB2), mRNA [NM_0021 0.20 0 2208 10877 0.18 0 1823 10074
A√ M,W,N IGFBP6  insulin-like growth factor binding protein 6 (IGFBP6), m 0.09 0 380 4180 0.25 6.62E-35 1172 4684
IGF2AS  insulin-like growth factor 2 antisense (IGF2AS), mRNA 2.11 4.82E-27 58563 27704
IGFL2  insulin growth factor-like family member 2 (IGFL2), mR 9.28 0 1256 136
IFITM1  interferon induced transmembrane protein 1 (9-27) (IF 0.33 0 6387 19636
IFNB1  interferon, beta 1, fibroblast (IFNB1), mRNA [NM_0021 3.93 1.69E-37 1779 454 3.32 6.07E-08 1778 531
IL6R  interleukin 6 receptor (IL6R), transcript variant 1, mRN 0.27 8.10E-26 401 1497 0.25 4.75E-30 391 1540
INHBB  inhibin, beta B (activin AB beta polypeptide) (INHBB), m 0.39 6.61E-31 1704 4376 0.30 3.39E-27 1254 4220
INSIG1  insulin induced gene 1 (INSIG1), transcript variant 2, m 0.40 1.62E-27 578 1448
IRF2  interferon regulatory factor 2 (IRF2), mRNA [NM_0021 0.46 1.11E-11 465 1009
IRS1  insulin receptor substrate 1 (IRS1), mRNA [NM_00554 3.33 0 2352 706 2.85 2.80E-45 1796 632
IRS2  insulin receptor substrate 2 (IRS2), mRNA [NM_00374 0.29 0 656 2298 0.25 0 574 2252
JAK2  Janus kinase 2 (a protein tyrosine kinase) (JAK2), mR 0.37 6.45E-11 374 1017
JUN  v-jun sarcoma virus 17 oncogene homolog (avian) (JU 0.46 0 19284 42331
KEAP1  kelch-like ECH-associated protein 1 (KEAP1), transcrip 22.79 0 145654 6363 12.33 0 41872 3400
KLF11  Kruppel-like factor 11 (KLF11), mRNA [NM_003597] 0.44 1.99E-36 711 1604
KLF15  Kruppel-like factor 15 (KLF15), mRNA [NM_014079] 0.06 0 420 7099 0.05 0 381 6998
KLF4  Kruppel-like factor 4 (gut) (KLF4), mRNA [NM_004235 0.39 1.61E-36 604 1565 0.37 1.33E-28 537 1468
KLF5  Kruppel-like factor 5 (intestinal) (KLF5), mRNA [NM_00 0.14 1.36E-27 246 1790 0.21 0 315 1533
LMO1  LIM domain only 1 (rhombotin 1) (LMO1), mRNA [NM_ 3.31 0 10384 3142
LRP12  low density lipoprotein-related protein 12 (LRP12), mR 3.07 1.17E-28 1692 549 3.41 3.36E-44 1774 517
LRP12 2.19 6.24E-17 1885 862 2.55 1.80E-31 2427 947
LTBP2  latent transforming growth factor beta binding protein 2 0.38 3.97E-12 350 911
LZTS1  leucine zipper, putative tumor suppressor 1 (LZTS1), m 4.86 9.00E-27 1363 278 11.63 0 3849 331
S√ M MAFB  v-maf musculoaponeurotic fibrosarcoma oncogene ho 5.15 1.70E-31 22863 4306 6.55 1.54E-44 29490 4420
MARK4  MAP/microtubule affinity-regulating kinase 4 (MARK4), 4.14 2.24E-27 10234 2427 3.61 2.85E-28 10009 2684
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MATK  megakaryocyte-associated tyrosine kinase (MATK), tra 0.20 0 317 1576 0.19 0 306 1616
A√ M MDK  midkine (neurite growth-promoting factor 2) (MDK), tra 5.72 0 20422 3560 2.19 0 7458 3399
MTA1  metastasis associated 1 (MTA1), mRNA [NM_004689] 2.10 2.56E-24 13619 6494
MTSS1  metastasis suppressor 1 (MTSS1), mRNA [NM_01475 0.06 0 308 4795 0.24 0 1117 4639
MXI1  MAX interactor 1 (MXI1), transcript variant 2, mRNA [N 0.38 0 1877 4889 0.48 1.76E-37 2295 4811
S>R  IHC. MYC  v-myc myelocytomatosis viral oncogene homolog (avia 0.23 0 901 3971 0.29 1.77E-21 1390 4801
NAP1L1  nucleosome assembly protein 1-like 1 (NAP1L1), trans 0.38 1.49E-12 5696 15278
NCK1  NCK adaptor protein 1 (NCK1), mRNA [NM_006153] 0.39 4.68E-27 1455 3765 0.46 0 1693 3677
NDNL2  necdin-like 2 (NDNL2), mRNA [NM_138704] 2.11 0 5155 2437
NF2  neurofibromin 2 (bilateral acoustic neuroma) (NF2), tra 2.05 9.72E-09 8013 3760 2.37 5.02E-11 10628 4433
NFIA  nuclear factor I/A (NFIA), mRNA [NM_005595] 0.49 2.71E-09 2368 4909 0.39 1.75E-16 1596 4117
OSMR  oncostatin M receptor, mRNA (cDNA clone IMAGE:519 2.30 8.04E-23 1588 689 2.01 0.0001 1085 506
P8  p8 protein (candidate of metastasis 1) (P8), mRNA [NM 0.29 0 6713 23553 0.32 1.26E-44 7565 23440
PA2G4  proliferation-associated 2G4, 38kDa (PA2G4), mRNA [ 0.44 6.31E-20 546 1237 0.48 1.28E-12 609 1251
PA2G4 0.40 2.73E-22 1240 3110 0.49 1.85E-25 1541 3183
PA2G4 0.48 3.60E-40 2390 4972
PARD6G  par-6 partitioning defective 6 homolog gamma (C. eleg 3.84 2.32E-36 1119 292 2.84 1.31E-11 789 270
PARD6G 5.28 0 15323 2887 3.71 0 10648 2856
PBEF1  pre-B-cell colony enhancing factor 1 (PBEF1), transcrip 0.13 0 1721 13112 0.12 0 1061 8553
PBEF1 0.29 0 793 2784 0.10 0 1227 11912
PBEF1 0.16 0 1150 7013 0.29 0 792 2718
PDGFC  platelet derived growth factor C (PDGFC), mRNA [NM_ 2.19 6.40E-20 3513 1597 2.44 0 3722 1522
PDGFRL  platelet-derived growth factor receptor-like (PDGFRL), 2.07 0 10733 5180 2.49 0 12350 4951
PHF17  PHD finger protein 17 (PHF17), transcript variant S, m 0.15 0 888 5923 0.17 0 1111 6726
PHF17 0.28 9.40E-10 148 519 0.39 0.00005 146 388
PHF17 0.28 0.00001 111 387 0.27 1.64E-08 154 540
PLA2G2A  phospholipase A2, group IIA (platelets, synovial fluid) ( 0.08 0 3708 46224 0.13 0 6986 52284
PLCE1  phospholipase C, epsilon 1 (PLCE1), mRNA [NM_016 0.39 3.10E-25 409 1040
PMP22  peripheral myelin protein 22 (PMP22), transcript varian 0.38 3.66E-23 9496 24739 0.40 6.56E-13 11892 30112
PMS2L3  postmeiotic segregation increased 2-like 3 (PMS2L3), 2.05 2.62E-35 5298 2578
POLM  polymerase (DNA directed), mu (POLM), mRNA [NM_0 2.12 2.90E-32 95537 45003
POLR3D  polymerase (RNA) III (DNA directed) polypeptide D, 44 3.31 0 6658 2013
S√ IHC,M,PCR POSTN  periostin, osteoblast specific factor (POSTN), mRNA [N53.68 0 36596 691 60.23 0 85449 1436
PPP1CB  protein phosphatase 1, catalytic subunit, beta isoform 2.16 2.92E-07 2033 935
PPP1R15A  protein phosphatase 1, regulatory (inhibitor) subunit 15 0.40 0 4405 11039 0.41 0 3443 8480
S√  M PRG4  proteoglycan 4 (PRG4), mRNA [NM_005807] 0.01 0 482 44080 0.12 0 4826 40787
A√ M PRSS11  protease, serine, 11 (IGF binding) (PRSS11), mRNA [N10.16 4.1E-25 336708 30601 9.49 4.58E-33 287922 29149
PSMD2  proteasome (prosome, macropain) 26S subunit, non-A 2.19 6.49E-37 2965 1354
PTTG1  pituitary tumor-transforming 1 (PTTG1), mRNA [NM_00 6.60 3.18E-37 25146 3703 4.53 1.38E-19 14803 3078
S√ M PTN  pleiotrophin (heparin binding growth factor 8, neurite g 2.81 0 2525 899 3.69 0 3590 973
PTN 3.83 0 24907 6515 4.78 0 29309 6130
PTTG1  pituitary tumor-transforming 1 (PTTG1), mRNA [NM_00 6.60 3.18E-37 25146 3703 4.53 1.38E-19 14803 3078
PYY  peptide YY (PYY), mRNA [NM_004160] 2.46 4.82E-31 6012 2444
RAB4B  RAB4B, member RAS oncogene family (RAB4B), mRN 2.04 0.00009 589 294 6.30 0 4529 719
RAB4B 7.66 7.99E-44 7188 929
RAB7B  RAB7B, member RAS oncogene family (RAB7B), mRN 3.39 5.75E-18 1015 296 3.19 1.12E-23 967 306
RAB7L1  RAB7, member RAS oncogene family-like 1 (RAB7L1) 5.34 0 20566 3837 2.81 2.53E-26 11410 3977
RAB15  RAB15, member RAS onocogene family (RAB15), mR 9.30 0 3957 425
RAB23  RAB23, member RAS oncogene family (RAB23), trans 2.01 1.72E-09 957 472 2.23 1.06E-11 1088 497
S√ M RAB31  RAB31, member RAS oncogene family (RAB31), mRN 2.31 0 3893 1686 5.23 0 8902 1695
2.72 0 4903 1801 3.71 0 7026 1895
RABL2A  RAB, member of RAS oncogene family-like 2A (RABL2 0.43 0 39552 91802 0.44 9.82E-38 34872 79770
RARRES1  retinoic acid receptor responder (tazarotene induced) 1 0.19 0 1375 7208 0.26 0 1677 6560
aggressive / reference superficial / reference
Appendix Gene list A
ratio pvalue aggr ref ratio pvalue superfic ref
S>A IHC,PCR RB1  retinoblastoma 1 (including osteosarcoma) (RB1), mRN 2.46 5.89E-17 6151 2449
RBL2  retinoblastoma-like 2 (p130) (RBL2), mRNA [NM_0056 0.45 1.21E-08 702 1544
RBM9  RNA binding motif protein 9 (RBM9), mRNA [NM_0143 2.41 0 4295 1777 2.13 9.32E-31 3682 1726
REC8L1  REC8-like 1 (yeast) (REC8L1), mRNA [NM_005132] 5.42 3.17E-13 1900 336 2.98 1.72E-18 765 256
REV3L  REV3-like, catalytic subunit of DNA polymerase zeta (y 0.32 1.54E-44 1770 5590 0.48 1.32E-15 2489 5152
RFC3  replication factor C (activator 1) 3, 38kDa (RFC3), tran 0.44 3.61E-09 312 707 0.46 1.93E-09 298 647
RHOQ  ras homolog gene family, member Q (RHOQ), mRNA [ 0.48 0.00007 353 720
RHOQ 0.46 2.72E-10 694 1505
RHOQ 0.50 4.74E-27 817 1642
RHOU  ras homolog gene family, member U (RHOU), mRNA [ 0.30 4.59E-13 216 703 0.35 2.59E-09 244 672
RHOV  ras homolog gene family, member V (RHOV), mRNA [ 4.03 0 9178 2279 2.76 0 5242 1896
S100A11  S100 calcium binding protein A11 (calgizzarin) (S100A 0.36 0 4436 12460 0.40 9.20E-20 5010 12502
S100B  S100 calcium binding protein, beta (neural) (S100B), m 0.32 1.64E-30 638 2013 0.30 0 638 2104
SASH1  SAM and SH3 domain containing 1 (SASH1), mRNA [N 0.21 0 2757 12841 0.24 0 2536 10612
SASH1 0.22 6.10E-25 9263 43988 0.21 2.93E-33 8295 39542
SDC1  syndecan 1 (SDC1), transcript variant 1, mRNA [NM_0 9.81 0 6976 700 4.68 3.17E-24 2507 533
SHC1  SHC (Src homology 2 domain containing) transforming 2.15 4.28E-24 3620 1681
SLC19A2  solute carrier family 19 (thiamine transporter), member 0.26 0 1599 6110 0.15 0 832 5596
SMAD3  SMAD, mothers against DPP homolog 3 (Drosophila) ( 0.32 0 695 2149 0.41 1.24E-20 927 2249
SMAD3 0.28 1.33E-29 1180 4180 0.47 7.25E-26 2007 4272
S√ M SPARC  secreted protein, acidic, cysteine-rich (osteonectin) (SP12.85 1.1E-44 440326 31435 13.33 0 433979 31064
SPHK2  sphingosine kinase 2 (SPHK2), mRNA [NM_020126] 3.40 3.82E-17 12997 3825 2.76 0 7948 2880
SSTR1  somatostatin receptor 1 (SSTR1), mRNA [NM_001049 2.43 0 5910 2435
ST13  suppression of tumorigenicity 13 (colon carcinoma) (H 0.49 1.38E-10 1092 2239 0.49 4.44E-15 947 1968
ST13 0.47 4.43E-41 2983 6358 0.49 5.65E-20 2455 4997
TACSTD2  tumor-associated calcium signal transducer 2 (TACST 0.49 6.55E-11 442 899 0.48 2.15E-10 479 1017
TAOK2  TAO kinase 2 (TAOK2), mRNA [NM_016151] 2.07 0 58320 28140
TAX1BP3  Tax1 (human T-cell leukemia virus type I) binding prote 3.23 4.80E-39 1990 617 2.03 9.97E-17 1150 563
TBC1D8  TBC1 domain family, member 8 (with GRAM domain) ( 0.29 1.08E-27 1157 4024 0.37 4.37E-23 1578 4241
S√ IHC, ELISA,M TGFB2  transforming growth factor, beta 2 (TGFB2), mRNA [NM_003238] 3.06 1.82E-11 703 238
A√ M TGFB3  transforming growth factor, beta 3 (TGFB3), mRNA [NM 9.31 0 6452 684 8.77 0 6492 736
S√ IHC. TGFB3 5.77 0.0002 305 64
S√ 2D-GE TGFBI  transforming growth factor, beta-induced, 68kDa (TGF 4.56 1.2E-33 162242 35015 7.27 0 289821 39235
A>R  W TGFBR2  transforming growth factor, beta receptor II (70/80kDa) 0.44 4.88E-15 382 861
S√ M, PCR TNC  tenascin C (hexabrachion) (TNC), mRNA [NM_002160 2.48 0 5955 2403 8.99 0 41901 4677
TNFAIP2  tumor necrosis factor, alpha-induced protein 2 (TNFAIP 0.47 5.55E-39 5521 11687
A√ M TNFRSF11B tumor necrosis factor receptor superfamily, member 11 0.30 0 557 1869 0.17 0 600 3514
TNFRSF11B 0.26 0 894 3480 0.22 8.31E-32 379 1742
TNFRSF12A tumor necrosis factor receptor superfamily, member 12 4.56 5.51E-37 2834 618 4.80 6.36E-25 2906 602
TNFRSF19  tumor necrosis factor receptor superfamily, member 19 20.61 3.90E-28 3316 158 6.43 2.25E-16 866 127
TNFRSF19 2.38 0.0823 178 77
TNFRSF25  tumor necrosis factor receptor superfamily, member 25 3.18 4.98E-31 3460 1091 3.93 0 4083 1035
A√ M TNFSF4  tumor necrosis factor (ligand) superfamily, member 4 ( 5.44 0 1755 323 7.01 0 2308 329
TNFRSF7  tumor necrosis factor receptor superfamily, member 7 3.39 0 21208 6249 2.76 2.36E-18 13492 4887
UBE2C  ubiquitin-conjugating enzyme E2C (UBE2C), transcript 11.78 0 27438 2235 8.14 0 17445 2109
UHRF1  ubiquitin-like, containing PHD and RING finger domain 4.56 8.76E-13 620 137
VAV3  vav 3 oncogene (VAV3), mRNA [NM_006113] 5.48 0 2197 401 2.21 1.07E-09 649 289
VEGF  vascular endothelial growth factor, mRNA (cDNA clone MGC:70609 IMAGE:6006890), com 0.48 5.79E-16 1188 2446
A√ M WISP1  WNT1 inducible signaling pathway protein 1 (WISP1), 3.03 0 9133 3017 2.57 0.00001 4174 1751
A√ IHC,N,W,PCR WT1  Wilms tumor 1 (WT1), transcript variant B, mRNA [NM 2.05 7.86E-06 695 344
WTAP  Wilms tumor 1 associated protein (WTAP), transcript v 0.49 8.90E-11 426 859 0.49 1.30E-11 2345 4811
WTAP 0.40 2.06E-21 1831 4645
ZFP36L2  zinc finger protein 36, C3H type-like 2 (ZFP36L2), mRN 0.30 1.96E-29 11253 36799 0.31 1.12E-43 13537 43156
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8) Cytoskeleton
ratio pvalue aggr ref ratio pvalue superfic ref
APC  adenomatosis polyposis coli (APC), mRNA [NM_00003 2.16 1.20E-07 802 377
ACTB  actin, beta (ACTB), mRNA [NM_001101] 2.11 2.8E-19 35553 16645 2.01 0 53091 26364
ACTL6B  actin-like 6B (ACTL6B), mRNA [NM_016188] 2.64 0 16004 6052 2.17 0 8315 3849
ACTN1  actinin, alpha 1 (ACTN1), mRNA [NM_001102] 2.20 1.46E-15 3378 1532 2.14 2.18E-26 3488 1626
ACTN3  actinin, alpha 3 (ACTN3), mRNA [NM_001104] 2.29 3.01E-06 701 312 2.05 0.00036 531 274
CALD1  caldesmon 1 (CALD1), transcript variant 1, mRNA [NM 2.52 2.14E-28 1385 550
CALD1 2.41 3.22E-34 6018 2506
CALD1 2.39 3.83E-12 65096 27298
CDC42EP5  CDC42 effector protein (Rho GTPase binding) 5 (CDC 2.05 1.72E-20 20833 10114
CGNL1  cingulin-like 1 (CGNL1), mRNA [NM_032866] 0.23 3.40E-38 970 4222 0.48 2.23E-19 1766 3688
CKAP4  cytoskeleton-associated protein 4 (CKAP4), mRNA [NM11.05 0 30543 2709 6.60 0 16551 2505
CMIP  c-Maf-inducing protein (CMIP), transcript variant C-mip 3.31 3.53E-27 2456 736 4.07 2.43E-41 50177 12410
CMIP 5.61 0 105445 18435
DLC1  deleted in liver cancer 1 (DLC1), transcript variant 3, m 4.19 0 7643 1822 2.27 4.16E-39 3105 1368
DYSF  dysferlin, limb girdle muscular dystrophy 2B (autosoma 0.44 1.48E-12 1222 2811 0.42 0 884 2127
FSD1  fibronectin type III and SPRY domain containing 1 (FSD10.16 0 12113 1185 5.82 0 4401 753
GEFT  RAC/CDC42 exchange factor (GEFT), transcript varian 0.37 2.26E-10 773 2110 0.45 3.07E-08 829 1828
ITGAV  integrin, alpha V (vitronectin receptor, alpha polypeptid 3.14 6.26E-22 1077 344 4.90 8.06E-32 1832 378
2.94 0 10769 3662 5.04 0 19513 3872
MGC8685  tubulin, beta polypeptide paralog (RP11-506K6.1), mR 5.97 0 2153 361 12.51 0 7336 587
MYH10  myosin, heavy polypeptide 10, non-muscle (MYH10), m 3.53 0.0056 263 72
MYLIP  myosin regulatory light chain interacting protein (MYLIP 0.33 7.39E-18 474 1426
MYO1B  myosin IB (MYO1B), mRNA [NM_012223] 3.07 0 4383 1423 4.87 0 7170 1467
MYO1G  myosin IG (MYO1G), mRNA [NM_033054] 2.90 0 2737 942
MYO3A  myosin IIIA (MYO3A), mRNA [NM_017433] 3.19 1.21E-12 602 190 2.34 5.74E-06 565 254
MYO7A  myosin VIIA (Usher syndrome 1B (autosomal recessiv 0.28 0 1720 6137 0.34 0 1798 5223
MYOC  myocilin, trabecular meshwork inducible glucocorticoid 0.02 0 786 49667 0.07 0 3387 51303
SSPN  sarcospan (Kras oncogene-associated gene) (SSPN), 2.28 3.86E-08 3787 1622 2.28 2.43E-11 4128 1826
A√ M TRO  trophinin (TRO), transcript variant 3, mRNA [NM_0161 3.12 0 3220 1031 2.71 1.39E-43 2270 835
TUBA1  tubulin, alpha 1 (testis specific) (TUBA1), mRNA [NM_ 2.08 3.90E-24 12561 6022 2.35 0 13249 5633
TUBA6  tubulin alpha 6 (TUBA6), mRNA [NM_032704] 2.26 1.21E-16 2690 1187 2.20 9.72E-41 2487 1130
TUBA6  tubulin alpha 6 (TUBA6), mRNA [NM_032704] 2.33 0 4288 1838 2.47 0 4499 1824
TUBA6  tubulin alpha 6 (TUBA6), mRNA [NM_032704] 2.15 3.62E-14 8531 3952 2.37 3.97E-18 9490 3928
TUBA6  tubulin alpha 6 (TUBA6), mRNA [NM_032704] 2.04 1.12E-11 54810 27011
TUBB  tubulin, beta polypeptide (TUBB), mRNA [NM_178014] 2.14 1.33E-11 1928 902
TUBB  tubulin, beta polypeptide (TUBB), mRNA [NM_178014] 2.05 2.36E-27 9860 4799
TUBB2  tubulin, beta 2 (TUBB2), mRNA [NM_001069] 2.57 1.19E-31 3370 1309 3.35 0 4566 1363
TUBB2  tubulin, beta 2 (TUBB2), mRNA [NM_001069] 2.06 4.80E-35 14200 6874 2.97 0 21249 7131
TUBB3  tubulin, beta 3 (TUBB3), mRNA [NM_006086] 6.89 0 8233 1187 8.87 0 12157 1363
TUBB4  tubulin, beta 4 (TUBB4), mRNA [NM_006087] 2.54 0.00005 602 245 2.84 7.11E-09 631 232
TUBB6  tubulin, beta 6 (TUBB6), mRNA [NM_032525] 2.22 8.17E-35 3865 1743 2.77 0 4544 1638
TUBB6  tubulin, beta 6 (TUBB6), mRNA [NM_032525] 2.02 1.46E-07 30253 14783 2.06 1.91E-08 31022 14838
VAV3  vav 3 oncogene (VAV3), mRNA [NM_006113] 5.48 0 2197 401 2.21 1.07E-09 649 289
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9) Complement and coagulation cascades
ratio pvalue aggr ref ratio pvalue superfic ref
C1RL  complement component 1, r subcomponent-like (C1RL 0.21 0 675 3281 0.32 0 1033 3244
C6  complement component 6 (C6), mRNA [NM_000065] 0.31 5.69E-10 176 570 0.35 3.06E-10 180 522
C7  complement component 7 (C7), mRNA [NM_000587] 0.25 6.47E-22 217 854
CFH  complement factor H (CFH), transcript variant 1, mRNA 0.30 7.71E-10 563 1957 0.46 3.53E-11 1027 2260
CFHL3  complement factor H-related 3 (CFHL3), mRNA [NM_0 0.18 0 1660 9307 0.30 0 2345 7813
CLU  clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repres 0.21 0 7749 36239
DF  D component of complement (adipsin) (DF), mRNA [N 0.03 0 1567 46254 0.18 0 8228 45963
EDN1  endothelin 1 (EDN1), mRNA [NM_001955] 0.13 0 628 5007 0.26 0 1125 4354
FANCE  Fanconi anemia, complementation group E (FANCE), 0.47 5.88E-18 1186 2509 0.45 4.45E-18 1119 2525
F2R  coagulation factor II (thrombin) receptor (F2R), mRNA 3.01 5.57E-13 871 292 2.68 6.69E-23 963 361
F2RL2  coagulation factor II (thrombin) receptor-like 2 (F2RL2) 15.96 0 3448 213 5.05 1.89E-20 1023 196
NM_001014 complement factor H (CFH), transcript variant 2, mRNA 0.17 0 2372 13784 0.28 0 4265 15181
PLG  plasminogen (PLG), mRNA [NM_000301] 5.56 0 43311 7793 3.39 0 24010 7092
PTGER3  prostaglandin E receptor 3 (subtype EP3) (PTGER3), t 3.17 1.01E-20 1600 507
RGC32  response gene to complement 32 (RGC32), mRNA [NM_014059] 0.32 0 1323 4177
0.40 0 4193 10390
SERPINA3  serine (or cysteine) proteinase inhibitor, clade A (alpha 0.08 0 526 6291 0.09 0 544 5783
0.15 0 426 2793 0.21 0 477 2342
SERPINA5  serine (or cysteine) proteinase inhibitor, clade A (alpha 4.73 4.20E-16 3499 728 2.80 9.34E-08 1838 668
SERPINA10 serine (or cysteine) proteinase inhibitor, clade A (alpha 2.59 3.16E-31 1487 575
SERPING1  serine (or cysteine) proteinase inhibitor, clade G (C1 in 0.26 0 1289 4950 0.34 3.82E-39 1445 4214
S√ M,W SERPINH1  serine (or cysteine) proteinase inhibitor, clade H (heat 9.87 0 4017 406 5.35 2.61E-38 2103 395
10) Others
ratio pvalue aggr ref ratio pvalue superfic ref
ADRA1D  adrenergic, alpha-1D-, receptor (ADRA1D), mRNA [NM 2.15 1.52E-13 163378 76489
ARMC6  armadillo repeat containing 6 (ARMC6), mRNA [NM_0 2.16 3.09E-23 143428 66521
ARMC7  armadillo repeat containing 7 (ARMC7), mRNA [NM_0 5.82 1.97E-35 11705 1990 3.00 1.35E-23 3413 1095
C1QTNF2  C1q and tumor necrosis factor related protein 2 (C1QT 2.08 1.72E-08 1165 553 2.04 4.28E-11 1151 556
A√ M C1QTNF3  C1q and tumor necrosis factor related protein 3 (C1QT 11.89 0 6987 590 11.35 0 8272 727
C1QTNF3 13.49 0 7533 560 13.14 0 7899 601
C1QTNF6  C1q and tumor necrosis factor related protein 6 (C1QT 10.52 0 3173 301 6.53 0 2006 306
CEBPD  CCAAT/enhancer binding protein (C/EBP), delta (CEB 0.15 0 18519 125697 0.06 0 9484 148572
CDO1  cysteine dioxygenase, type I (CDO1), mRNA [NM_001 0.03 0 777 30290 0.07 0 1715 24644
CRISP2  cysteine-rich secretory protein 2 (CRISP2), mRNA [NM 15.55 0 14461 936 7.65 1.14E-38 3562 445
CUTL2  cut-like 2 (Drosophila) (CUTL2), mRNA [NM_015267] 3.73 0 8809 2354 2.65 6.20E-25 6437 2408
EBF  early B-cell factor (EBF), mRNA [NM_024007] 0.22 1.13E-22 242 1101 0.44 3.40E-17 545 1217
A√ M EGFL3  EGF-like-domain, multiple 3 (EGFL3), mRNA [NM_001 2.68 2.70E-32 4527 1680 2.26 2.07E-41 3866 1708
EGFL8  EGF-like-domain, multiple 8 (EGFL8), mRNA [NM_030 2.87 4.18E-25 33463 11545 2.31 1.64E-16 28862 12244
FBL  fibrillarin (FBL), mRNA [NM_001436] 0.43 0 8560 19792 0.44 0 8539 19643
FCN2  ficolin (collagen/fibrinogen domain containing lectin) 2 5.26 5.00E-12 1144 222 3.48 3.79E-08 651 202
G1P2  interferon, alpha-inducible protein (clone IFI-15K) (G1P 11.97 0 129497 10868 7.08 0 55435 7835
GPR32  G protein-coupled receptor 32 (GPR32), mRNA [NM_0 8.36 0 61762 7388 3.68 0 22196 6022
GPR44  G protein-coupled receptor 44 (GPR44), mRNA [NM_0 4.52 1.09E-12 1207 273 2.69 6.88E-07 669 267
HOMER1  homer homolog 1 (Drosophila) (HOMER1), mRNA [NM 8.18 1.18E-40 1471 178 3.75 5.80E-10 555 142
HOMER3  homer homolog 3 (Drosophila) (HOMER3), mRNA [NM 2.25 9.08E-07 20525 8873 2.71 1.87E-12 24002 8610
HMGN4  high mobility group nucleosomal binding domain 4 (HM 7.68 0 75900 10029 4.67 0 32987 7089
KSP37  Ksp37 protein (KSP37), mRNA [NM_031950] 0.06 0 677 10918 0.09 0 223 2471
KSP37  Ksp37 protein (KSP37), mRNA [NM_031950] 0.09 0 244 2828 0.07 0 747 11234
LRRN1  leucine rich repeat neuronal 1 (LRRN1), mRNA [NM_0 26.52 3.92E-44 8611 313 12.28 0 3647 297
MT1E  metallothionein 1E (functional) (MT1E), mRNA [NM_17 0.08 0 3279 41968 0.08 0 3447 41415
MT1F  metallothionein 1F (functional) (MT1F), mRNA [NM_00 0.10 0 1578 16487 0.09 0 1451 16283
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MT1G  metallothionein 1G (MT1G), mRNA [NM_005950] 0.49 2.4E-09 5030 10352 0.12 0 5451 45621
MT1G 0.12 0 6055 49536 0.44 1.21E-20 4976 11330
MT1H  metallothionein 1H (MT1H), mRNA [NM_005951] 0.22 2.1E-37 9213 42366 0.09 0 11311 127953
MT1H 0.08 0 9452 118841 0.23 7.25E-21 10485 45262
MT1K  metallothionein 1K (MT1K), mRNA [NM_176870] 0.06 0 6888 120968 0.07 0 7659 118336
MT1L H.sapiens mRNA for metallothionein isoform 1R. [X972 0.10 0 6213 64974 0.10 0 5744 58986
MT1X  metallothionein 1X (MT1X), mRNA [NM_005952] 0.05 0 2270 43244 0.08 0 6336 83461
MT1X 0.07 0 6067 83774 0.06 0 2870 47936
MT2A  metallothionein 2A (MT2A), mRNA [NM_005953] 0.07 0 18135 261463 0.07 0 21591 312045
MT2A 0.09 0 27444 329337 0.06 0 19012 317402
MT2A 0.08 0 24253 307394 0.06 0 14725 257171
MT1A  metallothionein 1A (functional) (MT1A), mRNA [NM_00 0.27 2.67E-27 19328 71913 0.26 4.45E-27 19352 73783
MT1B  metallothionein 1B (functional) (MT1B), mRNA [NM_00 0.19 0 8004 42231 0.20 0 7785 38743
MT1J  metallothionein 1J (MT1J), mRNA [NM_175622] 0.25 3.06E-34 1208 4921 0.22 0 1311 5876
PGLYRP2  peptidoglycan recognition protein 2 (PGLYRP2), mRNA31.70 0 15454 489 22.90 0 9589 417
PPIC  peptidylprolyl isomerase C (cyclophilin C) (PPIC), mRN 14.58 5.80E-40 51453 3318 8.43 3.46E-34 36495 4222
PPIC 6.56 6.17E-40 16507 2479 4.08 9.35E-33 9176 2240
POU4F2  POU domain, class 4, transcription factor 2 (POU4F2), 2.45 0 4067 1657
RAB11FIP1  RAB11 family interacting protein 1 (class I) (RAB11FIP 9.03 0 4919 545 3.62 1.63E-11 1316 341
REC8L1  REC8-like 1 (yeast) (REC8L1), mRNA [NM_005132] 5.42 3.17E-13 1900 336 2.98 1.72E-18 765 256
S100A8  S100 calcium binding protein A8 (calgranulin A) (S100 0.05 0 416 8235 0.04 0 267 7661
S100A9  S100 calcium binding protein A9 (calgranulin B) (S100 0.06 0 126 1957 0.08 0 117 1559
SMARCC2  SWI/SNF related, matrix associated, actin dependent r 2.11 2.81E-40 234430 110879
SOD2  superoxide dismutase 2, mitochondrial (SOD2), mRNA 0.07 0 464 6867 0.15 0 451 3016
SOD2 0.22 1.41E-25 644 2891 0.08 0 607 7158
SOX3  SRY (sex determining region Y)-box 3 (SOX3), mRNA 6.64 0 87131 12896 4.90 2.42E-37 58713 11748
TADA3L  transcriptional adaptor 3 (NGG1 homolog, yeast)-like ( 6.12 2.35E-39 7142 1152 3.31 3.12E-30 2703 806
TXNIP  thioredoxin interacting protein (TXNIP), mRNA [NM_00 0.07 0 10673 160139 0.08 0 13384 161028
UBOX5  U-box domain containing 5 (UBOX5), transcript variant 0.31 1.03E-16 241909 791541 0.34 6.18E-15 281568 826316
URB  steroid sensitive gene 1 (URB), transcript variant 1, mR13.49 0 6181 461 12.12 0 6165 511
URB 11.32 0 1502 134 5.79 2.26E-16 770 140
VIT  vitrin (VIT), mRNA [NM_053276] 0.11 0 263 2319 0.19 0 405 2134
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Gene list B: Genes differentially expressed between aggressive and superficial fibromatosis 
For each gene, its expression ratios aggr/ref and super/ref are also shown, if they fulfill the stringent selection criteria for significant differential gene expression. 
Therefore, no numbers in the columns Aggr/Ref and/or Super/Ref indicate no statistically signifcant difference in the expressions of the corresponding gene.
The different colors in the front column indicate the differential expression of the corresponding gene between the three tissues:
Aggr > Ref > Super Aggr > Super, Ref Aggr ≠ Super
Aggr > Super > Ref Aggr < Super, Ref
Aggr < Super < Ref
Super > Ref > Aggr Super > Aggr, Ref
Super > Aggr > Ref Super < Aggr, Ref
Super < Aggr < Ref
Genes whose differential expressions between fibromatoses and reference tissue (as it is mostly the case) or between the the two types of fibromatoses (seldom)
have been described in the literature are marked with the according informations in the first column. Abbreviations: 
A Aggressive fibromatosis
S Superficial fibromatosis
R Reference fibrous tissue
√ Differential expression described in the literature could be confirmed by own results
no √ Differential expression described in the literature could not be confirmed, the result published in the literature is indicated, e.g. A = R
IHC. Result published in the literature obtained by immunohistochemical analysis
M Result published in the literature obtained by microarray gene expression analysis
W Result published in the literature obtained by Western blot analysis
N Result published in the literature obtained by Northern blot analysis
ELISA Result published in the literature obtained by ELISA analysis
2D-GE Result published in the literature obtained by two-dimensional gel electrophoresis, followed by mass-spectrometry (MS) analysis
PCR Result published in the literature obtained by RT-PCR or real-time RT-PCR
Appendix Gene list B
1) Wnt signalling pathway
ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
APC2  adenomatosis polyposis coli 2 (APC2), mRNA [NM_005883] 0.26 8.35E-13 174 709 7.02 8.65E-19 741 104
3.29 4.20E-45 11283 3425
AXIN2  axin 2 (conductin, axil) (AXIN2), mRNA [NM_004655] 0.48 2.87E-07 330 702 2.32 0.00002 711 312 2.18 0.00006 1179 564
0.36 4.59E-21 1247 3478 5.54 5.43E-33 3650 661
CD44  CD44 antigen (homing function and Indian blood group system) (CD44), transcript variant 1, mRNA [NM 2.52 2.66E-37 14277 5645 0.29 1.37E-29 5892 20369
CYR61  cysteine-rich, angiogenic inducer, 61 (CYR61), mRNA [NM_001554] 0.36 1.57E-24 2411 6778 0.34 7.99E-22 3162 9385
CYR61  cysteine-rich, angiogenic inducer, 61 (CYR61), mRNA [NM_001554] 0.33 2.85E-24 4793 14540 0.23 6.16E-25 5002 21658
CYR61  cysteine-rich, angiogenic inducer, 61 (CYR61), mRNA [NM_001554] 0.37 1.66E-10 12641 34956 0.25 1.29E-13 13257 53481
DKK2  dickkopf homolog 2 (Xenopus laevis) (DKK2), mRNA [NM_014421] 0.37 1.15E-18 279 755 2.40 3.08E-09 748 315
0.39 7.87E-35 568 1451 2.80 1.19E-27 1557 558
DKK3  dickkopf homolog 3 (Xenopus laevis) (DKK3), mRNA [NM_015881] 5.12 0 44149 8622 2.57 5.36E-32 9506 3729
5.36 0 36184 6749 3.24 0 29583 9072
3.40 4.76E-44 9139 2689 2.96 0 40095 13548
EDN1  endothelin 1 (EDN1), mRNA [NM_001955] 2.10 2.24E-22 1193 568 0.13 0 628 5007 0.26 0 1125 4354
FGF18  fibroblast growth factor 18 (FGF18), transcript variant 1, mRNA [NM_003862] 3.05 0.00002 986 348 3.55 4.64E-30 1118 318
FRZB  frizzled-related protein (FRZB), mRNA [NM_001463] 0.28 6.13E-33 532 1890 0.21 3.34E-35 526 2460
0.30 1.85E-23 733 2484
FST  follistatin (FST), transcript variant FST344, mRNA [NM_013409] 0.15 0 470 3057 3.95 0 3536 893
FZD2  frizzled homolog 2 (Drosophila) (FZD2), mRNA [NM_001466] 0.49 1.72E-09 473 980 4.42 2.77E-24 1038 237
FZD8  frizzled homolog 8 (Drosophila) (FZD8), mRNA [NM_031866] 3.40 4.22E-25 946 281 0.40 5.93E-09 276 706
GREM1  gremlin 1 homolog, cysteine knot superfamily (Xenopus laevis) (GREM1), mRNA [NM_013372] 0.14 9.75E-30 823 5990 5.54 0 6083 1090
A=R  PCR LEF1  lymphoid enhancer-binding factor 1 (LEF1), mRNA [NM_016269] 0.39 1.19E-34 1327 3422 7.67 0 3569 467 3.11 1.69E-13 1260 392
MET  met proto-oncogene (hepatocyte growth factor receptor) (MET), mRNA [NM_000245] 3.49 0 4439 1270 0.32 0 1270 3907
A>R  M,PCR MMP3  matrix metalloproteinase 3 (stromelysin 1, progelatinase) (MMP3), mRNA [NM_002422] 0.08 2.40E-29 54 651 0.01 0 3050 286788 0.01 0 3432 279991
PITX2  paired-like homeodomain transcription factor 2 (PITX2), transcript variant 2, mRNA [NM_153426] 0.12 0 373 3142 8.89 0 3500 394
AvR √ IHC,N,W PTGS2  prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2), mR 0.25 7.43E-15 150 606 2.83 1.27E-18 713 252
SFRP2  secreted frizzled-related protein 2 (SFRP2), mRNA [NM_003013] 0.35 0 2281 6510 10.58 0 26378 2490 3.66 0 1964 537
0.54 5.51E-28 14362 26469 10.13 0 7482 740 2.91 0 3466 1192
0.46 5.28E-24 3671 8022 5.73 0 7945 1388 5.98 0 11575 1934
SFRP4  secreted frizzled-related protein 4 (SFRP4), mRNA [NM_003014] 2.69 0 71925 26775 16.57 0 29554 1781 30.97 0 73816 2390
SP5  Sp5 transcription factor (SP5), mRNA [NM_001003845] 0.18 7.79E-40 313 1811 4.65 0 1989 429
 Sp5 transcription factor (SP5), mRNA [NM_001003845] 0.11 2.58E-31 238 2194 5.18 5.17E-16 2214 428
AvR √ PCR TCF7L2  transcription factor 7-like 2 (T-cell specific, HMG-box) (TCF7L2), mRNA [NM_030756] 0.38 1.94E-08 221 563 0.36 1.45E-09 229 651
TLE1  transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) (TLE1), mRNA [NM_005077] 0.43 8.83E-25 742 1737
TNFRSF19  tumor necrosis factor receptor superfamily, member 19 (TNFRSF19), transcript variant 2, mRNA [NM_14 0.32 7.05E-33 904 2779 20.61 3.90E-28 3316 158 6.43 2.25E-16 866 127
 tumor necrosis factor receptor superfamily, member 19 (TNFRSF19), transcript variant 1, mRNA [NM_018647] 2.38 0.0823 178 77
superficial / referencesuperficial / aggressive aggressive / reference
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ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
WIF1  WNT inhibitory factor 1 (WIF1), mRNA [NM_007191] 0.05 0 160 3201 14.17 0 2929 206
WISP2  WNT1 inducible signaling pathway protein 2 (WISP2), mRNA [NM_003881] 4.11 1.40E-32 29137 6995 0.23 9.48E-29 5443 23926
WNT2  wingless-type MMTV integration site family member 2 (WNT2), mRNA [NM_003391] 0.47 4.88E-09 441 959 3.43 7.80E-13 975 289
WNT4  wingless-type MMTV integration site family, member 4 (WNT4), mRNA [NM_030761] 0.50 4.48E-16 1843 3704 2.85 1.33E-39 3693 1293
AvR √ M WNT5A  wingless-type MMTV integration site family, member 5A (WNT5A), mRNA [NM_003392] 0.14 0 849 5937 14.40 0 5461 378 2.27 4.47E-09 657 295
2) TGFβ signalling pathway
ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
AvR √ M ASPN  asporin (LRR class 1) (ASPN), mRNA [NM_017680] 2.92 5.51E-14 104503 34787 14.89 0 36546 2424 27.27 0 91077 3308
BAMBI  BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) (BAMBI), mRNA [NM_012342] 3.11 0 5244 1685 3.73 3.34E-43 4795 1283
S=R  PCR BMP7  bone morphogenetic protein 7 (osteogenic protein 1) (BMP7), mRNA [NM_001719] 0.31 6.31E-44 638 2062 16.33 0 2205 136 5.36 9.92E-13 552 99
CDKN1C  cyclin-dependent kinase inhibitor 1C (p57, Kip2) (CDKN1C), mRNA [NM_000076] 2.27 3.55E-19 14786 6496
CDKN2D  cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) (CDKN2D), transcript variant 1, mRNA [NM_00 1.92 0 5936 3092
CILP  cartilage intermediate layer protein, nucleotide pyrophosphohydrolase (CILP), mRNA [NM_003613] 4.23 3.99E-30 13165 3067 0.04 0 3778 87300 0.17 2.75E-22 12084 74050
A>R  M COMP  cartilage oligomeric matrix protein (COMP), mRNA [NM_000095] 3.53 0 50880 14435 0.12 7.40E-43 15337 131654
5.15 4.95E-40 75737 14436 0.18 0 17114 96665
EGR1  early growth response 1 (EGR1), mRNA [NM_001964] 0.39 1.00E-33 12036 30703 0.46 3.95E-15 10223 22395
FST  follistatin (FST), transcript variant FST344, mRNA [NM_013409] 0.15 0 470 3057 3.95 0 3536 893
FSTL3  follistatin-like 3 (secreted glycoprotein) (FSTL3), mRNA [NM_005860] 0.41 7.45E-08 208 509 2.04 0.00002 531 263
GDF10  growth differentiation factor 10 (GDF10), mRNA [NM_004962] 2.18 5.68E-17 1634 742
GREM1  gremlin 1 homolog, cysteine knot superfamily (Xenopus laevis) (GREM1), mRNA [NM_013372] 0.14 9.75E-30 823 5990 5.54 0 6083 1090
ID4  inhibitor of DNA binding 4, dominant negative helix-loop-helix protein (ID4), mRNA [NM_001546] 0.25 0 681 2777 0.33 0 636 1910
INHBA  inhibin, beta A (activin A, activin AB alpha polypeptide) (INHBA), mRNA [NM_002192] 0.2 0 4'082 20'587 4.57 0 22595 4945
LGALS3  lectin, galactoside-binding, soluble, 3 (galectin 3) (LGALS3), mRNA [NM_002306] 2.06 0 22673 10983 0.31 0 11067 35700
OGN  osteoglycin (osteoinductive factor, mimecan) (OGN), transcript variant 1, mRNA [NM_033014] 0.46 3.55E-23 3863 8405 16.59 0 8686 524 7.88 0 3775 480
PITX2  paired-like homeodomain transcription factor 2 (PITX2), transcript variant 2, mRNA [NM_153426] 0.12 0 373 3142 8.89 0 3500 394
THBS3  thrombospondin 3 (THBS3), mRNA [NM_007112] 2.17 1.59E-18 54594 24955
THBS4  thrombospondin 4 (THBS4), mRNA [NM_003248] 7.99 2.8E-45 67565 8263 0.31 1.44E-15 6783 21857 2.59 4.00E-07 65044 23708
superficial / aggressive aggressive / reference superficial / reference
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3) PI3K-AKT signalling pathway
ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
AREG  amphiregulin (schwannoma-derived growth factor) (AREG), mRNA [NM_001657] 0.07 0 598 8751 9.51 0 8522 881
FGF18  fibroblast growth factor 18 (FGF18), transcript variant 1, mRNA [NM_003862] 3.05 0.00002 986 348 3.55 4.64E-30 1118 318
AvR √ M,W,N IGFBP6  insulin-like growth factor binding protein 6 (IGFBP6), mRNA [NM_002178] 3.33 1.69E-25 1118 339 0.09 0 380 4180 0.25 6.62E-35 1172 4684
IGFBP7  insulin-like growth factor binding protein 7 (IGFBP7), mRNA [NM_001553] 2.42 0 174079 71860 2.65 2.79E-19 153744 57411
IGFL2  insulin growth factor-like family member 2 (IGFL2), mRNA [NM_001002915] 0.19 6.57E-16 225 1117 9.28 0 1256 136
IL13RA1  interleukin 13 receptor, alpha 1 (IL13RA1), mRNA [NM_001560] 2.11 4.60E-10 26206 12259 0.36 2.33E-09 12656 36105
IL17RB  interleukin 17 receptor B (IL17RB), transcript variant 2, mRNA [NM_172234] 0.45 5.44E-14 419 949
MET  met proto-oncogene (hepatocyte growth factor receptor) (MET), mRNA [NM_000245] 3.49 0 4439 1270 0.32 0 1270 3907
PDGFRB  platelet-derived growth factor receptor, beta polypeptide (PDGFRB), mRNA [NM_002609] 2.06 2.73E-19 38724 18703 2.32 5.85E-18 33903 14521
4) Extracellular matrix (ECM)
ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
ADAMTS1  a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 1 (ADAMTS1), 0.16 0 779 4846 2.24 1.74E-25 4604 2051 0.45 1.98E-18 846 1849
0.22 0 1021 4714 2.39 2.92E-25 5726 2390 0.33 0 719 2196
ADAMTS4  a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 4 (ADAMTS4), 0.48 3.87E-42 5291 11115
ADAMTS9  a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 9 (ADAMTS9), 0.33 1.91E-15 373 1114 3.39 6.16E-34 1189 351
0.45 1.02E-25 669 1505 2.15 5.39E-08 1456 684
0.17 0 2494 14527 5.07 0 15164 2987
AGC1  aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, antigen identified by mo 3.77 0 49888 13236 5.74 0 43167 7532
ANGPTL7  angiopoietin-like 7 (ANGPTL7), mRNA [NM_021146] 66.93 0 12779 192 0.005 0 1284 274406 0.05 0 11741 233940
AvR √ M ASPN  asporin (LRR class 1) (ASPN), mRNA [NM_017680] 2.92 5.51E-14 104503 34787 14.89 0 36546 2424 27.27 0 91077 3308
CILP  cartilage intermediate layer protein, nucleotide pyrophosphohydrolase (CILP), mRNA [NM_003613] 4.23 3.99E-30 13165 3067 0.04 0 3778 87300 0.17 2.75E-22 12084 74050
AvR √ M CLEC3B  C-type lectin domain family 3, member B (CLEC3B), mRNA [NM_003278] 3.23 0 18295 5652 0.38 1.08E-30 5534 14635
S<R M
AvR √ M COL11A1  collagen, type XI, alpha 1 (COL11A1), transcript variant B, mRNA [NM_080629] 0.29 0 3126 10831 16.45 0 11610 708 5.43 0 3027 556
COL17A1  collagen, type XVII, alpha 1 (COL17A1), transcript variant long, mRNA [NM_000494] 3.51 3.46E-13 507 145
SvR √ IHC. COL4A5  collagen, type IV, alpha 5 (Alport syndrome) (COL4A5), transcript variant 2, mRNA [NM_033380] 0.28 1.47E-24 224 797 2.30 3.38E-13 805 351 4.00 0 2598 649
2.32 9.87E-21 1315 564
7.93 0 7045 883
AvR √ M COL5A1  collagen, type V, alpha 1 (COL5A1), mRNA [NM_000093] 0.38 1.30E-20 2185 5709 12.82 0 53506 4187 7.85 0 23475 3005
28.83 0 5889 206 15.60 0 2091 134
COL8A2  collagen, type VIII, alpha 2 (COL8A2), mRNA [NM_005202] 2.93 5.32E-33 15516 5262 2.20 5.66E-15 4848 2176 5.85 0 14811 2511
A>R M COMP  cartilage oligomeric matrix protein (COMP), mRNA [NM_000095] 3.53 0 50880 14435 0.12 7.40E-43 15337 131654
5.15 4.95E-40 75737 14436 0.18 0 17114 96665
superficial / reference
superficial / aggressive aggressive / reference superficial / reference
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ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
CYR61  cysteine-rich, angiogenic inducer, 61 (CYR61), mRNA [NM_001554] 0.36 1.57E-24 2411 6778 0.34 7.99E-22 3162 9385
0.33 2.85E-24 4793 14540 0.23 6.16E-25 5002 21658
0.37 1.66E-10 12641 34956 0.25 1.29E-13 13257 53481
AvR √ M EFEMP1  EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1), transcript variant 1, mRNA [NM_0041 2.72 1.44E-28 10928 3990 0.33 5.54E-13 4514 13834
EGR1  early growth response 1 (EGR1), mRNA [NM_001964] 0.39 1.00E-33 12036 30703 0.46 3.95E-15 10223 22395
FNDC1 Fibronectin type III domain containing 1 3.35 0 28913 8642
HS3ST3B1  heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1, mRNA (cDNA clone MGC:71688 IMAGE:3034 0.25 4.57E-16 221 857 5.11 3.26E-06 637 115
LGALS3  lectin, galactoside-binding, soluble, 3 (galectin 3) (LGALS3), mRNA [NM_002306] 2.06 0 22673 10983 0.31 0 11067 35700
S>R   2D-GE MFAP4  microfibrillar-associated protein 4 (MFAP4), mRNA [NM_002404] 0.31 1.28E-25 13129 41989 3.87 2.37E-21 44700 11483
AvR √ PCR MMP1  matrix metalloproteinase 1 (interstitial collagenase) (MMP1), mRNA [NM_002421] 0.39 8.22E-27 1098 2832 3.40 0 3132 923
AvR √ PCR MMP11  matrix metalloproteinase 11 (stromelysin 3) (MMP11), mRNA [NM_005940] 0.30 0 6151 20758 18.57 0 21077 1139 8.93 0 6272 693
MMP19  matrix metalloproteinase 19 (MMP19), transcript variant rasi-6, mRNA [NM_022791] 0.32 1.68E-30 1252 3972 10.78 0 3898 362 3.43 4.58E-21 1259 360
MMP23B  matrix metalloproteinase 23B (MMP23B), mRNA [NM_006983] 0.40 0 1706 4317 6.09 0 4386 719 2.75 1.54E-42 1210 439
A>R  M,PCR MMP3  matrix metalloproteinase 3 (stromelysin 1, progelatinase) (MMP3), mRNA [NM_002422] 0.08 2.40E-29 54 651 0.01 0 3050 286788 0.01 0 3432 279991
A<R  M NID2  nidogen 2 (osteonidogen) (NID2), mRNA [NM_007361] 2.02 1.26E-13 6022 2972 7.30 0 2909 396 12.24 0 5659 460
NOV  nephroblastoma overexpressed gene (NOV), mRNA [NM_002514] 8.90 0 9069 1018 9.90 0 8761 886
OGN  osteoglycin (osteoinductive factor, mimecan) (OGN), transcript variant 1, mRNA [NM_033014] 0.46 3.55E-23 3863 8405 16.59 0 8686 524 7.88 0 3775 480
PLAT  plasminogen activator, tissue (PLAT), transcript variant 1, mRNA [NM_000930] 0.16 0 2024 12582 2.01 2.33E-08 13121 6523 0.33 6.95E-27 1738 5366
PLAU  plasminogen activator, urokinase (PLAU), mRNA [NM_002658] 2.50 1.11E-30 18274 7260 4.10 0 17120 4155
SvR √  M PRG4  proteoglycan 4 (PRG4), mRNA [NM_005807] 18.71 0 4629 246 0.01 0 482 44080 0.12 0 4826 40787
SERPINA5  serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 (SERPIN 4.02 0.04679 659 147 4.73 4.20E-16 3499 728 2.80 9.34E-08 1838 668
A>R  M SPARCL1  SPARC-like 1 (mast9, hevin) (SPARCL1), mRNA [NM_004684] 2.46 1.35E-34 153223 62080
AvR √ M SPON2  spondin 2, extracellular matrix protein (SPON2), mRNA [NM_012445] 3.12 7.47E-20 282110 88387 9.59 1.19E-41 103308 10375 23.98 0 278300 11395
THBS3  thrombospondin 3 (THBS3), mRNA [NM_007112] 2.17 1.59E-18 54594 24955
THBS4  thrombospondin 4 (THBS4), mRNA [NM_003248] 7.99 2.8E-45 67565 8263 0.31 1.44E-15 6783 21857 2.59 4.00E-07 65044 23708
SvR √ M, PCR TNC  tenascin C (hexabrachion) (TNC), mRNA [NM_002160] 5.24 0 40057 7601 2.48 0 5955 2403 8.99 0 41901 4677
TNXB  tenascin XB (TNXB), transcript variant XB, mRNA [NM_019105] 5.99 0 22076 3653 0.13 0 3271 25201
superficial / aggressive aggressive / reference superficial / reference
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5) ECM-receptor interaction
ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
ACTN2  actinin, alpha 2 (ACTN2), mRNA [NM_001103] 0.06 0 64 1129 16.32 1.67E-42 1217 74
CD34  CD34 antigen (CD34), mRNA [NM_001773] 2.46 1.56E-23 8200 3313 0.38 0 3624 9566
CD44  CD44 antigen (homing function and Indian blood group system) (CD44), transcript variant 1, mRNA [NM 2.52 2.66E-37 14277 5645 0.29 1.37E-29 5892 20369
AvR √ M COL11A1  collagen, type XI, alpha 1 (COL11A1), transcript variant B, mRNA [NM_080629] 0.29 0 3126 10831 16.45 0 11610 708 5.43 0 3027 556
COL17A1  collagen, type XVII, alpha 1 (COL17A1), transcript variant long, mRNA [NM_000494] 3.51 3.46E-13 507 145
SvR √ IHC. COL4A5  collagen, type IV, alpha 5 (Alport syndrome) (COL4A5), transcript variant 2, mRNA [NM_033380] 0.28 1.47E-24 224 797 2.30 3.38E-13 805 351 4.00 0 2598 649
2.32 9.87E-21 1315 564
7.93 0 7045 883
AvR √ M COL5A1  collagen, type V, alpha 1 (COL5A1), mRNA [NM_000093] 0.38 1.30E-20 2185 5709 12.82 0 53506 4187 7.85 0 23475 3005
28.83 0 5889 206 15.60 0 2091 134
COL8A2  collagen, type VIII, alpha 2 (COL8A2), mRNA [NM_005202] 2.93 5.32E-33 15516 5262 2.20 5.66E-15 4848 2176 5.85 0 14811 2511
A>R  M COMP  cartilage oligomeric matrix protein (COMP), mRNA [NM_000095] 3.53 0 50880 14435 0.12 7.40E-43 15337 131654
5.15 4.95E-40 75737 14436 0.18 0 17114 96665
CYR61  cysteine-rich, angiogenic inducer, 61 (CYR61), mRNA [NM_001554] 0.36 1.57E-24 2411 6778 0.34 7.99E-22 3162 9385
0.33 2.85E-24 4793 14540 0.23 6.16E-25 5002 21658
0.37 1.66E-10 12641 34956 0.25 1.29E-13 13257 53481
EDIL3  EGF-like repeats and discoidin I-like domains 3 (EDIL3), mRNA [NM_005711] 2.78 1.03E-41 21930 7892 8.77 0 8573 968 20.14 0 18664 922
FIGF  c-fos induced growth factor (vascular endothelial growth factor D) (FIGF), mRNA [NM_004469] 0.48 1.84E-22 824 1716
FLRT3  fibronectin leucine rich transmembrane protein 3 (FLRT3), transcript variant 2, mRNA [NM_198391] 0.49 1.1E-12 397 824 2.24 9.58E-08 763 345
FNDC1 Fibronectin type III domain containing 1 3.35 0 28913 8642
ITGA8  integrin, alpha 8 (ITGA8), mRNA [NM_003638] 3.84 7.06E-41 2259 590 6.47 0 2527 391
ITGA9  integrin, alpha 9 (ITGA9), mRNA [NM_002207] 2.42 3.60E-12 1010 406 3.57 6.80E-13 921 247
MAPK10  mitogen-activated protein kinase 10 (MAPK10), transcript variant 3, mRNA [NM_138980] 0.44 0.00005 238 503 2.09 7.54E-06 510 246
MET  met proto-oncogene (hepatocyte growth factor receptor) (MET), mRNA [NM_000245] 3.49 0 4439 1270 0.32 0 1270 3907
S>R   2D-GE MFAP4  microfibrillar-associated protein 4 (MFAP4), mRNA [NM_002404] 0.31 1.28E-25 13129 41989 3.87 2.37E-21 44700 11483
MYL1  myosin, light polypeptide 1, alkali; skeletal, fast (MYL1), transcript variant 3f, mRNA [NM_079422] 0.12 1.24E-29 118 1031 4.51 3.12E-19 1018 229
MYLK  myosin, light polypeptide kinase (MYLK), transcript variant 1, mRNA [NM_053025] 0.50 5.35E-43 2955 5636 2.35 1.52E-20 5877 2481
2.03 3.58E-11 24837 12243
NEDD9  neural precursor cell expressed, developmentally down-regulated 9 (NEDD9), mRNA [NM_006403] 2.24 1.42E-10 692 313 0.45 2.92E-07 350 761
A<R  M NID2  nidogen 2 (osteonidogen) (NID2), mRNA [NM_007361] 2.02 1.26E-13 6022 2972 7.30 0 2909 396 12.24 0 5659 460
PDGFRB  platelet-derived growth factor receptor, beta polypeptide (PDGFRB), mRNA [NM_002609] 2.06 2.73E-19 38724 18703 2.32 5.85E-18 33903 14521
PPP1R12B  protein phosphatase 1, regulatory (inhibitor) subunit 12B (PPP1R12B), transcript variant 2, mRNA [NM_0 0.44 9.97E-12 5587 12707
SDC1  syndecan 1 (SDC1), transcript variant 1, mRNA [NM_001006946] 0.34 3.75E-34 2339 6979 9.81 0 6976 700 4.68 3.17E-24 2507 533
SORBS1  sorbin and SH3 domain containing 1 (SORBS1), mRNA [NM_015385] 0.32 2.25E-38 659 2046 0.40 1.45E-12 1055 2618
0.20 7.39E-23 639 3261
SPARCL1  SPARC-like 1 (mast9, hevin) (SPARCL1), mRNA [NM_004684] 2.46 1.35E-34 153223 62080
superficial / aggressive aggressive / reference superficial / reference
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ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
AvR √ M SPON2  spondin 2, extracellular matrix protein (SPON2), mRNA [NM_012445] 3.12 7.47E-20 282110 88387 9.59 1.19E-41 103308 10375 23.98 0 278300 11395
THBS3  thrombospondin 3 (THBS3), mRNA [NM_007112] 2.17 1.59E-18 54594 24955
THBS4  thrombospondin 4 (THBS4), mRNA [NM_003248] 7.99 2.8E-45 67565 8263 0.31 1.44E-15 6783 21857 2.59 4.00E-07 65044 23708
SvR √ M, PCR TNC  tenascin C (hexabrachion) (TNC), mRNA [NM_002160] 5.24 0 40057 7601 2.48 0 5955 2403 8.99 0 41901 4677
A<R  M TNFAIP6  tumor necrosis factor, alpha-induced protein 6 (TNFAIP6), mRNA [NM_007115] 2.52 3.04E-25 2109 830 2.78 8.97E-39 2084 749
TNXB  tenascin XB (TNXB), transcript variant XB, mRNA [NM_019105] 5.99 0 22076 3653 0.13 0 3271 25201
TTN  titin (TTN), transcript variant novex-3, mRNA [NM_133379] 0.11 0 633 5824 11.65 0 5738 492
VAV3  vav 3 oncogene (VAV3), mRNA [NM_006113] 0.39 1.28E-32 802 2046 5.48 0 2197 401 2.21 1.07E-09 649 289
6) Adherens junction and cell adhesion molecules (CAMs)
ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
AOC3  amine oxidase, copper containing 3 (vascular adhesion protein 1) (AOC3), mRNA [NM_003734] 0.48 5.68E-11 1117 2339
CD34  CD34 antigen (CD34), mRNA [NM_001773] 2.46 1.56E-23 8200 3313 0.38 0 3624 9566
CD44  CD44 antigen (homing function and Indian blood group system) (CD44), transcript variant 1, mRNA [NM 2.52 2.66E-37 14277 5645 0.29 1.37E-29 5892 20369
CD9  CD9 antigen (p24) (CD9), mRNA [NM_001769] 2.36 3.17E-42 4833 2044 0.35 0 2124 6096
CDH13  cadherin 13, H-cadherin (heart) (CDH13), mRNA [NM_001257] 4.69 1.40E-45 8831 1877 0.49 6.95E-17 1565 3222 2.24 0 9760 4354
CPXM2  carboxypeptidase X (M14 family), member 2 (CPXM2), mRNA [NM_198148] 4.43 0 8399 1896 2.63 7.45E-23 8418 3173
FLRT3  fibronectin leucine rich transmembrane protein 3 (FLRT3), transcript variant 2, mRNA [NM_198391] 0.49 1.1E-12 397 824 2.24 9.58E-08 763 345
A=R  PCR LEF1  lymphoid enhancer-binding factor 1 (LEF1), mRNA [NM_016269] 0.39 1.19E-34 1327 3422 7.67 0 3569 467 3.11 1.69E-13 1260 392
MET  met proto-oncogene (hepatocyte growth factor receptor) (MET), mRNA [NM_000245] 3.49 0 4439 1270 0.32 0 1270 3907
S>R   2D-GE MFAP4  microfibrillar-associated protein 4 (MFAP4), mRNA [NM_002404] 0.31 1.28E-25 13129 41989 3.87 2.37E-21 44700 11483
PCDH7  BH-protocadherin (brain-heart) (PCDH7), transcript variant c, mRNA [NM_032457] 2.52 7.67E-08 831 313 2.66 4.57E-23 938 353 2.75 2.98E-30 1160 423
19.74 8.38E-25 740 40
2.29 0.11056 140 60
SORBS1  sorbin and SH3 domain containing 1 (SORBS1), mRNA [NM_015385] 0.32 2.25E-38 659 2046 0.40 1.45E-12 1055 2618
0.20 7.39E-23 639 3261
AvR √ PCR TCF7L2  transcription factor 7-like 2 (T-cell specific, HMG-box) (TCF7L2), mRNA [NM_030756] 0.38 1.94E-08 221 563 0.36 1.45E-09 229 651
THBS3  thrombospondin 3 (THBS3), mRNA [NM_007112] 2.17 1.59E-18 54594 24955
THBS4  thrombospondin 4 (THBS4), mRNA [NM_003248] 7.99 2.8E-45 67565 8263 0.31 1.44E-15 6783 21857 2.59 4.00E-07 65044 23708
A<R  M TNFAIP6  tumor necrosis factor, alpha-induced protein 6 (TNFAIP6), mRNA [NM_007115] 2.52 3.04E-25 2109 830 2.78 8.97E-39 2084 749
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7) Proliferation
ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
ADAMTS1  a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 1 (ADAMTS1), 0.16 0 779 4846 2.24 1.74E-25 4604 2051 0.45 1.98E-18 846 1849
0.22 0 1021 4714 2.39 2.92E-25 5726 2390 0.33 0 719 2196
AvR √ M AHR  aryl hydrocarbon receptor (AHR), mRNA [NM_001621] 0.34 0 3183 9481 2.24 2.10E-21 10103 4460
AKR1C3  aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) (AKR1C3), m 3.06 0 3500 1145 0.24 0 1268 5216
ANGPTL7  angiopoietin-like 7 (ANGPTL7), mRNA [NM_021146] 66.93 0 12779 192 0.005 0 1284 274406 0.05 0 11741 233940
APC2  adenomatosis polyposis coli 2 (APC2), mRNA [NM_005883] 0.26 8.35E-13 174 709 7.02 8.65E-19 741 104
3.29 4.20E-45 11283 3425
APCDD1  adenomatosis polyposis coli down-regulated 1 (APCDD1), mRNA [NM_153000] 0.08 0 2023 26641 15.19 0 27565 1777
AREG  amphiregulin (schwannoma-derived growth factor) (AREG), mRNA [NM_001657] 0.07 0 598 8751 9.51 0 8522 881
S=R  PCR BMP7  bone morphogenetic protein 7 (osteogenic protein 1) (BMP7), mRNA [NM_001719] 0.31 6.31E-44 638 2062 16.33 0 2205 136 5.36 9.92E-13 552 99
CD44  CD44 antigen (homing function and Indian blood group system) (CD44), transcript variant 1, mRNA [NM 2.52 2.66E-37 14277 5645 0.29 1.37E-29 5892 20369
CD86  CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) (CD86), transcript variant 2, mRNA [NM_006889] 3.30 2.90E-20 5172 1567 0.26 5.94E-14 1320 5417
CD9  CD9 antigen (p24) (CD9), mRNA [NM_001769] 2.36 3.17E-42 4833 2044 0.35 0 2124 6096
CMIP  c-Maf-inducing protein (CMIP), transcript variant C-mip, mRNA [NM_198390] 0.45 2.80E-45 1052 2363 3.31 3.53E-27 2456 736 4.07 2.43E-41 50177 12410
CMIP 5.61 0 105445 18435
CYR61  cysteine-rich, angiogenic inducer, 61 (CYR61), mRNA [NM_001554] 0.36 1.57E-24 2411 6778 0.34 7.99E-22 3162 9385
0.33 2.85E-24 4793 14540 0.23 6.16E-25 5002 21658
0.37 1.66E-10 12641 34956 0.25 1.29E-13 13257 53481
DCD  dermcidin (DCD), mRNA [NM_053283] 22.74 0 12859 566 23.48 0 12034 513
EDN1  endothelin 1 (EDN1), mRNA [NM_001955] 2.10 2.24E-22 1193 568 0.13 0 628 5007 0.26 0 1125 4354
EGR1  early growth response 1 (EGR1), mRNA [NM_001964] 0.39 1.00E-33 12036 30703 0.46 3.95E-15 10223 22395
EML4  echinoderm microtubule associated protein like 4 (EML4), mRNA [NM_019063] 0.32 2.29E-27 2311 7308 2.82 1.66E-23 5363 1867
0.38 0 2501 6619 2.64 0 7006 2651
EPLIN  epithelial protein lost in neoplasm beta (EPLIN), mRNA [NM_016357] 2.13 2.53E-06 13649 6186
EPS8  epidermal growth factor receptor pathway substrate 8 (EPS8), mRNA [NM_004447] 2.44 1.28E-19 4533 1848 0.26 1.37E-31 2022 7828 0.61 3.38E-06 4557 7430
EREG  epiregulin (EREG), mRNA [NM_001432] 0.12 5.57E-38 150 1261 3.05 1.18E-15 629 205 3.45 7.21E-16 537 155
5.93 2.27E-14 1257 215
FGF18  fibroblast growth factor 18 (FGF18), transcript variant 1, mRNA [NM_003862] 3.05 0.00002 986 348 3.55 4.64E-30 1118 318
FIGF  c-fos induced growth factor (vascular endothelial growth factor D) (FIGF), mRNA [NM_004469] 0.48 1.84E-22 824 1716
FSTL3  follistatin-like 3 (secreted glycoprotein) (FSTL3), mRNA [NM_005860] 0.41 7.45E-08 208 509 2.04 0.00002 531 263
GPNMB  glycoprotein (transmembrane) nmb (GPNMB), transcript variant 1, mRNA [NM_001005340] 2.06 6.44E-12 16496 7956 2.67 1.13E-23 15867 5948
AvR √ M,W,N IGFBP6  insulin-like growth factor binding protein 6 (IGFBP6), mRNA [NM_002178] 3.33 1.69E-25 1118 339 0.09 0 380 4180 0.25 6.62E-35 1172 4684
IGFBP7  insulin-like growth factor binding protein 7 (IGFBP7), mRNA [NM_001553] 2.42 0 174079 71860 2.65 2.79E-19 153744 57411
INHBA  inhibin, beta A (activin A, activin AB alpha polypeptide) (INHBA), mRNA [NM_002192] 0.2 0 4'082 20'587 4.57 0 22595 4945
LGALS3  lectin, galactoside-binding, soluble, 3 (galectin 3) (LGALS3), mRNA [NM_002306] 2.06 0 22673 10983 0.31 0 11067 35700
LHFP  lipoma HMGIC fusion partner (LHFP), mRNA [NM_005780] 5.45 0 60602 11123 4.02 1.05E-40 61702 15117
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LZTS1  leucine zipper, putative tumor suppressor 1 (LZTS1), mRNA [NM_021020] 2.74 2.09E-38 3604 1317 4.86 9.00E-27 1363 278 11.63 0 3849 331
AvR √ M MDK  midkine (neurite growth-promoting factor 2) (MDK), transcript variant 1, mRNA [NM_001012334] 0.41 2.85E-34 8098 19914 5.72 0 20422 3560 2.19 0 7458 3399
MET  met proto-oncogene (hepatocyte growth factor receptor) (MET), mRNA [NM_000245] 3.49 0 4439 1270 0.32 0 1270 3907
MPHOSPH6  M-phase phosphoprotein 6 (MPHOSPH6), mRNA [NM_005792] 0.43 1.22E-06 322 798 3.24 2.59E-11 681 213
MTSS1  metastasis suppressor 1 (MTSS1), mRNA [NM_014751] 3.18 9.86E-18 1068 344 0.06 0 308 4795 0.24 0 1117 4639
NEDD9  neural precursor cell expressed, developmentally down-regulated 9 (NEDD9), mRNA [NM_006403] 2.24 1.42E-10 692 313 0.45 2.92E-07 350 761
NOV  nephroblastoma overexpressed gene (NOV), mRNA [NM_002514] 8.90 0 9069 1018 9.90 0 8761 886
AvR √ M NRG1  neuregulin 1 (NRG1), transcript variant GGF2, mRNA [NM_013962] 0.30 7.15E-25 418 1435 3.31 4.10E-26 1439 437
NRG1 0.33 4.17E-42 662 2015 8.10 0 2935 364
NRG1 0.14 0 402 2809
PAWR  PRKC, apoptosis, WT1, regulator (PAWR), mRNA [NM_002583] 0.47 5.90E-39 1703 3594 3.20 0 4239 1326
PDGFRB  platelet-derived growth factor receptor, beta polypeptide (PDGFRB), mRNA [NM_002609] 2.06 2.73E-19 38724 18703 2.32 5.85E-18 33903 14521
PLA2G2A  phospholipase A2, group IIA (platelets, synovial fluid) (PLA2G2A), mRNA [NM_000300] 2.67 0 4906 1835 0.08 0 3708 46224 0.13 0 6986 52284
PLK2  polo-like kinase 2 (Drosophila) (PLK2), mRNA [NM_006622] 0.37 1.31E-37 5208 13943
SvR √  M PRG4  proteoglycan 4 (PRG4), mRNA [NM_005807] 18.71 0 4629 246 0.01 0 482 44080 0.12 0 4826 40787
RAB18  RAB18, member RAS oncogene family (RAB18), mRNA [NM_021252] 2.75 1.54E-19 121724 44300
RAB7L1  RAB7, member RAS oncogene family-like 1 (RAB7L1), mRNA [NM_003929] 0.49 9.43E-12 10499 21494 5.34 0 20566 3837 2.81 2.53E-26 11410 3977
RAB31  RAB31, member RAS oncogene family (RAB31), mRNA [NM_006868] 2.02 3.78E-21 9459 4676 2.31 0 3893 1686 5.23 0 8902 1695
2.72 0 4903 1801 3.71 0 7026 1895
REC8L1  REC8-like 1 (yeast) (REC8L1), mRNA [NM_005132] 0.47 4.40E-17 771 1631 5.42 3.17E-13 1900 336 2.98 1.72E-18 765 256
RGS1  regulator of G-protein signalling 1 (RGS1), mRNA [NM_002922] 0.19 0 644 3415 2.39 6.25E-41 3591 1503 0.47 8.97E-20 620 1340
S100A4  S100 calcium binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog) (S 3.09 1.14E-33 29119 9360 2.32 3.91E-11 29080 12255
SDC1  syndecan 1 (SDC1), transcript variant 1, mRNA [NM_001006946] 0.34 3.75E-34 2339 6979 9.81 0 6976 700 4.68 3.17E-24 2507 533
SPARCL1  SPARC-like 1 (mast9, hevin) (SPARCL1), mRNA [NM_004684] 2.46 1.35E-34 153223 62080
SvR √ M, PCR TNC  tenascin C (hexabrachion) (TNC), mRNA [NM_002160] 5.24 0 40057 7601 2.48 0 5955 2403 8.99 0 41901 4677
A<R  M TNFAIP6  tumor necrosis factor, alpha-induced protein 6 (TNFAIP6), mRNA [NM_007115] 2.52 3.04E-25 2109 830 2.78 8.97E-39 2084 749
TNMD  tenomodulin (TNMD), mRNA [NM_022144] 24.00 0 5597 233 0.07 0 156 2131 2.32 2.71E-29 4991 2142
TNXB  tenascin XB (TNXB), transcript variant XB, mRNA [NM_019105] 5.99 0 22076 3653 0.13 0 3271 25201
VAV3  vav 3 oncogene (VAV3), mRNA [NM_006113] 0.39 1.28E-32 802 2046 5.48 0 2197 401 2.21 1.07E-09 649 289
WFDC1  WAP four-disulfide core domain 1 (WFDC1), mRNA [NM_021197] 0.41 4.08E-20 720 1769 2.60 1.04E-13 1764 682
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8) Cytoskeleton
ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
S>R  IHC,ISH,W,MACTA2 actin, alpha 2, smooth muscle, aorta (ACTA2), mRNA [NM_001613] 0.48 0 8420 17567 2.24 0 19617 8719
AvR √ M ACTG2  actin, gamma 2, smooth muscle, enteric (ACTG2), mRNA [NM_001615] 0.06 0 1556 25717 9.96 0 26552 2637 0.47 6.91E-12 840 1821
ACTN2  actinin, alpha 2 (ACTN2), mRNA [NM_001103] 0.06 0 64 1129 16.32 1.67E-42 1217 74
ANK3  ankyrin 3, node of Ranvier (ankyrin G) (ANK3), transcript variant 1, mRNA [NM_020987] 2.71 3.07E-18 1044 380 0.41 4.40E-21 411 1006
APC2  adenomatosis polyposis coli 2 (APC2), mRNA [NM_005883] 0.26 8.35E-13 174 709 7.02 8.65E-19 741 104
3.29 4.20E-45 11283 3425
BDKRB1  bradykinin receptor B1 (BDKRB1), mRNA [NM_000710] 0.35 7.22E-14 214 607 3.94 1.35E-10 591 152
BDKRB2  bradykinin receptor B2 (BDKRB2), mRNA [NM_000623] 0.48 3.83E-32 2138 4493 2.29 0 4322 1888
CGNL1  cingulin-like 1 (CGNL1), mRNA [NM_032866] 2.14 6.80E-30 1888 884 0.23 3.40E-38 970 4222 0.48 2.23E-19 1766 3688
CMIP  c-Maf-inducing protein (CMIP), transcript variant C-mip, mRNA [NM_198390] 0.45 2.80E-45 1052 2363 3.31 3.53E-27 2456 736 4.07 2.43E-41 50177 12410
CMIP 5.61 0 105445 18435
DST  dystonin (DST), transcript variant 1eA, mRNA [NM_015548] 2.03 2.43E-13 1029 502 5.29 6.99E-20 642 123
2.10 1.30E-17 4993 2375 2.91 4.13E-10 1031 338
2.10 3.96E-12 4612 2188
DTNA  dystrobrevin, alpha, mRNA (cDNA clone MGC:12368 IMAGE:3933795), complete cds. [BC005300] 3.10 0.10767 823 230
EML4  echinoderm microtubule associated protein like 4 (EML4), mRNA [NM_019063] 0.32 2.29E-27 2311 7308 2.82 1.66E-23 5363 1867
0.38 0 2501 6619 2.64 0 7006 2651
EPLIN  epithelial protein lost in neoplasm beta (EPLIN), mRNA [NM_016357] 2.13 2.53E-06 13649 6186
FGF18  fibroblast growth factor 18 (FGF18), transcript variant 1, mRNA [NM_003862] 3.05 0.00002 986 348 3.55 4.64E-30 1118 318
FSD1  fibronectin type III and SPRY domain containing 1 (FSD1), mRNA [NM_024333] 0.49 1.24E-27 5712 11598 10.16 0 12113 1185 5.82 0 4401 753
ITGA8  integrin, alpha 8 (ITGA8), mRNA [NM_003638] 3.84 7.06E-41 2259 590 6.47 0 2527 391
ITGA9  integrin, alpha 9 (ITGA9), mRNA [NM_002207] 2.42 3.60E-12 1010 406 3.57 6.80E-13 921 247
KIF13B  kinesin family member 13B (KIF13B), mRNA [NM_015254] 2.40 1.43E-31 12112 5041
KIF5C  mRNA for KIAA0531 protein, partial cds. [AB011103] 3.79 6.90E-20 1458 373 10.77 1.60E-18 1560 136
MGC8685  tubulin, beta polypeptide paralog (RP11-506K6.1), mRNA [NM_178012] 3.03 0 7027 2317 5.97 0 2153 361 12.51 0 7336 587
MYBPC1  myosin binding protein C, slow type (MYBPC1), transcript variant 2, mRNA [NM_206819] 0.41 0.00109 240 673 0.23 4.43E-15 221 988
MYBPH  myosin binding protein H (MYBPH), mRNA [NM_004997] 0.42 2.26E-18 679 1637
MYL1  myosin, light polypeptide 1, alkali; skeletal, fast (MYL1), transcript variant 3f, mRNA [NM_079422] 0.12 1.24E-29 118 1031 4.51 3.12E-19 1018 229
MYLK  myosin, light polypeptide kinase (MYLK), transcript variant 1, mRNA [NM_053025] 0.50 5.35E-43 2955 5636 2.35 1.52E-20 5877 2481
2.03 3.58E-11 24837 12243
MYO10  myosin X (MYO10), mRNA [NM_012334] 0.47 8.67E-42 1068 2284
MYO5A  myosin VA (heavy polypeptide 12, myoxin) (MYO5A), mRNA [NM_000259] 2.21 2.34E-18 3233 1456
MYOC  myocilin, trabecular meshwork inducible glucocorticoid response (MYOC), mRNA [NM_000261] 10.52 0 3158 300 0.02 0 786 49667 0.07 0 3387 51303
NEB  nebulin (NEB), mRNA [NM_004543] 0.21 0 384 1805 3.76 1.01E-34 1731 462
PDGFRB  platelet-derived growth factor receptor, beta polypeptide (PDGFRB), mRNA [NM_002609] 2.06 2.73E-19 38724 18703 2.32 5.85E-18 33903 14521
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PPP1R12B  protein phosphatase 1, regulatory (inhibitor) subunit 12B (PPP1R12B), transcript variant 2, mRNA [NM_0 0.44 9.97E-12 5587 12707
TNNT1  troponin T1, skeletal, slow, mRNA (cDNA clone IMAGE:3531880), partial cds. [BC022086] 0.17 0 318 1876 5.81 5.92E-15 1930 331
TTN  titin (TTN), transcript variant novex-3, mRNA [NM_133379] 0.11 0 633 5824 11.65 0 5738 492
VAV3  vav 3 oncogene (VAV3), mRNA [NM_006113] 0.39 1.28E-32 802 2046 5.48 0 2197 401 2.21 1.07E-09 649 289
9) Complement and coagulation cascades
ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
AKR1C3  aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) (AKR1C3), m 3.06 0 3500 1145 0.24 0 1268 5216
BDKRB1  bradykinin receptor B1 (BDKRB1), mRNA [NM_000710] 0.35 7.22E-14 214 607 3.94 1.35E-10 591 152
BDKRB2  bradykinin receptor B2 (BDKRB2), mRNA [NM_000623] 0.48 3.83E-32 2138 4493 2.29 0 4322 1888
BF  B-factor, properdin (BF), mRNA [NM_001710] 3.08 5.41E-22 1658 528 0.30 5.87E-33 594 1973
C2  complement component 2 (C2), mRNA [NM_000063] 2.46 1.15E-33 16874 6818
CD44  CD44 antigen (homing function and Indian blood group system) (CD44), transcript variant 1, mRNA [NM 2.52 2.66E-37 14277 5645 0.29 1.37E-29 5892 20369
CFH  complement factor H (CFH), transcript variant 1, mRNA [NM_000186] 2.07 0.0007 1015 522 0.30 7.71E-10 563 1957 0.46 3.53E-11 1027 2260
DF  D component of complement (adipsin) (DF), mRNA [NM_001928] 5.98 0 7807 1306 0.03 0 1567 46254 0.18 0 8228 45963
EDN1  endothelin 1 (EDN1), mRNA [NM_001955] 2.10 2.24E-22 1193 568 0.13 0 628 5007 0.26 0 1125 4354
F2RL2  coagulation factor II (thrombin) receptor-like 2 (F2RL2), mRNA [NM_004101] 0.26 0 962 3654 15.96 0 3448 213 5.05 1.89E-20 1023 196
F3  coagulation factor III (thromboplastin, tissue factor) (F3), mRNA [NM_001993] 0.27 3.52E-23 303 1161 0.32 1.49E-09 218 659
FGA  fibrinogen, A alpha polypeptide (FGA), transcript variant alpha-E, mRNA [NM_000508] 0.03 2.51E-15 94 1879
HRH1  histamine receptor H1 (HRH1), mRNA [NM_000861] 2.15 1.62E-12 1587 744
2.08 6.10E-09 3428 1640
PLAT  plasminogen activator, tissue (PLAT), transcript variant 1, mRNA [NM_000930] 0.16 0 2024 12582 2.01 2.33E-08 13121 6523 0.33 6.95E-27 1738 5366
PLAU  plasminogen activator, urokinase (PLAU), mRNA [NM_002658] 2.50 1.11E-30 18274 7260 4.10 0 17120 4155
PLCB2  phospholipase C, beta 2 (PLCB2), mRNA [NM_004573] 2.49 6.98E-39 2585 1038 2.40 0 30170 12586
PTGFR  prostaglandin F receptor (FP) (PTGFR), mRNA [NM_000959] 2.30 3.57E-28 1334 580 0.20 2.80E-45 585 2951
AvR √ M PTGIS  prostaglandin I2 (prostacyclin) synthase (PTGIS), mRNA [NM_000961] 4.84 0 33151 6851 0.40 8.8E-32 5830 14554
AvR √ IHC,N,W PTGS2  prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2), mR 0.25 7.43E-15 150 606 2.83 1.27E-18 713 252
SELE  selectin E (endothelial adhesion molecule 1) (SELE), mRNA [NM_000450] 2.34 9.56E-10 903 397 0.37 1.17E-09 414 1132
SELP  selectin P (granule membrane protein 140kDa, antigen CD62) (SELP), mRNA [NM_003005] 2.34 9.80E-14 910 394 0.47 1.79E-09 353 744
SERPINA5  serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 (SERPIN 4.02 0.04679 659 147 4.73 4.20E-16 3499 728 2.80 9.34E-08 1838 668
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ratio pvalue superfic aggr ratio pvalue aggr ref ratio pvalue superfic ref
ARMC7  armadillo repeat containing 7 (ARMC7), mRNA [NM_024585] 0.45 5.21E-32 5836 13129 5.82 1.97E-35 11705 1990 3.00 1.35E-23 3413 1095
CDO1  cysteine dioxygenase, type I (CDO1), mRNA [NM_001801] 3.49 1.76E-34 1743 502 0.03 0 777 30290 0.07 0 1715 24644
CEBPD  CCAAT/enhancer binding protein (C/EBP), delta (CEBPD), mRNA [NM_005195] 0.40 3.01E-34 7233 18105 0.15 0 18519 125697 0.06 0 9484 148572
CRISP2  cysteine-rich secretory protein 2 (CRISP2), mRNA [NM_003296] 0.42 6.68E-15 5332 12672 15.55 0 14461 936 7.65 1.14E-38 3562 445
CMYA3  cardiomyopathy associated 3, mRNA (cDNA clone IMAGE:4338489), complete cds. [BC022888] 0.11 3.67E-42 195 1687
0.23 4.37E-07 87 408
AvR √ M CRIP1  cysteine-rich protein 1 (intestinal) (CRIP1), mRNA [NM_001311] 4.89 4.94E-17 2471 506 0.31 6.83E-35 488 1556
DMRT2  doublesex and mab-3 related transcription factor 2 (DMRT2), mRNA [NM_006557] 12.29 0 1886 154 8.02 0 1688 211
EBF  early B-cell factor (EBF), mRNA [NM_024007] 2.48 6.72E-07 503 196 0.22 1.13E-22 242 1101 0.44 3.40E-17 545 1217
FCN2  ficolin (collagen/fibrinogen domain containing lectin) 2 (hucolin) (FCN2), transcript variant SV0, mRNA [N 0.48 7.24E-10 504 1064 5.26 5.00E-12 1144 222 3.48 3.79E-08 651 202
G1P2  interferon, alpha-inducible protein (clone IFI-15K) (G1P2), mRNA [NM_005101] 0.46 2.17E-23 59237 128260 11.97 0 129497 10868 7.08 0 55435 7835
GPNMB  glycoprotein (transmembrane) nmb (GPNMB), transcript variant 1, mRNA [NM_001005340] 2.06 6.44E-12 16496 7956 2.67 1.13E-23 15867 5948
GPR32  G protein-coupled receptor 32 (GPR32), mRNA [NM_001506] 0.42 3.87E-26 25679 61517 8.36 0 61762 7388 3.68 0 22196 6022
GPR44  G protein-coupled receptor 44 (GPR44), mRNA [NM_004778] 0.38 9.49E-14 438 1184 4.52 1.09E-12 1207 273 2.69 6.88E-07 669 267
HEXA HEXA {HEXA4bpDeltaA mutation, exon 11} [human, Tay-Sachs disease patient, mRNA Partial Mutant, 7 0.46 3.92E-13 22564 49195 11.62 0 48620 4175 6.04 0 19539 3225
3.51 0 3599 1025
HMGN4  high mobility group nucleosomal binding domain 4 (HMGN4), mRNA [NM_006353] 0.49 0 40423 83263 7.68 0 75900 10029 4.67 0 32987 7089
HOMER1  homer homolog 1 (Drosophila) (HOMER1), mRNA [NM_004272] 0.43 1.95E-25 630 1461 8.18 1.18E-40 1471 178 3.75 5.80E-10 555 142
IGHG3 Human Ig gamma3 heavy chain disease OMM protein mRNA. [J00231] 0.42 1.19E-35 1026 2435 4.11 0 2541 619
ITM2B  integral membrane protein 2B (ITM2B), mRNA [NM_021999] 2.07 1.55E-38 29225 14116
KCNMB1  potassium large conductance calcium-activated channel, subfamily M, beta member 1 (KCNMB1), mRN 0.38 0 1256 3292 2.82 3.14E-38 3270 1156
LRRN1  leucine rich repeat neuronal 1 (LRRN1), mRNA [NM_020873] 0.36 0 3754 10566 26.52 3.92E-44 8611 313 12.28 0 3647 297
NFIB  nuclear factor I/B (NFIB), mRNA [NM_005596] 2.13 1.33E-07 1123 544 0.41 6.77E-11 568 1391
NFIX  nuclear factor I/X (CCAAT-binding transcription factor) (NFIX), mRNA [NM_002501] 2.84 2.18E-26 11767 4098
NR2F1  nuclear receptor subfamily 2, group F, member 1 (NR2F1), mRNA [NM_005654] 0.15 0 479 3120 8.84 0 3649 413
NR4A1  nuclear receptor subfamily 4, group A, member 1 (NR4A1), transcript variant 1, mRNA [NM_002135] 0.22 0 5225 23757 0.20 0 5256 26534
NR4A2  nuclear receptor subfamily 4, group A, member 2 (NR4A2), transcript variant 1, mRNA [NM_006186] 0.30 0 810 2678
NUMA1  nuclear mitotic apparatus protein 1 (NUMA1), mRNA [NM_006185] 2.04 3.99E-13 2485 1223 0.34 4.87E-32 1279 3755
PTPNS1  protein tyrosine phosphatase, non-receptor type substrate 1 (PTPNS1), mRNA [NM_080792] 2.04 5.20E-09 2889 1413 0.33 1.68E-22 1479 4567
RAB11FIP1  RAB11 family interacting protein 1 (class I) (RAB11FIP1), transcript variant 2, mRNA [NM_001002233] 0.40 3.79E-31 1872 4650 9.03 0 4919 545 3.62 1.63E-11 1316 341
RARB Human retinoic acid receptor-beta associated open reading frame, complete sequence. [M62303] 0.13 1.82E-08 50 451
REC8L1  REC8-like 1 (yeast) (REC8L1), mRNA [NM_005132] 0.47 4.40E-17 771 1631 5.42 3.17E-13 1900 336 2.98 1.72E-18 765 256
RPA4  replication protein A4, 34kDa (RPA4), mRNA [NM_013347] 2.21 5.62E-19 1322 593 0.33 5.08E-40 817 2457
TADA3L  transcriptional adaptor 3 (NGG1 homolog, yeast)-like (TADA3L), transcript variant 1, mRNA [NM_006354 0.48 9.81E-44 3412 7108 6.12 2.35E-39 7142 1152 3.31 3.12E-30 2703 806
S<R  M TFPI2  tissue factor pathway inhibitor 2 (TFPI2), mRNA [NM_006528] 0.39 9.07E-17 362 935 2.02 1.14E-16 1000 494
TPST1  tyrosylprotein sulfotransferase 1 (TPST1), mRNA [NM_003596] 0.47 2.95E-38 3601 7677 3.21 2.14E-22 8549 2620
superficial / aggressive aggressive / reference superficial / reference
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TREM1  triggering receptor expressed on myeloid cells 1 (TREM1), mRNA [NM_018643] 2.36 5.49E-15 874 375 0.45 6.05E-09 321 710
TSPAN2  tetraspanin 2 (TSPAN2), mRNA [NM_005725] 2.31 6.48E-12 1139 503 4.40 2.54E-36 1049 240
UBOX5  U-box domain containing 5 (UBOX5), transcript variant 1, mRNA [NM_014948] 0.41 9.01E-12 241337 588394 0.31 1.03E-16 241909 791541 0.34 6.18E-15 281568 826316
ZNF365  mRNA for zinc finger protein (ZNF365A gene). [AJ505147] 4.16 1.68E-16 651 160
superficial / aggressive aggressive / reference superficial / reference
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Gene list C: Gene expression studies published in the literature that could be confirmed by our own data
in Gene lists A or B 
Experiment description Statement
ACTG2 Actin, gamma 2, smooth muscle, enteric Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super < Ref, Super < Aggr
ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha)
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) Shih et al.,  2009 Super tissue samples and cell cultures: Super > control (RT-PCR) Super > Ref Aggr > Ref, Super > Ref
AHR Aryl hydrocarbon receptor Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super < Aggr
AKR1C1 Aldo-keto reductase family 1, member C1 Pan et al.,  2003 Super frozen tissues: 6 Super palmar fascia vs 2 Ref (normal palmar fascia): Super < Ref (Atlas 
microarray) Super < Ref
Aggr < Ref, Super < Ref, 
Super > Aggr
ALDH2 Aldehyde dehydrogenase 2 family (mitochondrial) Pan et al.,  2003 Super
frozen tissues: 6 Super palmar fascia vs 2 Ref (normal palmar fascia): Super < Ref (Atlas 
microarray) Super < Ref Aggr < Ref, Super < Ref
ANGPTL2 Angiopoietin-like 2 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref
Aggr > Ref, Super > Ref, 
Super > Aggr
APP Amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease) 
Pan et al.,  2003; 
Qian et al ., 2004 Super
Pan et al. , 2003: frozen tissues: 6 Super palmar fascia vs 2 Ref (normal palmar fascia): Super > 
Ref (Atlas microarray)  Qian et al ., 2004: frozent tissues: 9 Super palmar fasica vs adjacent 
normal tendon: Super > Ref (Atlas microarray) 
Super > Ref Aggr > Ref, Super > Ref
ARL4C ADP-ribosylation factor-like 4C (ARL7) Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
ASPN Asporin (LRR class 1) Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref
Aggr > Ref, Super > Ref, 
Super > Aggr
BMP1 Bone morphogenetic protein 1 Shin et al.,  2004 Super cell culture: nodule and cord Super fibroblasts vs normal palmar fascia fibroblasts: Super = Ref (RT-PCR) Super = Ref Aggr > Ref
BMP10 Bone morphogenetic protein 10 Shin et al.,  2004 Super cell culture: nodule and cord Super fibroblasts vs normal palmar fascia fibroblasts: Super = Ref (no expression) (RT-PCR) Super = Ref not differentially expressed
BMP2 Bone morphogenetic protein 2 Shin et al.,  2004 Super cell culture: nodule and cord Super fibroblasts vs normal palmar fascia fibroblasts: Super = Ref (no expression) (RT-PCR) Super = Ref not differentially expressed
BMP3 Bone morphogenetic protein 3 Shin et al.,  2004 Super cell culture: nodule and cord Super fibroblasts vs normal palmar fascia fibroblasts: Super = Ref (no expression) (RT-PCR) Super = Ref not differentially expressed
BMP5 Bone morphogenetic protein 5 Shin et al.,  2004 Super cell culture: nodule and cord Super fibroblasts vs normal palmar fascia fibroblasts: Super = Ref (no expression) (RT-PCR) Super = Ref not differentially expressed
C1QTNF3 C1q and tumor necrosis factor related protein 3
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
CACNA2D3 Calcium channel, voltage-dependent, 
alpha 2/delta 3 subunit 
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super < Aggr
Own resultsPaperGene Paper Literature
Appendix Gene list C
Experiment description Statement
CALB2 Calbindin 2, 29kDa (calretinin) Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super < Aggr
CCND1 Cyclin D1 Saito et al. , 2002; Saito et al. , 2001 Aggr
Saito et al ., 2002: frozen samples (12 Aggrs) Aggr > skeletal muscle (real time RT-PCR), 3 Aggrs 
with beta-catenin mutated > unmutated (real time RT-PCR)  Saito et al. , 2001: paraffin blocks (38 
Aggrs) Association between nuclear beta-cat and CCND1 expr. (IHC)
Aggr > Ref Aggr > Ref, Super > Ref
CCND2 Cyclin D2 Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
CHN1 Chimerin (chimaerin) 1 (GTPase-
activating protein, rho, 2, RHOGAP2) Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fascia: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref
CLEC11A C-type lectin domain family 11, member A Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref
CLEC2B C-type lectin domain family 2, member B (CLECSF2) Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super < Aggr
CLEC3B
C-type lectin domain family 3, member B 
(tetranectin TNA (plasminogen binding 
protein)) 
Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Aggr < Ref, Super > Aggr
CNN1 Calponin 1, basic, smooth muscle Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super < Aggr
COL1 Collagen, type I Zamora et al. , 1994; Kopp et al. , 2006 Super
Zamora et al ., 1994: paraffin blocks: 36 nodular Super vs 24 cord Super: nodular > cord (IHC)  
Kopp et al ., 2006: cell culture: cord Super fibroblasts vs. control tissue fibroblasts: Super > Ref 
(Western) 
Super > Ref Aggr > Ref, Super > Ref
COL11A1 Collagen, type XI, alpha 1 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref
Aggr > Ref, Super > Ref, 
Super < Aggr
COL12A1 Collagen, type XII, alpha 1 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref
COL14A1 Collagen, type XIV, alpha 1 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
COL1A1 Collagen, type I, alpha 1
Naito et al ., 1998; 
Skubitz and Skubitz, 
2004 
Aggr
Naito et al ., 1998: cell culture: 6 Aggrs vs. human skin fibroblasts (HSF): Aggr = HSF (real time 
RT-PCR)  Skubitz and Skubitz, 2004:  frozen samples (12 Aggrs): Aggr > 16 non-neoplastic 
tissues (Affymetrix array)
Aggr > Ref Aggr > Ref, Super > Ref
COL2A Collagen, type II, alpha Qian et al ., 2004 Super frozent tissues: 9 Super palmar fasica vs adjacent normal tendon: Super > Ref (Atlas microarray) Super > Ref Super > Ref
COL3 Collagen, type III Howard et al ., 2003 Super old reference: cord Super > normal palmar fascia Super > Ref Aggr > Ref, Super > Ref, Super < Aggr (COL3A1)
COL3A1 Collagen, type III, alpha 1
Naito et al ., 1998; 
Skubitz and Skubitz, 
2004 
Aggr
Naito et al ., 1998: cell culture: 6 Aggrs vs. human skin fibroblasts (HSF): Aggr > HSF (real time 
RT-PCR)  Skubitz and Skubitz, 2004:  frozen samples (12 Aggrs): Aggr > 16 non-neoplastic 
tissues (Affymetrix array)
Aggr > Ref Aggr > Ref, Super > Ref, Super < Aggr
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COL4 Collagen, type IV
Berndt et al ., 1994; 
Kosmehl et al. , 1995; 
Magro et al. , 1997
Super
Berndt et al ., 1994: 13 nodular palmar Super: expression restricted to active proliferating nodules 
(ACTA2+) compared to nearby palmar aponeurosis (IHC)  Kosmehl et al ., 1995: nodular palmar 
Super (? cases): proliferative noduli > surrounding aponeurosis (IHC)  Magro et al ., 1997: 24 
nodular palmar Super: expression restricted to proliferative phase compared to involutional and 
residual phase (IHC)
Super > Ref Aggr > Ref, Super > Ref (COL4A1)
COL5A1 Collagen, type V, alpha 1 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref
Aggr > Ref, Super > Ref, 
Super < Aggr
COL5A2 Collagen, type V, alpha 2 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
COL5A2 Collagen, type V, alpha 2 Lee et al. , 2006; Zhang et al ., 2008 Super
Lee et al ., 2006: frozen tissues: cord Super (4) vs. Super-adjacent control fascia (4) vs. normal 
palmar fascia (3): Super > Ref (cDNA Array); Zhang et al ., 2008: Dupuytren's diseased cord 
tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray)
Super > Ref Aggr > Ref, Super > Ref
COL6 Collagen, type VI Thurston, 2003; Magro et al. , 1995 Super
Magro et al ., 1995: 26 palmar/plantar Super: proliferative phase > involutional, residual phase 
and normal aponeurosis (IHC) Super > Ref
Aggr > Ref, Super > Ref 
(COL6A1,2,3)
COL6A1 Collagen, type VI, alpha 1
Skubitz and Skubitz, 
2004; Denys et al ., 
2004b 
Aggr
Skubitz and Skubitz, 2004: frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues 
(Affymetrix array)  Denys et al ., 2004b : cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix 
array)
Aggr > Ref Aggr > Ref, Super > Ref
COL6A2 Collagen, type VI, alpha 2
Skubitz and Skubitz, 
2004; Denys et al ., 
2004b 
Aggr
Skubitz and Skubitz, 2004: frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues 
(Affymetrix array) Denys et al., 2004b: cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix 
array)
Aggr > Ref Aggr > Ref, Super > Ref
COL6A3 Collagen, type VI, alpha 3 Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
COL6A3 Collagen, type VI, alpha 3 Kraljevic Pavelic et 
al ., 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref Aggr > Ref, Super > Ref
COL8A1 Collagen, type VIII, alpha 1 Lee et al. , 2006; Zhang et al ., 2008 Super
Lee et al. , 2006: frozen tissues: cord Super (4) vs. Super-adjacent control fascia (4) vs. normal 
palmar fascia (3): Super > Ref (cDNA Array); Zhang et al ., 2008: Dupuytren's diseased cord 
tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray)
Super > Ref Aggr > Ref, Super > Ref 
CRIP1 Cysteine-rich protein 1 (intestinal) Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Aggr < Ref, Super > Aggr
CRLF1 Cytokine receptor-like factor 1 Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Aggr < Ref, Super < Ref
CSRP2 Cysteine and glycine-rich protein 2 Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
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CTNNB1 Catenin (cadherin-associated protein), beta 1, 88kDa 
Tejpar et al ., 1999; 
Saito et al ., 2002; 
Montgomery et al ., 
2001; Carlson et al ., 
2007; Alman et al. , 
1997b; Ferenc et al ., 
2009
Aggr
Tejpar et al ., 1999: paraffin blocks (42 Aggrs) Aggr (cytopl, nuc) > normal marginal facial tissue 
(IHC)  Saito et al ., 2002: frozen samples (12 Aggrs) Aggr > skeletal muscle (real time RT-PCR), 3 
Aggrs with beta-catenin mutated > unmutated (real time RT-PCR), frozen samples (12 Aggrs): 
nucl. accumulation in all samples (IHC) Montgomery et al. , 2001: paraffin blocks 5 Aggrs: nuclear 
staining in all five cases tested (IHC)  Carlson et al. , 2007: paraffin blocks: nuclear accumulation 
Aggr > several other spindle cell lesions (IHC) Alman et al ., 1997b: six cases of sporadic 
aggressive fibromatosis: higher level of β-catenin protein than surrounding normal tissue  Ferenc 
et al. , 2009: 35 cases of aggressive fibromatoses: nuclear and cytoplasmic β-catenin staining
Aggr > Ref Aggr > Ref
CTSK Cathepsin K (pycnodysostosis) Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
CYB5 Cytochrome b-5 Pan et al., 2003 Super frozen tissues: 6 Super palmar fascia vs 2 Ref (normal palmar fascia): Super < Ref (Atlas 
microarray) Super < Ref Super < Ref
DCN Decorin (bone proteoglycan II; dermatan 
sulphate proteoglycans II)
Kozma et al ., 2005, 
Qian et al ., 2004 Super
Kozma et al ., 2005: frozen tissues: 15 Super fascia vs 14 normal palmar fasica: DS chain 
molecular mass increase, iduronate disaccarid clusters increase, oversulfatation  Qian et al ., 
2004: frozent tissues: 9 Super palmar fasica vs adjacent normal tendon: Super < Ref (Atlas 
microarray)
Super < Ref Aggr < Ref, Super < Ref
EFEMP1 EGF-containing fibulin-like extracellular 
matrix protein 1 Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Aggr < Ref, Super > Aggr
EGFL3 EGF-like-domain, multiple 3 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
ELN Elastin Naito et al., 1998 Aggr cell culture: 6 Aggrs vs. human skin fibroblasts (HSF): Aggr > HSF (real time RT-PCR) Aggr > Ref Aggr > Ref, Super > Ref
EPHB3 Ephrin receptor EphB3 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
FAP Fibroblast activation protein, alpha Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
FAP Fibroblast activation protein, alpha Zhang et al., 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref Aggr > Ref, Super > Ref
FN Fibronectin
Zamora et al ., 1994; 
Tomasek et al ., 1986; 
Halliday et al ., 1994; 
Magro et al. , 1995b, 
Kosmehl et al ., 1995; 
Berndt et al ., 1995, 
Magro et al. , 1997; 
Howard et al ., 2004; 
Lee et al. , 2006
Super
Zamora et al ., 1994: paraffin blocks: 36 nodular superfic vs 24 cord superfic: nodular  > cord 
(IHC)   Tomasek et al ., 1986: nodular palmar superfic (? cases) vs normal palmar fascia 
fibroblasts: Superfic > Ref (IHC) Halliday et al., 1994: Superfic (? cases) vs normal palmar fascia: 
proliferative, involutional phase: A-FN > B-FN; residual phase: weakly A-FN, not B-FN; normal 
fascia: A-FN, B-FN not present; thus: Superfic > Ref (IHC)  Magro et al ., 1995b: 23 Superfic: 
proliferative, involutional phase > residual phase (IHC)  Kosmehl et al ., 1995: nodular palmar 
superfic (? cases): proliferative noduli > surrounding aponeurosis (IHC, ISH)  Berndt et al ., 1995:  
nodular palmar superfic (? cases): proliferative noduli > surrounding aponeurosis (ISH, IHC)  
Magro et al ., 1997: 24 nodular palmar superfic: expression restricted to proliferative phase 
compared to involutional and residual phase (IHC)  Howard et al. , 2004: palmar superfic (? 
cases) tissue and cell culture vs adjacent normal palmar fascia: Superfic > Ref (IHC, western)  
Lee et al. , 2006: frozen tissues: cord superfic (4) vs. superfic-adjacent control fascia (4) vs. normal
Super > Ref Aggr > Ref, Super > Ref
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HMCN1 Hemicentin 1 (fibulin 6 FIBL-6) Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
HOXB2 Homeo box B2 Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
IGFBP6 Insulin-like growth factor binding protein 6 Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array, Northern, Western) Aggr < Ref Aggr < Ref, Super < Ref, Super > Aggr
IGSF4 Immunoglobulin superfamily, member 4 Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref, Super > Aggr
ITGB1
Integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes 
MDF2, MSK12)
Magro et al. , 1995b, 
Magro et al. , 1997; 
Lee et al ., 2006
Super
Magro et al ., 1995b: 23 Superfic: proliferative, involutional phase > residual phase (A5B1) (IHC)  
Magro et al ., 1997: 24 nodular palmar superfic: expression restricted to proliferative phase 
compared to involutional and residual phase (A5B1) (IHC)  Lee et al ., 2006: frozen tissues: cord 
superfic (4) vs. superfic-adjacent control fascia (4) vs. normal palmar fascia (3): Superfic > Ref 
(cDNA Array)
Super > Ref Aggr > Ref, Super > Ref
LAMB1 Laminin, beta 1 Kosmehl et al ., 1995 Super nodular palmar superfic (? cases): proliferative noduli > surrounding aponeurosis (IHC)  Super > Ref Aggr > Ref, Super > Ref
LGALS1 Galectin-1 Kraljevic Pavelic et 
al., 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref Aggr > Ref, Super > Ref
LIPE Lipase, hormone-sensitive Pan et al., 2003 Super frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref Aggr < Ref, Super < Ref
LRRC17 Leucine rich repeat containing 17 (LRRC17), mRNA [NM_005824]
Lee et al., 2006; 
Zhang et al., 2008 Super
Lee et al ., 2006: frozen tissues: cord superfic (4) vs. superfic-adjacent control fascia (4) vs. 
normal palmar fascia (3): Superfic > Ref (cDNA Array); Zhang et al ., 2008: Dupuytren's diseased 
cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray)
Super > Ref Aggr > Ref, Super > Ref
MAFB
v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog B (avian) (MAFB), 
mRNA [NM_005461]
Lee et al., 2006; 
Zhang et al., 2008 Super
70: frozen tissues: cord superfic (4) vs. superfic-adjacent control fascia (4) vs. normal palmar 
fascia (3): Superfic > Ref (cDNA Array); 74: Dupuytren's diseased cord tissue vs. normal 
transverse ligament of palmar fascia: Super > Ref (cDNA microarray)
Super > Ref Aggr > Ref, Super > Ref
MDK Midkine (neurite growth-promoting factor 2) Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref
Aggr > Ref, Super > Ref, 
Super < Aggr
MMP1 Matrix metalloproteinase 1 Denys et al ., 2004a Aggr cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr > Ref (real time RT-PCR) Aggr > Ref Aggr > Ref, Super < Aggr
MMP11 Matrix metalloproteinase 11 Denys et al ., 2004a; Kong et al. , 2004 Aggr
Denys et al. , 2004a: cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr > Ref (real time RT-PCR)  
Kong et al ., 2004: cell culture: 9 Aggrs from APC-KO-mice vs. 9 normal fascia from WT-mice: 
Aggr = Ref  (real time RT-PCR)
Aggr > Ref Aggr > Ref, Super > Ref, Super < Aggr
MMP14 Matrix metalloproteinase 14 Denys et al ., 2004a; Kong et al. , 2004 Aggr
Denys et al ., 2004a: cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr = Ref (real time RT-PCR)  
Kong et al. , 2004: cell culture: 9 Aggrs from APC-KO-mice vs. 9 normal fascia from WT-mice: 
Aggr = Ref  (real time RT-PCR)
Aggr = Ref Super > Ref
MMP14 Matrix metalloproteinase 14 Johnston et al ., 2007 Super frozen tissues: nodule superfic (? samples) vs normal palmar fascia (?): Superfic > Ref (realtime RT-PCR) Super > Ref Super > Ref
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MMP2 Matrix metalloproteinase 2 Ulrich et al. , 2003; Qian et al.,  2004 Super
Ulrich et al. , 2003: Sera and tissue samples of 22 superfic vs sera and palmar fascia of 20 
healthy controls: Superfic = Ref (ELISA for sera, IHC for tissue samples)  Qian et al ., 2004 : 
frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray)
Super > Ref Aggr > Ref, Super > Ref
MMP9 Matrix metalloproteinase 9 Denys et al ., 2004a; Kong et al. , 2004 Aggr
Denys et al. , 2004a: cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr = Ref (real time RT-PCR)  
Kong et al.,  2004: cell culture: 9 Aggrs from APC-KO-mice vs. 9 normal fascia from WT-mice: 
Aggr = Ref  (real time RT-PCR)
Aggr = Ref not differentially expressed
MMP9 Matrix metalloproteinase 9 Ulrich et al ., 2003 Super Sera and tissue samples of 22 superfic vs sera and palmar fascia of 20 healthy controls: Superfic 
= Ref (ELISA for sera, IHC for tissue samples) Super = Ref not differentially expressed
NEFH Neurofilament, heavy polypeptide 200kDa Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
NPTX2 Neuronal pentraxin II Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
NRG1 Neuregulin 1
Skubitz and Skubitz, 
2004; Denys et al. , 
2004b 
Aggr
Skubitz and Skubitz, 2004:  frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues 
(Affymetrix array)  Denys et al. , 2004b : cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix 
array)
Aggr > Ref Aggr > Ref, Super < Aggr
POSTN periostin, osteoblast specific factor 2 (OSF2)
Qian et al ., 2004,  Vi 
et al. , 2009; Shih et 
al. , 2009
Super
Qian et al. , 2004: frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > 
Ref (Atlas microarray)  Vi et al ., 2009: IHC: diseased cord > normal palmar fascia   Shih et al. , 
2009: tissue samples and cell cultures: Super > control (RT-PCR)
Super > Ref Aggr > Ref, Super > Ref
PRG4 Proteoglycan 4 Satish et al. , 2008 Super cell cultures superficial fibromatosis vs. normal fibroblasts (2 microarray platforms) Super < Ref Aggr < Ref, Super < Ref, Super > Aggr
PRSS11
HtrA serine peptidase 1 (HTRA1); IGFBP5-
protease; protease, serine, 11 (IGF 
binding) 
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
PTGIS Prostaglandin I2 (prostacyclin) synthase Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Aggr < Ref, Super > Ref, Super > Aggr
PTGS2 Prostaglandin-endoperoxide synthase 2 = 
cyclooxygenase 2b (COX-2)
Poon et al ., 2001; 
Sharma et al ., 2003 Aggr
Poon et al ., 2001: frozen samples (6 Aggrs): Aggr > Fasica (Northern, Western)  Sharma et al. , 
2003: case report: Aggr < adjoining tissue (IHC) Aggr > Ref Aggr > Ref, Super < Aggr
PTN
Pleiotrophin (OSF1, heparin binding 
growth factor 8, neurite growth-promoting 
factor 1)
Qian et al. , 2004 Super frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray) Super > Ref Aggr > Ref, Super > Ref
PTX3 Pentraxin-related gene, rapidly induced by IL-1 beta (TNFAIP5) Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Aggr < Ref, Super < Ref
RAB31 Member 31 RAS oncogene family Zhang et al., 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref Aggr > Ref, Super > Ref
SALL4 Sal-like 4 (Drosophila) Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
SC65 Synaptonemal complex protein SC65 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref
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SERPINE1
serpin peptidase inhibitor, clade E, 
member 1 (plasminogen activator inhibitor 
type 1, PAI-1)
Kopp et al. , 2006 Super cell culture: cord superfic fibroblasts vs. control tissue fibroblasts: Superfic = Ref (Western) Super = Ref not differentially expressed
SERPINH1
serpin peptidase inhibitor, clade H (heat 
shock protein 47), member 1, (collagen 
binding protein 1)
Howard et al ., 2004; 
Lee et al. , 2006 Super
Howard et al. , 2004: palmar superfic (? cases) tissue and cell culture vs adjacent normal palmar 
fascia: Superfic > Ref (western)  Lee et al. , 2006: frozen tissues: cord superfic (4) vs. superfic-
adjacent control fascia (4) vs. normal palmar fascia (3): Superfic > Ref (cDNA Array)
Super > Ref Aggr > Ref, Super > Ref
SPARC secreted protein, acidic, cysteine-rich (osteonectin) Zhang et al., 2008 Super
Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref 
(cDNA microarray) Super > Ref Aggr > Ref, Super > Ref
SPON2 Spondin 2, extracellular matrix protein Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref
Aggr > Ref, Super > Ref, 
Super > Aggr
TCF7 T cell specific transcription factor 7 (TCF1) Tejpar et al ., 2001 Aggr frozen samples (10 Aggrs): Aggr = Ref (10 Fascia same patients) (not expressed !) (RT-PCR) Aggr = Ref not differentially expressed
TCF7L1 T cell specific transcription factor 7-like 1 (TCF3) Tejpar et al ., 2001 Aggr frozen samples (10 Aggrs): Aggr = Ref (10 Fascia same patients) (all 10 expressed it !) (RT-PCR) Aggr = Ref not differentially expressed
TCF7L2 T cell specific transcription factor 7-like 2 (TCF4) Tejpar et al ., 2001 Aggr frozen samples (10 Aggrs): Aggr (3/10) > Ref (10 Fascia same patients) (0/10) (RT-PCR) Aggr = Ref Super < Ref, Super < Aggr
TGFB2 Transforming growth factor beta 2
Badalamente et al. , 
1996; Kuhn et al. , 
2001;  Kuhn et al., 
2002; Berndt et al. , 
1995; Lee et al. , 
2006; Zhang et al. , 
2008
Super
Badalamente et al. , 1996: Superfic (? cases): high intracellular expression in myofibroblasts in the 
proliferative and involutional stages. Fibroblasts in the residual stage did not contain TGFB2.  It is 
not present in the ECM (IHC). Cell cultures with superfic myofibroblasts: addition of TGFB2: 
proliferation increases, but TGFB2 > TGFB1.  Kuhn et al. , 2001: human superfic explants and 
transfered in rat. In rat: addition of TGFB2: increase of COL1 and COL3. Cell cultures: treatemtent 
with TGFB2: increase of DNA synthesis, protein production and fibroblast kinetics.   Kuhn et al. , 
2002: cell cultures: superfic vs normal carpal tunnel affected fascia: Superfic > Ref (ELISA)  
Berndt et al. , 1995: nodular palmar superfic (? cases): expression exclusively in proliferative 
noduli, not in surrounding aponeurosis (IHC)  Lee et al.,  2006: frozen tissues: cord superfic (4) vs. 
superfic-adjacent control fascia (4) vs. normal palmar fascia (3): Superfic > Ref (cDNA Array)  
Zhang et al. , 2008: cord superfic  vs. superfic-adjacent control fascia (cDNA Array)
Super > Ref Super > Ref
TGFB3 Transforming growth factor beta 3 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
TGFB3 Transforming growth factor beta 3 Berndt et al ., 1995; Zhang et al. , 2008 Super
Berndt et al. , 1995: nodular palmar superfic (? cases): proliferative noduli > surrounding 
aponeurosis (IHC)  Zhang et al ., 2008: cord superfic  vs. superfic-adjacent control fascia (cDNA 
Array): not differentially expressed !
Super > Ref Aggr > Ref, Super > Ref
TGFBI Transforming growth factor, beta-induced, 68kDa 
Kraljevic Pavelic et 
al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref Aggr > Ref, Super > Ref
THBS2 Thrombospondin 2 Zhang et al. , 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref Aggr > Ref, Super > Ref
TIMP2 Metallopeptidase inhibitor 2 (tissue inhibitor of metalloproteinase 2) Ulrich et al. , 2003 Super
37: Sera and tissue samples of 22 superfic vs sera and palmar fascia of 20 healthy controls: 
Superfic > Ref (IHC for tissue samples)  Super > Ref Aggr > Ref, Super > Ref
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TIMP3 Metallopeptidase inhibitor 3 (tissue inhibitor of metalloproteinase 3) Denys et al., 2004a Aggr cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr < Ref (real time RT-PCR) Aggr < Ref Aggr < Ref
TMSB4X Thymosin, beta 4, X-linked Qian et al. , 2004 Super frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray) Super > Ref Super > Ref
TNC Tenascin C Lee et al. , 2006; Shih 
et al. , 2009 Super
Lee et al. , 2006: frozen tissues: cord superfic (4) vs. superfic-adjacent control fascia (4) vs. 
normal palmar fascia (3): Superfic > Ref (cDNA Array)   Shih et al ., 2009: tissue samples and cell 
cultures: Super > control (RT-PCR)
Super > Ref Aggr > Ref, Super > Ref, Super > Aggr
TNFRSF11B
Tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin OPG) 
Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Aggr < Ref, Super < Ref
TNFSF4 Tumor necrosis factor (ligand) 
superfamily, member 4 (CD134 ligand)
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
TP53 Tumor protein p53 (Li-Fraumeni 
syndrome)
Muller et al. , 1996; 
Sharma et al.,  2003 Aggr
Muller et al ., 1996: frozen samples: 13 Aggrs vs. 6 Superfic: Aggr = Superfic (RT-PCR, IHC)  
Sharma et al. , 2003: case report: Aggr = adjoining tissue (IHC) Aggr = Super Aggr < Ref, Super < Ref
TPI1 Triosephosphate isomerase Kraljevic Pavelic et 
al. , 2009 Superic frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref Aggr > Ref, Super > Ref
TRO Trophinin Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
VSNL1 Visinin-like 1 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
WISP1 WNT1 inducible signaling pathway protein 1
Skubitz and Skubitz, 
2004 Aggr 74:  frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr > Ref, Super > Ref
WNT5A Wingless-type MMTV integration site family, member 5A Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref
Aggr > Ref, Super > Ref, 
Super < Aggr
WT1 Wilms tumor 1 Nik et al. , 2005 Aggr cell culture: 5 Aggrs vs 5 Fascia: Aggr > Ref (real-time RT-PCR, northern, western, IHC) Aggr > Ref Aggr > Ref
ZIC1 Zic family member 1 (odd-paired homolog, Drosophila) Denys et al.,  2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Aggr > Ref, Super < Aggr
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ACP5 acid phosphatase 5, tartrate resistant (TRAP) Pan et al. , 2003 Super
frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
ACTA2 Actin, alpha 2, smooth muscle, aorta 
Bisson et al ., 2003; 
Kopp et al.,  2006; 
Pagnotta et al ., 2003; 
Lubahn et al. , 2007; 
Tomasek et al. , 1995; 
Berndt et al. , 1995; Lee 
et al.,  2006    
Super
Bisson et al. , 2003: cell culture: nodule and cord superfic fibroblasts vs flexor retinaculum 
fibroblasts: Superfic > Ref (IHC) Kopp et al ., 2006: cell culture: cord superfic fibroblasts vs. 
control tissue fibroblasts: Superfic > Ref (Western)   Pagnotta et al. , 2003: cell culture: nodule 
superfic fibroblasts (10 patients) vs normal palmar fasica fibroblasts (4) : Superfic > Ref (IHC)  
Lubahn et al. , 2007: frozen tissues: superfic (25 samples) vs control tissue (5 samples): Superfic 
> Ref (IHC)  Tomasek et al ., 1995: cell culture: nodule superfic fibroblasts (11 patients) vs normal 
palmar fascia fibroblasts: Superfic > Ref (IHC)   Berndt et al ., 1995: frozen tissues: Active 
proliferative palmar noduli superfic vs. surrounding aponeurotic tissues: Superfic > Ref (ISH)   Lee 
et al. , 2006 : frozen tissues: cord superfic (4) vs. superfic-adjacent control fascia (4) vs. normal 
palmar fascia (3): Superfic > Ref (cDNA Array)
Super > Ref Aggr > Ref, Super < Aggr
ACTG1 Actin, cytoplasmic 2 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
ADAMTS14 ADAM metallopeptidase with thrombospondin type 1 motif, 14 Johnston et al ., 2007 Super
frozen tissues: nodule superfic (? samples) vs normal palmar fascia (?): Superfic > Ref (realtime 
RT-PCR) Super > Ref not differentially expressed
AKT v-akt murine thyoma viral oncogene homolog
Kraljevic Pavelic et al. , 
2009 Super frozen tissues: 12 cases disease vs. control (Western) Super > Ref not differentially expressed
ALCAM Activated leukocyte cell adhesion 
molecule Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
ALDH1A3 Aldehyde dehydrogenase 1 family, 
member A3 (ALDH6) Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Super > Aggr
ALDH5A1
Aldehyde dehydrogenase 5 family, 
member A1 (succinate-semialdehyde 
dehydrogenase)
Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
ARCN1 Archain 1 (archain vesicle transport protein 1; coatomer delta subunit) Pan et al. , 2003 Super
frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic > Ref (Atlas 
microarray) Super > Ref not differentially expressed
ARHGDIA Rho GDP dissociation inhibitor (GDI) 
alpha 
Qian et al. , 2004; 
Kraljevic Pavelic et al. , 
2009
Super
Qian et al ., 2004: frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > 
Ref (Atlas microarray)   Kraljevic Pavelic et al. , 2009: frozen tissues: 12 cases disease vs. control 
(2D-gelelectrophoresis, MS)
Super > Ref not differentially expressed
ARL4C ADP-ribosylation factor like 4C Zhang et al ., 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref not differentially expressed
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ATF5 Activating transcription factor 5 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
ATP7B ATPase, Cu++ transporting, beta polypeptide Qian et al. , 2004 Super
frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
BASP1 Brain abundant membrane attached 
signal protein 1 Zhang et al ., 2008 Super
Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref 
(cDNA microarray) Super > Ref not differentially expressed
BGN Biglycan (bone/cartilage proteoglycan-I; dermatan sulphate proteoglycan I)
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref not differentially expressed
BMP4 Bone morphogenetic protein 4 Shin et al. , 2004 Super cell culture: nodule and cord superfic fibroblasts vs normal palmar fascia fibroblasts: Superfic < Ref  (RT-PCR, Western, IHC) Super < Ref not differentially expressed
BMP6 Bone morphogenetic protein 6 Shin et al. , 2004 Super cell culture: nodule and cord superfic fibroblasts vs normal palmar fascia fibroblasts: Superfic < Ref  (RT-PCR) Super < Ref not differentially expressed
BMP7 Bone morphogenetic protein 7 Shin et al. , 2004 Super cell culture: nodule and cord superfic fibroblasts vs normal palmar fascia fibroblasts: Superfic = Ref (no expression) (RT-PCR) Super = Ref
Aggr > Ref, Super > Ref, 
Super < Aggr
BMPR1A Bone morphogenetic protein receptor 1A Shin et al. , 2004 Super
cell culture: nodule and cord superfic fibroblasts vs normal palmar fascia fibroblasts: Superfic < 
Ref  (RT-PCR) Super < Ref not differentially expressed
BMPR1B Bone morphogenetic protein receptor 1B Shin et al. , 2004 Super
cell culture: nodule and cord superfic fibroblasts vs normal palmar fascia fibroblasts: Superfic < 
Ref  (RT-PCR) Super < Ref not differentially expressed
BMPR2 Bone morphogenetic protein receptor 2 Shin et al. , 2004 Super cell culture: nodule and cord superfic fibroblasts vs normal palmar fascia fibroblasts: Superfic < Ref  (RT-PCR) Super < Ref not differentially expressed
BRF2 Subunit of RNA polymerase III transcription initiation factor, BRF1-like Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
C20orf103 Chromosome 20 open reading frame 103 
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref not differentially expressed
CALR Calrecticulin Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
CCL5 Chemokine (C-C motif) ligand 5 (RANTES) Qian et al. , 2004 Super
frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
CCT2 T-complex protein 1 subunit beta Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
CD14 CD14 antigen Pan et al. , 2003 Super frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref Aggr > Ref
CD81 CD81 antigen (target of antiproliferative 
antibody 1) Pan et al. , 2003 Super
frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, WAF1, Cip1)
Kraljevic Pavelic et al. , 
2009 Super frozen tissues: 12 cases disease vs. control (Western) Super > Ref not differentially expressed
CEECAM1 Cerebral endothelial cell adhesion 
molecule 1
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref not differentially expressed
CLEC3B
C-type lectin domain family 3, member 
B (tetranectin; plasminogen binding 
protein) 
Pan et al ., 2003 Super frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref Aggr < Ref, Super > Aggr
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CNTN1 Contactin 1 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref not differentially expressed
CNTN1 Contactin 1, mRNA (cDNA clone MGC:41894 IMAGE:5273941) Lee et al. , 2006 Super
frozen tissues: cord superfic (4) vs. superfic-adjacent control fascia (4) vs. normal palmar fascia 
(3): Superfic > Ref (cDNA Array) Super > Ref not differentially expressed
COL15A1 Collagen, type XV, alpha 1 Satish et al. , 2008 Super cell cultures superficial fibromatosis vs. normal fibroblasts (2 microarray platforms) Super < Ref not differentially expressed
COMP Cartilage oligomeric matrix protein Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref Aggr < Ref, Super > Aggr
CREBL1 cAMP responsive element binding protein-like 1 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
CRYAB Crystallin, alpha B Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
CRYAB Crystallin, alpha B Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
CSF Colony stimulating factor 2 (granulocyte-
macrophage GM-CSF) Qian et al ., 2004 Super
frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray) Super > Ref not differentially expressed
CSPG2 Chondroitin sulfate proteoglycan 2 (versican) 
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref not differentially expressed
CTNNA1 Catenin (cadherin-associated protein), 
alpha 1 (alpha-catenin) Qian et al. , 2004 Super
frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray) Super > Ref not differentially expressed
CTNNB1 Catenin (cadherin-associated protein), beta 1, 88kDa 
Carlson and Fletcher, 
2007; Montgomery et 
al ., 2001; Varallo et al ., 
2003
Super
Carlson and Fletcher, 2007: 25 cases of superficial fibromatoses: nuclear positivity present in 14 
cases (IHC). Montgomery et al. , 2001: 22 palmar, 5 plantar cases of superficial fibromatoses: 
Nuclear accumulation of β-catenin present in 86% of superficial fibromatosis cases ranging from 5-
100% of nuclei (IHC). Varallo et al ., 2003: Several patient-matched superficial fibromatosis 
specimens: lesional tissues expressed increasing amounts of β-catenin compared to normal 
appearing control fascia (Western, IHC).
Super > Ref not differentially expressed
CTTN Cortactin Qian et al.,  2004 Super frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray) Super > Ref not differentially expressed
CXCL12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1 SDF1) Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Super > Ref, Super > Aggr
DAD1 Defender against cell death 1 Qian et al.,  2004 Super frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray) Super > Ref not differentially expressed
DES Desmin Kosmehl et al. , 1995; Berndt et al. , 1995 Super
Kosmehl et al. , 1995: nodular palmar superfic (? cases): proliferative noduli > surrounding 
aponeurosis (IHC)   Berndt et al. , 1995: nodular palmar superfic (? cases): proliferative noduli > 
surrounding aponeurosis (IHC)
Super > Ref not differentially expressed
ECHS1 Enoyl Coenzyme A hydratase, short 
chain, 1, mitochondrial Pan et al. , 2003 Super
frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
ENG Endoglin (Osler-Rendu-Weber 
syndrome 1) Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
ERBB2 v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2
Kraljevic Pavelic et al. , 
2009 Super frozen tissues: 12 cases disease vs. control (Western) Super > Ref not differentially expressed
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EPB49 Erythrocyte membrane protein band 4.9 (dematin) Pan et al ., 2003 Super
frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
FBLN1 Fibulin-1 Satish et al. , 2008 Super cell cultures superficial fibromatosis vs. normal fibroblasts (2 microarray platforms) Super < Ref not differentially expressed
FGF2 Fibroblast growth factor 2 (bFGF)
Lappi et al. , 1992; 
Gonzalez et al. , 1992; 
Berndt et al ., 1995
Super
Lappi et al ., 1992: cell culture: Superfic expresses FGF2 (northern)  Gonzalez et al. , 1992: 9 
superfic vs 3 normal fascia: Superfic > Ref (ISH)  Berndt et al ., 1995:  nodular palmar superfic (? 
cases): proliferative noduli > surrounding aponeurosis (ISH, IHC)
Super > Ref not differentially expressed
FGFR1
Fibroblast growth factor receptor 1 (fms-
related tyrosine kinase 2, Pfeiffer 
syndrome)
Gonzalez et al. , 1992 Super 9 superfic vs 3 normal fascia: Superfic > Ref (ISH) Super > Ref not differentially expressed
FLNB Filamin B, beta (actin binding protein 278) Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
Kraljevic Pavelic et al. , 
2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
GARS Glycyl-tRNA synthetase Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
GAS1 Growth arrest-specific 1 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
GNAS
GNAS complex locus (G-s-alpha; 
adenylate cyclase-stimulating G alpha 
protein)
Qian et al.,  2004 Super frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray) Super > Ref Aggr > Ref
GPD1 Glycerol-3-phosphate dehydrogenase 1 (soluble) Pan et al., 2003 Super
frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
GSN Gelsolin Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
HMMR Hyaluronan-mediated motility receptor (RHAMM) Tolg et al. , 2003 Aggr frozen samples (6 Aggrs): Aggr > normal fascia (RT-PCR, IHC) Aggr > Ref not differentially expressed
HNRPH3 Heterogeneous nuclear 
ribonucleoprotein H3
Kraljevic Pavelic et al. , 
2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
HSPA1A Heat shock 70kDa protein 1 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
HSPA2 Heat shock 70kDa protein 2 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
HSPA8 Heat shock cognate 71kD protein Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
HSPB1 Heat shock 27kDa protein 1 Qian et al.,  2004 Super frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray) Super > Ref not differentially expressed
ICAM2 Intercellular adhesion molecule 2 Pan et al., 2003 Super frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
IFI30 Interferon, gamma-inducible protein 30 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
IGF1R Insulin-like growth factor 1 receptor Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (Western) Super > Ref not differentially expressed
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IGF2 Insulin-like growth factor 2 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
ITPR3 Inositol 1,4,5-triphosphate receptor, type 3 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
JUNB Jun B proto-oncogene Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
KRT10 Keratin 10 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
KRT18 Keratin 18 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
KRT7 Keratin 7 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
KRT9 Keratin 9 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
LAMB2 Laminin, beta 2 (Laminin S) Kosmehl et al. , 1995 Super nodular palmar superfic (? cases): proliferative noduli > surrounding aponeurosis (IHC)  Super > Ref Aggr < Ref (LAMC1, formerly LAMB2)
LAMB3 Laminin, beta 3 Pan et al., 2003 Super frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
LEF1 Lymphoid enhancer-binding factor 1 Tejpar et al. , 2001 Aggr frozen samples (10 Aggrs): Aggr = Ref (10 Fascia same patients): all are negative (RT-PCR) Aggr = Ref Aggr > Ref, Super > Ref, Super < Aggr
LDHB L-lactate dehydrogenase B chain Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref Super < Ref
LGALS3BP Lectin, galactoside-binding, soluble, 3 binding protein Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
MAB21L1 Mab-21-like 1 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
MALL Mal, T-cell differentiation protein-like (BENE) Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
MFAP4 Microfibrillar-associated protein 4 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref Aggr > Super, Aggr > Ref
MFGE8 Milk fat globule-EGF factor 8 protein Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
MMP12 Matrix metalloproteinase 12 Denys et al. , 2004a Aggr cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr > Ref (real time RT-PCR) Aggr > Ref not differentially expressed
MMP13 Matrix metalloproteinase 13 Denys et al. , 2004a Aggr cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr > Ref (real time RT-PCR) Aggr > Ref not differentially expressed
MMP13 Matrix metalloproteinase 13 Johnston et al.,  2007 Super frozen tissues: nodule superfic (? samples) vs normal palmar fascia (?): Superfic > Ref (realtime RT-PCR) Super > Ref not differentially expressed
MMP2 Matrix metalloproteinase 2 Denys et al. , 2004a; Kong et al.,  2004 Aggr
Denys et al. , 2004a: cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr = Ref (real time RT-PCR)  
Kong et al. , 2004: cell culture: 9 Aggrs from APC-KO-mice vs. 9 normal fascia from WT-mice: 
Aggr = Ref  (real time RT-PCR)
Aggr = Ref Aggr > Ref, Super > Ref
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MMP3 Matrix metalloproteinase 3
Denys et al. , 2004a; 
Kong et al.,  2004; 
Denys et al.,  2004b
Aggr
Denys et al. , 2004a: cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr > Ref (real time RT-PCR)  
Kong et al. , 2004: cell culture: 9 Aggrs from APC-KO-mice vs. 9 normal fascia from WT-mice: 
Aggr > Ref  (real time RT-PCR)  Denys et al. , 2004b: cell culture:  4 Aggrs vs. 4 Fasica: Aggr > 
Ref (Affymetrix array)
Aggr > Ref Aggr < Ref, Super < Ref, Super < Aggr
MMP7 Matrix metalloproteinase 7
Denys et al. , 2004a; 
Kong et al.,  2004; 
Denys et al.,  2004b
Aggr
Denys et al. , 2004a: cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr > Ref (real time RT-PCR)  
Kong et al ., 2004: cell culture: 9 Aggrs from APC-KO-mice vs. 9 normal fascia from WT-mice: 
Aggr = Ref  (real time RT-PCR)  Denys et al. , 2004b: cell culture:  4 Aggrs vs. 4 Fasica: Aggr > 
Ref (Affymetrix array)
Aggr > Ref not differentially expressed
MMP7 Matrix metalloproteinase 7 Johnston et al.,  2007 Super frozen tissues: nodule superfic (? samples) vs normal palmar fascia (?): Superfic (nodule and 
cord) > Ref (realtime RT-PCR) Super > Ref not differentially expressed
MXRA5 Matrix-remodelling associated 5 (adlican)
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref not differentially expressed
MYC v-myc myelocytomatosis viral oncogene homolog (avian) (c-myc) Jemec et al. , 1999 Super
paraffin blocks: superfic (21 samples) vs recurrent superfic (9) vs normal fascia (6) vs flexor 
retinaculum (12): superfic > recurrent superfic = normal fascia > flexor retinaculum (negative!) 
(IHC)
Super > Ref Aggr < Ref, Super < Ref
MYL3 Myosin, light polypeptide 3 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
MYL6 Myosin, light polypeptide 6 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
MYL9 Myosin, light polypeptide 9, regulatory (MYRL2) Denys et al. , 2004b Aggr 76: cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
NADP Isocitrate dehydrogenase (NADP) Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
NCAM1 Neural cell adhesion molecule Zhang et al., 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref not differentially expressed
NID2 Nidogen 2 (osteonidogen) Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Aggr > Ref, Super > Ref, Super > Aggr
PARK7 Onocgene DJI Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
PCBP1 Poly(rC)-binding protein 1 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
PDGFB Platelet-derived growth factor beta Alman et al.,  1995 Aggr frozen samples:  Aggr, fibrous displasia, recurrent Superfic > Superfic, plantar fascia, mature scar (RT-PCR, ISH) Aggr > Super not differentially expressed
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PDGFB Platelet-derived growth factor beta
Terek et al. , 1995; 
Alman et al. , 1996; 
Tarpila et al. , 1996; 
Hindman et al.,  2003 
Super
Terek et al ., 1995: Superfic (6 cases) vs normal fascia (? cases): Superfic > Ref (RT-PCR, 
southern)  Alman et al. , 1996: cell cultures: palmar superfic (8 cases) vs uninvolved palmar fascia 
(4) vs normal palmar fascia (4): cyclic mechanical strain to these cultures: PDGFA expression 
increased in Superfic and uninvolved palmar tissue. PDGFB was increased only in Superfic. 
Normal fascia did not express any PDGF.  Tarpila et al. , 1996 : cell cultures: nodular superfic (10 
cases, late stage) vs forearm control fibroblasts (? cases): contraction of collagen latices: control 
fibroblasts > superfic ! PDGFB, but not PDGFA, increased chemotactic activity in superfic and 
control fibroblasts  Hindman et al. : cell culture (5 superfic): PDGFB treatement: expression of 
ACTA2 decreases (western), but proliferation increases 
Super > Ref not differentially expressed
PGK1 Phosphoglycerate kinase 1 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
PKM2 Pyruvate kinase isoenzymes M1/M2 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
PENK Proenkephalin Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
PLS3 Plastin 3 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
PODXL Podocalyxin-like Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
PRC1 Protein regulator of cytokinesis Zhang et al., 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref not differentially expressed
PRDXI Peroxiredoxin Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
PRG1 Proteoglycan 1, secretory granule Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Super < Ref
PRKX Protein kinase, X-linked Pan et al., 2003 Super frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic > Ref (Atlas 
microarray) Super > Ref not differentially expressed
PTK7 Protein tyrosine kinase 7 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
QSCN6 Quiescin Q6 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
RACK1 Lung cancer oncogene 7 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
RB1 Retinoblastoma 1 (including 
osteosarcoma) 
Muller et al. , 1996; 
Hoos et al. , 2001 Aggr
Muller et al ., 1996: frozen samples: 13 Aggrs vs. 6 Superfic: Aggr < Superfic (RT-PCR, IHC)  
Hoos et al ., 2001: frozen samples, paraffin blocks: 24 Aggrs vs 39 Fibrosarcoma (LG, HG): 
Fibrosarcoma < Aggr (IHC)
Aggr < Super Aggr > Ref
RB1 Retinoblastoma 1 (including 
osteosarcoma) Muller et al. , 1996 Super Palmar superfic (6 cases) vs Aggr (13 cases): Superfic > Aggr (IHC, RT-PCR) Super > Aggr Aggr > Ref
RCAN Regulator of calcineurin Zhang et al., 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref not differentially expressed
Gene Paper Literature Paper Own results
Appendix Gene list D
Experiment description Statement
RGS3 Regulator of G protein signalling 3 Zhang et al., 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref not differentially expressed
RHOA Ras homolog gene family, member A Qian et al.,  2004 Super frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray) Super > Ref not differentially expressed
SEMA3C
Sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3C 
Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Super > Ref
SERPINE1
Serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator inhibitor 
type 1 = PAI1), member 1 
Li et al. , 2005 Aggr frozen samples: 6 Aggrs vs 6 normal fascia: Aggr > Ref (RT-PCR, IHC) Aggr > Ref not differentially expressed
SERPINF1 Pigment epithelium-derived factor Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
SFRP1 Secreted frizzled-related protein 1 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
SGCD Sarcoglycan, delta (35kDa dystrophin-
associated glycoprotein) Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
SHOX2 Short stature homeobox 2 Skubitz and Skubitz, 2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref not differentially expressed
SLC7A8 Solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 8 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref not differentially expressed
SORCS1 Sortilin-related VPS10 domain 
containing receptor 1
Skubitz and Skubitz, 
2004 Aggr frozen samples (12 Aggrs): Aggr > 16 non-neoplastic tissues (Affymetrix array) Aggr > Ref not differentially expressed
SOX4 SRY (sex determining region Y)-box 17 Zhang et al., 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref not differentially expressed
SPARCL1 SPARC-like 1 (mast9, hevin) Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr > Ref (Affymetrix array) Aggr > Ref Super > Aggr
STIP1 Stess-induced-phosphoprotein 1 Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
SYMPK Symplekin Pan et al., 2003 Super frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
TAGLN Transgelin Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref Super > Aggr
TCF4 Transcription factor 4 (SEF2-1B; not (!!) TCF7L2) Pan et al., 2003 Super
frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic > Ref (Atlas 
microarray) Super > Ref Aggr > Ref
TFPI2 Tissue factor pathway inhibitor 2 Pan et al., 2003 Super frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref Aggr > Ref, Super < Aggr
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TGFB1 Transforming growth factor beta 1
Badalamente et al. , 
1996; Bisson et al. , 
2003; Kopp et al., 
2006; Berndt et al. , 
1995; Hindman et al ., 
2003; Zhang et al. , 
2008
Super
Badalamente et al ., 1996: Superfic (? cases): high intracellular expression in fibroblasts, 
myofibroblasts and endothelial cells in all superfic samples, regardless of disease stage. It is not 
present in the ECM (IHC). Cell cultures with superfic myofibroblasts: addition of TGFB1: 
proliferation increases, but TGFB1 < TGFB2.  Bisson et al. , 2003: cell culture: nodular superfic vs 
cord superfic: TGFB1 induces expression of ACTA2 in both cultures to a similar level, although 
the starting point was different: cord < nodul.  Kopp et al ., 2006: cell culture: superfic (? cases) 
vs. normal tendon pully fibroblasts: Superfic > Ref (Luciferase-assay)  34A: cell culture: Superfic 
vs. flexor retinaculum fibroblasts: Addition of TGFB1 (low dose): increase in ACTA2+ 
myofibroblasts in Superfic culture. Addition of high dose: contrary   Berndt et al. , 1995: nodular 
palmar superfic (? cases): proliferative noduli > surrounding aponeurosis (IHC)  Hindman et al. , 
2003: cell culture (5 superfic): TGFB1 treatement: expression of ACTA2 increases (western), but 
proliferation does not change  Zhang et al. , 2008: cord superfic  vs. superfic-adjacent control fascia
Super > Ref not differentially expressed
TGFBR1 Transforming growth factor beta 
receptor type 1 Locci et al ., 2001 Aggr cell culture:  Aggr fibroblasts vs. normal fibroblasts:  Aggr > Ref (Western) Aggr > Ref not differentially expressed
TGFBR2 Transforming growth factor beta 
receptor type 2 Locci et al ., 2001 Aggr cell culture:  Aggr fibroblasts vs. normal fibroblasts:  Aggr > Ref (Western) Aggr > Ref Aggr < Ref
TGFBR3 Transforming growth factor beta 
receptor type 3 Locci et al ., 2001 Aggr cell culture:  Aggr fibroblasts vs. normal fibroblasts:  Aggr = Ref (Western) Aggr = Ref Aggr < Ref, Super < Ref
TIMP1 Metallopeptidase inhibitor 1 (tissue inhibitor of metalloproteinase 1)
Denys et al. , 2004a; 
Kong et al. , 2004 Aggr
Denys et al. , 2004a: cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr < Ref (real time RT-PCR) 
Kong et al ., 2004: cell culture: 9 Aggrs from APC-KO-mice vs. 9 normal fascia from WT-mice: 
Aggr < Ref  (real time RT-PCR)
Aggr < Ref not differentially expressed
TIMP1 Metallopeptidase inhibitor 1 (tissue inhibitor of metalloproteinase 1)
Ulrich et al. , 2003; 
Johnston et al ., 2007 Super
Ulrich et al ., 2003: Sera and tissue samples of 22 superfic vs sera and palmar fascia of 20 
healthy controls: Superfic > Ref (ELISA for sera, IHC for tissue samples)   Johnston et al. , 2007: 
frozen tissues: nodule superfic (? samples) vs normal palmar fascia (?): Superfic > Ref (realtime 
RT-PCR)
Super > Ref not differentially expressed
TIMP2 Metallopeptidase inhibitor 2 (tissue inhibitor of metalloproteinase 2) Denys et al ., 2004a Aggr cell culture: 7 Aggrs vs. 7 matched Fascia: Aggr = Ref (real time RT-PCR) Aggr = Ref Aggr > Ref, Super > Ref
TP53 Tumor protein p53 (Li-Fraumeni 
syndrome)
Kraljevic Pavelic et al., 
2009 Super tissue Super vs. normal fascia: Super > Ref (Western) Super > Ref Aggr < Ref, Super < Ref
TMEM49 Transmembrane protein 49 Zhang et al., 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref not differentially expressed
TMEM158 Transmembrane protein 158 Zhang et al., 2008 Super Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref (cDNA microarray) Super > Ref not differentially expressed
TMSB10 Thymosin, beta 10 (migration-inducing gene 12) Qian et al.,  2004 Super
frozent tissues: 9 superfic palmar fasica vs adjacent normal tendon: Superfic > Ref (Atlas 
microarray) Super > Ref Aggr > Ref
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref Super > Ref, Super > Aggr
TNFSF12 Tumor necrosis factor (ligand) 
superfamily, member 12 Pan et al., 2003 Super
frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic < Ref (Atlas 
microarray) Super < Ref not differentially expressed
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TRH Thyrotropin-releasing hormone Denys et al. , 2004b Aggr cell culture:  4 Aggrs vs. 4 Fasica: Aggr < Ref (Affymetrix array) Aggr < Ref not differentially expressed
TUBA3 Tubulin, alpha 3 Pan et al., 2003 Super frozen tissues: 6 superfic palmar fascia vs 2 Ref (normal palmar fascia): Superfic > Ref (Atlas 
microarray) Super > Ref not differentially expressed
VCP Transitional endoplasmic reticulum ATPase (valosin-containing protein)
Kraljevic Pavelic et al. , 
2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
VIM Vimentin Kraljevic Pavelic et al. , 2009 Super frozen tissues: 12 cases disease vs. control (2D-gelelectrophoresis, MS) Super > Ref not differentially expressed
XRCC1 X-ray repair complementing defective 
repair Zhang et al., 2008 Super
Dupuytren's diseased cord tissue vs. normal transverse ligament of palmar fascia: Super > Ref 
(cDNA microarray) Super > Ref not differentially expressed
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Gene list E: WNT5A-induced differentially expressed genes in Aggr6
Ratio = WNT5A-treated cells vs. untreated (control) cells
WNT5A = absolute expression of the gene after WNT5A treatment
control = absolute expression of the gene in untreated cells
1) Proliferation
Ratio P-value WNT5A control
ANKRD15 ankyrin repeat domain 15 2.72 2.92E-09 4.52 1.70
APPBP1 amyloid beta precursor protein binding protein 1 3.57 4.21E-12 1.66 0.48
APPL1 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper conta 2.66 5.24E-09 0.76 0.29
APPL2 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper conta 3.87 7.17E-13 0.65 0.17
AREG amphiregulin (schwannoma-derived growth factor) 0.02 1.24E-22 0.00 0.18
ASPM asp (abnormal spindle) homolog, microcephaly associated (Drosophila) 14.20 1.82E-20 2.11 0.15
ATR ataxia telangiectasia and Rad3 related 2.61 8.41E-09 0.56 0.22
AURKA aurora kinase A 9.18 8.15E-19 1.43 0.16
AURKB aurora kinase B 5.99 2.21E-16 0.39 0.07
AXIN1 axin 1 0.48 2.64E-06 0.07 0.15
BAMBI BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) 0.37 4.44E-09 2.48 6.81
BBC3 BCL2 binding component 3 4.18 1.41E-13 1.65 0.41
BCL2L11 BCL2-like 11 (apoptosis facilitator) 0.10 2.72E-19 0.03 0.28
BCL2L12 BCL2-like 12 (proline rich) 2.23 4.98E-07 1.07 0.49
BCL7A B-cell CLL/lymphoma 7A 2.14 1.34E-06 0.39 0.19
BCOR BCL6 co-repressor 9.37 8.01E-19 0.20 0.02
BDKRB2 bradykinin receptor B2 6.25 1.28E-16 0.20 0.03
BDNF brain-derived neurotrophic factor 0.36 1.26E-09 0.11 0.32
BDNF brain-derived neurotrophic factor 0.40 2.96E-08 0.64 1.64
BIRC2 baculoviral IAP repeat-containing 2 2.51 2.22E-08 2.37 0.97
BIRC5 baculoviral IAP repeat-containing 5 (survivin) 3.98 0 6.56 1.70
BMP6 bone morphogenetic protein 6 0.07 2.52E-20 0.01 0.12
BMPER BMP binding endothelial regulator 2.28 3.02E-07 0.16 0.07
BRCA1 breast cancer 1, early onset 24.55 0 0.21 0.01
BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) 9.57 5.33E-19 1.02 0.11
BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) 10.18 2.97E-19 0.48 0.05
BUB3 BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) 7.68 6.37E-18 7.02 0.94
CAPRIN1 cell cycle associated protein 1 3.15 7.63E-11 2.63 0.86
CAPRIN2 caprin family member 2 2.15 1.20E-06 0.32 0.15
CCL2 chemokine (C-C motif) ligand 2 2.03 1.40E-45 0.16 0.08
CCNA2 cyclin A2 14.35 0 1.13 0.08
CCNB1 cyclin B1 6.63 4.61E-17 6.28 0.97
CCNB2 cyclin B2 5.14 2.62E-15 6.88 1.37
CCND1 cyclin D1 2.04 0 7.12 3.58
CCNE1 cyclin E1 0.40 3.19E-08 0.46 1.16
CCNG2 cyclin G2 5.31 1.52E-15 0.89 0.17
CCNL1 cyclin L1 0.30 2.64E-11 0.82 2.78
CCPG1 cell cycle progression 1 0.49 0 0.22 0.46
CCRK cell cycle related kinase 0.45 5.97E-07 0.08 0.18
CDC16 cell division cycle 16 homolog (S. cerevisiae) 2.77 1.83E-09 2.42 0.90
CDC2 cell division cycle 2, G1 to S and G2 to M 5.27 0 1.77 0.34
CDC20 cell division cycle 20 homolog (S. cerevisiae) 7.22 1.45E-17 0.56 0.08
CDC23 cell division cycle 23 homolog (S. cerevisiae) 3.51 6.17E-12 0.58 0.17
CDC25A cell division cycle 25 homolog A (S. pombe) 0.31 3.13E-11 0.10 0.32
CDC25B cell division cycle 25 homolog B (S. pombe) 3.15 8.04E-11 1.50 0.49
CDC25C cell division cycle 25 homolog C (S. pombe) 22.64 1.96E-21 0.16 0.01
CDC37L1 cell division cycle 37 homolog (S. cerevisiae)-like 1 2.88 7.12E-10 0.34 0.12
CDC40 cell division cycle 40 homolog (S. cerevisiae) 2.65 6.23E-09 0.24 0.09
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CDC45L CDC45 cell division cycle 45-like (S. cerevisiae) 3.59 3.71E-12 2.09 0.60
CDC7 cell division cycle 7 homolog (S. cerevisiae) 28.81 8.36E-22 0.16 0.01
CDCA2 cell division cycle associated 2 3.83 8.92E-13 2.16 0.58
CDCA3 cell division cycle associated 3 5.07 3.48E-15 0.49 0.10
CDCA5 cell division cycle associated 5 3.76 1.33E-12 2.34 0.64
CDCA7L cell division cycle associated 7-like 3.59 3.81E-12 0.62 0.18
CDCA8 cell division cycle associated 8 8.99 1.02E-18 4.26 0.49
CDK5RAP1 CDK5 regulatory subunit associated protein 1 2.21 6.14E-07 0.23 0.11
CDK5RAP2 CDK5 regulatory subunit associated protein 2 2.20 6.60E-07 0.84 0.39
CDK6 cyclin-dependent kinase 6 2.45 4.42E-08 3.60 1.51
CDK8 cyclin-dependent kinase 8 2.30 2.25E-07 0.43 0.19
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) 4.50 0 0.15 0.03
CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 0.45 0 0.09 0.21
CDKN2AIP CDKN2A interacting protein 0.44 3.25E-07 0.25 0.57
CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 5.86 2.93E-16 2.82 0.49
CDKN2D cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 2.66 5.32E-09 3.85 1.49
CGRRF1 cell growth regulator with ring finger domain 1 0.40 2.54E-08 0.21 0.53
CHAF1A chromatin assembly factor 1, subunit A (p150) 4.51 3.00E-14 1.44 0.33
CIZ1 CDKN1A interacting zinc finger protein 1 0.48 3.50E-06 0.44 0.93
CKS1B CDC28 protein kinase regulatory subunit 1B 4.06 2.50E-13 7.75 1.96
CUL1 cullin 1 4.07 2.43E-13 0.82 0.21
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 0.40 3.26E-08 0.09 0.24
CXCL2 chemokine (C-X-C motif) ligand 2 0.06 1.03E-20 0.02 0.30
CXCL3 chemokine (C-X-C motif) ligand 3 0.03 2.86E-22 0.04 1.32
CXCR7 Homo sapiens chemokine (C-X-C motif) receptor 7 (CXCR7), transcript variant 1, 0.21 1.03E-14 0.08 0.41
DCLRE1A DNA cross-link repair 1A (PSO2 homolog, S. cerevisiae) 8.39 4.05E-18 0.10 0.01
DKK1 dickkopf homolog 1 (Xenopus laevis) 0.17 1.74E-16 6.17 38.43
DLG7 discs, large homolog 7 (Drosophila) 5.86 2.95E-16 1.43 0.25
DMTF1 cyclin D binding myb-like transcription factor 1 2.57 1.27E-08 0.86 0.35
DTYMK deoxythymidylate kinase (thymidylate kinase) 2.25 3.71E-07 21.30 9.71
E2F6 E2F transcription factor 6 0.36 1.78E-09 0.30 0.87
E2F7 E2F transcription factor 7 3.24 3.85E-11 3.02 0.96
EAPP E2F-associated phosphoprotein 3.61 3.15E-12 1.43 0.41
EDNRA endothelin receptor type A 3.66 3.40E-12 0.11 0.03
EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene 2.24 0 0.34 0.16
EGR1 early growth response 1 5.97 2.22E-16 1.03 0.18
ESCO2 establishment of cohesion 1 homolog 2 (S. cerevisiae) 11.70 9.80E-20 0.21 0.02
FANCD2 Fanconi anemia, complementation group D2 2.67 4.90E-09 0.50 0.19
FGF18 fibroblast growth factor 18 0.05 2.00E-21 0.01 0.23
FGF2 fibroblast growth factor 2 (basic) 3.13 0 2.31 0.76
FGF5 fibroblast growth factor 5 6.57 6.23E-17 0.21 0.03
FGF7 fibroblast growth factor 7 (keratinocyte growth factor) 0.15 5.35E-17 0.09 0.59
FGF7 fibroblast growth factor 7 (keratinocyte growth factor) 0.26 7.53E-13 0.28 1.12
FGFBP3 fibroblast growth factor binding protein 3 0.32 1.06E-10 0.04 0.12
FGFR1 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrom 0.07 1.16E-20 0.02 0.35
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 0.01 4.77E-23 0.05 4.74
FST follistatin 0.37 2.66E-09 0.85 2.39
FZD2 frizzled homolog 2 (Drosophila) 3.38 1.47E-11 1.70 0.52
FZD4 frizzled homolog 4 (Drosophila) 4.19 1.39E-13 0.28 0.07
FZD5 frizzled homolog 5 (Drosophila) 0.29 1.03E-11 0.04 0.14
FZD6 frizzled homolog 6 (Drosophila) 2.14 1.47E-06 1.21 0.58
FZD7 frizzled homolog 7 (Drosophila) 8.84 1.23E-18 1.67 0.19
FZD8 frizzled homolog 8 (Drosophila) 0.47 2.23E-06 0.06 0.14
GADD45B growth arrest and DNA-damage-inducible, beta 12.07 6.22E-20 6.51 0.55
GAS1 growth arrest-specific 1 3.93 5.17E-13 0.31 0.08
GPS2 G protein pathway suppressor 2 2.09 3.08E-06 0.12 0.06
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H2AFX H2A histone family, member X 4.53 2.79E-14 23.57 5.35
HBEGF heparin-binding EGF-like growth factor 0.07 2.17E-20 0.02 0.32
HBEGF heparin-binding EGF-like growth factor 0.06 1.19E-20 0.01 0.15
HDAC4 histone deacetylase 4 4.73 2.04E-14 0.10 0.02
HRASLS3 HRAS-like suppressor 3 0.40 2.95E-08 1.44 3.68
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 2.07 3.24E-06 0.37 0.18
IFNE1 interferon epsilon 1 0.38 5.97E-09 0.06 0.15
IGF1R insulin-like growth factor 1 receptor 0.34 0 0.04 0.12
IGFBP3 insulin-like growth factor binding protein 3 0.32 7.54E-11 1.12 3.64
IL11 interleukin 11 0.06 8.03E-21 1.52 25.11
IL13RA2 interleukin 13 receptor, alpha 2 2.40 7.69E-08 0.99 0.43
IL1RAP interleukin 1 receptor accessory protein 0.13 7.61E-18 0.07 0.57
IL20RB interleukin 20 receptor beta 0.29 1.23E-11 0.06 0.23
IL6 interleukin 6 (interferon, beta 2) 0.44 0 0.56 1.29
IL8 interleukin 8 0.04 1.14E-21 0.01 0.19
INCENP inner centromere protein antigens 135/155kDa 8.39 2.22E-18 1.57 0.19
ING4 inhibitor of growth family, member 4 4.61 2.64E-14 0.13 0.03
JAG1 jagged 1 (Alagille syndrome) 0.18 5.86E-16 0.03 0.17
KIAA1787 KIAA1787 protein 3.07 1.78E-10 0.14 0.05
KIF11 kinesin family member 11 24.79 9.22E-22 0.54 0.02
KIF23 kinesin family member 23 8.14 3.16E-18 4.38 0.55
KNTC1 kinetochore associated 1 4.95 0 0.47 0.10
LZTS1 leucine zipper, putative tumor suppressor 1 4.95 5.34E-15 0.53 0.11
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 3.14 8.71E-11 1.80 0.59
MAPK7 mitogen-activated protein kinase 7 2.80 1.44E-09 0.39 0.14
MCM7 minichromosome maintenance complex component 7 2.17 1.04E-06 3.76 1.78
MCM8 minichromosome maintenance complex component 8 4.36 6.16E-14 0.38 0.09
MDC1 mediator of DNA damage checkpoint 1 4.48 3.64E-14 0.37 0.08
MDM2 Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) 0.36 0 0.04 0.12
MDM4 Mdm4, transformed 3T3 cell double minute 4, p53 binding protein (mouse) 0.39 1.16E-08 0.08 0.22
MINA MYC induced nuclear antigen 3.94 5.14E-13 0.26 0.07
MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) 2.13 1.58E-06 4.74 2.29
MPHOSPH1 M-phase phosphoprotein 1 40.56 2.30E-22 0.22 0.01
MPHOSPH8 M-phase phosphoprotein 8 3.39 1.35E-11 0.64 0.19
MPHOSPH9 M-phase phosphoprotein 9 5.76 4.75E-16 0.19 0.03
MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 3.06 0 1.55 0.52
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 2.61 0 5.63 2.22
NCAPD2 non-SMC condensin I complex, subunit D2 5.27 1.72E-15 0.72 0.14
NCAPG non-SMC condensin I complex, subunit G 16.08 7.99E-21 10.40 0.66
NEK3 NIMA (never in mitosis gene a)-related kinase 3 2.55 1.61E-08 0.37 0.15
NOLC1 nucleolar and coiled-body phosphoprotein 1 0.37 3.49E-09 1.80 4.99
PAFAH1B1 platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit 45kDa 4.55 2.58E-14 2.26 0.51
PARD3 par-3 partitioning defective 3 homolog (C. elegans) 0.37 4.67E-09 0.04 0.12
PDGFA platelet-derived growth factor alpha polypeptide 2.07 3.39E-06 1.85 0.92
PDGFRA platelet-derived growth factor receptor, alpha polypeptide 6.41 7.60E-17 0.82 0.13
PDRG1 p53 and DNA damage regulated 1 0.33 2.04E-10 0.24 0.74
PKMYT1 protein kinase, membrane associated tyrosine/threonine 1 3.59 3.71E-12 1.60 0.46
PMS1 PMS1 postmeiotic segregation increased 1 (S. cerevisiae) 6.21 1.24E-16 0.49 0.08
PPARD peroxisome proliferator-activated receptor delta 2.29 2.40E-07 1.30 0.58
PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa 3.47 1.09E-11 0.11 0.03
PTGFR prostaglandin F receptor (FP) 6.23 1.70E-16 0.12 0.02
PTP4A1 protein tyrosine phosphatase type IVA, member 1 0.22 2.97E-14 0.22 1.03
PTTG1 pituitary tumor-transforming 1 2.16 1.08E-06 13.88 6.60
PYCARD PYD and CARD domain containing 0.45 3.94E-07 0.28 0.64
RAD17 RAD17 homolog (S. pombe) 4.34 6.55E-14 1.97 0.47
RAD21 RAD21 homolog (S. pombe) 2.19 8.06E-07 4.28 2.01
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RASSF1 Ras association (RalGDS/AF-6) domain family 1 2.81 1.34E-09 2.62 0.96
RBBP6 retinoblastoma binding protein 6 2.40 7.59E-08 0.91 0.39
RBBP7 retinoblastoma binding protein 7 2.49 2.71E-08 13.50 5.56
RBL2 retinoblastoma-like 2 (p130) 2.38 1.14E-07 0.11 0.05
RCC2 regulator of chromosome condensation 2 3.05 1.74E-10 1.97 0.67
RGS2 regulator of G-protein signaling 2, 24kDa 0.39 1.44E-08 0.29 0.75
SASH1 SAM and SH3 domain containing 1 4.93 5.92E-15 0.36 0.07
SCAPER S phase cyclin A-associated protein in the ER 3.80 1.30E-12 0.17 0.05
SMC1A structural maintenance of chromosomes 1A 2.68 4.55E-09 0.51 0.20
SMC4 structural maintenance of chromosomes 4 4.13 1.76E-13 4.47 1.11
SNF1LK SNF1-like kinase 0.50 6.63E-06 0.49 1.00
SPAG5 sperm associated antigen 5 4.97 4.79E-15 3.93 0.81
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b 0.36 1.89E-09 0.17 0.48
TNFRSF12A tumor necrosis factor receptor superfamily, member 12A 3.19 5.93E-11 16.97 5.47
TNFRSF9 tumor necrosis factor receptor superfamily, member 9 0.39 2.31E-08 0.04 0.11
TP53AP1 TP53 activated protein 1 0.40 3.05E-08 0.37 0.93
TP53BP2 tumor protein p53 binding protein, 2 0.25 4.95E-13 0.59 2.38
TP53I13 tumor protein p53 inducible protein 13 0.49 5.11E-06 0.05 0.11
TRIM13 tripartite motif-containing 13 3.29 3.38E-11 0.15 0.05
U2AF1 U2 small nuclear RNA auxiliary factor 1 0.13 5.94E-18 0.06 0.50
UBE2C ubiquitin-conjugating enzyme E2C 3.59 3.64E-12 13.46 3.85
UHRF1 ubiquitin-like, containing PHD and RING finger domains, 1 2.68 6.09E-09 0.10 0.04
VASH1 vasohibin 1 2.38 1.04E-07 0.14 0.06
VEGFA vascular endothelial growth factor A 0.21 1.59E-14 0.06 0.29
VEGFA vascular endothelial growth factor A 0.41 0 1.36 3.36
VEGFA vascular endothelial growth factor A 0.30 2.10E-11 0.53 1.82
WNT5B wingless-type MMTV integration site family, member 5B 3.16 7.08E-11 1.46 0.47
ZWINT Homo sapiens ZW10 interactor (ZWINT), transcript variant 4, mRNA [NM_001005 4.40 4.80E-14 2.85 0.67
2) Intracellular signalling pathway components
Ratio P-value WNT5A control
ABL2 v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related g 0.02 7.45E-23 0.23 15.19
AKAP12 A kinase (PRKA) anchor protein (gravin) 12 0.48 2.63E-06 0.31 0.66
AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) 0.46 8.38E-07 0.08 0.17
ARHGAP11A Rho GTPase activating protein 11A 9.41 9.85E-19 0.13 0.01
ARHGAP18 Rho GTPase activating protein 18 6.18 1.38E-16 0.36 0.06
ARHGAP20 Rho GTPase activating protein 20 0.30 2.68E-11 0.03 0.10
ARHGAP22 Rho GTPase activating protein 22 3.90 5.90E-13 0.99 0.26
ARHGAP24 Rho GTPase activating protein 24 7.42 1.43E-17 0.14 0.02
ARHGAP29 Rho GTPase activating protein 29 2.75 2.55E-09 0.15 0.06
ARHGEF10L Rho guanine nucleotide exchange factor (GEF) 10-like 2.53 2.07E-08 0.21 0.09
ARHGEF17 Rho guanine nucleotide exchange factor (GEF) 17 6.35 8.67E-17 2.58 0.42
ARHGEF2 rho/rac guanine nucleotide exchange factor (GEF) 2 3.34 2.02E-11 0.46 0.14
ATF3 activating transcription factor 3 0.15 4.21E-17 0.10 0.69
BARD1 BRCA1 associated RING domain 1 2.25 3.85E-07 0.41 0.19
BCCIP BRCA2 and CDKN1A interacting protein 0.49 4.81E-06 0.07 0.15
BRAF v-raf murine sarcoma viral oncogene homolog B1 0.37 0 0.05 0.15
CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 2.95 3.99E-10 1.18 0.41
CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4 5.90 2.84E-16 0.35 0.06
CDC42SE1 CDC42 small effector 1 2.54 2.02E-08 0.13 0.05
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 0.43 1.22E-07 0.12 0.28
CREM cAMP responsive element modulator 0.13 4.34E-18 0.15 1.24
CREM cAMP responsive element modulator 0.13 5.31E-18 0.33 2.61
CREM cAMP responsive element modulator 0.44 3.40E-07 0.12 0.28
CREM cAMP responsive element modulator 0.11 6.97E-19 0.08 0.74
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CSK c-src tyrosine kinase 2.55 1.70E-08 0.17 0.07
CSNK1D casein kinase 1, delta 0.33 2.27E-10 2.45 7.58
CSNK1G1 casein kinase 1, gamma 1 0.29 9.30E-12 0.03 0.12
CSNK2A1 casein kinase 2, alpha 1 polypeptide 0.41 0 0.05 0.12
DUSP4 dual specificity phosphatase 4 0.03 3.96E-22 0.02 0.54
DVL2 dishevelled, dsh homolog 2 (Drosophila) 3.86 7.57E-13 0.75 0.20
ELK1 ELK1, member of ETS oncogene family 0.46 1.05E-06 0.08 0.19
FER Proto-oncogene tyrosine-protein kinase FER (EC 2.7.10.2) (p94-FER) (c- FER). [ 2.55 1.47E-08 0.73 0.30
GEM GTP binding protein overexpressed in skeletal muscle 0.13 9.02E-18 0.38 2.93
GSK3A glycogen synthase kinase 3 alpha 2.35 1.29E-07 5.17 2.26
IKIP IKK interacting protein 2.48 3.23E-08 1.29 0.54
MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 3.48 7.81E-12 0.49 0.15
MAFG v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian) 0.36 1.54E-09 0.51 1.46
MAFK v-maf musculoaponeurotic fibrosarcoma oncogene homolog K (avian) 0.45 4.45E-07 0.32 0.73
MAP2K2 mitogen-activated protein kinase kinase 2 0.34 2.91E-10 0.15 0.46
MAP2K3 mitogen-activated protein kinase kinase 3 0.30 2.55E-11 0.42 1.42
MAP3K5 mitogen-activated protein kinase kinase kinase 5 2.59 1.11E-08 0.17 0.07
MAP4K5 mitogen-activated protein kinase kinase kinase kinase 5 0.35 7.58E-10 0.19 0.57
MAPK11 mitogen-activated protein kinase 11 0.46 9.47E-07 0.11 0.25
MAPK14 mitogen-activated protein kinase 14 4.76 0 1.65 0.36
MAPK7 mitogen-activated protein kinase 7 2.80 1.44E-09 0.39 0.14
MAPKAP1 mitogen-activated protein kinase associated protein 1 2.10 2.36E-06 0.24 0.12
MAPKAPK2 mitogen-activated protein kinase-activated protein kinase 2 0.38 5.75E-09 0.16 0.43
NFAT5 Homo sapiens nuclear factor of activated T-cells 5, tonicity-responsive (NFAT5), 0.27 1.47E-12 0.09 0.34
NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 0.18 5.77E-16 0.05 0.30
NFKBIE nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilo 2.38 9.47E-08 0.21 0.09
NR4A2 nuclear receptor subfamily 4, group A, member 2 0.01 5.47E-23 0.00 0.21
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A 0.35 6.63E-10 0.67 1.98
RAB1A RAB1A, member RAS oncogene family 2.52 2.04E-08 17.29 7.04
RAB24 RAB24, member RAS oncogene family 0.35 7.71E-10 0.19 0.57
RAB2B RAB2B, member RAS oncogene family 3.09 1.69E-10 0.12 0.04
RAB31 RAB31, member RAS oncogene family 2.28 2.80E-07 1.32 0.60
RAB33A RAB33A, member RAS oncogene family 0.28 2.75E-12 0.23 0.86
RAB4A RAB4A, member RAS oncogene family 0.47 1.72E-06 0.63 1.37
RACGAP1 Rac GTPase activating protein 1 16.19 7.64E-21 3.96 0.25
RALA v-ral simian leukemia viral oncogene homolog A (ras related) 0.28 4.65E-12 1.69 6.16
RAN RAN, member RAS oncogene family 2.01 7.36E-06 0.51 0.26
RANBP6 RAN binding protein 6 2.65 6.36E-09 0.15 0.06
RANGAP1 Ran GTPase activating protein 1 2.51 2.45E-08 0.18 0.07
RAPH1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 2.31 2.01E-07 1.09 0.49
RASA1 RAS p21 protein activator (GTPase activating protein) 1 4.35 6.14E-14 1.64 0.39
RASSF1 Ras association (RalGDS/AF-6) domain family 1 2.81 1.34E-09 2.62 0.96
RASSF3 Homo sapiens cDNA FLJ26410 fis, clone HRT09622. [AK129920] 3.76 1.61E-12 0.22 0.06
RASSF4 Ras association (RalGDS/AF-6) domain family 4 2.70 4.53E-09 0.12 0.05
RASSF8 Ras association (RalGDS/AF-6) domain family 8 0.23 7.88E-14 0.05 0.21
REL v-rel reticuloendotheliosis viral oncogene homolog (avian) 0.20 8.63E-15 0.03 0.14
RELA v-rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa ligh 2.89 0 0.45 0.16
RELB v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa ligh 0.44 3.28E-07 1.51 3.52
RIN2 Ras and Rab interactor 2 8.57 1.74E-18 1.96 0.24
RND3 Rho family GTPase 3 0.29 0 7.75 27.75
RSU1 Ras suppressor protein 1 2.24 5.16E-07 0.14 0.06
SMAD1 SMAD family member 1 6.34 9.04E-17 0.49 0.08
SMAD3 SMAD family member 3 13.33 0 0.49 0.04
SMAD4 SMAD family member 4 2.06 0 0.24 0.12
TTRAP TRAF and TNF receptor associated protein 3.27 3.16E-11 2.45 0.77
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ADAM17 ADAM 17 precursor (EC 3.4.24.86) (A disintegrin and metalloproteinase domain 1 0.48 2.18E-06 0.30 0.64
ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 0.27 1.29E-12 0.59 2.27
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 0.09 9.44E-20 1.96 23.14
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 0.05 2.75E-21 1.16 23.09
ADAMTS14 ADAM metallopeptidase with thrombospondin type 1 motif, 14 7.39 1.06E-17 0.70 0.10
ADAMTS4 ADAM metallopeptidase with thrombospondin type 1 motif, 4 4.38 5.34E-14 0.76 0.18
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 (aggrecanase-2) 0.25 2.32E-13 0.31 1.30
ADAMTS6 ADAM metallopeptidase with thrombospondin type 1 motif, 6 2.12 1.78E-06 0.30 0.15
AJAP1 adherens junction associated protein 1 0.10 5.18E-19 0.03 0.25
ALCAM activated leukocyte cell adhesion molecule 0.44 2.88E-07 0.05 0.11
ARF6 ADP-ribosylation factor 6 0.46 9.66E-07 1.02 2.27
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 4.63 1.86E-14 0.86 0.19
CCL2 chemokine (C-C motif) ligand 2 2.03 1.40E-45 0.16 0.08
CDH4 cadherin 4, type 1, R-cadherin (retinal) 0.47 1.31E-06 0.08 0.19
CLDN11 claudin 11 (oligodendrocyte transmembrane protein) 0.37 3.02E-09 0.24 0.66
CNTNAP1 contactin associated protein 1 0.49 4.35E-06 0.06 0.12
COL4A1 collagen, type IV, alpha 1 0.44 3.32E-07 0.05 0.11
COL5A2 collagen, type V, alpha 2 0.42 1.01E-07 0.04 0.10
COL8A2 collagen, type VIII, alpha 2 0.42 8.88E-08 0.12 0.28
CTGF connective tissue growth factor 4.55 2.55E-14 9.65 2.18
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 0.34 4.89E-10 0.12 0.37
CTSL2 cathepsin L2 0.48 2.39E-06 0.09 0.19
DCBLD1 discoidin, CUB and LCCL domain containing 1 4.41 4.72E-14 0.62 0.14
DCBLD2 discoidin, CUB and LCCL domain containing 2 0.42 7.44E-08 0.34 0.82
DST dystonin 0.04 5.66E-22 0.01 0.34
EDG1 endothelial differentiation, sphingolipid G-protein-coupled receptor, 1 0.10 3.37E-19 0.11 1.11
EDIL3 EGF-like repeats and discoidin I-like domains 3 0.46 7.09E-07 0.32 0.72
EFS embryonal Fyn-associated substrate 12.45 4.86E-20 1.73 0.14
FAT FAT tumor suppressor homolog 1 (Drosophila) 0.49 4.37E-06 5.44 11.44
FBLIM1 filamin binding LIM protein 1 0.36 1.41E-09 0.07 0.22
FLRT2 fibronectin leucine rich transmembrane protein 2 2.11 2.33E-06 0.12 0.06
FLRT3 fibronectin leucine rich transmembrane protein 3 0.03 6.22E-22 0.00 0.12
GNE glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase 4.87 7.29E-15 0.59 0.12
GP9 glycoprotein IX (platelet) 0.38 1.01E-08 0.04 0.12
GPR56 G protein-coupled receptor 56 2.83 1.09E-09 0.75 0.27
HAPLN1 hyaluronan and proteoglycan link protein 1 0.22 2.24E-14 0.24 1.12
HAS1 hyaluronan synthase 1 0.02 9.08E-23 0.02 1.40
ICAM1 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor 0.27 0 0.03 0.11
ITGA11 integrin, alpha 11 0.24 1.67E-13 0.32 1.37
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 2.03 5.30E-06 0.32 0.16
ITGA6 integrin, alpha 6 2.91 5.52E-10 1.46 0.52
ITGA7 integrin, alpha 7 0.38 6.46E-09 0.07 0.19
LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein 0.49 4.26E-06 0.20 0.43
MAGI1 membrane associated guanylate kinase, WW and PDZ domain containing 1 0.20 3.96E-15 0.09 0.49
MCAM melanoma cell adhesion molecule 0.33 2.43E-10 0.08 0.26
MFAP4 microfibrillar-associated protein 4 0.38 7.51E-09 0.53 1.42
MFAP5 microfibrillar associated protein 5 0.46 7.13E-07 0.38 0.86
MMP1 matrix metallopeptidase 1 (interstitial collagenase) 4.23 0 57.95 14.07
MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) 7.26 1.32E-17 21.82 3.09
NFASC neurofascin homolog (chicken) 0.38 6.14E-09 0.59 1.60
NRP1 neuropilin 1 3.10 1.14E-10 3.42 1.13
NRP2 neuropilin 2 0.24 2.23E-13 0.08 0.35
PCLKC protocadherin LKC 0.39 1.87E-08 0.09 0.22
PKP3 plakophilin 3 0.29 1.64E-11 0.03 0.10
PLAU plasminogen activator, urokinase 6.13 0 2.70 0.45
PODXL podocalyxin-like 5.39 1.17E-15 4.93 0.94
PPFIBP1 PTPRF interacting protein, binding protein 1 (liprin beta 1) 4.33 6.67E-14 1.85 0.44
PTPRF protein tyrosine phosphatase, receptor type, F 0.47 2.13E-06 0.09 0.19
PXN paxillin 0.26 6.77E-13 0.04 0.15
SCARB1 scavenger receptor class B, member 1 0.45 5.37E-07 0.78 1.77
SCARF2 scavenger receptor class F, member 2 0.38 5.07E-09 0.18 0.51
SDC1 syndecan 1 2.11 2.07E-06 13.55 6.60
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), 3.79 0 17.52 4.74
SPG7 spastic paraplegia 7 (pure and complicated autosomal recessive) 2.64 6.08E-09 2.45 0.95
THBS3 thrombospondin 3 0.47 1.88E-06 0.78 1.70
TNFAIP6 tumor necrosis factor, alpha-induced protein 6 0.29 8.86E-12 0.08 0.27
Gene
Appendix Gene list E
Ratio P-value WNT5A control
TNFRSF12A tumor necrosis factor receptor superfamily, member 12A 3.19 5.93E-11 16.97 5.47
TPBG trophoblast glycoprotein 2.47 3.61E-08 5.66 2.36
U94903 Human soluble CD44 (CD44) mRNA, with exon v10 extension, partial cds. [U9490 0.18 8.41E-16 0.03 0.19
VCL vinculin 4.61 1.97E-14 12.24 2.73
Gene
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